{
  "items": "701",
  "sentiment_score_definition": "x <= -0.35: Bearish; -0.35 < x <= -0.15: Somewhat-Bearish; -0.15 < x < 0.15: Neutral; 0.15 <= x < 0.35: Somewhat_Bullish; x >= 0.35: Bullish",
  "relevance_score_definition": "0 < x <= 1, with a higher score indicating higher relevance.",
  "feed": [
    {
      "title": "$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today - AbbVie  ( NYSE:ABBV ) ",
      "url": "https://www.benzinga.com/insights/news/25/03/44108487/1000-invested-in-this-stock-5-years-ago-would-be-worth-this-much-today",
      "time_published": "20250304T141511",
      "authors": [
        "Benzinga Insights"
      ],
      "summary": "AbbVie ABBV has outperformed the market over the past 5 years by 3.61% on an annualized basis producing an average annual return of 19.92%. Currently, AbbVie has a market capitalization of $374.56 billion.",
      "banner_image": "https://www.benzinga.com/files/images/story/2025/1741097708_0.png",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.238974,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.95919",
          "ticker_sentiment_score": "0.384695",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Here's How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years - AbbVie  ( NYSE:ABBV ) ",
      "url": "https://www.benzinga.com/insights/news/25/02/43927882/heres-how-much-you-would-have-made-owning-abbvie-stock-in-the-last-10-years",
      "time_published": "20250224T220014",
      "authors": [
        "Benzinga Insights"
      ],
      "summary": "AbbVie ABBV has outperformed the market over the past 10 years by 2.09% on an annualized basis producing an average annual return of 13.09%. Currently, AbbVie has a market capitalization of $360.27 billion.",
      "banner_image": "https://www.benzinga.com/files/images/story/2025/1740434411_0.png",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.238974,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.95919",
          "ticker_sentiment_score": "0.384695",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "$100 Invested In AbbVie 5 Years Ago Would Be Worth This Much Today - AbbVie  ( NYSE:ABBV ) ",
      "url": "https://www.benzinga.com/insights/news/25/01/43372190/100-invested-in-abbvie-5-years-ago-would-be-worth-this-much-today",
      "time_published": "20250130T231513",
      "authors": [
        "Benzinga Insights"
      ],
      "summary": "AbbVie ABBV has outperformed the market over the past 5 years by 2.84% on an annualized basis producing an average annual return of 15.8%. Currently, AbbVie has a market capitalization of $310.89 billion.",
      "banner_image": "https://www.benzinga.com/files/images/story/2025/1738278910_0.png",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.238974,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.95919",
          "ticker_sentiment_score": "0.384695",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "$1000 Invested In AbbVie 5 Years Ago Would Be Worth This Much Today - AbbVie  ( NYSE:ABBV ) ",
      "url": "https://www.benzinga.com/insights/news/25/01/43203561/1000-invested-in-abbvie-5-years-ago-would-be-worth-this-much-today",
      "time_published": "20250124T214519",
      "authors": [
        "Benzinga Insights"
      ],
      "summary": "AbbVie ABBV has outperformed the market over the past 5 years by 2.03% on an annualized basis producing an average annual return of 15.25%. Currently, AbbVie has a market capitalization of $299.79 billion.",
      "banner_image": "https://www.benzinga.com/files/images/story/2025/1737755115_0.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.238974,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.95919",
          "ticker_sentiment_score": "0.384695",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Here's How Much $1000 Invested In AbbVie 5 Years Ago Would Be Worth Today - AbbVie  ( NYSE:ABBV ) ",
      "url": "https://www.benzinga.com/insights/news/25/01/42864060/heres-how-much-1000-invested-in-abbvie-5-years-ago-would-be-worth-today",
      "time_published": "20250107T231523",
      "authors": [
        "Benzinga Insights"
      ],
      "summary": "AbbVie ABBV has outperformed the market over the past 5 years by 3.09% on an annualized basis producing an average annual return of 15.5%. Currently, AbbVie has a market capitalization of $317.41 billion.",
      "banner_image": "https://www.benzinga.com/files/images/story/2025/1736291720_0.png",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.238974,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.95919",
          "ticker_sentiment_score": "0.384695",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "$100 Invested In AbbVie 5 Years Ago Would Be Worth This Much Today - AbbVie  ( NYSE:ABBV ) ",
      "url": "https://www.benzinga.com/insights/news/24/12/42675709/100-invested-in-abbvie-5-years-ago-would-be-worth-this-much-today",
      "time_published": "20241224T204520",
      "authors": [
        "Benzinga Insights"
      ],
      "summary": "AbbVie ABBV has outperformed the market over the past 5 years by 1.88% on an annualized basis producing an average annual return of 15.25%. Currently, AbbVie has a market capitalization of $317.86 billion.",
      "banner_image": "https://www.benzinga.com/files/images/story/2024/1735073117_0.png",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.238974,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.95919",
          "ticker_sentiment_score": "0.384695",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Here's How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years - AbbVie  ( NYSE:ABBV ) ",
      "url": "https://www.benzinga.com/insights/news/25/04/45075044/heres-how-much-you-would-have-made-owning-abbvie-stock-in-the-last-10-years",
      "time_published": "20250429T161515",
      "authors": [
        "Benzinga Insights"
      ],
      "summary": "AbbVie ABBV has outperformed the market over the past 10 years by 1.58% on an annualized basis producing an average annual return of 11.78%. Currently, AbbVie has a market capitalization of $344.00 billion.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_3.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        }
      ],
      "overall_sentiment_score": 0.25,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.941873",
          "ticker_sentiment_score": "0.382786",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today - AbbVie  ( NYSE:ABBV ) ",
      "url": "https://www.benzinga.com/insights/news/25/04/44884133/100-invested-in-this-stock-5-years-ago-would-be-worth-this-much-today",
      "time_published": "20250418T141517",
      "authors": [
        "Benzinga Insights"
      ],
      "summary": "AbbVie ABBV has outperformed the market over the past 5 years by 2.54% on an annualized basis producing an average annual return of 16.57%. Currently, AbbVie has a market capitalization of $308.15 billion.",
      "banner_image": "https://www.benzinga.com/files/images/story/2025/1744985713_0.png",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        }
      ],
      "overall_sentiment_score": 0.25,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.941873",
          "ticker_sentiment_score": "0.382786",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "$1000 Invested In This Stock 10 Years Ago Would Be Worth This Much Today - AbbVie  ( NYSE:ABBV ) ",
      "url": "https://www.benzinga.com/insights/news/25/03/44458564/1000-invested-in-this-stock-10-years-ago-would-be-worth-this-much-today",
      "time_published": "20250324T140013",
      "authors": [
        "Benzinga Insights"
      ],
      "summary": "AbbVie ABBV has outperformed the market over the past 10 years by 2.91% on an annualized basis producing an average annual return of 13.64%. Currently, AbbVie has a market capitalization of $371.20 billion.",
      "banner_image": "https://www.benzinga.com/files/images/story/2025/1742824809_0.png",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        }
      ],
      "overall_sentiment_score": 0.25,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.941873",
          "ticker_sentiment_score": "0.382786",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "This Is What Whales Are Betting On AbbVie - AbbVie  ( NYSE:ABBV ) ",
      "url": "https://www.benzinga.com/insights/options/24/11/41885894/this-is-what-whales-are-betting-on-abbvie",
      "time_published": "20241111T184652",
      "authors": [
        "Benzinga Insights"
      ],
      "summary": "Deep-pocketed investors have adopted a bullish approach towards AbbVie ABBV, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.",
      "banner_image": "https://www.benzinga.com/files/images/story/2024/1731350809_0.png",
      "source": "Benzinga",
      "category_within_source": "Markets",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.989041"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.189632,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MS",
          "relevance_score": "0.070105",
          "ticker_sentiment_score": "0.021212",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.840758",
          "ticker_sentiment_score": "0.292652",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "C",
          "relevance_score": "0.070105",
          "ticker_sentiment_score": "0.021212",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "AbbVie Vs. Novartis: Which Has The Technical Edge Before Q4 Earnings? - Novartis  ( NYSE:NVS ) ",
      "url": "https://www.benzinga.com/general/biotech/25/01/43350321/abbvie-vs-novartis-which-has-the-technical-edge-before-q4-earnings",
      "time_published": "20250130T193953",
      "authors": [
        "Surbhi Jain"
      ],
      "summary": "Novartis shows strong bullish momentum, while AbbVie remains range-bound ahead of its Q4 earnings reports. Investors should watch key resistance levels - ABBV above $177 and NVS above $106 - for potential post-earnings moves. Get the Real Story Behind Every Major Earnings Report As AbbVie Inc.",
      "banner_image": "https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/30131850/Screenshot-2025-01-30-at-11.40.39-PM.png",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.890401"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.365926"
        }
      ],
      "overall_sentiment_score": 0.108594,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "NVS",
          "relevance_score": "0.291182",
          "ticker_sentiment_score": "-0.089769",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.829093",
          "ticker_sentiment_score": "-0.01664",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "3 Stocks Breaking Out Right Now",
      "url": "https://www.zacks.com/stock/news/2427441/3-stocks-breaking-out-right-now",
      "time_published": "20250307T165500",
      "authors": [
        "Tracey Ryniec"
      ],
      "summary": "Think every stock is selling off right now on tariff fears? Zacks Stock Strategist, Tracey Ryniec, shares a group of stocks bucking the trend.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e7/2427.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.997405"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.614606"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.199417,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "AON",
          "relevance_score": "0.527969",
          "ticker_sentiment_score": "0.311925",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.782378",
          "ticker_sentiment_score": "0.399453",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "BRK-A",
          "relevance_score": "0.527969",
          "ticker_sentiment_score": "0.161846",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Decoding AbbVie's Options Activity: What's the Big Picture? - AbbVie  ( NYSE:ABBV ) ",
      "url": "https://www.benzinga.com/insights/options/25/03/44569560/decoding-abbvies-options-activity-whats-the-big-picture",
      "time_published": "20250331T190118",
      "authors": [
        "Benzinga Insights"
      ],
      "summary": "Deep-pocketed investors have adopted a bullish approach towards AbbVie ABBV, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.",
      "banner_image": "https://www.benzinga.com/files/images/story/2025/1743447675_0.png",
      "source": "Benzinga",
      "category_within_source": "Markets",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.989041"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.191816,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "WFC",
          "relevance_score": "0.079392",
          "ticker_sentiment_score": "0.045261",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.768309",
          "ticker_sentiment_score": "0.309429",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Recession Worries? Here's 1 of the Best Dividend Stocks for Turbulent Times",
      "url": "https://www.fool.com/investing/2025/05/11/recession-worries-heres-1-of-the-best-dividend/",
      "time_published": "20250511T130000",
      "authors": [
        "Bradley Guichard"
      ],
      "summary": "J.P. Morgan stated last month that it believes there is a 60% chance of a recession in 2025 due to trade wars and tariffs. The raging bull market that started at the beginning of 2023 is in jeopardy. No one knows precisely when the bulls will get tired and the bears will come out of hibernation.",
      "banner_image": "https://media.ycharts.com/charts/6493f2f107317528c6e70031b2886004.png",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.980922"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.538269"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.105446,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "IVZ",
          "relevance_score": "0.058047",
          "ticker_sentiment_score": "0.093255",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.756001",
          "ticker_sentiment_score": "0.323622",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Spotlight on AbbVie: Analyzing the Surge in Options Activity - AbbVie  ( NYSE:ABBV ) ",
      "url": "https://www.benzinga.com/insights/options/25/04/44936104/spotlight-on-abbvie-analyzing-the-surge-in-options-activity",
      "time_published": "20250422T200203",
      "authors": [
        "Benzinga Insights"
      ],
      "summary": "Investors with a lot of money to spend have taken a bullish stance on AbbVie ABBV. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.",
      "banner_image": "https://www.benzinga.com/files/images/story/2025/1745352119_0.png",
      "source": "Benzinga",
      "category_within_source": "Markets",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.962106"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.122878,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "GS",
          "relevance_score": "0.073773",
          "ticker_sentiment_score": "-0.082013",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MS",
          "relevance_score": "0.073773",
          "ticker_sentiment_score": "-0.082013",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.733479",
          "ticker_sentiment_score": "0.142135",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "AbbVie Jumps After Q4 Earnings Beat, Skyrizi And Rinvoq Boom Offsets Humira Decline - AbbVie  ( NYSE:ABBV ) ",
      "url": "https://www.benzinga.com/news/earnings/25/01/43392796/abbvie-jumps-after-q4-earnings-beat-skyrizi-and-rinvoq-boom-offsets-humira-decline",
      "time_published": "20250131T150059",
      "authors": [
        "Nabaparna Bhattacharya"
      ],
      "summary": "AbbVie Q4 adjusted EPS of $2.16 beat estimates, with strong sales of Skyrizi ( +57.9% ) and Rinvoq ( +47.1% ) boosting revenue growth. AbbVie raises 2027 revenue forecast for Skyrizi and Rinvoq to $31 billion, including $20B for Skyrizi and $11B for Rinvoq. AbbVie Inc.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2025/01/31/Galicia--Spain-June-8--2020--Smart-Phone.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999763"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        }
      ],
      "overall_sentiment_score": 0.261547,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.733479",
          "ticker_sentiment_score": "0.344602",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "AbbVie Inks a Deal With Neomorph for Molecular Glue Degraders",
      "url": "https://www.zacks.com/stock/news/2402747/abbvie-inks-a-deal-with-neomorph-for-molecular-glue-degraders",
      "time_published": "20250124T131800",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Per the terms of the deal, AbbVie will use Neomorph's proprietary platform to develop novel drugs targeting oncology and immunology indications.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/36/1919.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.538269"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.144404,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "NVO",
          "relevance_score": "0.261117",
          "ticker_sentiment_score": "0.135587",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.733479",
          "ticker_sentiment_score": "0.262908",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "BIIB",
          "relevance_score": "0.261117",
          "ticker_sentiment_score": "0.135587",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Here's How Many Shares of AbbVie You Need to Own to Get $1,000 in Yearly Dividends",
      "url": "https://www.fool.com/investing/2025/03/20/heres-how-many-shares-of-abbvie-you-need-to-own-to/",
      "time_published": "20250320T133100",
      "authors": [
        "Selena Maranjian"
      ],
      "summary": "So, you want to invest in AbbVie ( NYSE: ABBV ) because it's a promising dividend-paying stock, and you also want to receive $1,000 per year in dividend income from it. How many shares should you buy? The answer requires a little simple math.Shares of AbbVie were recently trading for $212 apiece, ...",
      "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F811522%2Fdisabled-senior-man-in-wheelchair-indoors-playing-with-a-pet-dog.jpg&op=resize&w=700",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.25891,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.730954",
          "ticker_sentiment_score": "0.40853",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.12546",
          "ticker_sentiment_score": "0.213298",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "AbbVie Unusual Options Activity For January 10 - AbbVie  ( NYSE:ABBV ) ",
      "url": "https://www.benzinga.com/insights/options/25/01/42919289/abbvie-unusual-options-activity-for-january-10",
      "time_published": "20250110T163029",
      "authors": [
        "Benzinga Insights"
      ],
      "summary": "Deep-pocketed investors have adopted a bullish approach towards AbbVie ABBV, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.",
      "banner_image": "https://www.benzinga.com/files/images/story/2025/1736526625_0.png",
      "source": "Benzinga",
      "category_within_source": "Markets",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.962106"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.241674,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.723894",
          "ticker_sentiment_score": "0.311906",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Check Out What Whales Are Doing With ABBV - AbbVie  ( NYSE:ABBV ) ",
      "url": "https://www.benzinga.com/insights/options/24/12/42395060/check-out-what-whales-are-doing-with-abbv",
      "time_published": "20241209T170107",
      "authors": [
        "Benzinga Insights"
      ],
      "summary": "Financial giants have made a conspicuous bullish move on AbbVie. Our analysis of options history for AbbVie ABBV revealed 10 unusual trades. Delving into the details, we found 70% of traders were bullish, while 10% showed bearish tendencies.",
      "banner_image": "https://www.benzinga.com/files/images/story/2024/1733763664_0.png",
      "source": "Benzinga",
      "category_within_source": "Markets",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.365926"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.201855,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MS",
          "relevance_score": "0.077845",
          "ticker_sentiment_score": "0.088904",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.717589",
          "ticker_sentiment_score": "0.254758",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "C",
          "relevance_score": "0.077845",
          "ticker_sentiment_score": "0.088904",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Is AbbVie Stock a Buy?",
      "url": "https://www.fool.com/investing/2025/04/20/is-abbvie-stock-a-buy/",
      "time_published": "20250420T121500",
      "authors": [
        "Justin Pope"
      ],
      "summary": "The pharmaceutical giant has been a roller coaster over the past several months.",
      "banner_image": "https://media.ycharts.com/charts/2318a3cb70f1b8b9bf80349e81121021.png",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.988787"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.5855"
        }
      ],
      "overall_sentiment_score": 0.069931,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "SPGI",
          "relevance_score": "0.052918",
          "ticker_sentiment_score": "-0.057939",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.71174",
          "ticker_sentiment_score": "0.194376",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.052918",
          "ticker_sentiment_score": "0.053728",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "1 Magnificent S&P 500 Dividend Stock Down 14% to Buy and Hold Forever",
      "url": "https://www.fool.com/investing/2024/12/12/1-magnificent-sp-500-dividend-stock-down-14-to-buy/",
      "time_published": "20241212T110000",
      "authors": [
        "Bradley Guichard"
      ],
      "summary": "This will go down in history as an incredible year for stocks. The S&P 500 hit a new all-time high 50 times. For perspective, there are about 250 trading days in the year. So, on average, the market made history every five days this year.",
      "banner_image": "https://media.ycharts.com/charts/04690dae5cdf0318f153ec25dd40dcfc.png",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.316726"
        }
      ],
      "overall_sentiment_score": 0.214907,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.70826",
          "ticker_sentiment_score": "0.380907",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.076358",
          "ticker_sentiment_score": "0.22722",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "AbbVie Stock Rises After Leerink Partners Upgrades Its Rating",
      "url": "https://www.zacks.com/stock/news/2374957/abbvie-stock-rises-after-leerink-partners-upgrades-its-rating",
      "time_published": "20241125T200000",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Leerink Partners upgrades its rating on ABBV stock from Market Perform to Outperform.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ab/2180.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.682689"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.207105,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "PFE",
          "relevance_score": "0.138997",
          "ticker_sentiment_score": "0.092227",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.70655",
          "ticker_sentiment_score": "0.331203",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Looking At AbbVie's Recent Unusual Options Activity - AbbVie  ( NYSE:ABBV ) ",
      "url": "https://www.benzinga.com/insights/options/25/02/43444693/looking-at-abbvies-recent-unusual-options-activity",
      "time_published": "20250203T183031",
      "authors": [
        "Benzinga Insights"
      ],
      "summary": "Investors with a lot of money to spend have taken a bearish stance on AbbVie ABBV. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.",
      "banner_image": "https://www.benzinga.com/files/images/story/2025/1738607428_0.png",
      "source": "Benzinga",
      "category_within_source": "Markets",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.989041"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.171252,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.706081",
          "ticker_sentiment_score": "0.205319",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "C",
          "relevance_score": "0.069697",
          "ticker_sentiment_score": "0.071503",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "AbbVie Options Trading: A Deep Dive into Market Sentiment - AbbVie  ( NYSE:ABBV ) ",
      "url": "https://www.benzinga.com/insights/options/25/03/44203447/abbvie-options-trading-a-deep-dive-into-market-sentiment",
      "time_published": "20250307T203050",
      "authors": [
        "Benzinga Insights"
      ],
      "summary": "Whales with a lot of money to spend have taken a noticeably bullish stance on AbbVie. Looking at options history for AbbVie ABBV we detected 29 trades. If we consider the specifics of each trade, it is accurate to state that 51% of the investors opened trades with bullish expectations and 41% ...",
      "banner_image": "https://www.benzinga.com/files/images/story/2025/1741379447_0.png",
      "source": "Benzinga",
      "category_within_source": "Markets",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.990999"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.219836,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "WFC",
          "relevance_score": "0.083541",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.705799",
          "ticker_sentiment_score": "0.239334",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "AbbVie Options Trading: A Deep Dive into Market Sentiment - AbbVie  ( NYSE:ABBV ) ",
      "url": "https://www.benzinga.com/insights/options/25/03/44424599/abbvie-options-trading-a-deep-dive-into-market-sentiment",
      "time_published": "20250320T200048",
      "authors": [
        "Benzinga Insights"
      ],
      "summary": "Investors with a lot of money to spend have taken a bullish stance on AbbVie ABBV. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.",
      "banner_image": "https://www.benzinga.com/files/images/story/2025/1742500845_0.png",
      "source": "Benzinga",
      "category_within_source": "Markets",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.962106"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.176198,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "WFC",
          "relevance_score": "0.074926",
          "ticker_sentiment_score": "-0.001025",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.699089",
          "ticker_sentiment_score": "0.226389",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "AbbVie Adds More Than $24B in 6 Months: How to Play ABBV Stock",
      "url": "https://www.zacks.com/stock/news/2556093/abbvie-adds-more-than-24b-in-6-months-how-to-play-abbv-stock",
      "time_published": "20250627T140800",
      "authors": [
        "Kinjel Shah"
      ],
      "summary": "ABBV adds $24B in market cap as Skyrizi and Rinvoq drive growth post-Humira, with more upside from a strong pipeline.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/db/3038.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.459462"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.875462"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.31089,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.107175",
          "ticker_sentiment_score": "0.102416",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.107175",
          "ticker_sentiment_score": "0.102416",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.698365",
          "ticker_sentiment_score": "0.477668",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "How Will Skyrizi and Rinvoq Sales Aid AbbVie's Upcoming Q2 Results?",
      "url": "https://www.zacks.com/stock/news/2567013/how-will-skyrizi-and-rinvoq-sales-aid-abbvies-upcoming-q2-results",
      "time_published": "20250708T122700",
      "authors": [
        "Sundeep Ganoria"
      ],
      "summary": "ABBV leans on Skyrizi and Rinvoq sales strength to offset Humira's decline ahead of its Q2 earnings report.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/36/1919.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        }
      ],
      "overall_sentiment_score": 0.292577,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.266101",
          "ticker_sentiment_score": "0.218304",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.692191",
          "ticker_sentiment_score": "0.450901",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.067727",
          "ticker_sentiment_score": "0.046221",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.134968",
          "ticker_sentiment_score": "0.10605",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Smart Money Is Betting Big In ABBV Options - AbbVie  ( NYSE:ABBV ) ",
      "url": "https://www.benzinga.com/insights/options/25/03/44476416/smart-money-is-betting-big-in-abbv-options",
      "time_published": "20250325T154557",
      "authors": [
        "Benzinga Insights"
      ],
      "summary": "Investors with significant funds have taken a bearish position in AbbVie ABBV, a development that retail traders should be aware of. This was brought to our attention today through our monitoring of publicly accessible options data at Benzinga.",
      "banner_image": "https://www.benzinga.com/files/images/story/2025/1742917554_0.png",
      "source": "Benzinga",
      "category_within_source": "Markets",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.980922"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.139756,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "WFC",
          "relevance_score": "0.081001",
          "ticker_sentiment_score": "-0.026871",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.690822",
          "ticker_sentiment_score": "0.176348",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Smart Money Is Betting Big In ABBV Options - AbbVie  ( NYSE:ABBV ) ",
      "url": "https://www.benzinga.com/insights/options/24/11/41948590/smart-money-is-betting-big-in-abbv-options",
      "time_published": "20241113T174530",
      "authors": [
        "Benzinga Insights"
      ],
      "summary": "Whales with a lot of money to spend have taken a noticeably bullish stance on AbbVie. Looking at options history for AbbVie ABBV we detected 15 trades. If we consider the specifics of each trade, it is accurate to state that 53% of the investors opened trades with bullish expectations and 33% ...",
      "banner_image": "https://www.benzinga.com/files/images/story/2024/1731519926_0.png",
      "source": "Benzinga",
      "category_within_source": "Markets",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.225301,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.686739",
          "ticker_sentiment_score": "0.377712",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Check Out What Whales Are Doing With ABBV - AbbVie  ( NYSE:ABBV ) ",
      "url": "https://www.benzinga.com/insights/options/24/12/42324626/check-out-what-whales-are-doing-with-abbv",
      "time_published": "20241204T194604",
      "authors": [
        "Benzinga Insights"
      ],
      "summary": "Financial giants have made a conspicuous bullish move on AbbVie. Our analysis of options history for AbbVie ABBV revealed 13 unusual trades. Delving into the details, we found 46% of traders were bullish, while 30% showed bearish tendencies.",
      "banner_image": "https://www.benzinga.com/files/images/story/2024/1733341561_0.png",
      "source": "Benzinga",
      "category_within_source": "Markets",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.365926"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.2646,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MS",
          "relevance_score": "0.079921",
          "ticker_sentiment_score": "0.119497",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.684305",
          "ticker_sentiment_score": "0.335951",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Unpacking the Latest Options Trading Trends in AbbVie - AbbVie  ( NYSE:ABBV ) ",
      "url": "https://www.benzinga.com/insights/options/24/11/42095848/unpacking-the-latest-options-trading-trends-in-abbvie",
      "time_published": "20241120T180037",
      "authors": [
        "Benzinga Insights"
      ],
      "summary": "Whales with a lot of money to spend have taken a noticeably bullish stance on AbbVie. Looking at options history for AbbVie ABBV we detected 8 trades. If we consider the specifics of each trade, it is accurate to state that 50% of the investors opened trades with bullish expectations and 37% ...",
      "banner_image": "https://www.benzinga.com/files/images/story/2024/1732125634_0.png",
      "source": "Benzinga",
      "category_within_source": "Markets",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.413559"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.183212,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MS",
          "relevance_score": "0.158519",
          "ticker_sentiment_score": "0.033958",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.682689",
          "ticker_sentiment_score": "0.206552",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "C",
          "relevance_score": "0.079656",
          "ticker_sentiment_score": "0.025698",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Zacks Market Edge Highlights: Berkshire Hathaway, Aon plc and AbbVie",
      "url": "https://www.zacks.com/stock/news/2427877/zacks-market-edge-highlights-berkshire-hathaway-aon-plc-and-abbvie",
      "time_published": "20250310T144700",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Berkshire Hathaway, Aon plc and AbbVie are part of the Zacks Market Edge article.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/39/1249.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.999995"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.614606"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.219309,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "AON",
          "relevance_score": "0.43816",
          "ticker_sentiment_score": "0.278993",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.680008",
          "ticker_sentiment_score": "0.378279",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "BRK-A",
          "relevance_score": "0.43816",
          "ticker_sentiment_score": "0.14403",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "ABBV to Acquire Nimble Therapeutics to Strengthen Immunology Pipeline",
      "url": "https://www.zacks.com/stock/news/2383942/abbv-to-acquire-nimble-therapeutics-to-strengthen-immunology-pipeline",
      "time_published": "20241216T144200",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "AbbVie is set to acquire privately held biotech, Nimble Therapeutics, for $200 million to strengthen its immunology pipeline.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/31/1512.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.928139"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.275853,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.677342",
          "ticker_sentiment_score": "0.544626",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "CTMX",
          "relevance_score": "0.208017",
          "ticker_sentiment_score": "0.006632",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SPRO",
          "relevance_score": "0.1568",
          "ticker_sentiment_score": "0.033883",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CSTL",
          "relevance_score": "0.208017",
          "ticker_sentiment_score": "0.084645",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "AbbVie Stock Falls 11% in a Month: Should You Buy the Dip?",
      "url": "https://www.zacks.com/stock/news/2371100/abbvie-stock-falls-11-in-a-month-should-you-buy-the-dip",
      "time_published": "20241115T150800",
      "authors": [
        "Kinjel Shah"
      ],
      "summary": "Investors who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth next year.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/d5/8276.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.503496"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.904684"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.360215"
        }
      ],
      "overall_sentiment_score": 0.234354,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.068112",
          "ticker_sentiment_score": "0.082567",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.068112",
          "ticker_sentiment_score": "0.082567",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.674346",
          "ticker_sentiment_score": "0.376455",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "AbbVie Unusual Options Activity - AbbVie  ( NYSE:ABBV ) ",
      "url": "https://www.benzinga.com/insights/options/25/05/45355106/abbvie-unusual-options-activity",
      "time_published": "20250512T170234",
      "authors": [
        "Benzinga Insights"
      ],
      "summary": "Investors with a lot of money to spend have taken a bullish stance on AbbVie ABBV. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't know.",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "Markets",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.54554"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.16695,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "EVR",
          "relevance_score": "0.064797",
          "ticker_sentiment_score": "-0.01306",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.670742",
          "ticker_sentiment_score": "0.17661",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "MS",
          "relevance_score": "0.064797",
          "ticker_sentiment_score": "-0.01306",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PLSQF",
          "relevance_score": "0.064797",
          "ticker_sentiment_score": "0.144074",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "ABBV's Acquisition Spree Continues: Buy, Sell or Hold the Stock?",
      "url": "https://www.zacks.com/stock/news/2384030/abbvs-acquisition-spree-continues-buy-sell-or-hold-the-stock",
      "time_published": "20241216T151700",
      "authors": [
        "Kinjel Shah"
      ],
      "summary": "Investors who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth next year.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/07/905.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.962106"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.795202"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.650727"
        }
      ],
      "overall_sentiment_score": 0.252571,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.073886",
          "ticker_sentiment_score": "0.06785",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.073886",
          "ticker_sentiment_score": "0.06785",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.669807",
          "ticker_sentiment_score": "0.39222",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "AbbVie's Options Frenzy: What You Need to Know - AbbVie  ( NYSE:ABBV ) ",
      "url": "https://www.benzinga.com/insights/options/25/04/45049901/abbvies-options-frenzy-what-you-need-to-know",
      "time_published": "20250428T190120",
      "authors": [
        "Benzinga Insights"
      ],
      "summary": "Investors with a lot of money to spend have taken a bullish stance on AbbVie ABBV. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.",
      "banner_image": "https://www.benzinga.com/files/images/story/2025/1745866876_0.png",
      "source": "Benzinga",
      "category_within_source": "Markets",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.413559"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.164399,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "EVR",
          "relevance_score": "0.070517",
          "ticker_sentiment_score": "-0.004045",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.669671",
          "ticker_sentiment_score": "0.158256",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "GS",
          "relevance_score": "0.070517",
          "ticker_sentiment_score": "-0.004045",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MS",
          "relevance_score": "0.070517",
          "ticker_sentiment_score": "-0.004045",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "AbbVie's Venclexta Misses Goal in Myelodysplastic Syndromes Study",
      "url": "https://www.zacks.com/stock/news/2506666/abbvies-venclexta-misses-goal-in-myelodysplastic-syndromes-study",
      "time_published": "20250617T143000",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Venclexta fails to meet survival goals in ABBV's phase III MDS study, marking another clinical setback for the cancer drug.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/36/1919.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.682689"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.1111,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "AGEN",
          "relevance_score": "0.344074",
          "ticker_sentiment_score": "0.037265",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IMCR",
          "relevance_score": "0.233556",
          "ticker_sentiment_score": "0.141855",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.665629",
          "ticker_sentiment_score": "0.178357",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Looking At AbbVie's Recent Unusual Options Activity - AbbVie  ( NYSE:ABBV ) ",
      "url": "https://www.benzinga.com/insights/options/25/04/44592823/looking-at-abbvies-recent-unusual-options-activity",
      "time_published": "20250401T184536",
      "authors": [
        "Benzinga Insights"
      ],
      "summary": "Investors with a lot of money to spend have taken a bearish stance on AbbVie ABBV. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.",
      "banner_image": "https://www.benzinga.com/files/images/story/2025/1743533132_0.png",
      "source": "Benzinga",
      "category_within_source": "Markets",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.980922"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.192618,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "WFC",
          "relevance_score": "0.076847",
          "ticker_sentiment_score": "0.021478",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.66527",
          "ticker_sentiment_score": "0.168334",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "AbbVie's Rally Looks Stretched-Could a Reversal Be Next? - AbbVie  ( NYSE:ABBV ) ",
      "url": "https://www.benzinga.com/trading-ideas/technicals/25/04/45072193/stock-of-the-day-abbvies-rally-looks-stretched-could-a-reversal-be-next",
      "time_published": "20250429T151208",
      "authors": [
        "Mark Putrino"
      ],
      "summary": "Shares of AbbVie ( ABBV ) appear to be overbought. The recent move higher may pause or even end. Don't face extreme market conditions unprepared. Get the professional edge with Benzinga Pro's exclusive alerts, news advantage, and volatility tools at 60% ( discount ends Wednesday! )",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2025/04/29/Abbvie.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.413559"
        }
      ],
      "overall_sentiment_score": 0.106903,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.664604",
          "ticker_sentiment_score": "0.162204",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "This Top Dividend Stock Just Entered The Weight Loss Market: Is It a Buy?",
      "url": "https://www.fool.com/investing/2025/03/10/this-top-dividend-stock-just-entered-the-weight/",
      "time_published": "20250310T115700",
      "authors": [
        "Prosper Junior Bakiny"
      ],
      "summary": "It's not too often that pharmaceutical drugs become household names, but that's happening with medicines in the weight loss market. Brands such as Wegovy and Zepbound -- the leading anti-obesity therapies -- are now well known and are generating billions of dollars in annual sales.",
      "banner_image": "https://g.foolcdn.com/editorial/images/810254/pharmacist-talking-to-patient.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.614606"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        }
      ],
      "overall_sentiment_score": 0.25668,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "NVO",
          "relevance_score": "0.062597",
          "ticker_sentiment_score": "0.074144",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.654016",
          "ticker_sentiment_score": "0.377813",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.062597",
          "ticker_sentiment_score": "0.225566",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Market Whales and Their Recent Bets on ABBV Options - AbbVie  ( NYSE:ABBV ) ",
      "url": "https://www.benzinga.com/insights/options/24/11/42171031/market-whales-and-their-recent-bets-on-abbv-options",
      "time_published": "20241125T180037",
      "authors": [
        "Benzinga Insights"
      ],
      "summary": "Financial giants have made a conspicuous bearish move on AbbVie. Our analysis of options history for AbbVie ABBV revealed 13 unusual trades. Delving into the details, we found 38% of traders were bullish, while 53% showed bearish tendencies.",
      "banner_image": "https://www.benzinga.com/files/images/story/2024/1732557634_0.png",
      "source": "Benzinga",
      "category_within_source": "Markets",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.221777,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.653656",
          "ticker_sentiment_score": "0.1653",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Buy Stock in These Healthcare Leaders as Q1 Earnings Approach? ABBV, HCA",
      "url": "https://www.zacks.com/stock/news/2454297/buy-stock-in-these-healthcare-leaders-as-q1-earnings-approach-abbv-hca",
      "time_published": "20250423T230800",
      "authors": [
        "Shaun Pruitt"
      ],
      "summary": "The medical sector can provide a defensive hedge against economic uncertainty, and investors may be eyeing AbbVie (ABBV) and HCA Healthcare (HCA) stock ahead of their Q1 reports on Friday, April 25.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/0e/879.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.94762"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.316726"
        }
      ],
      "overall_sentiment_score": 0.36403,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.653175",
          "ticker_sentiment_score": "0.477033",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "HCA",
          "relevance_score": "0.825817",
          "ticker_sentiment_score": "0.546941",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "AbbVie  ( ABBV )  Gains As Market Dips: What You Should Know",
      "url": "https://www.zacks.com/stock/news/2479911/abbvie-abbv-gains-as-market-dips-what-you-should-know",
      "time_published": "20250530T214503",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "The latest trading day saw AbbVie (ABBV) settling at $186.11, representing a +0.26% change from its previous close.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default232.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.928769"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        }
      ],
      "overall_sentiment_score": 0.155684,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.649828",
          "ticker_sentiment_score": "0.300066",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "AbbVie Secures FDA Nod for New ADC Drug Emrelis in Lung Cancer",
      "url": "https://www.zacks.com/stock/news/2471828/abbvie-secures-fda-nod-for-new-adc-drug-emrelis-in-lung-cancer",
      "time_published": "20250515T124200",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Following the approval, ABBV's Emrelis becomes the first FDA-approved therapy for previously treated advanced NSCLC patients with high c-Met protein overexpression.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/31/1512.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.682689"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.171231,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ADPT",
          "relevance_score": "0.279015",
          "ticker_sentiment_score": "0.170999",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "AGEN",
          "relevance_score": "0.224903",
          "ticker_sentiment_score": "0.064371",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.646889",
          "ticker_sentiment_score": "0.179103",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Unpacking the Latest Options Trading Trends in AbbVie - AbbVie  ( NYSE:ABBV ) ",
      "url": "https://www.benzinga.com/insights/options/25/01/43200540/unpacking-the-latest-options-trading-trends-in-abbvie",
      "time_published": "20250124T191613",
      "authors": [
        "Benzinga Insights"
      ],
      "summary": "Whales with a lot of money to spend have taken a noticeably bearish stance on AbbVie. Looking at options history for AbbVie ABBV we detected 9 trades. If we consider the specifics of each trade, it is accurate to state that 22% of the investors opened trades with bullish expectations and 66% ...",
      "banner_image": "https://www.benzinga.com/files/images/story/2025/1737746170_0.png",
      "source": "Benzinga",
      "category_within_source": "Markets",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.929393"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.205991,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.640349",
          "ticker_sentiment_score": "0.201024",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Why AbbVie Stock Is Jumping Today",
      "url": "https://www.fool.com/investing/2025/01/31/why-abbvie-stock-is-jumping-today/",
      "time_published": "20250131T174203",
      "authors": [
        "Keith Speights"
      ],
      "summary": "Shares of AbbVie ( NYSE: ABBV ) were jumping 7.1% higher as of 11:10 a.m. ET on Friday after rising as much as 9.2% earlier in the day. The nice gain stemmed from the big drugmaker's 2024 fourth-quarter update on Friday morning.AbbVie reported Q4 net revenue of $15.1 billion, up 5.6% and higher ...",
      "banner_image": "https://g.foolcdn.com/editorial/images/806042/smiling-man-holding-fist-up.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.98396"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        }
      ],
      "overall_sentiment_score": 0.276386,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.639616",
          "ticker_sentiment_score": "0.497212",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Should Investors Be Worried About Dividend King AbbVie?",
      "url": "https://www.fool.com/investing/2025/04/28/should-investors-be-worried-about-dividend-king-ab/",
      "time_published": "20250428T084200",
      "authors": [
        "Keith Speights"
      ],
      "summary": "Nearly everything looked great with AbbVie's ( NYSE: ABBV ) first-quarter results. The big drugmaker's revenue jumped 8.4% year over year, thanks largely to spectacular growth from autoimmune disease drugs Skyrizi and Rinvoq. AbbVie beat Wall Street's top- and bottom-line estimates.",
      "banner_image": "https://g.foolcdn.com/editorial/images/816104/getty-debt-worry-worried-concern.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.917436"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.360215"
        }
      ],
      "overall_sentiment_score": 0.007288,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.637818",
          "ticker_sentiment_score": "-0.011134",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Time to Dump or Double Up on SCHD?",
      "url": "https://www.fool.com/investing/2025/01/04/time-to-dump-or-double-up-on-schd/",
      "time_published": "20250104T133500",
      "authors": [
        "CPA",
        "Mark Roussin"
      ],
      "summary": "SCHD shares have fallen nearly 10% in a month.",
      "banner_image": "https://g.foolcdn.com/editorial/images/802868/gettyimages-1415511622.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.917436"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.175564,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "KO",
          "relevance_score": "0.636698",
          "ticker_sentiment_score": "0.342457",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.636698",
          "ticker_sentiment_score": "0.342457",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.636698",
          "ticker_sentiment_score": "0.342457",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "AbbVie Unusual Options Activity - AbbVie  ( NYSE:ABBV ) ",
      "url": "https://www.benzinga.com/insights/options/25/04/44773955/abbvie-unusual-options-activity",
      "time_published": "20250411T200108",
      "authors": [
        "Benzinga Insights"
      ],
      "summary": "Financial giants have made a conspicuous bearish move on AbbVie. Our analysis of options history for AbbVie ABBV revealed 20 unusual trades. Delving into the details, we found 45% of traders were bullish, while 55% showed bearish tendencies.",
      "banner_image": "https://www.benzinga.com/files/images/story/2025/1744401665_0.png",
      "source": "Benzinga",
      "category_within_source": "Markets",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.413559"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.177409,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "GS",
          "relevance_score": "0.089462",
          "ticker_sentiment_score": "0.005253",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MS",
          "relevance_score": "0.089462",
          "ticker_sentiment_score": "0.005253",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.631282",
          "ticker_sentiment_score": "0.07595",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Spotlight on AbbVie: Analyzing the Surge in Options Activity - AbbVie  ( NYSE:ABBV ) ",
      "url": "https://www.benzinga.com/insights/options/24/11/42250104/spotlight-on-abbvie-analyzing-the-surge-in-options-activity",
      "time_published": "20241129T191541",
      "authors": [
        "Benzinga Insights"
      ],
      "summary": "Investors with a lot of money to spend have taken a bearish stance on AbbVie ABBV. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.",
      "banner_image": "https://www.benzinga.com/files/images/story/2024/1732907738_0.png",
      "source": "Benzinga",
      "category_within_source": "Markets",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.316726"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.195096,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.627711",
          "ticker_sentiment_score": "0.173201",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Why AbbVie Stock Popped While the Market Flopped on Monday",
      "url": "https://www.fool.com/investing/2025/01/27/why-abbvie-stock-popped-while-the-market-flopped-o/",
      "time_published": "20250127T232137",
      "authors": [
        "Eric Volkman"
      ],
      "summary": "Monday was a grim day for a great many stocks, but luckily for its investors, AbbVie ( NYSE: ABBV ) wasn't one of them. The storied pharmaceutical company saw its share price rise by almost 4%, on the back of a pair of pre-earnings price target bumps from analysts.",
      "banner_image": "https://g.foolcdn.com/editorial/images/805468/two-people-in-white-lab-coats-looking-at-a-computer-display.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.24505,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "GS",
          "relevance_score": "0.140896",
          "ticker_sentiment_score": "0.247012",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.62523",
          "ticker_sentiment_score": "0.292601",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Why This Beaten-Down Dividend Stock Is a No-Brainer Buy on the Dip",
      "url": "https://www.fool.com/investing/2024/11/18/why-this-beaten-down-dividend-stock-is-no-brainer/",
      "time_published": "20241118T120000",
      "authors": [
        "Prosper Junior Bakiny"
      ],
      "summary": "Last year, pharmaceutical giant AbbVie ( NYSE: ABBV ) lost patent exclusivity for its biggest cash cow, immunology medicine Humira. The drugmaker has rebounded quite nicely since. AbbVie returned to top-line growth in the second quarter, much earlier than many anticipated.",
      "banner_image": "https://media.ycharts.com/charts/b63c3632776abbc24451d4797e859620.png",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.161647"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.097256,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.624578",
          "ticker_sentiment_score": "0.054928",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Is AbbVie Stock a Buy?",
      "url": "https://www.fool.com/investing/2025/01/24/is-abbvie-stock-a-buy/",
      "time_published": "20250124T104800",
      "authors": [
        "Justin Pope"
      ],
      "summary": "Although AbbVie has lost patent exclusivity for its flagship drug, Humira, the company may soon be bigger and better.",
      "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F803391%2Fabbvie-long-term-sales-projection.png&op=resize&w=700",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.413559"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.818451"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.389474,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.624423",
          "ticker_sentiment_score": "0.601047",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.050465",
          "ticker_sentiment_score": "0.122299",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "AbbVie  ( ABBV )  Stock Moves -0.32%: What You Should Know",
      "url": "https://www.zacks.com/stock/news/2393285/abbvie-abbv-stock-moves--032-what-you-should-know",
      "time_published": "20250107T224519",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "In the most recent trading session, AbbVie (ABBV) closed at $179.53, indicating a -0.32% shift from the previous trading day.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default19.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.917436"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.413559"
        }
      ],
      "overall_sentiment_score": 0.149916,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.624172",
          "ticker_sentiment_score": "0.285955",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "AbbVie  ( ABBV )  Gains As Market Dips: What You Should Know",
      "url": "https://www.zacks.com/stock/news/2390216/abbvie-abbv-gains-as-market-dips-what-you-should-know",
      "time_published": "20241231T224519",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "AbbVie (ABBV) concluded the recent trading session at $177.70, signifying a +0.85% move from its prior day's close.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default212.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.961735"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.365926"
        }
      ],
      "overall_sentiment_score": 0.135657,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.624172",
          "ticker_sentiment_score": "0.251917",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "AbbVie To Present Cancer Trial Data At Upcoming ASCO Event - AbbVie  ( NYSE:ABBV ) ",
      "url": "https://www.benzinga.com/25/05/45621885/abbvie-highlights-cancer-trial-data-presentation-at-upcoming-asco-annual-meeting",
      "time_published": "20250527T152158",
      "authors": [
        "Vandana Singh"
      ],
      "summary": "Temab-A showed a 63% ORR in advanced EGFR-mutated NSCLC; 54% had responses lasting \u22656 months. Pivekimab sunirine achieved 85% ORR and 70% CCR in untreated BPDCN patients, with median CCR duration of 9.8 months. Get stock picks, daily rankings, and pro-level trading tools in one powerful ...",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2025/05/27/Abbvie.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.316726"
        }
      ],
      "overall_sentiment_score": 0.023575,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.622414",
          "ticker_sentiment_score": "0.10364",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "AbbVie Becomes Another Big Pharma To Enter Obesity Treatment Race - GUBRA A S by GUBRA A S  ( OTC:GUBRF ) , AbbVie  ( NYSE:ABBV ) ",
      "url": "https://www.benzinga.com/25/03/44089215/abbvie-becomes-another-big-pharma-to-enter-obesity-treatment-race",
      "time_published": "20250303T190745",
      "authors": [
        "Vandana Singh"
      ],
      "summary": "AbbVie will pay Gubra $350 million upfront, with up to $1.875 billion in milestone payments. GUB014295, an amylin analog for obesity, is currently in Phase 1 trials. Our government trade tracker caught Pelosi's 169% AI winner. Discover how to track all 535 Congress member stock trades today.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2025/03/03/Doctor-Measuring-Obese-Man-Waist-Body-Fa.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        }
      ],
      "overall_sentiment_score": 0.157912,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.173958",
          "ticker_sentiment_score": "0.059533",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.173958",
          "ticker_sentiment_score": "0.059533",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.620664",
          "ticker_sentiment_score": "0.343737",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "AbbVie Falls 8% in 3 Months: Buy, Hold or Sell the Stock?",
      "url": "https://www.zacks.com/stock/news/2396718/abbvie-falls-8-in-3-months-buy-hold-or-sell-the-stock",
      "time_published": "20250114T162200",
      "authors": [
        "Kinjel Shah"
      ],
      "summary": "Investors who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth next year.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/58/608.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.459462"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.714479"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.538269"
        }
      ],
      "overall_sentiment_score": 0.180454,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.077218",
          "ticker_sentiment_score": "0.068198",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.077218",
          "ticker_sentiment_score": "0.068198",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.616996",
          "ticker_sentiment_score": "0.283013",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "AbbVie  ( ABBV )  Stock Sinks As Market Gains: Here's Why",
      "url": "https://www.zacks.com/stock/news/2434422/abbvie-abbv-stock-sinks-as-market-gains-heres-why",
      "time_published": "20250324T214514",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "The latest trading day saw AbbVie (ABBV) settling at $209.17, representing a -0.4% change from its previous close.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default226.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.976913"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.316726"
        }
      ],
      "overall_sentiment_score": 0.160258,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.615462",
          "ticker_sentiment_score": "0.225952",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "AbbVie  ( ABBV )  Stock Dips While Market Gains: Key Facts",
      "url": "https://www.zacks.com/stock/news/2556462/abbvie-abbv-stock-dips-while-market-gains-key-facts",
      "time_published": "20250627T214504",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "AbbVie (ABBV) closed at $182.31 in the latest trading session, marking a -2.4% move from the prior day.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default205.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.938793"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        }
      ],
      "overall_sentiment_score": 0.239124,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.613743",
          "ticker_sentiment_score": "0.333655",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "AbbVie Immunology Portfolio Poised For Growth Through Humira Erosion: Analyst - Johnson & Johnson  ( NYSE:JNJ ) , AbbVie  ( NYSE:ABBV ) ",
      "url": "https://www.benzinga.com/25/04/45050728/abbvies-immunology-portfolio-poised-to-continue-growing-through-humira-erosion-analyst",
      "time_published": "20250428T192742",
      "authors": [
        "Vandana Singh"
      ],
      "summary": "AbbVie Q1 sales rose 8.4% to $13.34 billion, and adjusted EPS grew 6.5% to $2.46, beating Wall Street estimates. Skyrizi sales jumped 70.5% to $3.43 billion, and Rinvoq sales climbed 57.2% to $1.72 billion, exceeding forecasts. Don't face extreme market conditions unprepared.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2025/04/28/Abbvie.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.744043"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.220967,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MS",
          "relevance_score": "0.075874",
          "ticker_sentiment_score": "-0.163007",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.608634",
          "ticker_sentiment_score": "0.177386",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Company News for Apr 28, 2025",
      "url": "https://www.zacks.com/stock/news/2456422/company-news-for-apr-28-2025",
      "time_published": "20250428T091800",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Companies In The News Are: ABBV, SLB, CL, CHTR.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/07/420.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.9545"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.159441,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "SLB",
          "relevance_score": "0.331765",
          "ticker_sentiment_score": "-0.051987",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CL",
          "relevance_score": "0.608634",
          "ticker_sentiment_score": "0.444375",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.608634",
          "ticker_sentiment_score": "0.563457",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "CHTR",
          "relevance_score": "0.608634",
          "ticker_sentiment_score": "-0.09313",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "AbbVie  ( ABBV )  Rises As Market Takes a Dip: Key Facts",
      "url": "https://www.zacks.com/stock/news/2424790/abbvie-abbv-rises-as-market-takes-a-dip-key-facts",
      "time_published": "20250303T224510",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "AbbVie (ABBV) closed the most recent trading day at $211.48, moving +1.17% from the previous trading session.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default156.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.99246"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.365926"
        }
      ],
      "overall_sentiment_score": 0.16334,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.608634",
          "ticker_sentiment_score": "0.242845",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "AbbVie's Pipeline May Be A 2026 Story, But Analyst Likes The Setup Now - AbbVie  ( NYSE:ABBV ) ",
      "url": "https://www.benzinga.com/general/biotech/25/04/44937940/abbvies-pipeline-may-be-a-2026-story-but-analyst-likes-the-setup-now",
      "time_published": "20250422T204812",
      "authors": [
        "Vandana Singh"
      ],
      "summary": "Skyrizi and Rinvoq use in gastroenterology grew over 40% year-over-year. Cantor gave AbbVie an Overweight rating with a $210 price target. Markets are messy-but the right setups can still deliver triple-digit gains. Join Matt Maley live this Wednesday at 6 PM ET to see how he's trading it.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2025/04/22/Abbvie.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.576289"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.365926"
        }
      ],
      "overall_sentiment_score": 0.219002,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.606946",
          "ticker_sentiment_score": "0.180451",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "AbbVie  ( ABBV )  Laps the Stock Market: Here's Why",
      "url": "https://www.zacks.com/stock/news/2572028/abbvie-abbv-laps-the-stock-market-heres-why",
      "time_published": "20250710T214502",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "AbbVie (ABBV) closed the most recent trading day at $195, moving +2.3% from the previous trading session.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default262.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.976913"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.316726"
        }
      ],
      "overall_sentiment_score": 0.241292,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.605266",
          "ticker_sentiment_score": "0.343984",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Can New Cancer Drug Emrelis Drive AbbVie's Oncology Franchise?",
      "url": "https://www.zacks.com/stock/news/2487260/can-new-cancer-drug-emrelis-drive-abbvies-oncology-franchise",
      "time_published": "20250606T131200",
      "authors": [
        "Sundeep Ganoria"
      ],
      "summary": "Emrelis wins FDA approval, marking ABBV's first lung cancer drug and strengthening its oncology reach into solid tumors.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/36/1919.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.451494"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        }
      ],
      "overall_sentiment_score": 0.129583,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.60415",
          "ticker_sentiment_score": "0.239801",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "REGN",
          "relevance_score": "0.222838",
          "ticker_sentiment_score": "0.217956",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "AZN",
          "relevance_score": "0.362858",
          "ticker_sentiment_score": "0.165538",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.075161",
          "ticker_sentiment_score": "0.051675",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "AbbVie Raises Profit Outlook But Flags Tariff Risks In Pharma Sector - AbbVie  ( NYSE:ABBV ) ",
      "url": "https://www.benzinga.com/25/04/45011116/abbvie-q1-earnings-come-ahead-of-expectations-ceo-says-well-positioned-for-long-term",
      "time_published": "20250425T145132",
      "authors": [
        "Vandana Singh"
      ],
      "summary": "AbbVie's Q1 EPS of $2.46 beat estimates; sales rose 8.4% to $13.34 billion, topping consensus of $12.92 billion. Skyrizi and Rinvoq sales surged 70.5% and 57.2%, while Humira dropped 50.6%. Feel unsure about the market's next move?",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2025/04/25/Abbvie.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.996718"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.365926"
        }
      ],
      "overall_sentiment_score": 0.189549,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.60326",
          "ticker_sentiment_score": "0.409208",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Why AbbVie Stock Was Getting Mashed on Monday",
      "url": "https://www.fool.com/investing/2024/11/11/why-abbvie-stock-was-getting-mashed-on-monday/",
      "time_published": "20241111T202246",
      "authors": [
        "Eric Volkman"
      ],
      "summary": "A splashy recent acquisition by the company might not be panning out.",
      "banner_image": "https://g.foolcdn.com/editorial/images/797456/person-in-a-lab-gazing-into-a-microscope.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        }
      ],
      "overall_sentiment_score": 0.026567,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.600602",
          "ticker_sentiment_score": "0.053913",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "AbbVie Rises 8% Since Q4 Earnings: Buy, Hold or Sell the Stock?",
      "url": "https://www.zacks.com/stock/news/2410394/abbvie-rises-8-since-q4-earnings-buy-hold-or-sell-the-stock",
      "time_published": "20250205T172100",
      "authors": [
        "Kinjel Shah"
      ],
      "summary": "Those who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth in 2025.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/52/873.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.316726"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.917436"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.249043,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.070414",
          "ticker_sentiment_score": "0.046311",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.070414",
          "ticker_sentiment_score": "0.046311",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.598794",
          "ticker_sentiment_score": "0.311372",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "AbbVie  ( ABBV )  Stock Moves -1.64%: What You Should Know",
      "url": "https://www.zacks.com/stock/news/2452163/abbvie-abbv-stock-moves--164-what-you-should-know",
      "time_published": "20250421T214533",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "In the closing of the recent trading day, AbbVie (ABBV) stood at $170.16, denoting a -1.64% change from the preceding trading day.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default241.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.95493"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.316726"
        }
      ],
      "overall_sentiment_score": 0.131437,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.596978",
          "ticker_sentiment_score": "0.217637",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "ABBV to Boost Immunology Pipeline With Capstan Buyout for $2.1B",
      "url": "https://www.zacks.com/stock/news/2559650/abbv-to-boost-immunology-pipeline-with-capstan-buyout-for-21b",
      "time_published": "20250701T140500",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "AbbVie's $2.1 billion Capstan deal brings a novel in-vivo CAR-T therapy and tLNP platform to boost its immunology pipeline.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/36/1919.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.990678"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.238615,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "EXEL",
          "relevance_score": "0.259727",
          "ticker_sentiment_score": "0.241889",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.592742",
          "ticker_sentiment_score": "0.265816",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "SPRO",
          "relevance_score": "0.259727",
          "ticker_sentiment_score": "0.089994",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PBYI",
          "relevance_score": "0.196344",
          "ticker_sentiment_score": "0.191962",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "AbbVie and Simcere Zaiming Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma - AbbVie  ( NYSE:ABBV ) ",
      "url": "https://www.benzinga.com/pressreleases/25/01/n42945176/abbvie-and-simcere-zaiming-announce-partnership-to-develop-a-novel-trispecific-antibody-candidate-",
      "time_published": "20250113T140000",
      "authors": [
        "PRNewswire"
      ],
      "summary": "NORTH CHICAGO, Ill. and SHANGHAI, Jan. 13, 2025 /PRNewswire/ -- AbbVie ABBV and Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd ( HKEX: 2096 ) today announced an option to license agreement to develop SIM0500, an investigational new drug candidate.",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.250215,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "SMHGF",
          "relevance_score": "0.101154",
          "ticker_sentiment_score": "0.118092",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GOOG",
          "relevance_score": "0.050679",
          "ticker_sentiment_score": "0.144872",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "META",
          "relevance_score": "0.050679",
          "ticker_sentiment_score": "0.144872",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.59135",
          "ticker_sentiment_score": "0.329295",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Company News for Nov 12, 2024",
      "url": "https://www.zacks.com/stock/news/2368572/company-news-for-nov-12-2024",
      "time_published": "20241112T121300",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Companies In The News Are: ICL, ARMK, ABBV, SPNS.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/d5/8276.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.576289"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": -0.00491,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ARMK",
          "relevance_score": "0.588876",
          "ticker_sentiment_score": "-0.298045",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.588876",
          "ticker_sentiment_score": "0.154717",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ICL",
          "relevance_score": "0.588876",
          "ticker_sentiment_score": "0.414847",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "SPNS",
          "relevance_score": "0.588876",
          "ticker_sentiment_score": "-0.333173",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "AbbVie Q4 Earnings Loom: Buy or Sell ABBV Stock Ahead of Results?",
      "url": "https://www.zacks.com/stock/news/2404394/abbvie-q4-earnings-loom-buy-or-sell-abbv-stock-ahead-of-results",
      "time_published": "20250128T125700",
      "authors": [
        "Sundeep Ganoria"
      ],
      "summary": "Investors' focus will likely be on the sales performance of ABBV's blockbuster immunology drugs, Rinvoq and Skyrizi, when it reports Q4 results later this week.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/36/1919.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.990678"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        }
      ],
      "overall_sentiment_score": 0.282427,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.586141",
          "ticker_sentiment_score": "0.443977",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "AbbVie Stock Rises 16% Year to Date: Time to Buy, Sell or Hold?",
      "url": "https://www.zacks.com/stock/news/2439036/abbvie-stock-rises-16-year-to-date-time-to-buy-sell-or-hold",
      "time_published": "20250402T140600",
      "authors": [
        "Kinjel Shah"
      ],
      "summary": "Those who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth in 2025.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ca/2357.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.459462"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.875462"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.248787,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.108303",
          "ticker_sentiment_score": "0.107201",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.108303",
          "ticker_sentiment_score": "0.107201",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.58604",
          "ticker_sentiment_score": "0.336046",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Why AbbVie Stock Topped the Market Today",
      "url": "https://www.fool.com/investing/2025/04/25/why-abbvie-stock-topped-the-market-today/",
      "time_published": "20250425T211726",
      "authors": [
        "Eric Volkman"
      ],
      "summary": "A pair of convincing quarterly earnings beats -- not to mention a profitability guidance raise -- made AbbVie ( NYSE: ABBV ) stock an investor darling on Friday. The pharmaceutical company's performance pushed its stock to a more than 3% gain on the day, well higher than the 0.6% bump of the ...",
      "banner_image": "https://g.foolcdn.com/editorial/images/816182/two-people-participating-in-a-telehealth-session.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.997874"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        }
      ],
      "overall_sentiment_score": 0.432519,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.582526",
          "ticker_sentiment_score": "0.635415",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Regenxbio's Gene Therapy Outlook Dims As Rival Treatments Gain Ground, Goldman Sachs Warns - Regenxbio  ( NASDAQ:RGNX ) ",
      "url": "https://www.benzinga.com/general/biotech/25/02/43638468/regenxbios-gene-therapy-outlook-dims-as-rival-treatments-gain-ground-goldman-sachs-warns",
      "time_published": "20250211T202040",
      "authors": [
        "Vandana Singh"
      ],
      "summary": "Goldman Sachs downgraded Regenxbio, cutting the price target due to concerns over ABBV-RGX-314's market appeal. Data for ABBV-RGX-314 in wet AMD is expected in 2026, while Phase 3 program for diabetic retinopathy with suprachoroidal delivery is planned",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2025/02/11/Trauma-To-The-Eye.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        }
      ],
      "overall_sentiment_score": 0.116703,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "EYPT",
          "relevance_score": "0.071145",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RGNX",
          "relevance_score": "0.524949",
          "ticker_sentiment_score": "-0.11036",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.578355",
          "ticker_sentiment_score": "-0.017548",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GS",
          "relevance_score": "0.211191",
          "ticker_sentiment_score": "-0.081664",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "EWTX",
          "relevance_score": "0.071145",
          "ticker_sentiment_score": "0.24783",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "NPNKF",
          "relevance_score": "0.071145",
          "ticker_sentiment_score": "-0.118686",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "AbbVie Scores FDA Approval For Its Blockbuster Drug Rinvoq To Treat Type of Arthritis - AbbVie  ( NYSE:ABBV ) ",
      "url": "https://www.benzinga.com/general/biotech/25/04/45079377/abbvie-scores-fda-approval-for-its-blockbuster-drug-rinvoq-to-treat-type-of-arthritis",
      "time_published": "20250429T183410",
      "authors": [
        "Vandana Singh"
      ],
      "summary": "46.4% on Rinvoq hit sustained remission vs. 29.0% on placebo in Phase 3 giant cell arteritis trial. Rinvoq Q1 sales hit $1.72 billion, rising 57.2% year-over-year. Today's manic market swings are creating the perfect setup for Matt's next volatility trade. Get his next trade alert for free, ...",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2025/04/29/Abbvie_0.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.614606"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        }
      ],
      "overall_sentiment_score": 0.18214,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.575407",
          "ticker_sentiment_score": "0.0726",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "AbbVie  ( ABBV )  Stock Moves -0.22%: What You Should Know",
      "url": "https://www.zacks.com/stock/news/2403220/abbvie-abbv-stock-moves--022-what-you-should-know",
      "time_published": "20250124T224523",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "AbbVie (ABBV) closed at $170.30 in the latest trading session, marking a -0.22% move from the prior day.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default273.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "IPO",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.972476"
        }
      ],
      "overall_sentiment_score": 0.115431,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.571903",
          "ticker_sentiment_score": "0.163295",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "AbbVie Stock Down Around 13% in 3 Months: Time to Buy the Dip?",
      "url": "https://www.zacks.com/stock/news/2478809/abbvie-stock-down-around-13-in-3-months-time-to-buy-the-dip",
      "time_published": "20250529T133100",
      "authors": [
        "Kinjel Shah"
      ],
      "summary": "ABBV drops 12.6% in three months, but rising Skyrizi and Rinvoq sales, pipeline strength, and 2025 growth outlook support staying invested.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/62/5473.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.999365"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.875462"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.225618,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.104988",
          "ticker_sentiment_score": "0.101725",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.104988",
          "ticker_sentiment_score": "0.101725",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.571516",
          "ticker_sentiment_score": "0.312254",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Will AbbVie's Growing Oncology Portfolio Aid Top-line Growth?",
      "url": "https://www.zacks.com/stock/news/2543882/will-abbvies-growing-oncology-portfolio-aid-top-line-growth",
      "time_published": "20250624T122200",
      "authors": [
        "Sundeep Ganoria"
      ],
      "summary": "ABBV's growing oncology portfolio, now spanning five therapies, is helping offset Imbruvica's sales decline and boost top-line growth.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/31/1512.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.451494"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        }
      ],
      "overall_sentiment_score": 0.0,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "SKXJF",
          "relevance_score": "0.062761",
          "ticker_sentiment_score": "0.068015",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.568953",
          "ticker_sentiment_score": "0.034826",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DSKYF",
          "relevance_score": "0.062761",
          "ticker_sentiment_score": "0.068015",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AZN",
          "relevance_score": "0.247208",
          "ticker_sentiment_score": "-0.043412",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.062761",
          "ticker_sentiment_score": "0.05006",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.125134",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "AbbVie Cuts 2024 EPS Guidance to Include Acquisition Costs",
      "url": "https://www.zacks.com/stock/news/2392657/abbvie-cuts-2024-eps-guidance-to-include-acquisition-costs",
      "time_published": "20250107T115100",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "ABBV lowers adjusted earnings guidance for 2024 from $10.90-$10.94 per share to $10.02-$10.06 after incurring $1.6 billion in acquisition expenses in Q4.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/31/1512.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999759"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.097376,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.567144",
          "ticker_sentiment_score": "0.122731",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CTMX",
          "relevance_score": "0.078099",
          "ticker_sentiment_score": "-0.006262",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SPRO",
          "relevance_score": "0.155451",
          "ticker_sentiment_score": "0.072438",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CSTL",
          "relevance_score": "0.305058",
          "ticker_sentiment_score": "0.157379",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "PBYI",
          "relevance_score": "0.155451",
          "ticker_sentiment_score": "0.072438",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Why the Market Dipped But AbbVie  ( ABBV )  Gained Today",
      "url": "https://www.zacks.com/stock/news/2398554/why-the-market-dipped-but-abbvie-abbv-gained-today",
      "time_published": "20250116T224520",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "In the most recent trading session, AbbVie (ABBV) closed at $173.70, indicating a +1.37% shift from the previous trading day.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default154.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.928769"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.133636,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.566715",
          "ticker_sentiment_score": "0.268464",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "My Favorite Dividend King to Buy in November",
      "url": "https://www.fool.com/investing/2024/11/09/abbvie/",
      "time_published": "20241109T104800",
      "authors": [
        "Keith Speights"
      ],
      "summary": "This Dividend King truly wears the crown.",
      "banner_image": "https://g.foolcdn.com/editorial/images/796634/king-chess-piece-held-by-woman.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.962106"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.614606"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.335795,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.564693",
          "ticker_sentiment_score": "0.458944",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.05654",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Company News for Feb 3, 2025",
      "url": "https://www.zacks.com/stock/news/2408287/company-news-for-feb-3-2025",
      "time_published": "20250203T142700",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Companies in The News Are: ...",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/a4/2005.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.890401"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.279485,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.56415",
          "ticker_sentiment_score": "0.328536",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "CHTR",
          "relevance_score": "0.56415",
          "ticker_sentiment_score": "0.312294",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "CVX",
          "relevance_score": "0.56415",
          "ticker_sentiment_score": "0.123187",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ARCB",
          "relevance_score": "0.56415",
          "ticker_sentiment_score": "0.69843",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Do Options Traders Know Something About AbbVie  ( ABBV )  Stock We Don't?",
      "url": "https://www.zacks.com/stock/news/2403728/do-options-traders-know-something-about-abbvie-abbv-stock-we-dont",
      "time_published": "20250127T141700",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Investors need to pay close attention to AbbVie (ABBV) stock based on the movements in the options market lately.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/36/1919.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        }
      ],
      "overall_sentiment_score": 0.047874,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.56296",
          "ticker_sentiment_score": "0.051412",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Here's How to Play AbbVie Stock as it Enters the Obesity Space",
      "url": "https://www.zacks.com/stock/news/2425779/heres-how-to-play-abbvie-stock-as-it-enters-the-obesity-space",
      "time_published": "20250305T133800",
      "authors": [
        "Kinjel Shah"
      ],
      "summary": "Those who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth in 2025.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/39/612.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.316726"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.714479"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.252777,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.102158",
          "ticker_sentiment_score": "0.099136",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.558895",
          "ticker_sentiment_score": "0.291728",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "GS",
          "relevance_score": "0.034136",
          "ticker_sentiment_score": "0.11017",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AZN",
          "relevance_score": "0.034136",
          "ticker_sentiment_score": "0.11017",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.102158",
          "ticker_sentiment_score": "0.099136",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.034136",
          "ticker_sentiment_score": "0.11017",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Simcere Zaiming and AbbVie Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma - AbbVie  ( NYSE:ABBV ) ",
      "url": "https://www.benzinga.com/pressreleases/25/01/n42945394/simcere-zaiming-and-abbvie-announce-partnership-to-develop-a-novel-trispecific-antibody-candidate-",
      "time_published": "20250113T140500",
      "authors": [
        "PRNewswire"
      ],
      "summary": "SHANGHAI and NORTH CHICAGO, Ill., Jan. 13, 2025 /PRNewswire/ -- Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd ( HKEX: 2096 ) and AbbVie Inc. ABBV today announced an option to license agreement to develop SIM0500, an investigational new drug candidate.",
      "banner_image": "https://mma.prnewswire.com/media/2596532/Cooperation_Simcere_Zaiming_Abbvie.jpg",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.257065,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "SMHGF",
          "relevance_score": "0.100941",
          "ticker_sentiment_score": "0.119142",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GOOG",
          "relevance_score": "0.050572",
          "ticker_sentiment_score": "0.147875",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "META",
          "relevance_score": "0.050572",
          "ticker_sentiment_score": "0.147875",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.553402",
          "ticker_sentiment_score": "0.330636",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Why AbbVie  ( ABBV )  Dipped More Than Broader Market Today",
      "url": "https://www.zacks.com/stock/news/2428649/why-abbvie-abbv-dipped-more-than-broader-market-today",
      "time_published": "20250311T214516",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "In the latest trading session, AbbVie (ABBV) closed at $213.59, marking a -1.42% move from the previous day.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default340.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.938793"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        }
      ],
      "overall_sentiment_score": 0.070867,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.548363",
          "ticker_sentiment_score": "0.07366",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "5 Must-See Stocks with Perfect Earnings Charts",
      "url": "https://www.zacks.com/stock/news/2404156/5-must-see-stocks-with-perfect-earnings-charts",
      "time_published": "20250127T223100",
      "authors": [
        "Tracey Ryniec"
      ],
      "summary": "These 5 companies have not missed on earnings in 5 years. That's an impressive feat with the pandemic hitting in 2020.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default9.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.25"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.25"
        },
        {
          "topic": "IPO",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.25"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.538269"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.25"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.972193"
        }
      ],
      "overall_sentiment_score": 0.276831,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MSFT",
          "relevance_score": "0.074926",
          "ticker_sentiment_score": "0.134388",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "META",
          "relevance_score": "0.074926",
          "ticker_sentiment_score": "0.134388",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TSLA",
          "relevance_score": "0.074926",
          "ticker_sentiment_score": "0.134388",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SBUX",
          "relevance_score": "0.074926",
          "ticker_sentiment_score": "0.134388",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GM",
          "relevance_score": "0.074926",
          "ticker_sentiment_score": "0.134388",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "V",
          "relevance_score": "0.293214",
          "ticker_sentiment_score": "0.460939",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "NOW",
          "relevance_score": "0.361802",
          "ticker_sentiment_score": "0.206596",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "CL",
          "relevance_score": "0.489659",
          "ticker_sentiment_score": "0.454403",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.54816",
          "ticker_sentiment_score": "0.483936",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ICNB",
          "relevance_score": "0.074926",
          "ticker_sentiment_score": "0.220759",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "TSCO",
          "relevance_score": "0.074926",
          "ticker_sentiment_score": "0.134388",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DHR",
          "relevance_score": "0.361802",
          "ticker_sentiment_score": "0.153149",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Here's Why AbbVie  ( ABBV )  Fell More Than Broader Market",
      "url": "https://www.zacks.com/stock/news/2507949/heres-why-abbvie-abbv-fell-more-than-broader-market",
      "time_published": "20250617T214503",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "In the most recent trading session, AbbVie (ABBV) closed at $185.48, indicating a -2.82% shift from the previous trading day.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default350.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.961735"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.365926"
        }
      ],
      "overall_sentiment_score": 0.164828,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.546745",
          "ticker_sentiment_score": "0.1867",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Is AbbVie Stock a Buy Now?",
      "url": "https://www.fool.com/investing/2025/02/15/is-abbvie-stock-a-buy/",
      "time_published": "20250215T095500",
      "authors": [
        "Dan Victor"
      ],
      "summary": "AbbVie ( NYSE: ABBV ) closed out a pivotal 2024 with an excellent fourth-quarter earnings report. For the period ended Dec. 31, the biopharmaceuticals giant delivered 6% sales growth and $2.12 in adjusted earnings per share ( EPS ) , with both metrics exceeding initial guidance.",
      "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F806909%2Fabbvie-bullish-stock-outlook-2025.jpg&op=resize&w=700",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999999"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.316726"
        }
      ],
      "overall_sentiment_score": 0.409951,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.544495",
          "ticker_sentiment_score": "0.569423",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "AbbVie  ( ABBV )  Stock Moves -0.29%: What You Should Know",
      "url": "https://www.zacks.com/stock/news/2431776/abbvie-abbv-stock-moves--029-what-you-should-know",
      "time_published": "20250318T214516",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "AbbVie (ABBV) closed the most recent trading day at $213.85, moving -0.29% from the previous trading session.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default186.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.961735"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        }
      ],
      "overall_sentiment_score": 0.143303,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.543535",
          "ticker_sentiment_score": "0.204155",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "AbbVie  ( ABBV )  Stock Declines While Market Improves: Some Information for Investors",
      "url": "https://www.zacks.com/stock/news/2384199/abbvie-abbv-stock-declines-while-market-improves-some-information-for-investors",
      "time_published": "20241216T224516",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "In the most recent trading session, AbbVie (ABBV) closed at $171.63, indicating a -1% shift from the previous trading day.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default251.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.961735"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        }
      ],
      "overall_sentiment_score": 0.217213,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.538782",
          "ticker_sentiment_score": "0.330087",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "AbbVie  ( ABBV )  Increases Despite Market Slip: Here's What You Need to Know",
      "url": "https://www.zacks.com/stock/news/2486417/abbvie-abbv-increases-despite-market-slip-heres-what-you-need-to-know",
      "time_published": "20250605T214514",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "The latest trading day saw AbbVie (ABBV) settling at $187.66, representing a +0.17% change from its previous close.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default48.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.961735"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.316726"
        }
      ],
      "overall_sentiment_score": 0.177331,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.532556",
          "ticker_sentiment_score": "0.238472",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "AbbVie Builds Momentum With Immunology Growth, Goldman Remains Positive - AbbVie  ( NYSE:ABBV ) ",
      "url": "https://www.benzinga.com/25/01/43244657/goldman-sachs-raises-abbvies-price-forecast-sees-opportunity-despite-challenges",
      "time_published": "20250127T181300",
      "authors": [
        "Vandana Singh"
      ],
      "summary": "AbbVie forecasts 7% growth in 2025 and 10-11% in 2026-2027 for its immunology segment. Goldman Sachs raises AbbVie's price target to $208, citing Skyrizi and Rinvoq as key growth drivers. Get the Real Story Behind Every Major Earnings Report AbbVie Inc.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2025/01/27/abbvie-shutter.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.77141"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.302334,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "GS",
          "relevance_score": "0.368773",
          "ticker_sentiment_score": "0.274458",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.528475",
          "ticker_sentiment_score": "0.125728",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "What's Going On With Bristol-Myers Squibb Shares Monday? - Bristol-Myers Squibb  ( NYSE:BMY ) ",
      "url": "https://www.benzinga.com/trading-ideas/movers/24/11/41885969/whats-going-on-with-bristol-myers-squibb-shares-monday",
      "time_published": "20241111T184824",
      "authors": [
        "Dylan Berman"
      ],
      "summary": "Bristol-Myers Squibb Co BMY shares are trading higher Monday. The stock appears to be reacting positively after AbbVie Inc ABBV announced that its Phase 2 EMPOWER trials did not meet their primary endpoints.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2024/11/11/02-LVL-Exterior-Sign-101520-media.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        }
      ],
      "overall_sentiment_score": 0.330251,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.52706",
          "ticker_sentiment_score": "0.210718",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "BMY",
          "relevance_score": "0.610896",
          "ticker_sentiment_score": "0.546991",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Why AbbVie Stock Trounced the Market Today",
      "url": "https://www.fool.com/investing/2025/04/28/why-abbvie-stock-trounced-the-market-today/",
      "time_published": "20250428T230200",
      "authors": [
        "Eric Volkman"
      ],
      "summary": "The positive, post-earnings momentum lifting AbbVie's ( NYSE: ABBV ) stock price continued on Monday. The veteran healthcare company's shares booked a gain of more than 3% during the trading session. The key reason was a pair of bullish analyst notes on its business.",
      "banner_image": "https://g.foolcdn.com/editorial/images/816408/two-people-in-white-lab-coats-looking-at-a-computer-display.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.714479"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.796627"
        }
      ],
      "overall_sentiment_score": 0.318976,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.138464",
          "ticker_sentiment_score": "0.108871",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.514619",
          "ticker_sentiment_score": "0.461821",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "2 Excellent Dividend Stocks to Buy on the Dip",
      "url": "https://www.fool.com/investing/2024/12/23/2-excellent-dividend-stocks-to-buy-on-the-dip/",
      "time_published": "20241223T093200",
      "authors": [
        "Prosper Junior Bakiny"
      ],
      "summary": "AbbVie ( NYSE: ABBV ) and Amgen ( NASDAQ: AMGN ) have a lot in common. They are both leading drugmakers and have strong dividend track records. Both also recently saw their shares fall significantly in one day, following unimpressive clinical data for otherwise promising candidates.Despite their ...",
      "banner_image": "https://media.ycharts.com/charts/4bcb02efb3ae79099f939b6b71ea724e.png",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.108179"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        }
      ],
      "overall_sentiment_score": 0.26662,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.512596",
          "ticker_sentiment_score": "0.31906",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.055364",
          "ticker_sentiment_score": "0.085",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AMGN",
          "relevance_score": "0.373112",
          "ticker_sentiment_score": "0.395561",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "AZN",
          "relevance_score": "0.055364",
          "ticker_sentiment_score": "0.077088",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.055364",
          "ticker_sentiment_score": "0.21904",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Will AbbVie's Acquisition Spree Aid Pipeline Growth?",
      "url": "https://www.zacks.com/stock/news/2560194/will-abbvies-acquisition-spree-aid-pipeline-growth",
      "time_published": "20250702T124600",
      "authors": [
        "Sundeep Ganoria"
      ],
      "summary": "ABBV's $2.1 billion Capstan deal and 20+ recent acquisitions sharpen its pipeline edge across immunology and beyond.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/36/1919.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.495866"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.650727"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.257766,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "VIGL",
          "relevance_score": "0.05387",
          "ticker_sentiment_score": "0.171913",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.05387",
          "ticker_sentiment_score": "0.050946",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LLY",
          "relevance_score": "0.213048",
          "ticker_sentiment_score": "0.147094",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.500753",
          "ticker_sentiment_score": "0.311652",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "BPMC",
          "relevance_score": "0.05387",
          "ticker_sentiment_score": "0.171913",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "VERV",
          "relevance_score": "0.05387",
          "ticker_sentiment_score": "0.116736",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SNY",
          "relevance_score": "0.213048",
          "ticker_sentiment_score": "0.279623",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "2 High-Yield Dividend Stocks to Buy in May and Hold Forever",
      "url": "https://www.fool.com/investing/2025/05/10/2-high-yield-dividend-stocks-to-buy-in-may-and-hol/",
      "time_published": "20250510T124500",
      "authors": [
        "Prosper Junior Bakiny"
      ],
      "summary": "When investing in dividend stocks, paying attention to the right things is essential. A high yield can be attractive, but the most critical factor to consider is a company's underlying operations.Businesses that are solid enough to perform well over extended periods, while consistently raising ...",
      "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F817503%2Felderly-person-sitting-on-a-bed.jpg&op=resize&w=700",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.986714"
        }
      ],
      "overall_sentiment_score": 0.296452,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.499254",
          "ticker_sentiment_score": "0.472311",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.059636",
          "ticker_sentiment_score": "0.008014",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GILD",
          "relevance_score": "0.235252",
          "ticker_sentiment_score": "0.299975",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Have Skyrizi and Rinvoq Successfully Saved AbbVie From Humira LoE?",
      "url": "https://www.zacks.com/stock/news/2492211/have-skyrizi-and-rinvoq-successfully-saved-abbvie-from-humira-loe",
      "time_published": "20250610T130200",
      "authors": [
        "Sundeep Ganoria"
      ],
      "summary": "ABBV eyes $24.7 billion from Skyrizi and Rinvoq in 2025 as ex-Humira growth offsets sharp sales drop post-U.S. patent loss.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/31/1512.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.875462"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        }
      ],
      "overall_sentiment_score": 0.275354,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.262522",
          "ticker_sentiment_score": "0.217825",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.497391",
          "ticker_sentiment_score": "0.298315",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.066784",
          "ticker_sentiment_score": "0.046184",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.1331",
          "ticker_sentiment_score": "0.105275",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Is Trending Stock AbbVie Inc.  ( ABBV )  a Buy Now?",
      "url": "https://www.zacks.com/stock/news/2478081/is-trending-stock-abbvie-inc-abbv-a-buy-now",
      "time_published": "20250528T130015",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default71.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.503496"
        }
      ],
      "overall_sentiment_score": 0.195103,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.493128",
          "ticker_sentiment_score": "0.08394",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "AbbVie, Bitcoin And An Energy Stock On CNBC's 'Final Trades' - Baker Hughes  ( NASDAQ:BKR ) , AbbVie  ( NYSE:ABBV ) ",
      "url": "https://www.benzinga.com/24/11/42009260/abbvie-bitcoin-and-an-energy-stock-on-cnbcs-final-trades",
      "time_published": "20241115T141840",
      "authors": [
        "Avi Kapoor"
      ],
      "summary": "On CNBC's \"Halftime Report Final Trades,\" Jason Snipe of Odyssey Capital Advisors picked AbbVie Inc. ABBV. On Monday, AbbVie said two trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia failed two Phase 2 trials.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2024/11/15/abbvie-shutter.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.451494"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.12762,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "BKR",
          "relevance_score": "0.592742",
          "ticker_sentiment_score": "0.31361",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.492659",
          "ticker_sentiment_score": "-0.045156",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "C",
          "relevance_score": "0.131643",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CRYPTO:BTC",
          "relevance_score": "0.492659",
          "ticker_sentiment_score": "0.006495",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Investors Heavily Search AbbVie Inc.  ( ABBV ) : Here is What You Need to Know",
      "url": "https://www.zacks.com/stock/news/2443186/investors-heavily-search-abbvie-inc-abbv-here-is-what-you-need-to-know",
      "time_published": "20250410T130016",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default286.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999999"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.54554"
        }
      ],
      "overall_sentiment_score": 0.216986,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.49219",
          "ticker_sentiment_score": "0.120229",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "ALDX Up as FDA Accepts Resubmitted NDA for Eye Drug Reproxalap",
      "url": "https://www.zacks.com/stock/news/2372244/aldx-up-as-fda-accepts-resubmitted-nda-for-eye-drug-reproxalap",
      "time_published": "20241119T150000",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "The FDA accepts Aldeyra's resubmitted NDA for topical ocular reproxalap to treat the signs and symptoms of dry eye disease. Stock rises.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/49/1007.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.769861"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.142283,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ALDX",
          "relevance_score": "0.231332",
          "ticker_sentiment_score": "0.157292",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "IMCR",
          "relevance_score": "0.174587",
          "ticker_sentiment_score": "0.029381",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.491878",
          "ticker_sentiment_score": "0.406234",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "CSTL",
          "relevance_score": "0.231332",
          "ticker_sentiment_score": "0.091154",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "AbbVie Inc.  ( ABBV )  Is a Trending Stock: Facts to Know Before Betting on It",
      "url": "https://www.zacks.com/stock/news/2457638/abbvie-inc-abbv-is-a-trending-stock-facts-to-know-before-betting-on-it",
      "time_published": "20250429T130015",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default340.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.5855"
        }
      ],
      "overall_sentiment_score": 0.215177,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.491255",
          "ticker_sentiment_score": "0.117302",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "AbbVie Inc.  ( ABBV )  is Attracting Investor Attention: Here is What You Should Know",
      "url": "https://www.zacks.com/stock/news/2436053/abbvie-inc-abbv-is-attracting-investor-attention-here-is-what-you-should-know",
      "time_published": "20250327T130016",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default306.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999999"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.5855"
        }
      ],
      "overall_sentiment_score": 0.219428,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.491255",
          "ticker_sentiment_score": "0.132308",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "AbbVie Inc.  ( ABBV )  is Attracting Investor Attention: Here is What You Should Know",
      "url": "https://www.zacks.com/stock/news/2396466/abbvie-inc-abbv-is-attracting-investor-attention-here-is-what-you-should-know",
      "time_published": "20250114T140022",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default10.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.5855"
        }
      ],
      "overall_sentiment_score": 0.199851,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.491255",
          "ticker_sentiment_score": "0.096089",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Is Trending Stock AbbVie Inc.  ( ABBV )  a Buy Now?",
      "url": "https://www.zacks.com/stock/news/2372624/is-trending-stock-abbvie-inc-abbv-a-buy-now",
      "time_published": "20241120T140018",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default46.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.54554"
        }
      ],
      "overall_sentiment_score": 0.202136,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.491255",
          "ticker_sentiment_score": "0.083741",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "AbbVie  ( ABBV )  Gains As Market Dips: What You Should Know",
      "url": "https://www.zacks.com/stock/news/2495069/abbvie-abbv-gains-as-market-dips-what-you-should-know",
      "time_published": "20250611T214506",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "The latest trading day saw AbbVie (ABBV) settling at $191.50, representing a +1.06% change from its previous close.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default105.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.938793"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        }
      ],
      "overall_sentiment_score": 0.181266,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.490323",
          "ticker_sentiment_score": "0.262549",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "AbbVie Inc.  ( ABBV )  Is a Trending Stock: Facts to Know Before Betting on It",
      "url": "https://www.zacks.com/stock/news/2421796/abbvie-inc-abbv-is-a-trending-stock-facts-to-know-before-betting-on-it",
      "time_published": "20250226T140019",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default226.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999999"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.5855"
        }
      ],
      "overall_sentiment_score": 0.256916,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.490323",
          "ticker_sentiment_score": "0.156034",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Investors Heavily Search AbbVie Inc.  ( ABBV ) : Here is What You Need to Know",
      "url": "https://www.zacks.com/stock/news/2385145/investors-heavily-search-abbvie-inc-abbv-here-is-what-you-need-to-know",
      "time_published": "20241218T140022",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default150.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.54554"
        }
      ],
      "overall_sentiment_score": 0.206379,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.490323",
          "ticker_sentiment_score": "0.132523",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "AbbVie Inc.  ( ABBV )  Is a Trending Stock: Facts to Know Before Betting on It",
      "url": "https://www.zacks.com/stock/news/2389939/abbvie-inc-abbv-is-a-trending-stock-facts-to-know-before-betting-on-it",
      "time_published": "20241231T140020",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default165.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999999"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.5855"
        }
      ],
      "overall_sentiment_score": 0.233296,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.489394",
          "ticker_sentiment_score": "0.141458",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Why Is AbbVie Stock Trading Higher On Thursday? - AstraZeneca  ( NASDAQ:AZN ) , AbbVie  ( NYSE:ABBV ) ",
      "url": "https://www.benzinga.com/markets/biotech/25/07/46352525/why-is-abbvie-stock-trading-higher-on-thursday",
      "time_published": "20250710T183641",
      "authors": [
        "Vandana Singh"
      ],
      "summary": "IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation Inc., and AbbVie Inc. ABBV, on Thursday, announced an exclusive licensing agreement for IGI's lead investigational asset, ISB 2001, developed using IGI's proprietary BEAT protein platform, for oncology and ...",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2025/07/10/Abbvie.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        }
      ],
      "overall_sentiment_score": 0.18428,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.488777",
          "ticker_sentiment_score": "0.405452",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "AZN",
          "relevance_score": "0.257442",
          "ticker_sentiment_score": "-0.102789",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FTRK",
          "relevance_score": "0.087185",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BMY",
          "relevance_score": "0.257442",
          "ticker_sentiment_score": "0.065316",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BNTX",
          "relevance_score": "0.338582",
          "ticker_sentiment_score": "0.08126",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SMMT",
          "relevance_score": "0.173333",
          "ticker_sentiment_score": "0.089021",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "AbbVie Inc.  ( ABBV )  is Attracting Investor Attention: Here is What You Should Know",
      "url": "https://www.zacks.com/stock/news/2470284/abbvie-inc-abbv-is-attracting-investor-attention-here-is-what-you-should-know",
      "time_published": "20250514T130015",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default53.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.54554"
        }
      ],
      "overall_sentiment_score": 0.224291,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.488469",
          "ticker_sentiment_score": "0.120001",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "AbbVie's Early Parkinson's Candidate Hits Primary Goal In Pivotal Late-Stage Study - AbbVie  ( NYSE:ABBV ) ",
      "url": "https://www.benzinga.com/24/12/42393882/abbvies-early-parkinsons-candidate-hits-primary-goal-in-pivotal-late-stage-study",
      "time_published": "20241209T161639",
      "authors": [
        "Vandana Singh"
      ],
      "summary": "On Monday, AbbVie Inc. ABBV revealed topline results from its pivotal Phase 3 TEMPO-2 trial, which evaluated investigational tavapadon as a flexible-dose monotherapy in early Parkinson's disease. Tavapadon is the first and only D1/D5 partial agonist under investigation as a once-daily treatment ...",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2024/12/09/abbvie-shutter.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.127621,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.487546",
          "ticker_sentiment_score": "-0.106768",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Buy, Sell or Hold ABBV Stock? Key Tips Ahead of Q1 Earnings",
      "url": "https://www.zacks.com/stock/news/2453604/buy-sell-or-hold-abbv-stock-key-tips-ahead-of-q1-earnings",
      "time_published": "20250423T123400",
      "authors": [
        "Sundeep Ganoria"
      ],
      "summary": "Investors will likely focus on the sales performance of AbbVie's blockbuster immunology drugs, Rinvoq and Skyrizi, when it reports Q1 results later this week.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/31/1512.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.998917"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        }
      ],
      "overall_sentiment_score": 0.26602,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.486415",
          "ticker_sentiment_score": "0.22931",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Investors Heavily Search AbbVie Inc.  ( ABBV ) : Here is What You Need to Know",
      "url": "https://www.zacks.com/stock/news/2544220/investors-heavily-search-abbvie-inc-abbv-here-is-what-you-need-to-know",
      "time_published": "20250624T130004",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default279.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.54554"
        }
      ],
      "overall_sentiment_score": 0.226787,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.485711",
          "ticker_sentiment_score": "0.122622",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Here is What to Know Beyond Why AbbVie Inc.  ( ABBV )  is a Trending Stock",
      "url": "https://www.zacks.com/stock/news/2494142/here-is-what-to-know-beyond-why-abbvie-inc-abbv-is-a-trending-stock",
      "time_published": "20250611T130005",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default157.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.503496"
        }
      ],
      "overall_sentiment_score": 0.208448,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.485711",
          "ticker_sentiment_score": "0.12264",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Investors Heavily Search AbbVie Inc.  ( ABBV ) : Here is What You Need to Know",
      "url": "https://www.zacks.com/stock/news/2410934/investors-heavily-search-abbvie-inc-abbv-here-is-what-you-need-to-know",
      "time_published": "20250206T140029",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default258.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999999"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.5855"
        }
      ],
      "overall_sentiment_score": 0.246227,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.485711",
          "ticker_sentiment_score": "0.137496",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Jim Cramer: This Health Care Stock Is A 'Winner,' Buy Bitcoin Instead Of Coinbase - AbbVie  ( NYSE:ABBV ) ",
      "url": "https://www.benzinga.com/trading-ideas/long-ideas/25/02/43493237/jim-cramer-this-health-care-stock-is-a-winner-buy-bitcoin-instead-of-coinbase",
      "time_published": "20250205T132011",
      "authors": [
        "Avi Kapoor"
      ],
      "summary": "MongoDB is a trade and not an investment, Cramer says. Jim Cramer recommends buying AbbVie , saying it's \"just a gem.\" Next: Access Our New, Shockingly Simple 'Alert System' On CNBC's \"Mad Money Lightning Round,\" Jim Cramer recommended buying AbbVie Inc.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2025/02/05/Jim-Cramer-Photo-by-s-bukley-on-Shutters.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.682689"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.199672,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "SYK",
          "relevance_score": "0.205807",
          "ticker_sentiment_score": "0.273458",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "MDB",
          "relevance_score": "0.485711",
          "ticker_sentiment_score": "0.108733",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.485711",
          "ticker_sentiment_score": "0.142222",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CRNC",
          "relevance_score": "0.398148",
          "ticker_sentiment_score": "0.21654",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "MDT",
          "relevance_score": "0.205807",
          "ticker_sentiment_score": "0.273458",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "TEM",
          "relevance_score": "0.304428",
          "ticker_sentiment_score": "0.238014",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "COIN",
          "relevance_score": "0.398148",
          "ticker_sentiment_score": "0.222751",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "CRYPTO:BTC",
          "relevance_score": "0.205807",
          "ticker_sentiment_score": "0.455072",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Here is What to Know Beyond Why AbbVie Inc.  ( ABBV )  is a Trending Stock",
      "url": "https://www.zacks.com/stock/news/2378140/here-is-what-to-know-beyond-why-abbvie-inc-abbv-is-a-trending-stock",
      "time_published": "20241203T140018",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default304.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999999"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.5855"
        }
      ],
      "overall_sentiment_score": 0.217351,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.484798",
          "ticker_sentiment_score": "0.107282",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "AbbVie Stock Declines as Schizophrenia Studies Fail, BMY Gains",
      "url": "https://www.zacks.com/stock/news/2368841/abbvie-stock-declines-as-schizophrenia-studies-fail-bmy-gains",
      "time_published": "20241112T143000",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "ABBV stock tumbles 13% after two mid-stage schizophrenia studies on emraclidine fail to meet their primary endpoint. BMY stock rises.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/31/1512.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.451494"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.128822,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ALLO",
          "relevance_score": "0.254973",
          "ticker_sentiment_score": "0.123272",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.48457",
          "ticker_sentiment_score": "0.174106",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "BIIB",
          "relevance_score": "0.129168",
          "ticker_sentiment_score": "0.075917",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BMY",
          "relevance_score": "0.192694",
          "ticker_sentiment_score": "-0.166421",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "ABBV vs. MRK: Which Drug Giant is a Better Buy Now?",
      "url": "https://www.zacks.com/stock/news/2448518/abbv-vs-mrk-which-drug-giant-is-a-better-buy-now",
      "time_published": "20250414T143700",
      "authors": [
        "Kinjel Shah"
      ],
      "summary": "Both ABBV and MRK are leading pharmaceutical companies with strong portfolios in oncology and immunology.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f5/952.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.459462"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.998663"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.196468,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.068896",
          "ticker_sentiment_score": "0.07423",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.068896",
          "ticker_sentiment_score": "0.07423",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.483283",
          "ticker_sentiment_score": "0.413509",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "AbbVie Inc.  ( ABBV )  Is a Trending Stock: Facts to Know Before Betting on It",
      "url": "https://www.zacks.com/stock/news/2565584/abbvie-inc-abbv-is-a-trending-stock-facts-to-know-before-betting-on-it",
      "time_published": "20250707T130004",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default157.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999999"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.54554"
        }
      ],
      "overall_sentiment_score": 0.22379,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.482982",
          "ticker_sentiment_score": "0.13701",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "AbbVie Inc.  ( ABBV )  is Attracting Investor Attention: Here is What You Should Know",
      "url": "https://www.zacks.com/stock/news/2429512/abbvie-inc-abbv-is-attracting-investor-attention-here-is-what-you-should-know",
      "time_published": "20250313T130018",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default67.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.5855"
        }
      ],
      "overall_sentiment_score": 0.214767,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.482982",
          "ticker_sentiment_score": "0.154565",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "ABBV or BMY: Which Biopharma Giant Has Better Prospects for Now?",
      "url": "https://www.zacks.com/stock/news/2573739/abbv-or-bmy-which-biopharma-giant-has-better-prospects-for-now",
      "time_published": "20250711T140000",
      "authors": [
        "Ekta Bagri"
      ],
      "summary": "AbbVie edges ahead of Bristol Myers with strong Skyrizi and Rinvoq growth, offsetting Humira declines and portfolio headwinds.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/charts/4a/113096.jpg?v=258032489",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.992549"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.495866"
        }
      ],
      "overall_sentiment_score": 0.356849,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.478494",
          "ticker_sentiment_score": "0.413105",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "BMY",
          "relevance_score": "0.299478",
          "ticker_sentiment_score": "0.231552",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "AbbVie  ( ABBV )  Rises Yet Lags Behind Market: Some Facts Worth Knowing",
      "url": "https://www.zacks.com/stock/news/2387728/abbvie-abbv-rises-yet-lags-behind-market-some-facts-worth-knowing",
      "time_published": "20241224T224519",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "In the latest trading session, AbbVie (ABBV) closed at $180, marking a +0.9% move from the previous day.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default204.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.976913"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        }
      ],
      "overall_sentiment_score": 0.204024,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.47379",
          "ticker_sentiment_score": "0.326283",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "The Zacks Analyst Blog Highlights Johnson & Johnson and AbbVie",
      "url": "https://www.zacks.com/stock/news/2464083/the-zacks-analyst-blog-highlights-johnson-johnson-and-abbvie",
      "time_published": "20250507T124800",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Johnson & Johnson and AbbVie are part of the Zacks top Analyst Blog.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ff/1612.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.413559"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.99676"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.262143,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.464534",
          "ticker_sentiment_score": "0.464018",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.173126",
          "ticker_sentiment_score": "0.208679",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "2 Dividend Stocks to Buy for a Lifetime of Passive Income",
      "url": "https://www.fool.com/investing/2025/03/07/2-dividend-stocks-to-buy-for-a-lifetime-of-passive/",
      "time_published": "20250307T100300",
      "authors": [
        "Prosper Junior Bakiny"
      ],
      "summary": "Dividend investors don't buy shares of companies hoping they will suspend their payouts soon. The longer a corporation maintains its dividend program, the more attractive it is to income seekers, all else being equal.",
      "banner_image": "https://g.foolcdn.com/editorial/images/809353/physician-giving-medicine-to-elderly-patient.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.684621"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        }
      ],
      "overall_sentiment_score": 0.2653,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "AMGN",
          "relevance_score": "0.506613",
          "ticker_sentiment_score": "0.37115",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.462395",
          "ticker_sentiment_score": "0.324747",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.054607",
          "ticker_sentiment_score": "0.114801",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "AbbVie  ( ABBV )  Stock Moves -1.73%: What You Should Know",
      "url": "https://www.zacks.com/stock/news/2440084/abbvie-abbv-stock-moves--173-what-you-should-know",
      "time_published": "20250403T214515",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "In the closing of the recent trading day, AbbVie (ABBV) stood at $201.64, denoting a -1.73% change from the preceding trading day.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default169.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.976913"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        }
      ],
      "overall_sentiment_score": 0.159238,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.455525",
          "ticker_sentiment_score": "0.21532",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "ABBV Enters Obesity Bandwagon, Inks $2.2B Licensing Deal for Amylin Drug",
      "url": "https://www.zacks.com/stock/news/2424213/abbv-enters-obesity-bandwagon-inks-22b-licensing-deal-for-amylin-drug",
      "time_published": "20250303T135900",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Per the terms of the deal, AbbVie will lead the development and commercialization of the obesity drug developed by Gubra.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/31/1512.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.249816,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.237551",
          "ticker_sentiment_score": "0.119525",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "VKTX",
          "relevance_score": "0.179343",
          "ticker_sentiment_score": "0.015852",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.454511",
          "ticker_sentiment_score": "0.377141",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "GS",
          "relevance_score": "0.060236",
          "ticker_sentiment_score": "0.117066",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.237551",
          "ticker_sentiment_score": "0.151925",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "The Smartest Dividend Stocks to Buy With $300 Right Now",
      "url": "https://www.fool.com/investing/2025/07/12/the-smartest-dividend-stocks-to-buy-with-300-right/",
      "time_published": "20250712T091500",
      "authors": [
        "Keith Speights"
      ],
      "summary": "Are dividend stocks only for investors nearing or in retirement? Not at all. Consider that more than half of the S&P 500's ( SNPINDEX: ^GSPC ) total return over the last 50 years was due to reinvesting dividends. Importantly, you don't need much money to begin making money with dividend stocks, ...",
      "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F824521%2Ftransmission-lines-with-2-workers.jpg&op=resize&w=700",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.99977"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.938238"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.263994,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ENB",
          "relevance_score": "0.40225",
          "ticker_sentiment_score": "0.232249",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.453501",
          "ticker_sentiment_score": "0.375682",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "D",
          "relevance_score": "0.11983",
          "ticker_sentiment_score": "0.197653",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ENGS",
          "relevance_score": "0.060085",
          "ticker_sentiment_score": "0.106276",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "AbbVie's Schizophrenia Failure Disappoints But Analysts Show Confidence In Immunology Portfolio - AbbVie  ( NYSE:ABBV ) , Bristol-Myers Squibb  ( NYSE:BMY ) ",
      "url": "https://www.benzinga.com/general/biotech/24/11/41915173/abbvies-schizophrenia-failure-disappoints-but-analysts-show-confidence-in-immunology-portfolio",
      "time_published": "20241112T185244",
      "authors": [
        "Vandana Singh"
      ],
      "summary": "On Monday, AbbVie Inc ABBV stock plunged after two trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia failed two Phase 2 trials.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2024/11/12/abbvie-shutter.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        }
      ],
      "overall_sentiment_score": 0.18048,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.4499",
          "ticker_sentiment_score": "-0.174759",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "BMY",
          "relevance_score": "0.188928",
          "ticker_sentiment_score": "-0.071461",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NBIX",
          "relevance_score": "0.188928",
          "ticker_sentiment_score": "-0.035889",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "2 Top Dividend Stocks to Buy and Hold Through 2025 and Beyond",
      "url": "https://www.fool.com/investing/2024/12/19/2-top-dividend-stocks-to-buy-and-hold-through-2025/",
      "time_published": "20241219T110000",
      "authors": [
        "Prosper Junior Bakiny"
      ],
      "summary": "What will be the hottest investing trend on Wall Street next year? Maybe artificial intelligence will keep up its momentum, or perhaps interest in weight loss-focused pharmaceutical companies will increase. Whatever the answer is, it probably won't be dividend investing.",
      "banner_image": "https://g.foolcdn.com/editorial/images/800762/nurse-holding-patients-hands.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.214378"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.839681"
        }
      ],
      "overall_sentiment_score": 0.334899,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.448842",
          "ticker_sentiment_score": "0.366317",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.40375",
          "ticker_sentiment_score": "0.40553",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "The Stock Market Is Soaring but These 2 Stocks Are Still Dirt Cheap Buys",
      "url": "https://www.fool.com/investing/2024/11/23/the-stock-market-is-soaring-but-these-2-stocks-are/",
      "time_published": "20241123T141700",
      "authors": [
        "David Jagielski"
      ],
      "summary": "Earlier this month, the S&P 500 hit a record high of more than 6,000 for the first time ever. Based on that, you might assume that stocks may be too expensive to buy right now as the average stock in the index is trading at more than 25 times earnings. However, there are still many deals out ...",
      "banner_image": "https://g.foolcdn.com/editorial/images/798057/investor-at-home-looking-at-multiple-charts.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.503496"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.998663"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.209403,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.445352",
          "ticker_sentiment_score": "0.267213",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "CCZ",
          "relevance_score": "0.25726",
          "ticker_sentiment_score": "0.165724",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "JNJ vs. ABBV: Which Pharma Powerhouse Has Better Growth Prospects?",
      "url": "https://www.zacks.com/stock/news/2462793/jnj-vs-abbv-which-pharma-powerhouse-has-better-growth-prospects",
      "time_published": "20250506T122600",
      "authors": [
        "Kinjel Shah"
      ],
      "summary": "Both JNJ and ABBV expect their sales and profits to improve in 2025.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/charts/a5/102873.jpg?v=1609400312",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.365926"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.99676"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.25364,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.445179",
          "ticker_sentiment_score": "0.462869",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.125134",
          "ticker_sentiment_score": "0.186355",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Is the Trump Administration About to Cause AbbVie, Eli Lilly, and Johnson & Johnson Stocks to Crash?",
      "url": "https://www.fool.com/investing/2025/05/04/is-the-trump-administration-about-to-cause-abbvie/",
      "time_published": "20250504T084900",
      "authors": [
        "Keith Speights"
      ],
      "summary": "Investors often view Pharmaceutical stocks as safe havens during periods of market turbulence. Stock market volatility or even economic downturns usually don't affect drugmakers' underlying businesses much, if at all.",
      "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F816808%2Fpills-dollar-sign.jpg&op=resize&w=700",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.614606"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.650727"
        }
      ],
      "overall_sentiment_score": -0.026512,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.404925",
          "ticker_sentiment_score": "0.011249",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.445179",
          "ticker_sentiment_score": "0.002989",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.320676",
          "ticker_sentiment_score": "0.040274",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "AbbVie's Rinvoq Gets EU Nod for 8th Indication Giant Cell Arteritis",
      "url": "https://www.zacks.com/stock/news/2441800/abbvies-rinvoq-gets-eu-nod-for-8th-indication-giant-cell-arteritis",
      "time_published": "20250408T131500",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "European Commission approves ABBV's Rinvoq for its eighth indication, giant cell arteritis.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/85/906.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.232304,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.231884",
          "ticker_sentiment_score": "0.08105",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.444595",
          "ticker_sentiment_score": "0.430428",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "The Zacks Analyst Blog Merck and AbbVie",
      "url": "https://www.zacks.com/stock/news/2448875/the-zacks-analyst-blog-merck-and-abbvie",
      "time_published": "20250415T105400",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Merck and AbbVie are included in this Analyst Blog.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ef/472.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.365926"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.976913"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.235273,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.443626",
          "ticker_sentiment_score": "0.414817",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "AbbVie Stock Slips As $9 Billion Schizophrenia Studies Flunk, Bristol-Myers Stock Surges - AbbVie  ( NYSE:ABBV ) , Bristol-Myers Squibb  ( NYSE:BMY ) ",
      "url": "https://www.benzinga.com/general/biotech/24/11/41881546/abbvie-9billion-schizophrenia-studies-bristol-myers-stock-surges",
      "time_published": "20241111T152731",
      "authors": [
        "Vandana Singh"
      ],
      "summary": "On Monday, AbbVie Inc ABBV stock is trading lower after it released data from its two Phase 2 EMPOWER trials of emraclidine for schizophrenia. The trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2024/11/11/abbvie-shutter.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.316726"
        }
      ],
      "overall_sentiment_score": 0.09307,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.443626",
          "ticker_sentiment_score": "-0.165105",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "BMY",
          "relevance_score": "0.275867",
          "ticker_sentiment_score": "0.107884",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Strength Seen in Sanofi  ( SNY ) : Can Its 6.7% Jump Turn into More Strength?",
      "url": "https://www.zacks.com/stock/news/2385022/strength-seen-in-sanofi-sny-can-its-67-jump-turn-into-more-strength",
      "time_published": "20241218T113300",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Sanofi (SNY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default138.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.976913"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.316726"
        }
      ],
      "overall_sentiment_score": 0.170586,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.441698",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SNY",
          "relevance_score": "0.535653",
          "ticker_sentiment_score": "0.164605",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "LLY vs. ABBV: Which Pharma Powerhouse is the Better Bet?",
      "url": "https://www.zacks.com/stock/news/2519897/lly-vs-abbv-which-pharma-powerhouse-is-the-better-bet",
      "time_published": "20250620T132800",
      "authors": [
        "Kinjel Shah"
      ],
      "summary": "LLY's blockbuster obesity drugs fuel rapid growth but ABBV's valuation and pipeline may offer safer short-term upside.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/07/905.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.962106"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.995973"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.308322,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.458654",
          "ticker_sentiment_score": "0.330213",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "CVS",
          "relevance_score": "0.02866",
          "ticker_sentiment_score": "0.123233",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.434607",
          "ticker_sentiment_score": "0.49523",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "HIMS",
          "relevance_score": "0.02866",
          "ticker_sentiment_score": "0.123233",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.114273",
          "ticker_sentiment_score": "0.114339",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "2 Unstoppable Dividend Stocks to Buy If There's a Stock Market Sell-Off",
      "url": "https://www.fool.com/investing/2024/12/22/unstoppable-dividend-stocks-buy-if-sell-off/",
      "time_published": "20241222T115000",
      "authors": [
        "Dan Victor"
      ],
      "summary": "Stock market investors have plenty of reasons to celebrate as 2024 comes to a close. The S&P 500 index set multiple new record highs during the year, delivering a spectacular 25% return year to date amid a resilient economy and strong corporate earnings.That being said, it's always prudent to be ...",
      "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F801558%2Fdividend-healthcare-stocks-2025-bullish.jpg&op=resize&w=700",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.451494"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.997405"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.576289"
        }
      ],
      "overall_sentiment_score": 0.384712,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "PFE",
          "relevance_score": "0.331765",
          "ticker_sentiment_score": "0.383236",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.432291",
          "ticker_sentiment_score": "0.541209",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "2 Dividend Stocks to Buy for Decades of Passive Income",
      "url": "https://www.fool.com/investing/2025/07/06/2-dividend-stocks-to-buy-for-decades-of-passive-in/",
      "time_published": "20250706T124500",
      "authors": [
        "Prosper Junior Bakiny"
      ],
      "summary": "In 2013, AbbVie ( NYSE: ABBV ) became a publicly traded corporation after splitting from its former parent company, Abbott Laboratories ( NYSE: ABT ) . Since then, both have produced strong returns and have been great picks for income-seeking investors, thanks to consistent payout hikes.",
      "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F823870%2Fdoctor-with-patient-talking.jpg&op=resize&w=700",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.961735"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.375049,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.430251",
          "ticker_sentiment_score": "0.441601",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.386626",
          "ticker_sentiment_score": "0.479903",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Got $1,500? 3 Healthcare Stocks to Buy and Hold Forever",
      "url": "https://www.fool.com/investing/2025/01/21/got-1500-3-healthcare-stocks-to-buy-and-hold-forev/",
      "time_published": "20250121T232212",
      "authors": [
        "Keith Speights"
      ],
      "summary": "Many products sold by companies aren't must-have items. However, healthcare is a necessity. And the healthcare sector is poised to grow over the next decade and beyond with aging populations around the world.These factors make healthcare stocks a great addition to investors' portfolios.",
      "banner_image": "https://g.foolcdn.com/editorial/images/804777/young-woman-smiling-hands-behind-head.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.796627"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.650727"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.260001,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "VRTX",
          "relevance_score": "0.100518",
          "ticker_sentiment_score": "0.295848",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ISRG",
          "relevance_score": "0.247838",
          "ticker_sentiment_score": "0.301324",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.430251",
          "ticker_sentiment_score": "0.349378",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "2 Top Dividend Stocks That Could Set You Up for Life",
      "url": "https://www.fool.com/investing/2025/04/09/2-top-dividend-stocks-that-could-set-you-up-for/",
      "time_published": "20250409T110000",
      "authors": [
        "Prosper Junior Bakiny"
      ],
      "summary": "With equity markets in shambles due to President Donald Trump's trade policies, now might be as good a time as any to invest in excellent dividend stocks.For one, dividend-paying companies tend to be more resilient than their non-dividend-paying peers.",
      "banner_image": "https://media.ycharts.com/charts/d41e49999bc35bce83ff5adf491d2753.png",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "IPO",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.980922"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.77141"
        }
      ],
      "overall_sentiment_score": 0.217191,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.428632",
          "ticker_sentiment_score": "0.260848",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.112532",
          "ticker_sentiment_score": "0.027786",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GILD",
          "relevance_score": "0.3796",
          "ticker_sentiment_score": "0.25684",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Will AbbVie  ( ABBV )  Beat Estimates Again in Its Next Earnings Report?",
      "url": "https://www.zacks.com/stock/news/2393174/will-abbvie-abbv-beat-estimates-again-in-its-next-earnings-report",
      "time_published": "20250107T171014",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "AbbVie (ABBV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default11.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.99998"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.322635,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.424317",
          "ticker_sentiment_score": "0.462528",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Is Bayer  ( BAYRY )  Outperforming Other Medical Stocks This Year?",
      "url": "https://www.zacks.com/stock/news/2427275/is-bayer-bayry-outperforming-other-medical-stocks-this-year",
      "time_published": "20250307T144005",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Here is how Bayer Aktiengesellschaft (BAYRY) and AbbVie (ABBV) have performed compared to their sector so far this year.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default195.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.614606"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        }
      ],
      "overall_sentiment_score": 0.246521,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.423251",
          "ticker_sentiment_score": "0.223262",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "AbbVie Stock Up 9.2% After Key Signal",
      "url": "https://www.benzinga.com/markets/equities/25/04/44731565/abbvie-stock-up-9-2-after-key-signal",
      "time_published": "20250410T114333",
      "authors": [
        "Finit"
      ],
      "summary": "ALERT COMES AT LOW POINT FOR ABBV AND SIGNALS MAJOR REVERSAL OF OVER 15 POINTS Today, AbbVie, Inc. ( ABBV ) experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions.",
      "banner_image": "https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/09200742/Screenshot-2025-04-09-at-4.03.09%E2%80%AFPM-1009x1024.png",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.623304"
        }
      ],
      "overall_sentiment_score": 0.282245,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.421485",
          "ticker_sentiment_score": "0.328691",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Genmab to Vigorously Defend Alleged Claims of Trade Secret Misappropriation by AbbVie Inc.",
      "url": "https://www.globenewswire.com/news-release/2025/03/22/3047383/0/en/Genmab-to-Vigorously-Defend-Alleged-Claims-of-Trade-Secret-Misappropriation-by-AbbVie-Inc.html",
      "time_published": "20250322T032900",
      "authors": [
        "Genmab A/S"
      ],
      "summary": "Company Announcement ...",
      "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/368a5dab-dfc5-4e1d-bfa6-2af5e5216fce",
      "source": "GlobeNewswire",
      "category_within_source": "n/a",
      "source_domain": "www.globenewswire.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": -0.038646,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "GMAB",
          "relevance_score": "0.636698",
          "ticker_sentiment_score": "-0.022138",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.421485",
          "ticker_sentiment_score": "-0.034255",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Salesforce, AbbVie, Intuitive Surgical And An Industrial Stock On CNBC's 'Final Trades' - AbbVie  ( NYSE:ABBV ) , Salesforce  ( NYSE:CRM ) ",
      "url": "https://www.benzinga.com/trading-ideas/long-ideas/25/04/44947422/salesforce-abbvie-intuitive-surgical-and-an-industrial-stock-on-cnbcs-final-trades",
      "time_published": "20250423T123638",
      "authors": [
        "Avi Kapoor"
      ],
      "summary": "Rob Sechan picks Salesforce as his final trade. Joshua Brown is staying long on 3M Company. Feel unsure about the market's next move? Copy trade alerts from Matt Maley-a Wall Street veteran who consistently finds profits in volatile markets. Claim your 7-day free trial now.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2025/04/23/Fort-Lauderdale--Fla---usa---April-15--2.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.875462"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.130402,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "MMM",
          "relevance_score": "0.321673",
          "ticker_sentiment_score": "0.230921",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ISRG",
          "relevance_score": "0.419733",
          "ticker_sentiment_score": "0.026013",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.419733",
          "ticker_sentiment_score": "0.149496",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Pharma Stock Roundup: NVS, ABBV M&A Deals, FDA Nod to RHHBY, PFE Drugs",
      "url": "https://www.zacks.com/stock/news/2416025/pharma-stock-roundup-nvs-abbv-ma-deals-fda-nod-to-rhhby-pfe-drugs",
      "time_published": "20250214T130300",
      "authors": [
        "Kinjel Shah"
      ],
      "summary": "NVS and ABBV announce small M&A deals. FDA approves the expanded use of PFE and RHHBY's drugs.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/07/905.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.316726"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.047988,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.184363",
          "ticker_sentiment_score": "-0.103232",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "XLO",
          "relevance_score": "0.061949",
          "ticker_sentiment_score": "0.042254",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.413587",
          "ticker_sentiment_score": "-0.101069",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BX",
          "relevance_score": "0.061949",
          "ticker_sentiment_score": "0.061005",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SNY",
          "relevance_score": "0.302429",
          "ticker_sentiment_score": "-0.167767",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever",
      "url": "https://www.fool.com/investing/2025/07/05/want-decades-of-passive-income-3-stocks-to-buy-now/",
      "time_published": "20250705T094100",
      "authors": [
        "Keith Speights"
      ],
      "summary": "There's a strong parallel between investing for passive income and planting an apple tree. Both require some work up front. But if all goes well, you can reap the fruits of those labors ( literally, in the case of the apple tree ) for years afterward.Of course, there are some potential pitfalls.",
      "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F823590%2Fpassive-income.jpg&op=resize&w=700",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.858979"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.360215"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.321757,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ENB",
          "relevance_score": "0.365294",
          "ticker_sentiment_score": "0.350273",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.412861",
          "ticker_sentiment_score": "0.431858",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.054114",
          "ticker_sentiment_score": "0.081766",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "O",
          "relevance_score": "0.265666",
          "ticker_sentiment_score": "0.29213",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "AbbVie's Elahere Cuts Death Risk By 32%, Shows Consistent Survival Benefit In Long-Term Analysis For Certain Ovarian Cancer Patients - AbbVie  ( NYSE:ABBV ) ",
      "url": "https://www.benzinga.com/general/biotech/25/03/44361847/abbvies-elahere-cuts-death-risk-by-32-shows-consistent-survival-benefit-in-long-term-analysis-for",
      "time_published": "20250317T180223",
      "authors": [
        "Vandana Singh"
      ],
      "summary": "Elahere shows a 37% lower risk of tumor progression or death vs. chemotherapy, with a median PFS of 5.59 months vs. 3.98 months. Patients on Elahere have a median overall survival of 16.85 months, a 32% lower risk of death vs. chemotherapy's 13.34 months.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2025/03/17/Senior-Woman--Hug-Or-Medical-Caregiver-I.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        }
      ],
      "overall_sentiment_score": 0.049145,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.412861",
          "ticker_sentiment_score": "-0.039455",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "AbbVie Beats on Q4 Earnings & Sales, Raises Sales View for Key Drugs",
      "url": "https://www.zacks.com/stock/news/2407813/abbvie-beats-on-q4-earnings-sales-raises-sales-view-for-key-drugs",
      "time_published": "20250131T182200",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "ABBV's fourth-quarter earnings and sales beat estimates. Management raises the 2027 forecast for newer immunology drugs to more than $31 billion.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/31/1512.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999981"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.108694,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.412707",
          "ticker_sentiment_score": "0.277825",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.078611",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever",
      "url": "https://www.fool.com/investing/2024/11/30/want-decades-of-passive-income-3-stocks-to-buy-now/",
      "time_published": "20241130T104100",
      "authors": [
        "Keith Speights"
      ],
      "summary": "What's better than receiving passive income? Enjoying it for decades.Generating long-term passive income is easier than you might think. Here are three stocks to buy now and hold forever for a lifetime of dividends.Let's start with some bona fide dividend royalty.",
      "banner_image": "https://g.foolcdn.com/editorial/images/799307/passive-income.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.365926"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.650727"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.338842,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MFCSF",
          "relevance_score": "0.061159",
          "ticker_sentiment_score": "0.221149",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.408791",
          "ticker_sentiment_score": "0.341068",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "VZ",
          "relevance_score": "0.182047",
          "ticker_sentiment_score": "0.358505",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "O",
          "relevance_score": "0.182047",
          "ticker_sentiment_score": "0.144005",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "3 No-Brainer Healthcare Stocks to Buy With $1,000 Right Now",
      "url": "https://www.fool.com/investing/2025/03/14/3-no-brainer-healthcare-stocks-to-buy-with-1000-ri/",
      "time_published": "20250314T095100",
      "authors": [
        "Keith Speights"
      ],
      "summary": "Many investors view the healthcare sector as a safe haven when the stock market is turbulent. That's understandable. The demand for healthcare products and services typically holds up very well regardless of what's happening with the market or the economy.Some healthcare stocks are better picks ...",
      "banner_image": "https://g.foolcdn.com/editorial/images/810914/light-bulbs-with-dollar-sign-person-looking-up.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.451494"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.796627"
        }
      ],
      "overall_sentiment_score": 0.273695,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "VRTX",
          "relevance_score": "0.12165",
          "ticker_sentiment_score": "0.186264",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "KNSA",
          "relevance_score": "0.12165",
          "ticker_sentiment_score": "0.09687",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.407844",
          "ticker_sentiment_score": "0.354826",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Want $1 Million in Retirement? 3 Stocks to Buy Now and Hold for Decades.",
      "url": "https://www.fool.com/investing/2025/03/31/want-1-million-in-retirement-3-stocks-to-buy-now-a/",
      "time_published": "20250331T085300",
      "authors": [
        "Keith Speights"
      ],
      "summary": "Building a retirement portfolio of $1 million or more is within reach for many Americans. The primary things you'll need are time and money to invest.Do you want $1 million in retirement? There's no guarantee that you'll be able to achieve the goal, but your chances will be much higher if you ...",
      "banner_image": "https://g.foolcdn.com/editorial/images/812889/hands-behind-head-young-woman.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "IPO",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        }
      ],
      "overall_sentiment_score": 0.278335,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "AKESF",
          "relevance_score": "0.106305",
          "ticker_sentiment_score": "0.020401",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.407019",
          "ticker_sentiment_score": "0.32123",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ISRG",
          "relevance_score": "0.210731",
          "ticker_sentiment_score": "0.181202",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "HCSG",
          "relevance_score": "0.053271",
          "ticker_sentiment_score": "0.132948",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SMMT",
          "relevance_score": "0.106305",
          "ticker_sentiment_score": "0.366469",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "3 Stocks With Mouthwatering Dividends You Can Buy Right Now",
      "url": "https://www.fool.com/investing/2025/06/08/3-stocks-with-mouthwatering-dividends-you-can-buy/",
      "time_published": "20250608T103500",
      "authors": [
        "David Jagielski",
        "and Prosper Junior Bakiny",
        "Keith Speights"
      ],
      "summary": "How would you like to get paid every quarter ( and sometimes every month ) to own a stock? That's exactly what happens when you invest in dividend stocks. Sometimes, the amount you are paid to own these stocks can be very attractive.Three Motley Fool contributors believe they've found stocks you ...",
      "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F820734%2Fdividends-blackboard-sketch-doodle.jpg&op=resize&w=700",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.614606"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.999922"
        }
      ],
      "overall_sentiment_score": 0.206089,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "PFE",
          "relevance_score": "0.187463",
          "ticker_sentiment_score": "0.071217",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.40638",
          "ticker_sentiment_score": "0.27082",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "BMY",
          "relevance_score": "0.187463",
          "ticker_sentiment_score": "0.011081",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "3 High-Yielding Dividend Stocks That Could Be Ideal Investments for Retirees",
      "url": "https://www.fool.com/investing/2025/01/14/3-high-yielding-dividend-stocks-that-could-be-idea/",
      "time_published": "20250114T101500",
      "authors": [
        "David Jagielski"
      ],
      "summary": "If you're a retiree looking for dependable and reliable dividend income, there are many quality stocks out there that can be suitable options for your portfolio. The stocks I've listed below pay above-average yields, grow their dividends on a regular basis, and aren't volatile investments.",
      "banner_image": "https://g.foolcdn.com/editorial/images/803651/senior-couple-looking-at-a-laptop.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.5855"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.5"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.436332,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.405963",
          "ticker_sentiment_score": "0.491821",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.060694",
          "ticker_sentiment_score": "0.161035",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "KO",
          "relevance_score": "0.457566",
          "ticker_sentiment_score": "0.528621",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "PG",
          "relevance_score": "0.352223",
          "ticker_sentiment_score": "0.578296",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "2 No-Brainer Dividend Stocks to Buy With $250 in 2025",
      "url": "https://www.fool.com/investing/2025/01/06/2-no-brainer-dividend-stocks-to-buy-with-250-in-20/",
      "time_published": "20250106T091700",
      "authors": [
        "Cory Renauer"
      ],
      "summary": "When it comes to dividend investing, there are two basic paths you can take. You could seek out businesses that are raising their payouts at a rapid pace, but these stocks tend to offer low yields. The other basic option available to dividend investors is to buy stocks with really high yields.",
      "banner_image": "https://g.foolcdn.com/editorial/images/802887/individual-investors-at-home-getty.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.999956"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.495866"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.188554,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "EXR",
          "relevance_score": "0.047185",
          "ticker_sentiment_score": "0.164874",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.405651",
          "ticker_sentiment_score": "0.316273",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.047185",
          "ticker_sentiment_score": "0.107689",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "AbbVie  ( ABBV )  Q4 Earnings and Revenues Surpass Estimates",
      "url": "https://www.zacks.com/stock/news/2407358/abbvie-abbv-q4-earnings-and-revenues-surpass-estimates",
      "time_published": "20250131T134503",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "AbbVie (ABBV) delivered earnings and revenue surprises of 1.41% and 1.56%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default328.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999997"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        }
      ],
      "overall_sentiment_score": 0.141514,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.40348",
          "ticker_sentiment_score": "0.146419",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "AbbVie  ( ABBV )  Q1 Earnings and Revenues Beat Estimates",
      "url": "https://www.zacks.com/stock/news/2455646/abbvie-abbv-q1-earnings-and-revenues-beat-estimates",
      "time_published": "20250425T125502",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "AbbVie (ABBV) delivered earnings and revenue surprises of 2.93% and 3.39%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default90.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999997"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        }
      ],
      "overall_sentiment_score": 0.152789,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.139669",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.402403",
          "ticker_sentiment_score": "0.132932",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Got $500? 2 Healthcare Stocks to Buy and Hold Forever",
      "url": "https://www.fool.com/investing/2025/06/28/got-500-2-healthcare-stocks-to-buy-and-hold-foreve/",
      "time_published": "20250628T094900",
      "authors": [
        "Keith Speights"
      ],
      "summary": "I don't know if we'll be riding in personal aircraft 20 years from now, like George Jetson did in the cartoon TV series. I don't know if artificial intelligence ( AI ) will replace millions of jobs. But there's one thing I'm quite confident about: We'll still need healthcare products and services ...",
      "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F822817%2Fyoung-woman-smiling-hands-behind-head.jpg&op=resize&w=700",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.684621"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.360215"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.238245,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.401331",
          "ticker_sentiment_score": "0.173218",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.119532",
          "ticker_sentiment_score": "0.128994",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Meta, TJX, Taiwan Semiconductor Manufacturing And A Health Care Stock: CNBC's 'Final Trades' - Meta Platforms  ( NASDAQ:META ) , AbbVie  ( NYSE:ABBV ) ",
      "url": "https://www.benzinga.com/trading-ideas/long-ideas/25/04/44787339/meta-tjx-taiwan-semiconductor-manufacturing-and-a-health-care-stock-cnbcs-final-trades",
      "time_published": "20250414T124057",
      "authors": [
        "Avi Kapoor"
      ],
      "summary": "Brenda Vingiello says Meta Platforms is going to be a winner in the overall advertising. Kevin Simpson of Capital Wealth Planning says TJX is a standout name in a tough retail environment. China's new tariffs just reignited the same market patterns that led to triple- and quadruple-digit wins ...",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2025/04/14/Fort-Lauderdale--Fla---usa---April-15--2.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.2"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.2"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.2"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.2"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.2"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.34801,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "META",
          "relevance_score": "0.399734",
          "ticker_sentiment_score": "0.268641",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.399734",
          "ticker_sentiment_score": "0.14455",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "C",
          "relevance_score": "0.104228",
          "ticker_sentiment_score": "0.220542",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "TJX",
          "relevance_score": "0.487546",
          "ticker_sentiment_score": "0.606421",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "MS",
          "relevance_score": "0.104228",
          "ticker_sentiment_score": "0.006667",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TSM",
          "relevance_score": "0.30569",
          "ticker_sentiment_score": "0.253802",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "2 Dividend Stocks to Buy Hand Over Fist in November",
      "url": "https://www.fool.com/investing/2024/11/14/2-dividend-stocks-to-buy-hand-over-fist-november/",
      "time_published": "20241114T151500",
      "authors": [
        "Prosper Junior Bakiny"
      ],
      "summary": "These companies have solid businesses and excellent dividend growth track records.",
      "banner_image": "https://g.foolcdn.com/editorial/images/797409/pharmacist-talking-to-patient.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.938793"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        }
      ],
      "overall_sentiment_score": 0.30695,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "AMGN",
          "relevance_score": "0.528798",
          "ticker_sentiment_score": "0.274951",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.399734",
          "ticker_sentiment_score": "0.306577",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.052226",
          "ticker_sentiment_score": "0.023093",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "2 Dividend Stocks Defying the Market Dip to Buy for a Lifetime of Passive Income",
      "url": "https://www.fool.com/investing/2025/03/26/2-dividend-stocks-defying-the-market-dip-to-buy/",
      "time_published": "20250326T103000",
      "authors": [
        "Prosper Junior Bakiny"
      ],
      "summary": "Equities haven't performed well this year due to a combination of factors. Macroeconomic tensions are at the top of that list. Still, some companies are doing just fine amid the volatility, including AbbVie ( NYSE: ABBV ) and Abbott Laboratories ( NYSE: ABT ) .",
      "banner_image": "https://media.ycharts.com/charts/a183efe154e8c69ba4b94229ff633e9c.png",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.108179"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.413559"
        }
      ],
      "overall_sentiment_score": 0.230732,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.39736",
          "ticker_sentiment_score": "0.18105",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.484798",
          "ticker_sentiment_score": "0.340425",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "AbbVie's Cancer Drug Venetoclax Falls Short In Phase 3 Combination Trial For Myelodysplastic Syndromes - AbbVie  ( NYSE:ABBV ) ",
      "url": "https://www.benzinga.com/news/health-care/25/06/45975622/abbvies-cancer-drug-venetoclax-falls-short-in-phase-3-combination-trial-for-myelodysplastic-synd",
      "time_published": "20250617T144352",
      "authors": [
        "Vandana Singh"
      ],
      "summary": "VERONA trial failed to meet overall survival goal with HR of 0.908; p=0.3772. Venclexta Q1 sales reached $665 million, growing 8.3% year over year. Live on Wednesday June 18: 3 Summer \"Power Patterns\" Are About to Trigger ( One With 90% Win Rate ) . See Them Here.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2025/06/17/cancer.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.503496"
        }
      ],
      "overall_sentiment_score": 0.15388,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.397098",
          "ticker_sentiment_score": "0.134102",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Is Arcellx  ( ACLX )  Outperforming Other Medical Stocks This Year?",
      "url": "https://www.zacks.com/stock/news/2367446/is-arcellx-aclx-outperforming-other-medical-stocks-this-year",
      "time_published": "20241108T144011",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Here is how Arcellx, Inc. (ACLX) and AbbVie (ABBV) have performed compared to their sector so far this year.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default143.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.714479"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        }
      ],
      "overall_sentiment_score": 0.253974,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ACLX",
          "relevance_score": "0.755492",
          "ticker_sentiment_score": "0.460856",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.395012",
          "ticker_sentiment_score": "0.121331",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever",
      "url": "https://www.fool.com/investing/2024/12/15/want-decades-passive-income-stocks-buy-and-hold/",
      "time_published": "20241215T103500",
      "authors": [
        "Justin Pope"
      ],
      "summary": "These companies have ingrained competitive advantages in an evergreen industry backed by decades of dividend growth.",
      "banner_image": "https://g.foolcdn.com/editorial/images/800052/forever-investing.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.87644"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.576289"
        }
      ],
      "overall_sentiment_score": 0.243192,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.391158",
          "ticker_sentiment_score": "0.122827",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.051003",
          "ticker_sentiment_score": "-0.028898",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CAH",
          "relevance_score": "0.250902",
          "ticker_sentiment_score": "0.311697",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "SYK",
          "relevance_score": "0.29887",
          "ticker_sentiment_score": "0.34943",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "3 Relatively Safe Stocks to Buy Right Now",
      "url": "https://www.fool.com/investing/2025/03/29/3-relatively-safe-stocks-to-buy-right-now/",
      "time_published": "20250329T104500",
      "authors": [
        "and Prosper Junior Bakiny",
        "David Jagielski",
        "Keith Speights"
      ],
      "summary": "Investing in stocks comes with risks. There's no way around that fact. However, some stocks can be less risky than others during certain market conditions.Three Motley Fool contributors think they've found relatively safe stocks to buy right now with major market indexes remaining near correction ...",
      "banner_image": "https://g.foolcdn.com/editorial/images/812763/woman-with-fingers-crossed-laptop.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.990999"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.875462"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.255753,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.388209",
          "ticker_sentiment_score": "0.081397",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.178459",
          "ticker_sentiment_score": "0.197083",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.388209",
          "ticker_sentiment_score": "0.264782",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "3 Fantastic Dividend Stocks to Buy Sooner Rather Than Later",
      "url": "https://www.fool.com/investing/2024/12/01/3-fantastic-dividend-stocks-to-buy-sooner-rather-t/",
      "time_published": "20241201T105200",
      "authors": [
        "Keith Speights",
        "and Prosper Junior Bakiny",
        "David Jagielski"
      ],
      "summary": "You don't have to be an income investor to like dividends. Many billionaires who definitely don't need income still have dividend stocks in their portfolios.Which dividend stocks are great picks right now? Here's why three Fool.com contributors chose AbbVie ( NYSE: ABBV ) , Johnson & Johnson ( ...",
      "banner_image": "https://g.foolcdn.com/editorial/images/799375/dividends-blackboard-sketch-doodle.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.623304"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.857896"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.221663,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "PFE",
          "relevance_score": "0.260652",
          "ticker_sentiment_score": "0.131004",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.382274",
          "ticker_sentiment_score": "0.451133",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.342685",
          "ticker_sentiment_score": "0.199546",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "AbbVie's Migraine Drug Achieves Superiority In Preventing Headaches Compared To Generic Treatment In Head To Head Trial - AbbVie  ( NYSE:ABBV ) ",
      "url": "https://www.benzinga.com/markets/large-cap/25/06/46001795/abbvies-migraine-drug-achieves-superiority-in-preventing-headaches-compared-to-generic-treatmen",
      "time_published": "20250618T164258",
      "authors": [
        "Vandana Singh"
      ],
      "summary": "12.1% of patients on atogepant discontinued due to side effects vs. 29.6% on topiramate. 64.1% of atogepant users saw migraine days cut by half, compared to 39.3% for topiramate. Live on Wednesday: Historic Summer Setup: 3 \"Power Patterns\" Triggering in the next 75 Days. Get The Details Now",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2025/06/18/Abbvie.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        }
      ],
      "overall_sentiment_score": -0.038072,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.381463",
          "ticker_sentiment_score": "-0.097304",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "This Elastic Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday - AbbVie  ( NYSE:ABBV ) , Elastic  ( NYSE:ESTC ) ",
      "url": "https://www.benzinga.com/24/11/42137270/this-elastic-analyst-turns-bullish-here-are-top-5-upgrades-for-friday",
      "time_published": "20241122T134126",
      "authors": [
        "Avi Kapoor"
      ],
      "summary": "Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.",
      "banner_image": "https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22084048/image-245-1024x559.png",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.365926"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.392072,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "RBC",
          "relevance_score": "0.490323",
          "ticker_sentiment_score": "0.414187",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.379051",
          "ticker_sentiment_score": "0.478149",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "SAH",
          "relevance_score": "0.379051",
          "ticker_sentiment_score": "0.367035",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "FLS",
          "relevance_score": "0.379051",
          "ticker_sentiment_score": "0.478149",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ESTC",
          "relevance_score": "0.379051",
          "ticker_sentiment_score": "0.478149",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Where Will AbbVie Be in 5 Years?",
      "url": "https://www.fool.com/investing/2024/11/19/where-will-abbvie-be-in-5-years/",
      "time_published": "20241119T150000",
      "authors": [
        "Alex Carchidi"
      ],
      "summary": "Most pharmaceutical businesses are slow-moving by nature due to the lengthy amount of time it takes to develop a new medicine, and AbbVie ( NYSE: ABBV ) is no exception. Nonetheless, the next five years will likely see it growing faster than the last five years, and shareholders are apt to ...",
      "banner_image": "https://g.foolcdn.com/editorial/images/797891/two-investors-put-sticky-notes-on-glass-wall.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.650727"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        }
      ],
      "overall_sentiment_score": 0.133862,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.375251",
          "ticker_sentiment_score": "-0.031926",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "A Look Into AbbVie Inc's Price Over Earnings - AbbVie  ( NYSE:ABBV ) ",
      "url": "https://www.benzinga.com/insights/news/25/05/45388737/a-look-into-abbvie-incs-price-over-earnings",
      "time_published": "20250513T190037",
      "authors": [
        "Benzinga Insights"
      ],
      "summary": "In the current market session, AbbVie Inc. ABBV stock price is at $188.93, after a 0.60% drop. However, over the past month, the company's stock increased by 6.84%, and in the past year, by 15.33%.",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "Markets",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.495866"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.503496"
        }
      ],
      "overall_sentiment_score": 0.244895,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.374312",
          "ticker_sentiment_score": "0.133333",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PLSQF",
          "relevance_score": "0.097062",
          "ticker_sentiment_score": "0.154611",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Meta, Snowflake, PayPal And Health Care Stock On CNBC's 'Final Trades' - Meta Platforms  ( NASDAQ:META ) , AbbVie  ( NYSE:ABBV ) ",
      "url": "https://www.benzinga.com/markets/25/03/44560622/meta-snowflake-paypal-and-health-care-stock-on-cnbcs-final-trades",
      "time_published": "20250331T124642",
      "authors": [
        "Avi Kapoor"
      ],
      "summary": "Kevin Simpson says Meta Platforms is his top pick out of the Mag 7 names. Stephanie Link says Snowflake is down 23% from its highs. Pelosi's latest AI pick skyrocketed 169% in just one month. Click here to discover the next stock our government trade tracker is spotlighting-before it takes off.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2025/03/31/Fort-Lauderdale--Fla---usa---April-15--2.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.161647"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.354873,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "PYPL",
          "relevance_score": "0.372912",
          "ticker_sentiment_score": "0.492085",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "META",
          "relevance_score": "0.372912",
          "ticker_sentiment_score": "0.530864",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.372912",
          "ticker_sentiment_score": "0.389147",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "SNOW",
          "relevance_score": "0.45634",
          "ticker_sentiment_score": "0.142885",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "FDA Expands AbbVie's Mavyret Label To Include Pediatric Patients With Hepatitis C Infection - Enanta Pharma  ( NASDAQ:ENTA ) , AbbVie  ( NYSE:ABBV ) ",
      "url": "https://www.benzinga.com/news/fda/25/06/45890526/fda-expands-abbvies-mavyret-label-to-include-pediatric-patients-with-hepatitis-c-infection",
      "time_published": "20250611T174636",
      "authors": [
        "Vandana Singh"
      ],
      "summary": "Mavyret approved for acute HCV in patients aged 3+ with or without cirrhosis. Eight-week treatment shows 96% cure rate with mostly mild side effects. Ready to turn the market's comeback into steady cash flow? Grab the top 3 stocks to buy right here. The U.S.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2025/06/11/Silver-Spring--Md--Usa---June-25--2022-T.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        }
      ],
      "overall_sentiment_score": 0.116144,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ENTA",
          "relevance_score": "0.19117",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.371523",
          "ticker_sentiment_score": "0.108586",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Are Medical Stocks Lagging Anavex Life Sciences  ( AVXL )  This Year?",
      "url": "https://www.zacks.com/stock/news/2390053/are-medical-stocks-lagging-anavex-life-sciences-avxl-this-year",
      "time_published": "20241231T144012",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Here is how Anavex Life Sciences (AVXL) and AbbVie (ABBV) have performed compared to their sector so far this year.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default346.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.714479"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        }
      ],
      "overall_sentiment_score": 0.223951,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.370143",
          "ticker_sentiment_score": "0.118248",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AVXL",
          "relevance_score": "0.721785",
          "ticker_sentiment_score": "0.391836",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "AbbVie  ( ABBV )  Upgraded to Buy: What Does It Mean for the Stock?",
      "url": "https://www.zacks.com/stock/news/2390172/abbvie-abbv-upgraded-to-buy-what-does-it-mean-for-the-stock",
      "time_published": "20241231T170012",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "AbbVie (ABBV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default79.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.997845"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.658903"
        }
      ],
      "overall_sentiment_score": 0.305263,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.366961",
          "ticker_sentiment_score": "0.327276",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Wall Street Bulls Look Optimistic About AbbVie  ( ABBV ) : Should You Buy?",
      "url": "https://www.zacks.com/stock/news/2367388/wall-street-bulls-look-optimistic-about-abbvie-abbv-should-you-buy",
      "time_published": "20241108T143011",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "The average brokerage recommendation (ABR) for AbbVie (ABBV) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?",
      "banner_image": "https://staticx-tuner.zacks.com/images/yesopchart/brokerage_bar/ABBV_11082024.png",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.938238"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.459462"
        }
      ],
      "overall_sentiment_score": 0.329432,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.365294",
          "ticker_sentiment_score": "0.235285",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "2 Dividend Stocks to Buy Hand Over Fist in April",
      "url": "https://www.fool.com/investing/2025/04/05/2-dividend-stocks-to-buy-hand-over-fist-in-april/",
      "time_published": "20250405T123000",
      "authors": [
        "Eric Volkman"
      ],
      "summary": "One factor that keeps some investors away from healthcare stocks is the sector's dearth of generous and reliable dividend payers. This stands to reason, as nearly every stage of drug development and marketing is resource- and capital-intensive, and as a result, cash can be in short supply.In this ...",
      "banner_image": "https://g.foolcdn.com/editorial/images/813234/a-loose-collection-of-100-dollar-bills.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.77141"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        }
      ],
      "overall_sentiment_score": 0.31267,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "AMGN",
          "relevance_score": "0.472338",
          "ticker_sentiment_score": "0.35254",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.364275",
          "ticker_sentiment_score": "0.28532",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "3 Dividend Stocks to Buy and Hold for the Next Decade",
      "url": "https://www.fool.com/investing/2025/04/06/3-dividend-stocks-to-buy-and-hold-for-the-next-dec/",
      "time_published": "20250406T104400",
      "authors": [
        "Keith Speights",
        "and Prosper Junior Bakiny",
        "David Jagielski"
      ],
      "summary": "What should investors do when stocks are tanking over the short term? Probably the best answer is to think long term.Three Motley Fool contributors think they've found great dividend stocks to own for the long term that pay you to wait for better days.",
      "banner_image": "https://g.foolcdn.com/editorial/images/813642/dividends-on-sticky-note.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.839681"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.99977"
        }
      ],
      "overall_sentiment_score": 0.201928,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.264515",
          "ticker_sentiment_score": "0.198937",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "AMGN",
          "relevance_score": "0.363768",
          "ticker_sentiment_score": "0.099564",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.363768",
          "ticker_sentiment_score": "0.096284",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Brokers Suggest Investing in AbbVie  ( ABBV ) : Read This Before Placing a Bet",
      "url": "https://www.zacks.com/stock/news/2390006/brokers-suggest-investing-in-abbvie-abbv-read-this-before-placing-a-bet",
      "time_published": "20241231T143013",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "The average brokerage recommendation (ABR) for AbbVie (ABBV) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?",
      "banner_image": "https://staticx-tuner.zacks.com/images/yesopchart/brokerage_bar/ABBV_12312024.png",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.938238"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.503496"
        }
      ],
      "overall_sentiment_score": 0.320651,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.362254",
          "ticker_sentiment_score": "0.199317",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Boeing, Joby Aviation, Oracle And A Health Care Stock: CNBC's 'Final Trades' - AbbVie  ( NYSE:ABBV ) , Boeing  ( NYSE:BA ) ",
      "url": "https://www.benzinga.com/trading-ideas/long-ideas/25/07/46363784/boeing-joby-aviation-oracle-and-a-health-care-stock-cnbcs-final-trades",
      "time_published": "20250711T115311",
      "authors": [
        "Avi Kapoor"
      ],
      "summary": "Kevin Simpson says Boeing's MAX orders are up and the backlog is unbelievable. Jason Snipe likes Oracle's Stargate project. Get daily-updated rankings across momentum, growth, value, trends, and quality to spot the strongest stocks in any market.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2025/07/11/Analyst.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.25"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.25"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.25"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.25"
        }
      ],
      "overall_sentiment_score": 0.322906,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ORCL",
          "relevance_score": "0.362065",
          "ticker_sentiment_score": "0.350948",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.362065",
          "ticker_sentiment_score": "0.298434",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "JOBY",
          "relevance_score": "0.362065",
          "ticker_sentiment_score": "0.366933",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "BA",
          "relevance_score": "0.362065",
          "ticker_sentiment_score": "0.250814",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "3 Spectacular High-Yield Dividend Stocks to Buy in November",
      "url": "https://www.fool.com/investing/2024/11/10/spectacular-high-yield-dividend-stocks-to-buy-in/",
      "time_published": "20241110T143000",
      "authors": [
        "David Jagielski",
        "and Prosper Junior Bakiny",
        "Keith Speights"
      ],
      "summary": "High yields aren't a warning indicator with these three stocks.",
      "banner_image": "https://g.foolcdn.com/editorial/images/797003/scientists-in-a-lab-monitor-microscope.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.999922"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.795202"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.293865,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.361407",
          "ticker_sentiment_score": "0.434985",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.046816",
          "ticker_sentiment_score": "0.178476",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "GILD",
          "relevance_score": "0.402761",
          "ticker_sentiment_score": "0.326656",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.230892",
          "ticker_sentiment_score": "0.281124",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Do Options Traders Know Something About AbbVie  ( ABBV )  Stock We Don't?",
      "url": "https://www.zacks.com/stock/news/2452481/do-options-traders-know-something-about-abbvie-abbv-stock-we-dont",
      "time_published": "20250422T123000",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Investors need to pay close attention to AbbVie (ABBV) stock based on the movements in the options market lately.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/36/1919.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        }
      ],
      "overall_sentiment_score": 0.045342,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.360752",
          "ticker_sentiment_score": "0.040426",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "This American Water Works Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Tuesday - Avery Dennison  ( NYSE:AVY ) , AbbVie  ( NYSE:ABBV ) ",
      "url": "https://www.benzinga.com/25/04/44918966/this-american-water-works-analyst-begins-coverage-on-a-bearish-note-here-are-top-5-initiations-for-tuesday",
      "time_published": "20250422T113704",
      "authors": [
        "Avi Kapoor"
      ],
      "summary": "Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Needham analyst Mike Cikos initiated coverage on CoreWeave, Inc.",
      "banner_image": "https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/22073514/image-43-1024x625.png",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.25"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.413559"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.25"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.25"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.25"
        }
      ],
      "overall_sentiment_score": 0.239386,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CRWV",
          "relevance_score": "0.360752",
          "ticker_sentiment_score": "0.152831",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.360752",
          "ticker_sentiment_score": "-0.020426",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BCS",
          "relevance_score": "0.124164",
          "ticker_sentiment_score": "0.067626",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AVY",
          "relevance_score": "0.360752",
          "ticker_sentiment_score": "0.152831",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "AWK",
          "relevance_score": "0.468029",
          "ticker_sentiment_score": "0.266117",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "BZAI",
          "relevance_score": "0.360752",
          "ticker_sentiment_score": "0.152831",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "3 No-Brainer Stocks to Buy in July",
      "url": "https://www.fool.com/investing/2025/07/07/3-no-brainer-stocks-to-buy-in-july/",
      "time_published": "20250707T104000",
      "authors": [
        "Keith Speights",
        "David Jagielski",
        "and Prosper Junior Bakiny"
      ],
      "summary": "Don't let the summer heat keep you from making money. July is a great time to invest in the stocks of top-tier companies.Three Motley Fool contributors think they've found no-brainer stocks to buy this month. Here's why they picked healthcare stocks AbbVie ( NYSE: ABBV ) , Eli Lilly ( NYSE: LLY ) ...",
      "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F823995%2Fscientist-wearing-goggles-in-lab.jpg&op=resize&w=700",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.96136"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.413559"
        }
      ],
      "overall_sentiment_score": 0.220794,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.355588",
          "ticker_sentiment_score": "0.106897",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "VRTX",
          "relevance_score": "0.436009",
          "ticker_sentiment_score": "0.334879",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.355588",
          "ticker_sentiment_score": "0.321312",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.046006",
          "ticker_sentiment_score": "0.262403",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.046006",
          "ticker_sentiment_score": "-0.216274",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "3 Dividend Stocks to Double Up on Right Now",
      "url": "https://www.fool.com/investing/2025/06/29/3-dividend-stocks-to-double-up-on-right-now/",
      "time_published": "20250629T085100",
      "authors": [
        "Keith Speights"
      ],
      "summary": "Buy, sell, or hold? That's the question investors must continually ask about each stock in their portfolio.The correct answer might be to sell if your original investing thesis has changed. In many cases, the best course of action is to simply stay the course.",
      "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F822953%2Fdividend-laptop.jpg&op=resize&w=700",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "IPO",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.989041"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.293271,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.353898",
          "ticker_sentiment_score": "0.195411",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "O",
          "relevance_score": "0.12165",
          "ticker_sentiment_score": "0.077225",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Got $500? 2 Pharmaceutical Stocks to Buy and Hold Forever",
      "url": "https://www.fool.com/investing/2025/01/21/got-500-2-pharma-stocks-to-buy-and-hold-forever/",
      "time_published": "20250121T121000",
      "authors": [
        "Adria Cimino"
      ],
      "summary": "You've probably heard this before: Pharmaceutical stocks can bring an element of safety to your portfolio. Why is this the case? These companies make drugs doctors and patients rely on -- and that means no matter what the economy is doing, doctors will continue prescribing and patients will ...",
      "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F804545%2Fgettyimages-519517489-1.jpg&op=resize&w=700",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999822"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        }
      ],
      "overall_sentiment_score": 0.271762,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "PFE",
          "relevance_score": "0.297301",
          "ticker_sentiment_score": "0.288606",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.353059",
          "ticker_sentiment_score": "0.282017",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Kevin K Buckbee Executes Sell Order: Offloads $310K In AbbVie Stock - AbbVie  ( NYSE:ABBV ) ",
      "url": "https://www.benzinga.com/insights/news/24/12/42592937/kevin-k-buckbee-executes-sell-order-offloads-310k-in-abbvie-stock",
      "time_published": "20241219T150129",
      "authors": [
        "Benzinga Insights"
      ],
      "summary": "On December 18, a recent SEC filing unveiled that Kevin K Buckbee, SVP at AbbVie ABBV made an insider sell. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Wednesday showed that Buckbee sold 1,800 shares of AbbVie. The total transaction amounted to $310,032.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2023/insider_image_4.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.99676"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.999346"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.211132,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.352223",
          "ticker_sentiment_score": "0.254053",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Want $1 Million in Retirement? 2 Stocks to Buy Now and Hold for Decades.",
      "url": "https://www.fool.com/investing/2025/02/01/want-1-million-in-retirement-2-stocks-to-buy-now-a/",
      "time_published": "20250201T110500",
      "authors": [
        "Prosper Junior Bakiny"
      ],
      "summary": "Many people set a goal to save $1 million for retirement. This amount may or may not be sufficient in today's economy, but it's at least a good start. And to get there, investing in stocks is an excellent strategy.",
      "banner_image": "https://g.foolcdn.com/editorial/images/805108/pharmacist-talking-to-patient.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.650727"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.538269"
        }
      ],
      "overall_sentiment_score": 0.358763,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "NVO",
          "relevance_score": "0.295155",
          "ticker_sentiment_score": "0.423669",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.350564",
          "ticker_sentiment_score": "0.309291",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.120431",
          "ticker_sentiment_score": "0.115699",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Contact The Gross Law Firm by June 3, 2025 Deadline to Join Class Action Against Cerevel Therapeutics Holdings, Inc. ( ABBV )  - AbbVie  ( NYSE:ABBV ) ",
      "url": "https://www.benzinga.com/pressreleases/25/05/g45675918/contact-the-gross-law-firm-by-june-3-2025-deadline-to-join-class-action-against-cerevel-therapeuti",
      "time_published": "20250529T162209",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "NEW YORK, May 29, 2025 ( GLOBE NEWSWIRE ) -- The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. ABBV. Shareholders who purchased shares of ABBV during the class period listed are encouraged to contact the firm regarding possible lead ...",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "IPO",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.962106"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.063598,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.349575",
          "ticker_sentiment_score": "0.166321",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Cerevel Therapeutics Holdings, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before June 3, 2025 to Discuss Your Rights - ABBV - AbbVie  ( NYSE:ABBV ) ",
      "url": "https://www.benzinga.com/pressreleases/25/05/g45549596/cerevel-therapeutics-holdings-inc-sued-for-securities-law-violations-contact-the-gross-law-firm-be",
      "time_published": "20250521T172000",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "NEW YORK, May 21, 2025 ( GLOBE NEWSWIRE ) -- The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. ABBV. Shareholders who purchased shares of ABBV during the class period listed are encouraged to contact the firm regarding possible lead ...",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "IPO",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.962106"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.063598,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.349575",
          "ticker_sentiment_score": "0.166321",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of June 3, 2025 in Cerevel Therapeutics Holdings, Inc. Lawsuit - ABBV - AbbVie  ( NYSE:ABBV ) ",
      "url": "https://www.benzinga.com/pressreleases/25/05/g45261004/the-gross-law-firm-reminds-shareholders-of-a-lead-plaintiff-deadline-of-june-3-2025-in-cerevel-the",
      "time_published": "20250507T163500",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "NEW YORK, May 07, 2025 ( GLOBE NEWSWIRE ) -- The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. ABBV. Shareholders who purchased shares of ABBV during the class period listed are encouraged to contact the firm regarding possible lead ...",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "IPO",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.962106"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.063598,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.349575",
          "ticker_sentiment_score": "0.166321",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Shareholders that lost money on Cerevel Therapeutics Holdings, Inc.  ( ABBV )  Urged to Join Class Action - Contact The Gross Law Firm to Learn More - AbbVie  ( NYSE:ABBV ) ",
      "url": "https://www.benzinga.com/pressreleases/25/04/g45046121/shareholders-that-lost-money-on-cerevel-therapeutics-holdings-inc-abbv-urged-to-join-class-action-",
      "time_published": "20250428T164400",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "NEW YORK, April 28, 2025 ( GLOBE NEWSWIRE ) -- The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. ABBV. Shareholders who purchased shares of ABBV during the class period listed are encouraged to contact the firm regarding possible lead ...",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "IPO",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.962106"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.063598,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.349575",
          "ticker_sentiment_score": "0.166321",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Cerevel Therapeutics Holdings, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before June 3, 2025 to Discuss Your Rights - ABBV - AbbVie  ( NYSE:ABBV ) ",
      "url": "https://www.benzinga.com/pressreleases/25/04/g44959271/cerevel-therapeutics-holdings-inc-sued-for-securities-law-violations-investors-should-contact-the-",
      "time_published": "20250423T172500",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "NEW YORK, April 23, 2025 ( GLOBE NEWSWIRE ) -- The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. ABBV. Shareholders who purchased shares of ABBV during the class period listed are encouraged to contact the firm regarding possible lead ...",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "IPO",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.962106"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.063598,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.349575",
          "ticker_sentiment_score": "0.166321",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Investors who lost money on Cerevel Therapeutics Holdings, Inc. ( ABBV )  should contact The Gross Law Firm about pending Class Action - ABBV - AbbVie  ( NYSE:ABBV ) ",
      "url": "https://www.benzinga.com/pressreleases/25/04/g44872427/investors-who-lost-money-on-cerevel-therapeutics-holdings-inc-abbv-should-contact-the-gross-law-fi",
      "time_published": "20250417T171400",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "NEW YORK, April 17, 2025 ( GLOBE NEWSWIRE ) -- The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. ABBV. Shareholders who purchased shares of ABBV during the class period listed are encouraged to contact the firm regarding possible lead ...",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "IPO",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.962106"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.063598,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.349575",
          "ticker_sentiment_score": "0.166321",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever",
      "url": "https://www.fool.com/investing/2025/02/27/want-decades-of-passive-income-3-stocks-to-buy-now/",
      "time_published": "20250227T104700",
      "authors": [
        "Keith Speights"
      ],
      "summary": "Imagine being able to buy a machine that would work day after day and year after year to make you money. Now imagine being able to buy several such machines. This would be a utopia for anyone seeking passive income.The good news is you don't have to use your imagination.",
      "banner_image": "https://g.foolcdn.com/editorial/images/808909/passive-income.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.996023"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.423377,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "BIPC",
          "relevance_score": "0.348103",
          "ticker_sentiment_score": "0.465715",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.348103",
          "ticker_sentiment_score": "0.400565",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "O",
          "relevance_score": "0.178459",
          "ticker_sentiment_score": "0.288071",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Seeking Clues to AbbVie  ( ABBV )  Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics",
      "url": "https://www.zacks.com/stock/news/2452605/seeking-clues-to-abbvie-abbv-q1-earnings-a-peek-into-wall-street-projections-for-key-metrics",
      "time_published": "20250422T131519",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Besides Wall Street's top -and-bottom-line estimates for AbbVie (ABBV), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2025.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default233.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        }
      ],
      "overall_sentiment_score": 0.129145,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.346642",
          "ticker_sentiment_score": "0.19076",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Netflix, Sherwin-Williams, AbbVie And More On CNBC's 'Final Trades' - AbbVie  ( NYSE:ABBV ) , iShares U.S. Industrials ETF  ( BATS:IYJ ) ",
      "url": "https://www.benzinga.com/trading-ideas/long-ideas/25/04/45098653/netflix-sherwin-williams-abbvie-and-more-on-cnbcs-final-trades",
      "time_published": "20250430T123440",
      "authors": [
        "Avi Kapoor"
      ],
      "summary": "On CNBC's \"Halftime Report Final Trades,\" Joshua Brown of Ritholtz Wealth Management named Netflix, Inc. NFLX as his final trade. On the earnings front, Netflix reported first-quarter revenue of $10.54 billion on April 17, up 12.5% year-over-year.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2025/04/30/CNBC-LOGO.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.858979"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.990786"
        }
      ],
      "overall_sentiment_score": 0.266123,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "NFLX",
          "relevance_score": "0.445569",
          "ticker_sentiment_score": "0.303264",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.342487",
          "ticker_sentiment_score": "0.45029",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "SHW",
          "relevance_score": "0.445569",
          "ticker_sentiment_score": "0.427122",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "PLSQF",
          "relevance_score": "0.117486",
          "ticker_sentiment_score": "0.165826",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "2 Incredible Dividend Growth Stocks to Buy Now",
      "url": "https://www.fool.com/investing/2025/05/21/2-incredible-dividend-growth-stocks-to-buy-now/",
      "time_published": "20250521T104500",
      "authors": [
        "George Budwell"
      ],
      "summary": "Dividend growth stocks have long been reliable engines of wealth creation. Historically, companies with 10-year annualized dividend growth rates above 6% have consistently outperformed the S&P 500.The reason is simple. Sustained dividend growth typically signals strong underlying business ...",
      "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F818901%2Fdividends.jpg&op=resize&w=700",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.576289"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.365926"
        }
      ],
      "overall_sentiment_score": 0.550044,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.340915",
          "ticker_sentiment_score": "0.460406",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.058615",
          "ticker_sentiment_score": "0.240035",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "What Is Considered a Good Dividend Stock? 3 Healthcare Stocks That Fit the Bill",
      "url": "https://www.fool.com/investing/2025/07/11/what-good-dividend-stock-healthcare-stocks-buy/",
      "time_published": "20250711T075500",
      "authors": [
        "Justin Pope"
      ],
      "summary": "A steady dose of quality companies will keep your portfolio growing big and strong.",
      "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F824227%2Fstacking-blocks-up-arrows.jpg&op=resize&w=700",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.995077"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.714479"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.357602,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "KVUE",
          "relevance_score": "0.049939",
          "ticker_sentiment_score": "0.060822",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.338913",
          "ticker_sentiment_score": "0.369126",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.049939",
          "ticker_sentiment_score": "0.157193",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "MDT",
          "relevance_score": "0.338913",
          "ticker_sentiment_score": "0.462861",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.197816",
          "ticker_sentiment_score": "0.133026",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "AbbVie's Emraclidine For Schizophrenia 'Surprisingly Disappoints,' Analyst Says Pipeline Is Underappreciated - AbbVie  ( NYSE:ABBV ) , Bristol-Myers Squibb  ( NYSE:BMY ) ",
      "url": "https://www.benzinga.com/general/biotech/24/11/41884798/abbvies-emraclidine-for-schizophrenia-surprisingly-disappoints-analyst-says-pipeline-is-underappr",
      "time_published": "20241111T175156",
      "authors": [
        "Vandana Singh"
      ],
      "summary": "On Monday, AbbVie Inc ABBV stock plunged after two trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia failed two Phase 2 trials.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2024/11/11/Galicia--Spain-June-8--2020--Smart-Phone.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        }
      ],
      "overall_sentiment_score": 0.121284,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.33628",
          "ticker_sentiment_score": "-0.352805",
          "ticker_sentiment_label": "Bearish"
        },
        {
          "ticker": "BMY",
          "relevance_score": "0.228073",
          "ticker_sentiment_score": "-0.035589",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Got $1,500 to Invest? AbbVie Just Proved the Bull Thesis for Its Stock",
      "url": "https://www.fool.com/investing/2024/11/15/got-1500-to-invest-abbvie-just-proved-the-bull-the/",
      "time_published": "20241115T105000",
      "authors": [
        "Alex Carchidi"
      ],
      "summary": "The drugmaker has convincingly laid to rest the biggest threat to its top line.",
      "banner_image": "https://g.foolcdn.com/editorial/images/797564/scientists-lab-testing-blood-draw2.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.990893"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.796627"
        }
      ],
      "overall_sentiment_score": 0.164803,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.334008",
          "ticker_sentiment_score": "0.13892",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Lilly's Jaypirca Gets CHMP Nod for 2nd Leukemia Indication in Europe",
      "url": "https://www.zacks.com/stock/news/2424090/lillys-jaypirca-gets-chmp-nod-for-2nd-leukemia-indication-in-europe",
      "time_published": "20250303T105000",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "The CHMP gives a positive opinion to Eli Lilly's Jaypirca in patients with relapsed or refractory CLL in a post-BTK inhibitor setting.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/52/873.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.157981,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.52706",
          "ticker_sentiment_score": "0.203338",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.333257",
          "ticker_sentiment_score": "0.101481",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "FDA Fast-Tracks AbbVie's New Lung Cancer Therapy Emrelis For Tough Lung Cancer Cases - AbbVie  ( NYSE:ABBV ) , Roche Holding  ( OTC:RHHBY ) ",
      "url": "https://www.benzinga.com/general/biotech/25/05/45418687/fda-fast-tracks-abbvies-new-lung-cancer-therapy-emrelis-for-tough-lung-cancer-cases",
      "time_published": "20250514T192505",
      "authors": [
        "Vandana Singh"
      ],
      "summary": "Emrelis showed a 35% overall response rate and a 7.2-month median duration in high c-Met OE NSCLC patients ( n=84 ) . AbbVie and ADARx signed a $335 million upfront siRNA therapy deal, with potential for billions in milestones and royalties.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2025/05/14/Abbvie.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        }
      ],
      "overall_sentiment_score": 0.224446,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.331765",
          "ticker_sentiment_score": "0.113458",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Congressional Trading Report: Rep. Jared Moskowitz Bought Over $27K In AbbVie Stock - Broadcom  ( NASDAQ:AVGO ) , AbbVie  ( NYSE:ABBV ) ",
      "url": "https://www.benzinga.com/insights/government/25/05/45352060/congressional-trading-report-rep-jared-moskowitz-bought-over-27k-in-abbvie-stock",
      "time_published": "20250512T150019",
      "authors": [
        "Benzinga Insights"
      ],
      "summary": "May 9, 2025 records indicate that Representative Jared Moskowitz filed a purchase of AbbVie ABBV, valued between $27,027 and $405,000. According to the May filing, the transaction occurred on May 9, 2025. Currently, AbbVie shares are trading up 2.18% at $188.62.",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.990999"
        }
      ],
      "overall_sentiment_score": 0.175564,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.330286",
          "ticker_sentiment_score": "0.264375",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "3 Dividend Stocks That Are Screaming Buys in November",
      "url": "https://www.fool.com/investing/2024/11/23/dividend-stocks-that-are-screaming-buys-november/",
      "time_published": "20241123T122000",
      "authors": [
        "Justin Pope"
      ],
      "summary": "Political uncertainty has created buying opportunities among blue-chip healthcare stocks with big-time dividends.",
      "banner_image": "https://g.foolcdn.com/editorial/images/798476/healthcare-consulting.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.972193"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.692272"
        }
      ],
      "overall_sentiment_score": 0.179363,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "PFE",
          "relevance_score": "0.329237",
          "ticker_sentiment_score": "0.034308",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.329237",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.28442",
          "ticker_sentiment_score": "0.319877",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "A Congress Member Sold Up To $120K In AbbVie Stock: Here's What You Need To Know - AbbVie  ( NYSE:ABBV ) , Amazon.com  ( NASDAQ:AMZN ) ",
      "url": "https://www.benzinga.com/insights/government/25/04/44884412/a-congress-member-sold-up-to-120k-in-abbvie-stock-heres-what-you-need-to-know",
      "time_published": "20250418T150012",
      "authors": [
        "Benzinga Insights"
      ],
      "summary": "A report on April 17, 2025 shows that Representative Dwight Evans from Pennsylvania sale stock in AbbVie ABBV, valued between $8,008 and $120,000. According to the April filing, the transaction occurred on April 17, 2025. At the time of writing, AbbVie shares are trading up 1.47% at $174.2.",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.996023"
        }
      ],
      "overall_sentiment_score": 0.168648,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.323078",
          "ticker_sentiment_score": "0.225097",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "3 Dividend Growth Stocks to Buy and Hold",
      "url": "https://www.fool.com/investing/2025/07/12/3-dividend-growth-stocks-to-buy-and-hold/",
      "time_published": "20250712T104000",
      "authors": [
        "Keith Speights",
        "and Prosper Junior Bakiny",
        "David Jagielski"
      ],
      "summary": "What's better than a great dividend? A great dividend that's growing.Three Motley Fool contributors think they've found ideal dividend growth stocks to buy and hold -- and all three are healthcare stocks. Here's why they picked Abbott Laboratories ( NYSE: ABT ) , AbbVie ( NYSE: ABBV ) , and Eli ...",
      "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F824621%2Fwoman-smiling-laptop.jpg&op=resize&w=700",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.54554"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.961735"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.351968,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.277433",
          "ticker_sentiment_score": "0.287057",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.321273",
          "ticker_sentiment_score": "0.245366",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.1871",
          "ticker_sentiment_score": "0.096222",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.094204",
          "ticker_sentiment_score": "0.111698",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Is AbbVie  ( ABBV )  a Buy as Wall Street Analysts Look Optimistic?",
      "url": "https://www.zacks.com/stock/news/2506377/is-abbvie-abbv-a-buy-as-wall-street-analysts-look-optimistic",
      "time_published": "20250617T133003",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "The average brokerage recommendation (ABR) for AbbVie (ABBV) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?",
      "banner_image": "https://staticx-tuner.zacks.com/images/yesopchart/brokerage_bar/ABBV_06172025.png",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.890401"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.413559"
        }
      ],
      "overall_sentiment_score": 0.299642,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.320279",
          "ticker_sentiment_score": "0.196421",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Is It Worth Investing in AbbVie  ( ABBV )  Based on Wall Street's Bullish Views?",
      "url": "https://www.zacks.com/stock/news/2561676/is-it-worth-investing-in-abbvie-abbv-based-on-wall-streets-bullish-views",
      "time_published": "20250703T133003",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "According to the average brokerage recommendation (ABR), one should invest in AbbVie (ABBV). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?",
      "banner_image": "https://staticx-tuner.zacks.com/images/yesopchart/brokerage_bar/ABBV_07032025.png",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.890401"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.413559"
        }
      ],
      "overall_sentiment_score": 0.289247,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.318211",
          "ticker_sentiment_score": "0.190816",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "3 Cheap Dividend Growth Stocks to Buy Right Now",
      "url": "https://www.fool.com/investing/2025/06/04/3-cheap-dividend-growth-stocks-to-buy-right-now/",
      "time_published": "20250604T095000",
      "authors": [
        "David Jagielski"
      ],
      "summary": "Dividend growth stocks can be ideal long-term options for any investment portfolio. That's because they not only offer a good payout, but they may also rise over time, helping offset the negative effects of inflation.",
      "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F820086%2Fa-couple-shaking-hands-with-an-advisor.jpg&op=resize&w=700",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.752319"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.576289"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.290094,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.312423",
          "ticker_sentiment_score": "0.285107",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.064104",
          "ticker_sentiment_score": "0.121118",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "VZ",
          "relevance_score": "0.252332",
          "ticker_sentiment_score": "0.179826",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "XOM",
          "relevance_score": "0.312423",
          "ticker_sentiment_score": "0.394099",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Schwab US Dividend Equity ETF Reverses In December: What's Going On? - Schwab US Dividend Equity ETF  ( ARCA:SCHD ) ",
      "url": "https://www.benzinga.com/general/biotech/24/12/42660458/schwab-us-dividend-equity-etf-reverses-in-december-whats-going-on",
      "time_published": "20241223T205355",
      "authors": [
        "Erica Kollmann"
      ],
      "summary": "The Schwab US Dividend Equity ETF SCHD has given back more than half of its one-year gains in the last month, with the ETF falling more than 7% in December. Here's a look at what may be plaguing the fund.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2024/12/23/Stock-Exchange-Trading-Data-And-Financia.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.682689"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.905476"
        }
      ],
      "overall_sentiment_score": 0.179455,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "AMGN",
          "relevance_score": "0.312158",
          "ticker_sentiment_score": "0.048478",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.211191",
          "ticker_sentiment_score": "-0.167084",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.312158",
          "ticker_sentiment_score": "0.048478",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "How to Find Strong Medical Stocks Slated for Positive Earnings Surprises",
      "url": "https://www.zacks.com/stock/news/2393544/how-to-find-strong-medical-stocks-slated-for-positive-earnings-surprises",
      "time_published": "20250108T135012",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default76.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999937"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        }
      ],
      "overall_sentiment_score": 0.352802,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "UTHR",
          "relevance_score": "0.369685",
          "ticker_sentiment_score": "0.340447",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.311631",
          "ticker_sentiment_score": "0.340088",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "AbbVie's Ovarian Cancer Drug Elahere Gets Approval in Europe",
      "url": "https://www.zacks.com/stock/news/2371626/abbvies-ovarian-cancer-drug-elahere-gets-approval-in-europe",
      "time_published": "20241118T151700",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "The European Commission approves ABBV's Elahere for the treatment of platinum-resistant ovarian cancer.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/36/1919.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.972193"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.127468,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "IMCR",
          "relevance_score": "0.188193",
          "ticker_sentiment_score": "0.029373",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ANIP",
          "relevance_score": "0.249106",
          "ticker_sentiment_score": "0.255574",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.308504",
          "ticker_sentiment_score": "0.03441",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CSTL",
          "relevance_score": "0.249106",
          "ticker_sentiment_score": "0.088962",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "This House of Representative Just Bought Up To $915K In AbbVie Stock - Apple  ( NASDAQ:AAPL ) , AbbVie  ( NYSE:ABBV ) ",
      "url": "https://www.benzinga.com/insights/government/25/05/45256992/this-house-of-representative-just-bought-up-to-915k-in-abbvie-stock",
      "time_published": "20250507T150017",
      "authors": [
        "Benzinga Insights"
      ],
      "summary": "An official report on May 6, 2025 reveals Representative Marjorie Taylor Greene's recent purchase of AbbVie ABBV stock, valued between $61,061 and $915,000. The transaction took place on May 6, 2025, as per the May filing. At this time, AbbVie shares are trading up 0.45% at $188.0.",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.996023"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.175488,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "AMD",
          "relevance_score": "0.208464",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "COST",
          "relevance_score": "0.105141",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.308246",
          "ticker_sentiment_score": "0.221375",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "HD",
          "relevance_score": "0.105141",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Pharma Stock Roundup: BAYRY's Q4 Results, ABBV's Obesity Deal & More",
      "url": "https://www.zacks.com/stock/news/2427127/pharma-stock-roundup-bayrys-q4-results-abbvs-obesity-deal-more",
      "time_published": "20250307T130900",
      "authors": [
        "Kinjel Shah"
      ],
      "summary": "Bayer announces fourth-quarter results. NVO cuts cost of Wegovy for the uninsured. ABBV enters obesity space with new deal.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/07/905.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.360215"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        }
      ],
      "overall_sentiment_score": 0.002392,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.208464",
          "ticker_sentiment_score": "-0.068433",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.308246",
          "ticker_sentiment_score": "-0.098307",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.308246",
          "ticker_sentiment_score": "-0.067114",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Pharma Stock Roundup: BAYRY's Q4 Results, ABBV's Obesity Deal & More",
      "url": "https://www.zacks.com/stock/news/2427127/pharma-stock-roundup-bayrys-q4-results-abbvs-obesity-deal-more",
      "time_published": "20250307T120900",
      "authors": [
        "Kinjel Shah"
      ],
      "summary": "Bayer announces fourth-quarter results. NVO cuts cost of Wegovy for the uninsured. ABBV enters obesity space with new deal.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/07/905.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.360215"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        }
      ],
      "overall_sentiment_score": 0.002392,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.208464",
          "ticker_sentiment_score": "-0.068433",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.308246",
          "ticker_sentiment_score": "-0.098307",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.308246",
          "ticker_sentiment_score": "-0.067114",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "AbbVie Beats on Q1 Earnings & Sales, Raises '25 EPS View",
      "url": "https://www.zacks.com/stock/news/2456227/abbvie-beats-on-q1-earnings-sales-raises-25-eps-view",
      "time_published": "20250425T171800",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "ABBV's first-quarter earnings and sales beat estimates. The company raises its EPS guidance based on the strong sales performance of immunology drugs Rinvoq and Skyrizi.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/36/1919.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.995015"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.151509,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.307817",
          "ticker_sentiment_score": "0.239367",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.070105",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Recent Filing Shows That Rep. Robert Bresnahan Bought Over $28K Worth of AbbVie Stock - Advanced Micro Devices  ( NASDAQ:AMD ) , AbbVie  ( NYSE:ABBV ) ",
      "url": "https://www.benzinga.com/insights/government/25/06/45863242/recent-filing-shows-that-rep-robert-bresnahan-bought-over-28k-worth-of-abbvie-stock",
      "time_published": "20250610T150013",
      "authors": [
        "Benzinga Insights"
      ],
      "summary": "A June filing shows that Representative Robert Bresnahan reported a purchase in AbbVie ABBV, valued between $28,028 and $420,000. The transaction date is listed as May 15, 2025, with the report published on June 9, 2025. At present, AbbVie shares are trading up 0.34% at $189.81.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2023/insider_image_2.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.25"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.999186"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.25"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.25"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.25"
        }
      ],
      "overall_sentiment_score": 0.166375,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "AMD",
          "relevance_score": "0.207571",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.306963",
          "ticker_sentiment_score": "0.224897",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "COP",
          "relevance_score": "0.207571",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ELV",
          "relevance_score": "0.207571",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BRK-A",
          "relevance_score": "0.104683",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "3 High-Yield Dividend Stocks to Buy in 2025",
      "url": "https://www.fool.com/investing/2025/01/13/3-high-yield-dividend-stocks-to-buy-in-2025/",
      "time_published": "20250113T140000",
      "authors": [
        "and Prosper Junior Bakiny",
        "David Jagielski",
        "Keith Speights"
      ],
      "summary": "High-yield dividend stocks may not appeal to some investors. However, if you're among those investors looking for income, stocks that pay dividends regularly can be great additions to your portfolio.Three Motley Fool contributors have identified some especially great high-yield dividend stocks to ...",
      "banner_image": "https://g.foolcdn.com/editorial/images/803461/yield-with-coins.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.938238"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.998356"
        }
      ],
      "overall_sentiment_score": 0.277531,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.306963",
          "ticker_sentiment_score": "0.413873",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "AMGN",
          "relevance_score": "0.348103",
          "ticker_sentiment_score": "0.24875",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "AZN",
          "relevance_score": "0.04497",
          "ticker_sentiment_score": "0.125113",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.264897",
          "ticker_sentiment_score": "-0.028727",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies - Xilio Therapeutics  ( NASDAQ:XLO ) , AbbVie  ( NYSE:ABBV ) ",
      "url": "https://www.benzinga.com/pressreleases/25/02/n43653926/abbvie-and-xilio-therapeutics-announce-collaboration-and-option-agreement-to-develop-novel-tumor-a",
      "time_published": "20250212T123000",
      "authors": [
        "PRNewswire"
      ],
      "summary": "Collaboration will combine AbbVie's oncology expertise and Xilio's proprietary tumor-activation technology to develop novel immunotherapies, including masked T-cell engagers Xilio to host investor conference call and webcast today at 8:30 am EST",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Economy - Fiscal",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.891286"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.13857,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "GOOG",
          "relevance_score": "0.024029",
          "ticker_sentiment_score": "0.138296",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "META",
          "relevance_score": "0.024029",
          "ticker_sentiment_score": "0.138296",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "XLO",
          "relevance_score": "0.143415",
          "ticker_sentiment_score": "0.074153",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.304621",
          "ticker_sentiment_score": "0.115175",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Pfizer Signs Experimental Drug Licensing Agreement With 3SBio",
      "url": "https://www.zacks.com/stock/news/2474422/pfizer-signs-experimental-drug-licensing-agreement-with-3sbio",
      "time_published": "20250520T102800",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Pfizer inks Experimental Drug Licensing Deal With China-based company 3SBio.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/89/447.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.451494"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": -0.042966,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "NVS",
          "relevance_score": "0.304428",
          "ticker_sentiment_score": "0.090879",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.304428",
          "ticker_sentiment_score": "0.090879",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.75957",
          "ticker_sentiment_score": "-0.071115",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TRSBF",
          "relevance_score": "0.103778",
          "ticker_sentiment_score": "-0.002224",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Why Is AbbVie  ( ABBV )  Down 10.2% Since Last Earnings Report?",
      "url": "https://www.zacks.com/stock/news/2377271/why-is-abbvie-abbv-down-102-since-last-earnings-report",
      "time_published": "20241129T163142",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "AbbVie (ABBV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default118.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.998287"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.266143"
        }
      ],
      "overall_sentiment_score": 0.098416,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.302314",
          "ticker_sentiment_score": "0.185561",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Earnings Preview: AbbVie  ( ABBV )  Q4 Earnings Expected to Decline",
      "url": "https://www.zacks.com/stock/news/2403002/earnings-preview-abbvie-abbv-q4-earnings-expected-to-decline",
      "time_published": "20250124T150029",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default130.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.316726"
        }
      ],
      "overall_sentiment_score": 0.14793,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.299478",
          "ticker_sentiment_score": "0.002231",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "US Futures Gain Amid Back-To-Back Gains On Wall Street, Nikkei Opens In The Green, Dollar Edges Higher - Aon  ( NYSE:AON ) , AbbVie  ( NYSE:ABBV ) ",
      "url": "https://www.benzinga.com/markets/25/04/44999625/us-futures-gain-amid-back-to-back-gains-on-wall-street-nikkei-opens-in-the-green-dollar-edges-higher",
      "time_published": "20250425T015118",
      "authors": [
        "Vishaal Sanjay"
      ],
      "summary": "U.S. stock futures are up Thursday night following three back-to-back days in the green during the regular session, amid growing earnings optimism and easing trade tensions. The S&P 500 Futures are up 0.37%, at 5,531, followed by Nasdaq Futures at 19,416, up 0.49%, and finally Dow Futures trading ...",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2025/04/24/Double-Exposure-Image-Of-Coin-Stacks-On-.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Markets",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        },
        {
          "topic": "Economy - Macro",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.149751,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "AON",
          "relevance_score": "0.297661",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.297661",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HCA",
          "relevance_score": "0.297661",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "3 Dividend Stocks to Buy and Hold for the Next Decade",
      "url": "https://www.fool.com/investing/2025/04/28/3-dividend-stocks-to-buy-and-hold-for-the-next-dec/",
      "time_published": "20250428T114700",
      "authors": [
        "Keith Speights",
        "and Prosper Junior Bakiny",
        "David Jagielski"
      ],
      "summary": "Many income investors would love to have a low-maintenance portfolio that doesn't require constant attention. They'd prefer to buy great stocks and rake in the dividends without any hiccups.Three Motley Fool contributors believe they've identified fantastic dividend stocks to buy and hold for the ...",
      "banner_image": "https://g.foolcdn.com/editorial/images/816017/person-smiling-and-looking-at-laptop.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.875462"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.658903"
        }
      ],
      "overall_sentiment_score": 0.360652,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "PFE",
          "relevance_score": "0.375879",
          "ticker_sentiment_score": "0.383007",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.29689",
          "ticker_sentiment_score": "0.312283",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.256089",
          "ticker_sentiment_score": "0.245564",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Can J&J's Innovative Medicines Unit Sustain Growth Amid Stelara LOE?",
      "url": "https://www.zacks.com/stock/news/2503216/can-jjs-innovative-medicines-unit-sustain-growth-amid-stelara-loe",
      "time_published": "20250616T130000",
      "authors": [
        "Kinjel Shah"
      ],
      "summary": "JNJ's Innovative Medicines unit shows a growth trend, defying Stelara LOE and the negative impact of the Part D redesign.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f5/284.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.614606"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        }
      ],
      "overall_sentiment_score": 0.232431,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "AZN",
          "relevance_score": "0.151064",
          "ticker_sentiment_score": "0.154353",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.075874",
          "ticker_sentiment_score": "0.077269",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.224903",
          "ticker_sentiment_score": "0.192759",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.296761",
          "ticker_sentiment_score": "0.208815",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "AMGN",
          "relevance_score": "0.224903",
          "ticker_sentiment_score": "0.214512",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.224903",
          "ticker_sentiment_score": "0.204485",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "SNY",
          "relevance_score": "0.075874",
          "ticker_sentiment_score": "0.122375",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "3 Fabulous Dividend Stocks to Buy in February",
      "url": "https://www.fool.com/investing/2025/02/09/3-fabulous-dividend-stocks-to-buy-in-february/",
      "time_published": "20250209T193000",
      "authors": [
        "and Prosper Junior Bakiny",
        "Keith Speights",
        "David Jagielski"
      ],
      "summary": "February is the shortest month, but that doesn't mean income investors don't have much time to find great stocks. Three Motley Fool contributors believe they have identified fabulous dividend stocks to buy this month. Here's why they like AbbVie ( NYSE: ABBV ) , Amgen ( NASDAQ: AMGN ) , and ...",
      "banner_image": "https://g.foolcdn.com/editorial/images/806744/happy-stock-investor-holding-smartphone.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.623304"
        }
      ],
      "overall_sentiment_score": 0.275177,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "AMGN",
          "relevance_score": "0.334978",
          "ticker_sentiment_score": "0.220071",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.289462",
          "ticker_sentiment_score": "0.149472",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GILD",
          "relevance_score": "0.195419",
          "ticker_sentiment_score": "0.113217",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "3 High-Yield Dividend Stocks to Buy Now and Hold at Least a Decade",
      "url": "https://www.fool.com/investing/2025/01/04/3-high-yield-dividend-stocks-to-buy-now-and-hold-a/",
      "time_published": "20250104T101900",
      "authors": [
        "Cory Renauer"
      ],
      "summary": "If you're worried about having enough passive income to maintain your lifestyle during retirement, you're not alone. Having to spend more just to maintain their current standard of living is a constant concern for most families.There isn't much that you can do to stop the march of inflation, but ...",
      "banner_image": "https://g.foolcdn.com/editorial/images/802604/individual-investor-three-stock-charts-getty.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.451494"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.365926"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.858979"
        }
      ],
      "overall_sentiment_score": 0.100465,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.287762",
          "ticker_sentiment_score": "0.168234",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.049019",
          "ticker_sentiment_score": "0.076228",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MDT",
          "relevance_score": "0.194242",
          "ticker_sentiment_score": "0.03334",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BMY",
          "relevance_score": "0.287762",
          "ticker_sentiment_score": "0.056246",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "These 2 Dividend Stocks Are Absolute Bargains Right Now",
      "url": "https://www.fool.com/investing/2025/02/08/these-2-dividend-stocks-are-absolute-bargains-now/",
      "time_published": "20250208T133000",
      "authors": [
        "Prosper Junior Bakiny"
      ],
      "summary": "Dividend stocks are great for many reasons, not least because any company that can sustain growing payouts for a long time likely has a strong underlying business. It's even better to invest in excellent income stocks when they seem to be trading at attractive valuations, which isn't always easy ...",
      "banner_image": "https://g.foolcdn.com/editorial/images/806282/physician-giving-medicine-to-elderly-patient.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.988915"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        }
      ],
      "overall_sentiment_score": 0.261876,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.286193",
          "ticker_sentiment_score": "0.195708",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "GILD",
          "relevance_score": "0.49084",
          "ticker_sentiment_score": "0.317819",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "3 Magnificent Stocks That Are Passive Income Machines",
      "url": "https://www.fool.com/investing/2025/05/17/3-magnificent-stocks-that-are-passive-income-machi/",
      "time_published": "20250517T104000",
      "authors": [
        "and Prosper Junior Bakiny",
        "Keith Speights",
        "David Jagielski"
      ],
      "summary": "Make money without even trying: That's what passive income is all about. But good investment alternatives are required to make this \"easy\" money.Three Motley Fool contributors believe they have found some great dividend stocks that fit the bill.",
      "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F818484%2Fpassive-income.jpg&op=resize&w=700",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.413559"
        }
      ],
      "overall_sentiment_score": 0.344075,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "SPGI",
          "relevance_score": "0.04872",
          "ticker_sentiment_score": "0.134965",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.286082",
          "ticker_sentiment_score": "0.268248",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.193078",
          "ticker_sentiment_score": "0.227804",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.286082",
          "ticker_sentiment_score": "0.358714",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "3 Unstoppable Dividend-Growth Stocks Yielding More Than 3% That Income-Seeking Investors Want to Buy in 2025 and Hold Forever",
      "url": "https://www.fool.com/investing/2025/01/21/3-unstoppable-dividend-growth-stocks-yielding-more/",
      "time_published": "20250121T091700",
      "authors": [
        "Cory Renauer"
      ],
      "summary": "Investors seeking a steadily growing passive income stream want to turn their heads toward the healthcare sector. Unlike with enterprise software sales or consumer goods, spending on healthcare tends to move in a positive direction regardless of what's happening to the overall economy.In 2023, ...",
      "banner_image": "https://g.foolcdn.com/editorial/images/804374/investor-with-stock-chart-getty.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.360215"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        }
      ],
      "overall_sentiment_score": 0.236502,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.285526",
          "ticker_sentiment_score": "0.15898",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.048621",
          "ticker_sentiment_score": "0.084124",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MDT",
          "relevance_score": "0.285526",
          "ticker_sentiment_score": "0.215993",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "AZN",
          "relevance_score": "0.097062",
          "ticker_sentiment_score": "0.222534",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.145145",
          "ticker_sentiment_score": "0.133649",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies - Xilio Therapeutics  ( NASDAQ:XLO ) , AbbVie  ( NYSE:ABBV ) ",
      "url": "https://www.benzinga.com/pressreleases/25/02/g43654121/abbvie-and-xilio-therapeutics-announce-collaboration-and-option-agreement-to-develop-novel-tumor-a",
      "time_published": "20250212T123300",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "Collaboration will combine AbbVie's oncology expertise and Xilio's proprietary tumor-activation technology to develop novel immunotherapies, including masked T-cell engagers Xilio to host investor conference call and webcast today at 8:30 am EST",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Economy - Fiscal",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.891286"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.133937,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "GOOG",
          "relevance_score": "0.024029",
          "ticker_sentiment_score": "0.138296",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "META",
          "relevance_score": "0.024029",
          "ticker_sentiment_score": "0.138296",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "XLO",
          "relevance_score": "0.119711",
          "ticker_sentiment_score": "0.058178",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.282234",
          "ticker_sentiment_score": "0.104258",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "3 Cheap Stocks to Buy With Your Tax Refund Check",
      "url": "https://www.fool.com/investing/2025/03/07/3-cheap-stocks-to-buy-with-your-tax-refund-check/",
      "time_published": "20250307T103000",
      "authors": [
        "David Jagielski"
      ],
      "summary": "The average tax refund in 2024 was $3,138, which was similar to the $3,167 it averaged the previous year. While tax refunds will vary depending on a person's individual financial situation, if you receive one, it can provide you with some extra cash you can put toward paying down debt, adding to ...",
      "banner_image": "https://g.foolcdn.com/editorial/images/809460/a-family-meeting-with-an-advisor.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.980922"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.495866"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.28533,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "BABA",
          "relevance_score": "0.334008",
          "ticker_sentiment_score": "0.302491",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.280938",
          "ticker_sentiment_score": "0.391236",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "FDX",
          "relevance_score": "0.334008",
          "ticker_sentiment_score": "0.241755",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "EMA Panel Endorses Lilly's Omvoh for Expanded Use in Crohn's Disease",
      "url": "https://www.zacks.com/stock/news/2383727/ema-panel-endorses-lillys-omvoh-for-expanded-use-in-crohns-disease",
      "time_published": "20241216T122300",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "The CHMP's opinion is based on late-stage data, which show that LLY's Omvoh is effective in Crohn's disease patients with or without prior biologic failure.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.281043,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.331765",
          "ticker_sentiment_score": "0.295927",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.279015",
          "ticker_sentiment_score": "0.292425",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.056943",
          "ticker_sentiment_score": "0.157973",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.113597",
          "ticker_sentiment_score": "0.129758",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SNY",
          "relevance_score": "0.056943",
          "ticker_sentiment_score": "0.157973",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "AbbVie's Recently Acquired Parkinson's Drug Meets Third Study Goal",
      "url": "https://www.zacks.com/stock/news/2381629/abbvies-recently-acquired-parkinsons-drug-meets-third-study-goal",
      "time_published": "20241210T153900",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Data from a late-stage study shows that treatment with flexible doses of ABBV's tavapadon reduced the burden of Parkinson's disease.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/31/1512.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.928139"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.174388,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.273399",
          "ticker_sentiment_score": "0.138801",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CTMX",
          "relevance_score": "0.220308",
          "ticker_sentiment_score": "0.008688",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SPRO",
          "relevance_score": "0.166169",
          "ticker_sentiment_score": "0.03811",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CSTL",
          "relevance_score": "0.220308",
          "ticker_sentiment_score": "0.126897",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "2 High-Yield Dividend Stocks to Buy Now for a Lifetime of Passive Income",
      "url": "https://www.fool.com/investing/2024/11/26/2-high-yield-dividend-stocks-to-buy-now-for-a-life/",
      "time_published": "20241126T100300",
      "authors": [
        "Cory Renauer"
      ],
      "summary": "Investors looking for a way to pump up their passive income streams want to turn their attention toward the pharmaceutical industry. From the end of 2022 through Nov. 22, the benchmark S&P 500 index rose by a stunning 55.5%, but many of its drug-selling components haven't participated in the ...",
      "banner_image": "https://media.ycharts.com/charts/34d49543d4741856f5330321da34b958.png",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        }
      ],
      "overall_sentiment_score": 0.220953,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "BHVN",
          "relevance_score": "0.055751",
          "ticker_sentiment_score": "0.098877",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.273399",
          "ticker_sentiment_score": "0.08876",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.055751",
          "ticker_sentiment_score": "0.102879",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.37552",
          "ticker_sentiment_score": "0.427768",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "3 Incredible Dividend Stocks to Buy in 2025",
      "url": "https://www.fool.com/investing/2025/01/11/3-incredible-dividend-stocks-to-buy-in-2025/",
      "time_published": "20250111T083800",
      "authors": [
        "Justin Pope"
      ],
      "summary": "These wildly successful companies are poised to keep your dividend portfolio healthy in 2025 and beyond.",
      "banner_image": "https://g.foolcdn.com/editorial/images/803184/healthcare-dividend-stocks.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.459462"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.875462"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.346562,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.26928",
          "ticker_sentiment_score": "0.340948",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "MDT",
          "relevance_score": "0.181477",
          "ticker_sentiment_score": "0.133639",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HCSG",
          "relevance_score": "0.045743",
          "ticker_sentiment_score": "0.014794",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "UNH",
          "relevance_score": "0.181477",
          "ticker_sentiment_score": "0.107804",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Here's How Lilly's Non-Obesity Drugs are Contributing to Sales Growth",
      "url": "https://www.zacks.com/stock/news/2561639/heres-how-lillys-non-obesity-drugs-are-contributing-to-sales-growth",
      "time_published": "20250703T122000",
      "authors": [
        "Sundeep Ganoria"
      ],
      "summary": "LLY's non-obesity drugs like Verzenio and Taltz are fueling sales growth as investor focus stays on GLP-1 blockbusters.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.77141"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.239939,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.393977",
          "ticker_sentiment_score": "0.235995",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.269033",
          "ticker_sentiment_score": "0.239138",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Class Action Filed Against Cerevel Therapeutics Holdings, Inc.  ( ABBV )  - June 3, 2025 Deadline to Join - Contact Levi & Korsinsky - AbbVie  ( NYSE:ABBV ) ",
      "url": "https://www.benzinga.com/pressreleases/25/05/g45699823/class-action-filed-against-cerevel-therapeutics-holdings-inc-abbv-june-3-2025-deadline-to-join-con",
      "time_published": "20250530T163800",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "NEW YORK, May 30, 2025 ( GLOBE NEWSWIRE ) -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. ( \"Cerevel Therapeutics Holdings, Inc.\" or the \"Company\" ) ABBV of a class action securities lawsuit.",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "IPO",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.955357"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.136781,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.268294",
          "ticker_sentiment_score": "0.083819",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Cerevel Therapeutics Holdings, Inc.  ( ABBV )  Shareholders - AbbVie  ( NYSE:ABBV ) ",
      "url": "https://www.benzinga.com/pressreleases/25/05/g45501249/levi-korsinsky-announces-the-filing-of-a-securities-class-action-on-behalf-of-cerevel-therapeutics",
      "time_published": "20250519T173000",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "NEW YORK, May 19, 2025 ( GLOBE NEWSWIRE ) -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. ( \"Cerevel Therapeutics Holdings, Inc.\" or the \"Company\" ) ABBV of a class action securities lawsuit.",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "IPO",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.955357"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.136781,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.268294",
          "ticker_sentiment_score": "0.083819",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of June 3, 2025 in Cerevel Therapeutics Holdings, Inc. Lawsuit - ABBV - AbbVie  ( NYSE:ABBV ) ",
      "url": "https://www.benzinga.com/pressreleases/25/05/g45473716/levi-korsinsky-reminds-shareholders-of-a-lead-plaintiff-deadline-of-june-3-2025-in-cerevel-therape",
      "time_published": "20250516T171900",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "NEW YORK, May 16, 2025 ( GLOBE NEWSWIRE ) -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. ( \"Cerevel Therapeutics Holdings, Inc.\" or the \"Company\" ) ABBV of a class action securities lawsuit.",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "IPO",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.955357"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.136781,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.268294",
          "ticker_sentiment_score": "0.083819",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Levi & Korsinsky Notifies Shareholders of Cerevel Therapeutics Holdings, Inc. ( ABBV )  of a Class Action Lawsuit and an Upcoming Deadline - AbbVie  ( NYSE:ABBV ) ",
      "url": "https://www.benzinga.com/pressreleases/25/05/g45296118/levi-korsinsky-notifies-shareholders-of-cerevel-therapeutics-holdings-inc-abbv-of-a-class-action-l",
      "time_published": "20250508T175700",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "NEW YORK, May 08, 2025 ( GLOBE NEWSWIRE ) -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. ( \"Cerevel Therapeutics Holdings, Inc.\" or the \"Company\" ) ABBV of a class action securities lawsuit.",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "IPO",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.955357"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.136781,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.268294",
          "ticker_sentiment_score": "0.083819",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Cerevel Therapeutics Holdings, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before June 3, 2025 to Discuss Your Rights - ABBV - AbbVie  ( NYSE:ABBV ) ",
      "url": "https://www.benzinga.com/pressreleases/25/05/g45202669/cerevel-therapeutics-holdings-inc-sued-for-securities-law-violations-contact-levi-korsinsky-before",
      "time_published": "20250505T175300",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "NEW YORK, May 05, 2025 ( GLOBE NEWSWIRE ) -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. ( \"Cerevel Therapeutics Holdings, Inc.\" or the \"Company\" ) ABBV of a class action securities lawsuit.",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "IPO",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.955357"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.136781,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.268294",
          "ticker_sentiment_score": "0.083819",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Levi & Korsinsky Reminds Cerevel Therapeutics Holdings, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 3, 2025 - ABBV - AbbVie  ( NYSE:ABBV ) ",
      "url": "https://www.benzinga.com/pressreleases/25/04/g45077118/levi-korsinsky-reminds-cerevel-therapeutics-holdings-inc-investors-of-the-pending-class-action-law",
      "time_published": "20250429T171800",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "NEW YORK, April 29, 2025 ( GLOBE NEWSWIRE ) -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. ( \"Cerevel Therapeutics Holdings, Inc.\" or the \"Company\" ) ABBV of a class action securities lawsuit.",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "IPO",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.955357"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.136781,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.268294",
          "ticker_sentiment_score": "0.083819",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Cerevel Therapeutics Holdings, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before June 3, 2025 to Discuss Your Rights - ABBV - AbbVie  ( NYSE:ABBV ) ",
      "url": "https://www.benzinga.com/pressreleases/25/04/g44885643/cerevel-therapeutics-holdings-inc-sued-for-securities-law-violations-investors-should-contact-levi",
      "time_published": "20250418T170200",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "NEW YORK, April 18, 2025 ( GLOBE NEWSWIRE ) -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. ( \"Cerevel Therapeutics Holdings, Inc.\" or the \"Company\" ) ABBV of a class action securities lawsuit.",
      "banner_image": "https://ml.globenewswire.com/media/d91bd4e6-7d18-43f7-a479-4f992242a82a/small/gradient-box-png.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "IPO",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.955357"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.136781,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.268294",
          "ticker_sentiment_score": "0.083819",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "2 Magnificent Dividend Growth Stocks to Load Up On Right Now",
      "url": "https://www.fool.com/investing/2025/02/20/2-magnificent-dividend-growth-stocks-to-load-up-on/",
      "time_published": "20250220T103000",
      "authors": [
        "George Budwell"
      ],
      "summary": "Dividend stocks have been the backbone of market returns for over a century, contributing roughly two-thirds of total returns since 1900, according to a report by the Hartford Funds. Companies that consistently raise their dividends have been particularly strong performers, thanks to their ...",
      "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F808231%2Fdividends-alternative.jpg&op=resize&w=700",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.796627"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        }
      ],
      "overall_sentiment_score": 0.457042,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "SPGI",
          "relevance_score": "0.317527",
          "ticker_sentiment_score": "0.427834",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.266828",
          "ticker_sentiment_score": "0.369244",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Top Stock Reports for Eli Lilly, AbbVie & Gilead Sciences",
      "url": "https://www.zacks.com/research-daily/2380721/top-stock-reports-for-eli-lilly-abbvie-gilead-sciences",
      "time_published": "20241209T201500",
      "authors": [
        "Sheraz Mian"
      ],
      "summary": "Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), AbbVie Inc. (ABBV) and Gilead Sciences, Inc. (GILD), as well as two micro-cap stocks, Air T, Inc. (AIRT) and Fossil Group, Inc. (FOSL).",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default347.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.5"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.216563,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.199037",
          "ticker_sentiment_score": "0.206166",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.263231",
          "ticker_sentiment_score": "0.206527",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "FDX",
          "relevance_score": "0.06697",
          "ticker_sentiment_score": "0.096893",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FOSL",
          "relevance_score": "0.199037",
          "ticker_sentiment_score": "0.15323",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "GILD",
          "relevance_score": "0.199037",
          "ticker_sentiment_score": "0.316183",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "AIRT",
          "relevance_score": "0.13347",
          "ticker_sentiment_score": "0.107017",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "The Zacks Analyst Blog Highlights Visa, AbbVie, Analog Devices and Precipio",
      "url": "https://www.zacks.com/stock/news/2397870/the-zacks-analyst-blog-highlights-visa-abbvie-analog-devices-and-precipio",
      "time_published": "20250116T093000",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "Visa, AbbVie, Analog Devices and Precipio are included in this Analyst Blog.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/31/119.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.5"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.614606"
        }
      ],
      "overall_sentiment_score": 0.27906,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.262805",
          "ticker_sentiment_score": "0.177954",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "PRPO",
          "relevance_score": "0.159569",
          "ticker_sentiment_score": "0.086864",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ADI",
          "relevance_score": "0.159569",
          "ticker_sentiment_score": "0.154367",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "V",
          "relevance_score": "0.159569",
          "ticker_sentiment_score": "0.179513",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Why Investors Need to Take Advantage of These 2 Medical Stocks Now",
      "url": "https://www.zacks.com/stock/news/2457615/why-investors-need-to-take-advantage-of-these-2-medical-stocks-now",
      "time_published": "20250429T125008",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default97.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.87644"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.999996"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.375568,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "HUM",
          "relevance_score": "0.383905",
          "ticker_sentiment_score": "0.389152",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.261818",
          "ticker_sentiment_score": "0.302202",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "AbbVie  ( ABBV )  Earnings Expected to Grow: What to Know Ahead of Next Week's Release",
      "url": "https://www.zacks.com/stock/news/2451282/abbvie-abbv-earnings-expected-to-grow-what-to-know-ahead-of-next-weeks-release",
      "time_published": "20250418T140017",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default195.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.365926"
        }
      ],
      "overall_sentiment_score": 0.1357,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.260652",
          "ticker_sentiment_score": "0.063385",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Pharma Stock Roundup: JNJ's Q4 Earnings, FDA Nod to AZN, Daiichi Drug",
      "url": "https://www.zacks.com/stock/news/2403209/pharma-stock-roundup-jnjs-q4-earnings-fda-nod-to-azn-daiichi-drug",
      "time_published": "20250124T200000",
      "authors": [
        "Kinjel Shah"
      ],
      "summary": "J&J announces Q4 earnings. FDA approves AZN and Daiichi's Dato-DXd for breast cancer.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/66/1019.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.890401"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        }
      ],
      "overall_sentiment_score": 0.098807,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.258808",
          "ticker_sentiment_score": "0.062498",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AZN",
          "relevance_score": "0.258808",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.043898",
          "ticker_sentiment_score": "-0.297827",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "SNY",
          "relevance_score": "0.21686",
          "ticker_sentiment_score": "0.122958",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Why Investors Need to Take Advantage of These 2 Medical Stocks Now",
      "url": "https://www.zacks.com/stock/news/2408118/why-investors-need-to-take-advantage-of-these-2-medical-stocks-now",
      "time_published": "20250203T135012",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default344.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999855"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.316726"
        }
      ],
      "overall_sentiment_score": 0.391163,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "INSP",
          "relevance_score": "0.378094",
          "ticker_sentiment_score": "0.378134",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.257668",
          "ticker_sentiment_score": "0.311083",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "The Smartest Dividend Stocks to Buy With $1,000 Right Now",
      "url": "https://www.fool.com/investing/2024/12/26/the-smartest-dividend-stocks-to-buy-with-1000-now/",
      "time_published": "20241226T103500",
      "authors": [
        "Selena Maranjian"
      ],
      "summary": "If you're looking for attractive dividend-paying stocks, that's a smart move. If you're not, perhaps reconsider -- because:Here are three dividend stocks to consider for your long-term portfolio.Image source: Getty Images.Continue reading ...",
      "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F802040%2Fgetty-pointing-to-cash-fanned-out-in-hand.jpg&op=resize&w=700",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.87644"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.918141"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.343141,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "KVUE",
          "relevance_score": "0.130571",
          "ticker_sentiment_score": "0.044521",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.257668",
          "ticker_sentiment_score": "0.118563",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "T",
          "relevance_score": "0.130571",
          "ticker_sentiment_score": "0.193745",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.194763",
          "ticker_sentiment_score": "0.372067",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Worried About a Market Meltdown? 2 Dividend Stocks to Own Forever.",
      "url": "https://www.fool.com/investing/2025/03/12/worried-about-a-market-meltdown-2-dividend-stocks/",
      "time_published": "20250312T111000",
      "authors": [
        "Bradley Guichard"
      ],
      "summary": "I often say that investing rarely has a dull moment, which is why I find it so fascinating. The beginning of 2025 certainly has been no different.The new administration wasted no time implementing many policies, including sweeping layoffs of federal employees and tariffs and tariff threats.",
      "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F810419%2Fvici.png&op=resize&w=700",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.796627"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.206122,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "NVDA",
          "relevance_score": "0.052226",
          "ticker_sentiment_score": "0.17991",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "VICI",
          "relevance_score": "0.104228",
          "ticker_sentiment_score": "0.164697",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "CZR",
          "relevance_score": "0.052226",
          "ticker_sentiment_score": "0.095991",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.256719",
          "ticker_sentiment_score": "0.175644",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.052226",
          "ticker_sentiment_score": "0.155",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Is AbbVie Stock a Buy?",
      "url": "https://www.fool.com/investing/2024/12/23/is-abbvie-stock-a-buy/",
      "time_published": "20241223T133000",
      "authors": [
        "Alex Carchidi"
      ],
      "summary": "With its shares offering a total return of nearly 49% over the last three years, trumping the market's return of 33%, AbbVie ( NYSE: ABBV ) is a powerhouse big pharma that has a lot of upside to offer to investors.While there's no guarantee the next three years of the company's life will ...",
      "banner_image": "https://g.foolcdn.com/editorial/images/801761/one-investor-explains-something-to-another-at-a-cafe.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.538269"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.459462"
        }
      ],
      "overall_sentiment_score": 0.222893,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.255641",
          "ticker_sentiment_score": "0.243133",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Will These 5 Large Drug Maker Stocks Surpass Q1 Earnings Forecast?",
      "url": "https://www.zacks.com/stock/news/2452818/will-these-5-large-drug-maker-stocks-surpass-q1-earnings-forecast",
      "time_published": "20250422T130600",
      "authors": [
        "Ahan Chakraborty"
      ],
      "summary": "Let's look at five big pharma companies, GILD, BMY, MRK, ABBV and SNY slated to release their first-quarter 2025 results this week.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ba/1149.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.127052,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.254878",
          "ticker_sentiment_score": "0.097412",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GILD",
          "relevance_score": "0.183616",
          "ticker_sentiment_score": "0.081117",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AZN",
          "relevance_score": "0.03704",
          "ticker_sentiment_score": "-0.136139",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BMY",
          "relevance_score": "0.110802",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.074001",
          "ticker_sentiment_score": "0.041489",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SNY",
          "relevance_score": "0.219477",
          "ticker_sentiment_score": "-0.001688",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "3 Top AI-Powered Biotech Stocks to Buy in February",
      "url": "https://www.fool.com/investing/2025/02/06/3-top-ai-powered-biotech-stocks-to-buy-in-february/",
      "time_published": "20250206T144500",
      "authors": [
        "Dan Victor"
      ],
      "summary": "Artificial intelligence ( AI ) is transforming various industries as a major investing theme in 2025. The technology's ability to automate complex workflows and enhance productivity is seen as a game-changer for the next generation of innovation.Perhaps the most promising AI application is its ...",
      "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F806273%2Fai-powered-biotech-stocks-bullish-2025-outlook.jpg&op=resize&w=700",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.95493"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.918141"
        }
      ],
      "overall_sentiment_score": 0.455484,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MRNA",
          "relevance_score": "0.20279",
          "ticker_sentiment_score": "0.363408",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.251941",
          "ticker_sentiment_score": "0.292382",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "GILD",
          "relevance_score": "0.152821",
          "ticker_sentiment_score": "0.383349",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Why Is Nano-Cap Cancer-Focused Xilio Therapeutics Stock Trading Over 100% On Wednesday? - Xilio Therapeutics  ( NASDAQ:XLO ) ",
      "url": "https://www.benzinga.com/general/biotech/25/02/43662901/why-is-nano-cap-cancer-focused-xilio-therapeutics-stock-trading-over-100-on-wednesday",
      "time_published": "20250212T154446",
      "authors": [
        "Vandana Singh"
      ],
      "summary": "Xilio will receive $52M upfront, including a $10M equity investment, with up to $2.1B in potential milestone payments and tiered royalties. Xilio plans IND submissions for PSMA ( Q1 2027 ) , CLDN18.2 ( Q2 2027 ) , and STEAP1 ( H2 2027 ) as targets for various cancers.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2025/02/12/XLO.png?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.316726"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.110757,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "XLO",
          "relevance_score": "0.329551",
          "ticker_sentiment_score": "0.084101",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.250386",
          "ticker_sentiment_score": "0.277495",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "The Zacks Analyst Blog Highlights Eli Lilly, AbbVie, Gilead Sciences, Air T and Fossil Group",
      "url": "https://www.zacks.com/stock/news/2381245/the-zacks-analyst-blog-highlights-eli-lilly-abbvie-gilead-sciences-air-t-and-fossil-group",
      "time_published": "20241210T100000",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "Eli Lilly, AbbVie, Gilead Sciences, Air T and Fossil Group are included in this Analyst Blog.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.206635,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.189175",
          "ticker_sentiment_score": "0.119414",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.250386",
          "ticker_sentiment_score": "0.124977",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FDX",
          "relevance_score": "0.063594",
          "ticker_sentiment_score": "0.096533",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FOSL",
          "relevance_score": "0.189175",
          "ticker_sentiment_score": "0.073565",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GILD",
          "relevance_score": "0.189175",
          "ticker_sentiment_score": "0.223654",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "AIRT",
          "relevance_score": "0.126784",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "3 Dividend Stocks to Double Up on Right Now",
      "url": "https://www.fool.com/investing/2025/02/09/3-dividend-stocks-to-double-up-on-right-now/",
      "time_published": "20250209T104300",
      "authors": [
        "Keith Speights"
      ],
      "summary": "What's better than a good thing? More of a good thing.Income investors can find plenty of \"good things\" in the market these days. There are many stocks with exceptional dividends to check out. And some are especially worthy of investors' attention.Here are three dividend stocks to double up on ...",
      "banner_image": "https://g.foolcdn.com/editorial/images/806573/excited-investor-looks-at-financial-charts-on-computer.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.875462"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.263663,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ENB",
          "relevance_score": "0.30928",
          "ticker_sentiment_score": "0.332539",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.422493",
          "ticker_sentiment_score": "0.230647",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.249744",
          "ticker_sentiment_score": "0.078207",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "The Zacks Analyst Blog Highlights AbbVie, Amgen, Stryker, Dexcom and Medtronic",
      "url": "https://www.zacks.com/stock/news/2419902/the-zacks-analyst-blog-highlights-abbvie-amgen-stryker-dexcom-and-medtronic",
      "time_published": "20250224T091700",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "AbbVie, Amgen, Stryker, Dexcom and Medtronic are included in this Analyst Blog.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/5e/1093.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.996023"
        }
      ],
      "overall_sentiment_score": 0.297146,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "XLO",
          "relevance_score": "0.036255",
          "ticker_sentiment_score": "0.068088",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.249653",
          "ticker_sentiment_score": "0.193994",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "MDT",
          "relevance_score": "0.072435",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SYK",
          "relevance_score": "0.214937",
          "ticker_sentiment_score": "0.352535",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "AMGN",
          "relevance_score": "0.214937",
          "ticker_sentiment_score": "0.169687",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "DXCM",
          "relevance_score": "0.249653",
          "ticker_sentiment_score": "0.212881",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Healthy Returns: AbbVie is the newest potential weight loss drug market player",
      "url": "https://www.cnbc.com/2025/03/04/healthy-returns-abbvie-is-the-newest-potential-weight-loss-drug-player.html",
      "time_published": "20250304T195911",
      "authors": [],
      "summary": "AbbVie will pay up to $2.2 billion to develop Danish drugmaker Gubra's obesity drug. AI takes center stage at HIMSS conference gets underway in Vegas.",
      "banner_image": null,
      "source": "CNBC",
      "category_within_source": "Top News",
      "source_domain": "www.cnbc.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.236487,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MSFT",
          "relevance_score": "0.072",
          "ticker_sentiment_score": "0.155149",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "GOOG",
          "relevance_score": "0.036037",
          "ticker_sentiment_score": "0.10247",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GPCR",
          "relevance_score": "0.072",
          "ticker_sentiment_score": "-0.030489",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.248199",
          "ticker_sentiment_score": "0.15445",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "AZN",
          "relevance_score": "0.036037",
          "ticker_sentiment_score": "0.03011",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.036037",
          "ticker_sentiment_score": "0.03011",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Why Is Intra-Cellular Therapies Surging On Monday? - Intra-Cellular Therapies  ( NASDAQ:ITCI ) , Johnson & Johnson  ( NYSE:JNJ ) ",
      "url": "https://www.benzinga.com/general/biotech/25/01/42948170/like-bristol-myers-squibb-and-abbvie-johnson-johnson-seeks-to-bolster-neuropsychiatric-portfolio-",
      "time_published": "20250113T150327",
      "authors": [
        "Vandana Singh"
      ],
      "summary": "Johnson & Johnson to acquire Intra-Cellular Therapies for $132/share adding CNS-focused therapies to its portfolio. Caplyta, Intra-Cellular Therapies' approved drug for schizophrenia and bipolar depression, shows promise for expanded depression indications",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2025/01/13/Santa-Clara--Ca--Usa---Apr-29--2022-John.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        }
      ],
      "overall_sentiment_score": 0.049412,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.246999",
          "ticker_sentiment_score": "0.162359",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ITCI",
          "relevance_score": "0.598621",
          "ticker_sentiment_score": "0.018149",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BMY",
          "relevance_score": "0.166169",
          "ticker_sentiment_score": "0.200529",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.470894",
          "ticker_sentiment_score": "0.209247",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Alector/AbbVie-Partnered Alzheimer's Drug Disappoints In Mid-Stage Study; Alector Lays Off 17% Of Workforce - Alector  ( NASDAQ:ALEC ) ",
      "url": "https://www.benzinga.com/24/11/42192908/alectorabbvie-partnered-alzheimers-drug-disappoints-in-mid-stage-study-lays-off-17-of-workforce",
      "time_published": "20241126T152905",
      "authors": [
        "Vandana Singh"
      ],
      "summary": "On Monday, Alector, Inc. ALEC released results from the INVOKE-2 Phase 2 trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer's disease ( AD ) .",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2024/11/26/Understanding-Alzheimers.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        }
      ],
      "overall_sentiment_score": 0.061995,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "GSK",
          "relevance_score": "0.166169",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.246999",
          "ticker_sentiment_score": "0.08399",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ALEC",
          "relevance_score": "0.537213",
          "ticker_sentiment_score": "0.013123",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "J&J's Tremfya Gets FDA Nod for 2nd IBD Condition Crohn's Disease",
      "url": "https://www.zacks.com/stock/news/2433263/jjs-tremfya-gets-fda-nod-for-2nd-ibd-condition-crohns-disease",
      "time_published": "20250321T122800",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "FDA approves J&J's Tremfya for its fourth indication and the second IBD condition.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/07/905.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.214378"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.317022,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.182967",
          "ticker_sentiment_score": "0.212663",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.242285",
          "ticker_sentiment_score": "0.222042",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "RXDX",
          "relevance_score": "0.061473",
          "ticker_sentiment_score": "0.036066",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.061473",
          "ticker_sentiment_score": "0.110017",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.242285",
          "ticker_sentiment_score": "0.185271",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "SNY",
          "relevance_score": "0.061473",
          "ticker_sentiment_score": "0.110017",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "The Zacks Analyst Blog Highlights Alphabet, AbbVie and The Walt Disney",
      "url": "https://www.zacks.com/stock/news/2560692/the-zacks-analyst-blog-highlights-alphabet-abbvie-and-the-walt-disney",
      "time_published": "20250702T144600",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "GOOGL, ABBV, and DIS face rising costs and competition, but strong cloud, immunology, and parks growth continue to fuel optimism.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/aa/397.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.650727"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.25454,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MSFT",
          "relevance_score": "0.060848",
          "ticker_sentiment_score": "-0.08653",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GOOG",
          "relevance_score": "0.239895",
          "ticker_sentiment_score": "0.182602",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.239895",
          "ticker_sentiment_score": "0.115922",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DIS",
          "relevance_score": "0.181137",
          "ticker_sentiment_score": "0.135052",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Trump's Tariff Exemptions Include Semiconductors, Pharmaceuticals, Oil And More - Broadcom  ( NASDAQ:AVGO ) ",
      "url": "https://www.benzinga.com/news/global/25/04/44631606/trumps-tariff-exemptions-include-semiconductors-pharmaceuticals-oil-and-more",
      "time_published": "20250403T163042",
      "authors": [
        "Erica Kollmann"
      ],
      "summary": "Semiconductors, lumber, gold and oil are among the imports exempt from Trump's retaliatory tariffs. Pharmaceutical stocks are defying Thursday's broad market drop with shares of AbbVie and Johnson & Johnson both green.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2025/04/03/Economic-Tariffs-Concept--America-Tariff.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Markets",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.858979"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.116352,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.239698",
          "ticker_sentiment_score": "0.009484",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AVGO",
          "relevance_score": "0.16117",
          "ticker_sentiment_score": "-0.03527",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ASML",
          "relevance_score": "0.16117",
          "ticker_sentiment_score": "-0.03527",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.239698",
          "ticker_sentiment_score": "0.009484",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Nike To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Monday - Baker Hughes  ( NASDAQ:BKR ) , AbbVie  ( NYSE:ABBV ) ",
      "url": "https://www.benzinga.com/25/02/43443639/nike-to-rally-around-24-here-are-10-top-analyst-forecasts-for-monday",
      "time_published": "20250203T175939",
      "authors": [
        "Avi Kapoor"
      ],
      "summary": "Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. UBS cut Uber Technologies, Inc. UBER price target from $114 to $107. UBS analyst Lloyd Walmsley maintained ...",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2025/02/03/Nike-Inc-.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Markets",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.2"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.2"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.999701"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.2"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.2"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.2"
        }
      ],
      "overall_sentiment_score": 0.322456,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CRWD",
          "relevance_score": "0.237358",
          "ticker_sentiment_score": "0.324272",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "KMX",
          "relevance_score": "0.159569",
          "ticker_sentiment_score": "0.082889",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TPR",
          "relevance_score": "0.237358",
          "ticker_sentiment_score": "0.234097",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "BKR",
          "relevance_score": "0.237358",
          "ticker_sentiment_score": "0.268496",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "NKE",
          "relevance_score": "0.237358",
          "ticker_sentiment_score": "0.3326",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "TEAM",
          "relevance_score": "0.159569",
          "ticker_sentiment_score": "0.086864",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.237358",
          "ticker_sentiment_score": "0.292321",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "TRMK",
          "relevance_score": "0.237358",
          "ticker_sentiment_score": "0.211542",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "GS",
          "relevance_score": "0.159569",
          "ticker_sentiment_score": "0.086864",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "UBER",
          "relevance_score": "0.237358",
          "ticker_sentiment_score": "0.005513",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Pharma Stock Roundup: AZN, BAYRY's Earnings, ABBV's Pipeline Setback",
      "url": "https://www.zacks.com/stock/news/2371249/pharma-stock-roundup-azn-bayrys-earnings-abbvs-pipeline-setback",
      "time_published": "20241115T200000",
      "authors": [
        "Kinjel Shah"
      ],
      "summary": "AZN and BAYRY announce Q3 results. ABBV's studies on schizophrenia candidate, emraclidine, fail to meet goal.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f5/284.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.928139"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        }
      ],
      "overall_sentiment_score": 0.055653,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "AKESF",
          "relevance_score": "0.040078",
          "ticker_sentiment_score": "0.044",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.236972",
          "ticker_sentiment_score": "-0.037184",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AZN",
          "relevance_score": "0.348919",
          "ticker_sentiment_score": "0.159153",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "SMMT",
          "relevance_score": "0.040078",
          "ticker_sentiment_score": "0.044",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Pharma Stock Roundup: PFE's 2025 Outlook, MRK & ABBV's M&A Deals",
      "url": "https://www.zacks.com/stock/news/2386138/pharma-stock-roundup-pfes-2025-outlook-mrk-abbvs-ma-deals",
      "time_published": "20241220T122700",
      "authors": [
        "Kinjel Shah"
      ],
      "summary": "PFE issues its financial guidance for 2025. MRK and ABBV announce M&A deals. SNY/TEVA's IBD drug succeeds in a phase IIb study.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c3/648.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.576289"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        }
      ],
      "overall_sentiment_score": 0.180271,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.236205",
          "ticker_sentiment_score": "0.121229",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.079788",
          "ticker_sentiment_score": "-0.130229",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.311335",
          "ticker_sentiment_score": "0.109548",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SNY",
          "relevance_score": "0.236205",
          "ticker_sentiment_score": "0.126318",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "PFE, MRK, LLY & Other Drug Stocks Down Amid Tariff Jitters",
      "url": "https://www.zacks.com/stock/news/2438962/pfe-mrk-lly-other-drug-stocks-down-amid-tariff-jitters",
      "time_published": "20250402T134300",
      "authors": [
        "Kinjel Shah"
      ],
      "summary": "Stocks of PFE, MRK, ABBV, LLY and others declined on Tuesday due to uncertainty surrounding Trump's proposed tariffs on pharma imports.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/52/873.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.5"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.0,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "APG",
          "relevance_score": "0.078611",
          "ticker_sentiment_score": "0.055105",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LLY",
          "relevance_score": "0.306963",
          "ticker_sentiment_score": "0.009111",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.23281",
          "ticker_sentiment_score": "-0.114397",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.306963",
          "ticker_sentiment_score": "0.009111",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "IRWD Begins Apraglutide NDA Submission, Announces Job Cuts, Stock Falls",
      "url": "https://www.zacks.com/stock/news/2406927/irwd-begins-apraglutide-nda-submission-announces-job-cuts-stock-falls",
      "time_published": "20250130T164800",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Ironwood begins the rolling NDA filing for apraglutide to treat short bowel syndrome patients dependent on parenteral support.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/37/2337.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.769861"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        }
      ],
      "overall_sentiment_score": 0.076524,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "BMRN",
          "relevance_score": "0.175009",
          "ticker_sentiment_score": "0.066207",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RIGL",
          "relevance_score": "0.231884",
          "ticker_sentiment_score": "0.19743",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.231884",
          "ticker_sentiment_score": "0.1037",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IRWD",
          "relevance_score": "0.341699",
          "ticker_sentiment_score": "0.118363",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "3 Dividend Stocks to Buy for Reliable Passive Income",
      "url": "https://www.fool.com/investing/2025/03/19/3-dividend-stocks-to-buy-for-reliable-passive-inco/",
      "time_published": "20250319T113000",
      "authors": [
        "George Budwell"
      ],
      "summary": "You'll need passive income to live well in retirement, especially with Social Security's uncertain future. The Office of Retirement and Disability Policy says Social Security's funds might run out by 2037, which could cut benefits to about 76% of what people get now.That's why many investors are ...",
      "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F811592%2Fnapping.jpg&op=resize&w=700",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.413559"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.495866"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.543251,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CVX",
          "relevance_score": "0.231332",
          "ticker_sentiment_score": "0.36285",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.116914",
          "ticker_sentiment_score": "0.199074",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.231332",
          "ticker_sentiment_score": "0.537515",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "3 High-Yielding Dividend Stocks That Retirees Can Buy and Forget About",
      "url": "https://www.fool.com/investing/2025/04/03/3-high-yielding-dividend-stocks-that-retirees-can/",
      "time_published": "20250403T130000",
      "authors": [
        "David Jagielski"
      ],
      "summary": "\"Buy and hold\" is a simple strategy for investors, but it can be a hard one to stick to in actual practice. That's because many people want to pick stocks and trade them, and feel like they need to actively intervene to generate significant gains.",
      "banner_image": "https://g.foolcdn.com/editorial/images/812980/seniors-walking-together.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.999998"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.451494"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.256423,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "KMB",
          "relevance_score": "0.174167",
          "ticker_sentiment_score": "0.191595",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.230782",
          "ticker_sentiment_score": "0.172434",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.058472",
          "ticker_sentiment_score": "0.023982",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "XOM",
          "relevance_score": "0.230782",
          "ticker_sentiment_score": "0.305921",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Pharma Stock Roundup: JNJ's Q4 Earnings, FDA Nod to AZN, Daiichi Drug",
      "url": "https://www.zacks.com/stock/news/2403209/pharma-stock-roundup-jnjs-q4-earnings-fda-nod-to-azn-daiichi-drug",
      "time_published": "20250124T200000",
      "authors": [
        "Kinjel Shah"
      ],
      "summary": "J&J announces Q4 earnings. FDA approves AZN and Daiichi's Dato-DXd for breast cancer.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/66/1019.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.769861"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        }
      ],
      "overall_sentiment_score": 0.096412,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.230454",
          "ticker_sentiment_score": "0.062416",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AZN",
          "relevance_score": "0.230454",
          "ticker_sentiment_score": "-0.007273",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.046724",
          "ticker_sentiment_score": "-0.298767",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "SNY",
          "relevance_score": "0.185306",
          "ticker_sentiment_score": "0.116766",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "4 Seniors & Aging Demographics Stocks to Watch Right Now",
      "url": "https://www.zacks.com/stock/news/2419676/4-seniors-aging-demographics-stocks-to-watch-right-now",
      "time_published": "20250221T160600",
      "authors": [
        "Urmimala Biswas"
      ],
      "summary": "ABBV, AMGN, SYK and DXCM are well-poised to benefit from the evolving new opportunities in Seniors & Aging Demographics within healthcare.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c3/648.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.980922"
        }
      ],
      "overall_sentiment_score": 0.301822,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "XLO",
          "relevance_score": "0.038284",
          "ticker_sentiment_score": "0.068492",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.226653",
          "ticker_sentiment_score": "0.209437",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "SYK",
          "relevance_score": "0.18967",
          "ticker_sentiment_score": "0.401751",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "AMGN",
          "relevance_score": "0.18967",
          "ticker_sentiment_score": "0.18618",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "DXCM",
          "relevance_score": "0.226653",
          "ticker_sentiment_score": "0.244231",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "2 High-Yield Dividend Stocks to Buy for Passive Income",
      "url": "https://www.fool.com/investing/2025/04/23/2-high-yield-dividend-stocks-to-buy-for-passive-in/",
      "time_published": "20250423T123000",
      "authors": [
        "George Budwell"
      ],
      "summary": "Passive income is essential in retirement, but building a dependable stream isn't easy. Fortunately, top-tier dividend stocks can do the heavy lifting. The key is focusing on companies with strong yields, reliable payouts, and recession-resistant business models.In today's volatile market, where ...",
      "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F815615%2Fnapping.jpg&op=resize&w=700",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.744043"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.955357"
        }
      ],
      "overall_sentiment_score": 0.450331,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "PFE",
          "relevance_score": "0.170878",
          "ticker_sentiment_score": "0.364683",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.226477",
          "ticker_sentiment_score": "0.425765",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "VKTX Inks Manufacturing Deal With CordenPharma for Obesity Drug Supply",
      "url": "https://www.zacks.com/stock/news/2428877/vktx-inks-manufacturing-deal-with-cordenpharma-for-obesity-drug-supply",
      "time_published": "20250312T121800",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "The deal provides Viking Therapeutics with a secured dedicated annual supply of both injectable and oral versions of its obesity drug VK2735.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/82/41137.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.360215"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.176968,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "APG",
          "relevance_score": "0.056808",
          "ticker_sentiment_score": "0.250001",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "LLY",
          "relevance_score": "0.224383",
          "ticker_sentiment_score": "0.112483",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "VKTX",
          "relevance_score": "0.478692",
          "ticker_sentiment_score": "0.13805",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.224383",
          "ticker_sentiment_score": "0.123392",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GS",
          "relevance_score": "0.056808",
          "ticker_sentiment_score": "0.116",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.224383",
          "ticker_sentiment_score": "0.145207",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cerevel Therapeutics",
      "url": "https://www.benzinga.com/pressreleases/25/06/g45727829/shareholder-notice-faruqi-faruqi-llp-investigates-claims-on-behalf-of-investors-of-cerevel-therape",
      "time_published": "20250602T163302",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "Faruqi & Faruqi, LLP Securities Litigation Partner James ( Josh ) Wilson Encourages Investors Who Suffered Significant Losses In Cerevel To Contact Him Directly To Discuss Their Options",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.905476"
        }
      ],
      "overall_sentiment_score": 0.141424,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "META",
          "relevance_score": "0.056407",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.276491",
          "ticker_sentiment_score": "0.010625",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.222838",
          "ticker_sentiment_score": "-0.028734",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Faruqi & Faruqi Reminds Cerevel Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 3, 2025 - CERE",
      "url": "https://www.benzinga.com/pressreleases/25/05/g45337482/faruqi-faruqi-reminds-cerevel-therapeutics-investors-of-the-pending-class-action-lawsuit-with-a-le",
      "time_published": "20250511T122900",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "Faruqi & Faruqi, LLP Securities Litigation Partner James ( Josh ) Wilson Encourages Investors Who Suffered Significant Losses In Cerevel To Contact Him Directly To Discuss Their Options",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.905476"
        }
      ],
      "overall_sentiment_score": 0.141424,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "META",
          "relevance_score": "0.056407",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.276491",
          "ticker_sentiment_score": "0.010625",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.222838",
          "ticker_sentiment_score": "-0.028734",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cerevel Therapeutics",
      "url": "https://www.benzinga.com/pressreleases/25/04/g45027229/investor-alert-faruqi-faruqi-llp-investigates-claims-on-behalf-of-investors-of-cerevel-therapeutic",
      "time_published": "20250426T135000",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "Faruqi & Faruqi, LLP Securities Litigation Partner James ( Josh ) Wilson Encourages Investors Who Suffered Significant Losses In Cerevel To Contact Him Directly To Discuss Their Options",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/4c96193e-9e8a-4e5d-878a-3e41b441e24a/image1.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.905476"
        }
      ],
      "overall_sentiment_score": 0.141424,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "META",
          "relevance_score": "0.056407",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.276491",
          "ticker_sentiment_score": "0.010625",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.222838",
          "ticker_sentiment_score": "-0.028734",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "SNY, TEVA Stocks Jump on Encouraging Data From IBD Drug Study",
      "url": "https://www.zacks.com/stock/news/2385100/sny-teva-stocks-jump-on-encouraging-data-from-ibd-drug-study",
      "time_published": "20241218T132100",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Treatment with a Sanofi-Teva-partnered experimental drug meets the primary goals in a mid-stage study for Ulcerative colitis and Crohn's disease indications.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        }
      ],
      "overall_sentiment_score": 0.211447,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.222022",
          "ticker_sentiment_score": "0.24879",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "TEVA",
          "relevance_score": "0.178459",
          "ticker_sentiment_score": "0.050537",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.089797",
          "ticker_sentiment_score": "0.121313",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SNY",
          "relevance_score": "0.536492",
          "ticker_sentiment_score": "0.249183",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Lowey Dannenberg Notifies Cerevel Therapeutics Holdings, Inc.  ( \"Cerevel\" or the \"Company\" )   ( NASDAQ: CERE )  Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm",
      "url": "https://www.benzinga.com/pressreleases/25/04/g44796085/lowey-dannenberg-notifies-cerevel-therapeutics-holdings-inc-cerevel-or-the-company-nasdaq-cere-inv",
      "time_published": "20250414T165820",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "NEW YORK, April 14, 2025 ( GLOBE NEWSWIRE ) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against Cerevel Therapeutics Holdings, Inc. ( \"Cerevel\" or the \"Company\" ) CERE for violations of the ...",
      "banner_image": "https://ml.globenewswire.com/media/38c8d81f-4a6b-4f23-8411-e6be6a60dda1/small/ld-logo-png.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "IPO",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.929393"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": -0.048643,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "PFE",
          "relevance_score": "0.148731",
          "ticker_sentiment_score": "0.051084",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.221481",
          "ticker_sentiment_score": "-0.112111",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Lowey Dannenberg Notifies Cerevel Therapeutics Holdings, Inc.  ( \"Cerevel\" or the \"Company\" )   ( NASDAQ: CERE )  Investors of Securities Class Action Lawsuit and Encourages Investors with more than $50,000 in Losses to Contact the Firm",
      "url": "https://www.benzinga.com/pressreleases/25/05/g45471686/lowey-dannenberg-notifies-cerevel-therapeutics-holdings-inc-cerevel-or-the-company-nasdaq-cere-inv",
      "time_published": "20250516T152645",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "NEW YORK, May 16, 2025 ( GLOBE NEWSWIRE ) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against Cerevel Therapeutics Holdings, Inc. ( \"Cerevel\" or the \"Company\" ) CERE for violations of the federal ...",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "IPO",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.929393"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": -0.051065,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "PFE",
          "relevance_score": "0.148273",
          "ticker_sentiment_score": "0.050988",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.220809",
          "ticker_sentiment_score": "-0.111844",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Lowey Dannenberg Notifies Cerevel Therapeutics Holdings, Inc.  ( \"Cerevel\" or the \"Company\" )   ( NASDAQ: CERE )  Investors of Securities Class Action Lawsuit and Encourages Investors with more than $50,000 in Losses to Contact the Firm",
      "url": "https://www.benzinga.com/pressreleases/25/05/g45256118/lowey-dannenberg-notifies-cerevel-therapeutics-holdings-inc-cerevel-or-the-company-nasdaq-cere-inv",
      "time_published": "20250507T144200",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "NEW YORK, May 07, 2025 ( GLOBE NEWSWIRE ) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against Cerevel Therapeutics Holdings, Inc. ( \"Cerevel\" or the \"Company\" ) CERE for violations of the federal ...",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "IPO",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.929393"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": -0.051065,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "PFE",
          "relevance_score": "0.148273",
          "ticker_sentiment_score": "0.050988",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.220809",
          "ticker_sentiment_score": "-0.111844",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Lowey Dannenberg Notifies Cerevel Therapeutics Holdings, Inc.  ( \"Cerevel\" or the \"Company\" )   ( NASDAQ: CERE )  Investors of Securities Class Action Lawsuit and Encourages Investors with more than $50,000 in Losses to Contact the Firm",
      "url": "https://www.benzinga.com/pressreleases/25/04/g45069190/lowey-dannenberg-notifies-cerevel-therapeutics-holdings-inc-cerevel-or-the-company-nasdaq-cere-inv",
      "time_published": "20250429T140903",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "NEW YORK, April 29, 2025 ( GLOBE NEWSWIRE ) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against Cerevel Therapeutics Holdings, Inc. ( \"Cerevel\" or the \"Company\" ) CERE for violations of the ...",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "IPO",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.929393"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": -0.051065,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "PFE",
          "relevance_score": "0.148273",
          "ticker_sentiment_score": "0.050988",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.220809",
          "ticker_sentiment_score": "-0.111844",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Lowey Dannenberg Notifies Cerevel Therapeutics Holdings, Inc.  ( \"Cerevel\" or the \"Company\" )   ( NASDAQ: CERE )  Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm",
      "url": "https://www.benzinga.com/pressreleases/25/04/g45013696/lowey-dannenberg-notifies-cerevel-therapeutics-holdings-inc-cerevel-or-the-company-nasdaq-cere-inv",
      "time_published": "20250425T155618",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "NEW YORK, April 25, 2025 ( GLOBE NEWSWIRE ) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against Cerevel Therapeutics Holdings, Inc. ( \"Cerevel\" or the \"Company\" ) CERE for violations of the ...",
      "banner_image": "https://ml.globenewswire.com/media/38c8d81f-4a6b-4f23-8411-e6be6a60dda1/small/ld-logo-png.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "IPO",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.929393"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": -0.051065,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "PFE",
          "relevance_score": "0.148273",
          "ticker_sentiment_score": "0.050988",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.220809",
          "ticker_sentiment_score": "-0.111844",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "The Zacks Analyst Blog Highlights AbbVie, Lockheed Martin, Dell and Hamilton Beach Brands",
      "url": "https://www.zacks.com/stock/news/2430495/the-zacks-analyst-blog-highlights-abbvie-lockheed-martin-dell-and-hamilton-beach-brands",
      "time_published": "20250317T100600",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "AbbVie, Lockheed Martin, Dell and Hamilton Beach Brands are included in this Analyst Blog.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/3e/1190.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.77141"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.245412,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "LNVGF",
          "relevance_score": "0.044469",
          "ticker_sentiment_score": "-0.028997",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MSFT",
          "relevance_score": "0.044469",
          "ticker_sentiment_score": "0.253852",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "META",
          "relevance_score": "0.044469",
          "ticker_sentiment_score": "0.253852",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "NVDA",
          "relevance_score": "0.044469",
          "ticker_sentiment_score": "0.253852",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "LMT",
          "relevance_score": "0.176502",
          "ticker_sentiment_score": "0.11562",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HBCNF",
          "relevance_score": "0.044469",
          "ticker_sentiment_score": "0.21279",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "HBB",
          "relevance_score": "0.176502",
          "ticker_sentiment_score": "0.152174",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.21961",
          "ticker_sentiment_score": "0.12463",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DELL",
          "relevance_score": "0.132855",
          "ticker_sentiment_score": "0.053209",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "J&J Seeks FDA Approval for Tremfya for Psoriasis in Kids",
      "url": "https://www.zacks.com/stock/news/2378129/jj-seeks-fda-approval-for-tremfya-for-psoriasis-in-kids",
      "time_published": "20241203T135800",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "J&J files for FDA approval of Tremfya for plaque psoriasis and psoriatic arthritis indications in pediatric patients ...",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/7d/1177.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.214378"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.270878,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.219312",
          "ticker_sentiment_score": "0.221839",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.219312",
          "ticker_sentiment_score": "0.172527",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "RXDX",
          "relevance_score": "0.055492",
          "ticker_sentiment_score": "0.036",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.055492",
          "ticker_sentiment_score": "0.109865",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.219312",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SNY",
          "relevance_score": "0.110717",
          "ticker_sentiment_score": "0.088801",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "4 Surefire Dividend Stocks to Buy in the Stock Market Sell-Off",
      "url": "https://www.fool.com/investing/2025/04/26/4-surefire-dividend-stocks-to-buy-in-the-sell-off/",
      "time_published": "20250426T220500",
      "authors": [
        "Prosper Junior Bakiny"
      ],
      "summary": "It's always a good time to buy solid dividend stocks, but considering the challenging economic environment, now might be a particularly opportune time. Dividend-paying companies tend to have strong underlying operations and are generally more resilient than their non-dividend-paying counterparts.",
      "banner_image": "https://g.foolcdn.com/editorial/images/815642/gettyimages-2161678259.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.77141"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.962106"
        }
      ],
      "overall_sentiment_score": 0.306651,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ZTS",
          "relevance_score": "0.381625",
          "ticker_sentiment_score": "0.280911",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.21803",
          "ticker_sentiment_score": "0.270672",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.044141",
          "ticker_sentiment_score": "0.098191",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AMGN",
          "relevance_score": "0.175221",
          "ticker_sentiment_score": "0.176375",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "AZN",
          "relevance_score": "0.044141",
          "ticker_sentiment_score": "0.236682",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "BMY",
          "relevance_score": "0.088147",
          "ticker_sentiment_score": "0.19269",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "2 Brilliant Dividend Growth Stocks That Can Supercharge Your Portfolio",
      "url": "https://www.fool.com/investing/2025/01/14/2-brilliant-dividend-growth-stocks-that-can-superc/",
      "time_published": "20250114T131500",
      "authors": [
        "George Budwell"
      ],
      "summary": "Dividend growth investing is a powerful strategy for building lasting wealth. Companies that consistently raise their dividends tend to possess durable competitive advantages, robust cash flows, and shareholder-friendly management teams.These characteristics make dividend growth stocks compelling ...",
      "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F803818%2Fgetty-dividend-stocks-growing-money-income-cash.jpg&op=resize&w=700",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.795202"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.980922"
        }
      ],
      "overall_sentiment_score": 0.622361,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "V",
          "relevance_score": "0.164282",
          "ticker_sentiment_score": "0.413238",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.217834",
          "ticker_sentiment_score": "0.407952",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "The Zacks Analyst Blog Walmart, Visa, AbbVie and AstroNova",
      "url": "https://www.zacks.com/stock/news/2411708/the-zacks-analyst-blog-walmart-visa-abbvie-and-astronova",
      "time_published": "20250207T063400",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "Walmart, Visa, AbbVie and AstroNova are included in this Analyst Blog.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/0d/436.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.25"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.25"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.25"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.999992"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.25"
        }
      ],
      "overall_sentiment_score": 0.282743,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "RL",
          "relevance_score": "0.036091",
          "ticker_sentiment_score": "0.084051",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.213988",
          "ticker_sentiment_score": "0.176838",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ALOT",
          "relevance_score": "0.178989",
          "ticker_sentiment_score": "0.083412",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "V",
          "relevance_score": "0.213988",
          "ticker_sentiment_score": "0.210811",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "WMT",
          "relevance_score": "0.178989",
          "ticker_sentiment_score": "0.07643",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "IRWD Stock Down 15% as Q1 Earnings & Revenues Miss Estimates",
      "url": "https://www.zacks.com/stock/news/2465253/irwd-stock-down-15-as-q1-earnings-revenues-miss-estimates",
      "time_published": "20250508T135500",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Ironwood incurs a wider-than-expected loss in the first quarter of 2025. Revenues plunge year over year. Shares fall.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/37/2337.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.947132"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.097338,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ALPMF",
          "relevance_score": "0.053992",
          "ticker_sentiment_score": "0.147767",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ANIP",
          "relevance_score": "0.213517",
          "ticker_sentiment_score": "0.24134",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.213517",
          "ticker_sentiment_score": "0.061715",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IRWD",
          "relevance_score": "0.213517",
          "ticker_sentiment_score": "-0.069973",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AZN",
          "relevance_score": "0.213517",
          "ticker_sentiment_score": "0.107002",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "US Stock Futures Mixed After Three-Day Winning Streak: Expert Dismisses Market Pessimism, Says 'This Isn't Stuff You See In Bear Market' - Aon  ( NYSE:AON ) , AbbVie  ( NYSE:ABBV ) ",
      "url": "https://www.benzinga.com/markets/equities/25/04/45003860/us-stock-futures-mixed-after-three-day-winning-streak-expert-dismisses-market-pessimism-says-thi",
      "time_published": "20250425T104959",
      "authors": [
        "Vishaal Sanjay"
      ],
      "summary": "U.S. stock futures traded mixed on Friday after three consecutive days of gains, with S&P 500 futures edging higher amid rising earnings optimism and signs of easing U.S.-China trade tensions. The first quarter earnings report of Google-parent Alphabet Inc.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2025/04/25/Serious-Business-Man-Trader-Analyst-Look.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.25"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.25"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.25"
        },
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.980922"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.25"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.999919"
        },
        {
          "topic": "Economy - Macro",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.138892,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "AON",
          "relevance_score": "0.213517",
          "ticker_sentiment_score": "0.061681",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TMUS",
          "relevance_score": "0.107736",
          "ticker_sentiment_score": "0.010197",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GOOG",
          "relevance_score": "0.16099",
          "ticker_sentiment_score": "0.053811",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HCA",
          "relevance_score": "0.213517",
          "ticker_sentiment_score": "0.064936",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PG",
          "relevance_score": "0.16099",
          "ticker_sentiment_score": "-0.063166",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CL",
          "relevance_score": "0.107736",
          "ticker_sentiment_score": "0.101077",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PEP",
          "relevance_score": "0.16099",
          "ticker_sentiment_score": "-0.063166",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.213517",
          "ticker_sentiment_score": "0.060054",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SZIHF",
          "relevance_score": "0.053992",
          "ticker_sentiment_score": "0.073765",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CHTR",
          "relevance_score": "0.107736",
          "ticker_sentiment_score": "0.071613",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IVZ",
          "relevance_score": "0.053992",
          "ticker_sentiment_score": "0.323986",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Billionaire Ken Griffin Just Bought More Shares of These Unstoppable Dividend Stocks",
      "url": "https://www.fool.com/investing/2025/06/05/billionaire-ken-griffin-just-bought-more-shares-of/",
      "time_published": "20250605T120000",
      "authors": [
        "Prosper Junior Bakiny"
      ],
      "summary": "Some stock-trading platforms enable their users to automatically replicate the positions taken by experienced investors or other famous figures. Many investors might prefer to do their own research before buying shares of a company, but it's still a good idea to pay attention to some of the moves ...",
      "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F819969%2Fphysicians-in-an-operating-room.jpg&op=resize&w=700",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.976913"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.316726"
        }
      ],
      "overall_sentiment_score": 0.229479,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MDT",
          "relevance_score": "0.582526",
          "ticker_sentiment_score": "0.178191",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.213048",
          "ticker_sentiment_score": "0.272951",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "The Zacks Analyst Blog Highlights Gilead Sciences, Bristol Myers, Merck, AbbVie and Sanofi",
      "url": "https://www.zacks.com/stock/news/2453826/the-zacks-analyst-blog-highlights-gilead-sciences-bristol-myers-merck-abbvie-and-sanofi",
      "time_published": "20250423T132500",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Gilead Sciences, Bristol Myers, Merck, AbbVie and Sanofi are part of the Zacks top Analyst Blog.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ef/472.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.133928,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.213048",
          "ticker_sentiment_score": "0.063198",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GILD",
          "relevance_score": "0.142989",
          "ticker_sentiment_score": "0.045469",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AZN",
          "relevance_score": "0.035929",
          "ticker_sentiment_score": "-0.135631",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.071784",
          "ticker_sentiment_score": "0.041371",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SNY",
          "relevance_score": "0.247478",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Neurology-Focused Alector Downgraded On Failed Alzheimer's Study, BofA Securities Highlights Lack Of Catalysts - Alector  ( NASDAQ:ALEC ) ",
      "url": "https://www.benzinga.com/24/12/42324144/neurology-focused-alector-downgraded-on-failed-alzheimers-study-bofa-securities-highlights-lack-of-catalysts",
      "time_published": "20241204T192042",
      "authors": [
        "Vandana Singh"
      ],
      "summary": "Bank of America Securities has downgraded Alector, Inc. ALEC, citing the failure of its AL002 program. Alector recently released results from the INVOKE-2 Phase 2 trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer's disease ( AD ) .",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2024/12/04/Brain-Degenerative-Diseases-Parkinson--A.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.684621"
        }
      ],
      "overall_sentiment_score": 0.126421,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "BAC",
          "relevance_score": "0.107495",
          "ticker_sentiment_score": "-0.077788",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.213048",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ALEC",
          "relevance_score": "0.500753",
          "ticker_sentiment_score": "0.172942",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Bristol-Myers Squibb's $14 Billion Potential - Analyst Upgrades Stock - Bristol-Myers Squibb  ( NYSE:BMY ) ",
      "url": "https://www.benzinga.com/general/biotech/24/11/41913107/bristol-myers-squibbs-14-billion-potential-analyst-upgrades-stock",
      "time_published": "20241112T174839",
      "authors": [
        "Vandana Singh"
      ],
      "summary": "Leerink Partners has upgraded Bristol-Myers Squibb & Co BMY, stating that the company enters a catalyst-rich period in 2025-2027 beyond Cobenfy ( a schizophrenia drug ) and milvexian ( anticoagulant ) .",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2024/11/12/02-LVL-Exterior-Sign-101520-media.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.108179"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        }
      ],
      "overall_sentiment_score": 0.086575,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.213048",
          "ticker_sentiment_score": "0.04032",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.213048",
          "ticker_sentiment_score": "-0.333455",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "BMY",
          "relevance_score": "0.31482",
          "ticker_sentiment_score": "0.142037",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "IRWD's Q4 Earnings and Revenues Fall Shy of Estimates, Stock Down",
      "url": "https://www.zacks.com/stock/news/2423821/irwds-q4-earnings-and-revenues-fall-shy-of-estimates-stock-down",
      "time_published": "20250228T164300",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Ironwood reports weaker-than-expected results for the fourth quarter of 2024. The company maintains total revenue guidance for 2025.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/37/2337.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.99915"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.0899,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ALPMF",
          "relevance_score": "0.053629",
          "ticker_sentiment_score": "0.14773",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RIGL",
          "relevance_score": "0.263373",
          "ticker_sentiment_score": "0.179138",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.212115",
          "ticker_sentiment_score": "0.100967",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IRWD",
          "relevance_score": "0.263373",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AZN",
          "relevance_score": "0.212115",
          "ticker_sentiment_score": "0.106456",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "How Is The Market Feeling About AbbVie? - AbbVie  ( NYSE:ABBV ) ",
      "url": "https://www.benzinga.com/insights/short-sellers/25/02/43768529/how-is-the-market-feeling-about-abbvie",
      "time_published": "20250217T173015",
      "authors": [
        "Benzinga Insights"
      ],
      "summary": "AbbVie's ABBV short percent of float has risen 3.88% since its last report. The company recently reported that it has 18.93 million shares sold short, which is 1.07% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.73 days to cover their ...",
      "banner_image": "https://www.benzinga.com/files/images/story/2025/1739813412_0.png",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.365926"
        }
      ],
      "overall_sentiment_score": 0.289997,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.212115",
          "ticker_sentiment_score": "0.151778",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Looking Into AbbVie's Recent Short Interest - AbbVie  ( NYSE:ABBV ) ",
      "url": "https://www.benzinga.com/insights/short-sellers/24/12/42677800/looking-into-abbvies-recent-short-interest",
      "time_published": "20241225T130015",
      "authors": [
        "Benzinga Insights"
      ],
      "summary": "AbbVie's ABBV short percent of float has fallen 3.51% since its last report. The company recently reported that it has 19.32 million shares sold short, which is 1.1% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.62 days to cover their ...",
      "banner_image": "https://www.benzinga.com/files/images/story/2024/1735131612_0.png",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.365926"
        }
      ],
      "overall_sentiment_score": 0.264538,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.212115",
          "ticker_sentiment_score": "0.081887",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Top Research Reports for Visa, AbbVie & Analog Devices",
      "url": "https://www.zacks.com/research-daily/2397481/top-research-reports-for-visa-abbvie-analog-devices",
      "time_published": "20250115T214900",
      "authors": [
        "Mark Vickery"
      ],
      "summary": "Today's Research Daily features new research reports on 16 major stocks, including Visa Inc. (V), AbbVie Inc. (ABBV) and Analog Devices, Inc. (ADI), as well as a micro-cap stock Precipio, Inc. (PRPO).",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/eb/508.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.614606"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.263243,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.20698",
          "ticker_sentiment_score": "0.261904",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "PRPO",
          "relevance_score": "0.069697",
          "ticker_sentiment_score": "0.125577",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ADI",
          "relevance_score": "0.069697",
          "ticker_sentiment_score": "0.246692",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "V",
          "relevance_score": "0.069697",
          "ticker_sentiment_score": "0.329775",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "J&J's Drugs Get CHMP Recommendations for Blood Cancer Indications",
      "url": "https://www.zacks.com/stock/news/2535140/jjs-drugs-get-chmp-recommendations-for-blood-cancer-indications",
      "time_published": "20250623T131500",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "JNJ wins CHMP backing for Darzalex and Imbruvica in new blood cancer uses, paving the way for first-in-class approvals.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/7d/1177.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.769861"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.251134,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "AGEN",
          "relevance_score": "0.30569",
          "ticker_sentiment_score": "0.031767",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IMCR",
          "relevance_score": "0.206685",
          "ticker_sentiment_score": "0.128964",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.206685",
          "ticker_sentiment_score": "0.323929",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.256719",
          "ticker_sentiment_score": "0.284195",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "How Is The Market Feeling About AbbVie? - AbbVie  ( NYSE:ABBV ) ",
      "url": "https://www.benzinga.com/insights/short-sellers/25/06/45892370/how-is-the-market-feeling-about-abbvie",
      "time_published": "20250611T200105",
      "authors": [
        "Benzinga Insights"
      ],
      "summary": "AbbVie's ABBV short percent of float has fallen 20.35% since its last report. The company recently reported that it has 15.89 million shares sold short, which is 0.9% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.75 days to cover their ...",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.413559"
        }
      ],
      "overall_sentiment_score": 0.268841,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.205807",
          "ticker_sentiment_score": "0.079987",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Is the Market Bullish or Bearish on AbbVie? - AbbVie  ( NYSE:ABBV ) ",
      "url": "https://www.benzinga.com/insights/short-sellers/25/04/44900493/is-the-market-bullish-or-bearish-on-abbvie",
      "time_published": "20250421T150027",
      "authors": [
        "Benzinga Insights"
      ],
      "summary": "AbbVie's ABBV short percent of float has fallen 12.61% since its last report. The company recently reported that it has 17.14 million shares sold short, which is 0.97% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.22 days to cover their ...",
      "banner_image": "https://www.benzinga.com/files/images/story/2025/1745247624_0.png",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.413559"
        }
      ],
      "overall_sentiment_score": 0.268841,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.205807",
          "ticker_sentiment_score": "0.079987",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Is AbbVie Gaining or Losing Market Support? - AbbVie  ( NYSE:ABBV ) ",
      "url": "https://www.benzinga.com/insights/short-sellers/25/03/44443600/is-abbvie-gaining-or-losing-market-support",
      "time_published": "20250321T201527",
      "authors": [
        "Benzinga Insights"
      ],
      "summary": "AbbVie's ABBV short percent of float has fallen 5.41% since its last report. The company recently reported that it has 18.51 million shares sold short, which is 1.05% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.8 days to cover their ...",
      "banner_image": "https://www.benzinga.com/files/images/story/2025/1742588124_0.png",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.413559"
        }
      ],
      "overall_sentiment_score": 0.268841,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.205807",
          "ticker_sentiment_score": "0.079987",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Viking Fund Management Sells Big Oil Stocks In Q3, Cuts Tesla Position In Half, Adds To Largest Position Broadcom - Broadcom  ( NASDAQ:AVGO ) , AbbVie  ( NYSE:ABBV ) ",
      "url": "https://www.benzinga.com/trading-ideas/24/11/41997142/viking-fund-management-sells-big-oil-stocks-in-q3-cuts-tesla-position-in-half-adds-to-largest-posit",
      "time_published": "20241115T001326",
      "authors": [
        "Chris Katje"
      ],
      "summary": "A new 13F filing from Viking Fund Management reveals which companies the fund bought and sold in the third quarter, including exiting some oil companies ahead of the 2024 election. Third Quarter Exits: Viking Fund Management sold out of eight stocks completely in the third quarter, including ...",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2024/11/14/Stuttgart--Germany---08-20-2023-Person-H.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.166667"
        }
      ],
      "overall_sentiment_score": 0.152826,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ETR",
          "relevance_score": "0.204072",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AVGO",
          "relevance_score": "0.395012",
          "ticker_sentiment_score": "0.217509",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "DINO",
          "relevance_score": "0.204072",
          "ticker_sentiment_score": "0.192901",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.204072",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NTR",
          "relevance_score": "0.102888",
          "ticker_sentiment_score": "0.131969",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ES",
          "relevance_score": "0.204072",
          "ticker_sentiment_score": "0.192901",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "OVV",
          "relevance_score": "0.102888",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NEE",
          "relevance_score": "0.204072",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "QSR",
          "relevance_score": "0.204072",
          "ticker_sentiment_score": "0.192901",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "TPL",
          "relevance_score": "0.204072",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "POR",
          "relevance_score": "0.204072",
          "ticker_sentiment_score": "0.192901",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "TSLA",
          "relevance_score": "0.204072",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GTLS",
          "relevance_score": "0.204072",
          "ticker_sentiment_score": "0.192901",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "KGS",
          "relevance_score": "0.204072",
          "ticker_sentiment_score": "0.192901",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "XOM",
          "relevance_score": "0.204072",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RIO",
          "relevance_score": "0.204072",
          "ticker_sentiment_score": "0.410103",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "SCCO",
          "relevance_score": "0.204072",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SM",
          "relevance_score": "0.204072",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GE",
          "relevance_score": "0.102888",
          "ticker_sentiment_score": "0.131969",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FOREX:USD",
          "relevance_score": "0.102888",
          "ticker_sentiment_score": "0.08133",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Pharma Stock Roundup: J&J's ITCI Buyout, LLY's Weak Q4 Sales",
      "url": "https://www.zacks.com/stock/news/2399299/pharma-stock-roundup-jjs-itci-buyout-llys-weak-q4-sales",
      "time_published": "20250117T200000",
      "authors": [
        "Kinjel Shah"
      ],
      "summary": "J&J offers to buy ITCI for $14.6 billion. LLY announces disappointing preliminary sales numbers for the fourth quarter.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/41/2584.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.495866"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        }
      ],
      "overall_sentiment_score": -0.02428,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ITCI",
          "relevance_score": "0.16594",
          "ticker_sentiment_score": "-0.055472",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AZN",
          "relevance_score": "0.16594",
          "ticker_sentiment_score": "0.015683",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.033421",
          "ticker_sentiment_score": "-0.231987",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "LLY",
          "relevance_score": "0.442522",
          "ticker_sentiment_score": "0.027028",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SMHGF",
          "relevance_score": "0.033421",
          "ticker_sentiment_score": "0.03037",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SKXJF",
          "relevance_score": "0.066784",
          "ticker_sentiment_score": "0.068635",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.198493",
          "ticker_sentiment_score": "-0.055938",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DSKYF",
          "relevance_score": "0.066784",
          "ticker_sentiment_score": "0.068635",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.230704",
          "ticker_sentiment_score": "-0.089092",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "AstraZeneca In $15 Billion Talks For Drug That Could Upend Lung Cancer Treatment - AstraZeneca  ( NASDAQ:AZN ) , Summit Therapeutics  ( NASDAQ:SMMT ) ",
      "url": "https://www.benzinga.com/news/contracts/25/07/46249640/astrazeneca-in-15b-talks-for-drug-that-could-upend-lung-cancer-treatment",
      "time_published": "20250703T155602",
      "authors": [
        "Vandana Singh"
      ],
      "summary": "AstraZeneca may pay up to $15 billion for rights to Summit's lung cancer drug, ivonescimab. Bob Duggan owns nearly 75% of Summit, which is valued at $17.4 billion. From tariffs to inflation, macro risks are rising-Matt Maley reveals how he's trading it all, live this Wednesday July 9 at 6 PM ET.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2025/07/03/biotech-lab.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        }
      ],
      "overall_sentiment_score": 0.026396,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "AZN",
          "relevance_score": "0.466325",
          "ticker_sentiment_score": "-0.061892",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ONC",
          "relevance_score": "0.19661",
          "ticker_sentiment_score": "0.380163",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "SMMT",
          "relevance_score": "0.381463",
          "ticker_sentiment_score": "0.283608",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "AKESF",
          "relevance_score": "0.19661",
          "ticker_sentiment_score": "0.148002",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.19661",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BMY",
          "relevance_score": "0.19661",
          "ticker_sentiment_score": "-0.190636",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "BNTX",
          "relevance_score": "0.19661",
          "ticker_sentiment_score": "-0.190636",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "3 High-Yield Dividend Growth Stocks to Buy in December and Hold for a Decade or Longer",
      "url": "https://www.fool.com/investing/2024/12/03/3-high-yield-dividend-growth-stocks-to-buy-in-dece/",
      "time_published": "20241203T092400",
      "authors": [
        "Cory Renauer"
      ],
      "summary": "It's been a great couple of years for the stock market. From the end of 2022 through Nov. 29, the benchmark S&P 500 ( SNPINDEX: ^GSPC ) index rose a whopping 57.1% higher.During this bull run, stock prices have bounded forward much further than earnings from their underlying businesses.",
      "banner_image": "https://g.foolcdn.com/editorial/images/799277/board-room-chart-getty.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.999701"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.714479"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.275012,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "VRTX",
          "relevance_score": "0.049526",
          "ticker_sentiment_score": "0.156113",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "RPRX",
          "relevance_score": "0.196212",
          "ticker_sentiment_score": "0.173649",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.196212",
          "ticker_sentiment_score": "0.163973",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.049526",
          "ticker_sentiment_score": "0.149845",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BIPC",
          "relevance_score": "0.380736",
          "ticker_sentiment_score": "0.427828",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Charter Communications Posts Upbeat Earnings, Joins Atlassian, SkyWest, Eastman Chemical, AbbVie And Other Big Stocks Moving Higher On Friday - AbbVie  ( NYSE:ABBV ) , AST SpaceMobile  ( NASDAQ:ASTS ) ",
      "url": "https://www.benzinga.com/25/01/43393574/charter-communications-posts-upbeat-earnings-joins-atlassian-skywest-eastman-chemical-abbvie-and-other-big-stocks",
      "time_published": "20250131T151152",
      "authors": [
        "Avi Kapoor"
      ],
      "summary": "U.S. stocks were higher, with the Nasdaq Composite gaining more than 1% on Friday. Shares of Charter Communications, Inc. CHTR rose during Friday's session after the company reported better-than-expected fourth-quarter financial results.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2025/01/31/Charter-R-Logo-RGB.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.2"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.2"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.2"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.2"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.999336"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.2"
        }
      ],
      "overall_sentiment_score": 0.446253,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "VIAV",
          "relevance_score": "0.195814",
          "ticker_sentiment_score": "0.475993",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "JBLU",
          "relevance_score": "0.195814",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RDW",
          "relevance_score": "0.195814",
          "ticker_sentiment_score": "0.501186",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "CRDO",
          "relevance_score": "0.195814",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MBLY",
          "relevance_score": "0.195814",
          "ticker_sentiment_score": "0.501186",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "EMN",
          "relevance_score": "0.195814",
          "ticker_sentiment_score": "0.334487",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "BKR",
          "relevance_score": "0.195814",
          "ticker_sentiment_score": "0.626911",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "VRTX",
          "relevance_score": "0.195814",
          "ticker_sentiment_score": "0.331577",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.195814",
          "ticker_sentiment_score": "0.110137",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CLS",
          "relevance_score": "0.195814",
          "ticker_sentiment_score": "0.35332",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "CIFR",
          "relevance_score": "0.195814",
          "ticker_sentiment_score": "0.184004",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ASTS",
          "relevance_score": "0.195814",
          "ticker_sentiment_score": "0.334487",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "SKYW",
          "relevance_score": "0.195814",
          "ticker_sentiment_score": "0.60361",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "DGNX",
          "relevance_score": "0.195814",
          "ticker_sentiment_score": "0.129246",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RBC",
          "relevance_score": "0.195814",
          "ticker_sentiment_score": "0.407401",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "SFTBF",
          "relevance_score": "0.098659",
          "ticker_sentiment_score": "0.128275",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TEAM",
          "relevance_score": "0.195814",
          "ticker_sentiment_score": "0.347542",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "CHTR",
          "relevance_score": "0.380012",
          "ticker_sentiment_score": "0.321522",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "4 Big Drug Stocks That May Continue to Outperform in 2025",
      "url": "https://www.zacks.com/stock/news/2384649/4-big-drug-stocks-that-may-continue-to-outperform-in-2025",
      "time_published": "20241217T150300",
      "authors": [
        "Kinjel Shah"
      ],
      "summary": "Gilead, Eli Lilly, Vertex Pharmaceuticals and AbbVie have outperformed the industry this year and are likely to see continued momentum in 2025.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/cc/389.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.996675"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.310843"
        }
      ],
      "overall_sentiment_score": 0.196045,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.195025",
          "ticker_sentiment_score": "0.083643",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "VRTX",
          "relevance_score": "0.065595",
          "ticker_sentiment_score": "0.057058",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.195025",
          "ticker_sentiment_score": "0.141608",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields - AbbVie  ( NYSE:ABBV ) , Amgen  ( NASDAQ:AMGN ) ",
      "url": "https://www.benzinga.com/analyst-ratings/price-target/25/01/42783390/wall-streets-most-accurate-analysts-spotlight-on-3-health-care-stocks-delivering-hig",
      "time_published": "20250103T123942",
      "authors": [
        "Avi Kapoor"
      ],
      "summary": "During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.",
      "banner_image": "https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03044102/image-12.png",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.94762"
        }
      ],
      "overall_sentiment_score": 0.149824,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "AMGN",
          "relevance_score": "0.193465",
          "ticker_sentiment_score": "0.22133",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "CVS",
          "relevance_score": "0.193465",
          "ticker_sentiment_score": "-0.26505",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.193465",
          "ticker_sentiment_score": "0.195883",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "1 No-Brainer High-Yield Dividend ETF to Buy During the Stock Market Correction",
      "url": "https://www.fool.com/investing/2025/03/16/1-no-brainer-high-yield-dividend-etf-to-buy-during/",
      "time_published": "20250316T221900",
      "authors": [
        "Matt DiLallo"
      ],
      "summary": "Stock market sell-offs are often great opportunities to buy dividend stocks. That's because dividend yields move in the opposite direction of stock prices. So, with the stock market recently correcting ( defined as a decline of 10% or more from the peak ) , dividend yields are now higher.One of ...",
      "banner_image": "https://media.ycharts.com/charts/5dce1f79aff9e2ebe3965754b0ebbd6f.png",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.495866"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.358205,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.192694",
          "ticker_sentiment_score": "0.220689",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Earnings Season Scorecard and Fresh Research Reports for Walmart, Visa & AbbVie",
      "url": "https://www.zacks.com/research-daily/2411301/earnings-season-scorecard-and-fresh-research-reports-for-walmart-visa-abbvie",
      "time_published": "20250206T172100",
      "authors": [
        "Sheraz Mian"
      ],
      "summary": "A real-time update on the Q4 earnings season is part of today's Research Daily, in addition to fresh reports on Walmart (WMT), Visa (V), AbbVie (ABBV) and others, including a micro-cap stock AstroNova (ALOT).",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default269.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.25"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.25"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.25"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.999999"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.25"
        }
      ],
      "overall_sentiment_score": 0.288006,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "RL",
          "relevance_score": "0.038592",
          "ticker_sentiment_score": "0.081225",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.19117",
          "ticker_sentiment_score": "0.221279",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ALOT",
          "relevance_score": "0.15347",
          "ticker_sentiment_score": "0.10535",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "V",
          "relevance_score": "0.19117",
          "ticker_sentiment_score": "0.261154",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "WMT",
          "relevance_score": "0.15347",
          "ticker_sentiment_score": "0.085791",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields - AbbVie  ( NYSE:ABBV ) , Bristol-Myers Squibb  ( NYSE:BMY ) ",
      "url": "https://www.benzinga.com/24/12/42528916/wall-streets-most-accurate-analysts-weigh-in-on-3-health-care-stocks-with-over-3-dividend-yields",
      "time_published": "20241217T131911",
      "authors": [
        "Avi Kapoor"
      ],
      "summary": "During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.",
      "banner_image": "https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/17034652/image-141.png",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.967645"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.218458,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CVS",
          "relevance_score": "0.19117",
          "ticker_sentiment_score": "0.110518",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.19117",
          "ticker_sentiment_score": "0.285594",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "C",
          "relevance_score": "0.096283",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BMY",
          "relevance_score": "0.19117",
          "ticker_sentiment_score": "0.165861",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Does J&J's Innovative Medicine Unit Hold the Key to Q2 Sales Growth?",
      "url": "https://www.zacks.com/stock/news/2560282/does-jjs-innovative-medicine-unit-hold-the-key-to-q2-sales-growth",
      "time_published": "20250702T130700",
      "authors": [
        "Kinjel Shah"
      ],
      "summary": "JNJ is banking on Darzalex, Tremfya and new drugs to offset Stelara's LOE and Part D headwinds in Q2 Innovative Medicine sales.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/7d/1177.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.714479"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.684621"
        }
      ],
      "overall_sentiment_score": 0.206033,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "SSNLF",
          "relevance_score": "0.064104",
          "ticker_sentiment_score": "0.040341",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AZN",
          "relevance_score": "0.190667",
          "ticker_sentiment_score": "0.177455",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.127795",
          "ticker_sentiment_score": "0.088123",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.190667",
          "ticker_sentiment_score": "0.177455",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "AMGN",
          "relevance_score": "0.190667",
          "ticker_sentiment_score": "0.109641",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.127795",
          "ticker_sentiment_score": "0.138755",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SNY",
          "relevance_score": "0.064104",
          "ticker_sentiment_score": "0.119114",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "I Own 4 High-Yield Dividend Stocks. Here's Why I Own Each One.",
      "url": "https://www.fool.com/investing/2025/01/28/i-own-4-high-yield-dividend-stocks-heres-why-i-own/",
      "time_published": "20250128T111500",
      "authors": [
        "George Budwell"
      ],
      "summary": "When paired with dividend reinvestment, high-yield dividend stocks have demonstrated remarkable outperformance compared to the S&P 500 over holding periods of 20+ years. This outperformance stems from a fundamental truth: A sustainable high dividend yield often serves as a powerful indicator of ...",
      "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F805390%2Fhigh-yield-low-risk.jpg&op=resize&w=700",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "1.0"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.928769"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.415959,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.190043",
          "ticker_sentiment_score": "0.363179",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "HSBC",
          "relevance_score": "0.190043",
          "ticker_sentiment_score": "0.237216",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "PM",
          "relevance_score": "0.190043",
          "ticker_sentiment_score": "0.257846",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.190043",
          "ticker_sentiment_score": "0.244269",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Trump Orders FDA To Fast-Track US Drug Production As Tariff Threat Looms On Imported Medicines: Cites National Security Concerns - iShares Biotechnology ETF  ( NASDAQ:IBB ) , AbbVie  ( NYSE:ABBV ) ",
      "url": "https://www.benzinga.com/government/regulations/25/05/45215281/trump-orders-fda-to-fast-track-us-drug-production-as-tariff-threat-looms-on-imported-medic",
      "time_published": "20250506T092217",
      "authors": [
        "Tanya Rawat"
      ],
      "summary": "President Donald Trump signed an executive order Monday directing the Food and Drug Administration to accelerate approvals for domestic pharmaceutical manufacturing facilities as his administration prepares to announce new tariffs on imported medicines within two weeks",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2025/05/06/Tariffs_1.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Markets",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        }
      ],
      "overall_sentiment_score": 0.009672,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.188193",
          "ticker_sentiment_score": "-0.158059",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.188193",
          "ticker_sentiment_score": "-0.158059",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.188193",
          "ticker_sentiment_score": "-0.158059",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "PLSQF",
          "relevance_score": "0.094762",
          "ticker_sentiment_score": "0.153541",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "The Smartest Dividend Stocks to Buy With $500 Right Now",
      "url": "https://www.fool.com/investing/2025/01/06/the-smartest-dividend-stocks-to-buy-with-500-right/",
      "time_published": "20250106T104500",
      "authors": [
        "Justin Pope"
      ],
      "summary": "Some prominent healthcare and consumer stocks have fallen out of favor with the market, so now is the time to pounce on some great deals.",
      "banner_image": "https://g.foolcdn.com/editorial/images/802630/dividend-growth-investing.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.962106"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.5"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.890401"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.360215"
        }
      ],
      "overall_sentiment_score": 0.218391,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "PEP",
          "relevance_score": "0.277433",
          "ticker_sentiment_score": "0.08284",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.1871",
          "ticker_sentiment_score": "0.137059",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HSY",
          "relevance_score": "0.277433",
          "ticker_sentiment_score": "0.221086",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Big Pharma Stocks Dive Amid Trade War Jitters & Inflation Woes",
      "url": "https://www.zacks.com/stock/news/2441145/big-pharma-stocks-dive-amid-trade-war-jitters-inflation-woes",
      "time_published": "20250407T123700",
      "authors": [
        "Sundeep Ganoria"
      ],
      "summary": "Shares of pharma giants like PFE, J&J, AZN, MRK and ABBV decline on investor concerns that retaliatory tariffs could drive up drug prices for U.S. consumers.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/71/1337.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.5"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": -0.056827,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "AZN",
          "relevance_score": "0.062434",
          "ticker_sentiment_score": "0.055638",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.062434",
          "ticker_sentiment_score": "0.055638",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "APG",
          "relevance_score": "0.062434",
          "ticker_sentiment_score": "0.092812",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LLY",
          "relevance_score": "0.245959",
          "ticker_sentiment_score": "0.094459",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.185781",
          "ticker_sentiment_score": "0.089307",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AMGN",
          "relevance_score": "0.185781",
          "ticker_sentiment_score": "0.089307",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.185781",
          "ticker_sentiment_score": "0.089307",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Buy Johnson & Johnson  ( JNJ )  Stock for Higher Highs?",
      "url": "https://www.zacks.com/commentary/2425543/buy-johnson-johnson-jnj-stock-for-higher-highs",
      "time_published": "20250304T222600",
      "authors": [
        "Shaun Pruitt"
      ],
      "summary": "Amid recent market volatility, Johnson & Johnson (JNJ) stock hit new 52-week highs of nearly $170 on Tuesday.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ff/1612.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.818451"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        }
      ],
      "overall_sentiment_score": 0.17428,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.185306",
          "ticker_sentiment_score": "0.050963",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.185306",
          "ticker_sentiment_score": "0.050963",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.185306",
          "ticker_sentiment_score": "0.050963",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.802624",
          "ticker_sentiment_score": "0.175901",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Cerevel Therapeutics Holdings, Inc. Shareholder Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit on Behalf of Former CERE Shareholders",
      "url": "https://www.benzinga.com/pressreleases/25/04/g44672098/cerevel-therapeutics-holdings-inc-shareholder-notice-shareholder-rights-law-firm-robbins-llp-remin",
      "time_published": "20250407T181203",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "SAN DIEGO, April 07, 2025 ( GLOBE NEWSWIRE ) -- Robbins LLP reminds stockholders that a class action was filed against Cerevel Therapeutics Holdings, Inc. ( \"Cerevel\" or the \"Company\" ) , Bain Capital Investors, LLC ( \"Bain\" ) and Pfizer, Inc. ( \"Pfizer\" ) on behalf of a class ( the \"Class\" ) ...",
      "banner_image": "https://ml.globenewswire.com/media/f6c754ad-b344-4389-a551-cf97ce05752e/small/robbins-llp-logo-white-background1583450-1-png.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "IPO",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.955357"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.062895,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "PFE",
          "relevance_score": "0.123844",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.184834",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "CERE INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Cerevel Therapeutics Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit",
      "url": "https://www.benzinga.com/pressreleases/25/05/g45476176/cere-investor-alert-bronstein-gewirtz-grossman-llc-announces-that-cerevel-therapeutics-holdings-in",
      "time_published": "20250516T200000",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "NEW YORK, May 16, 2025 ( GLOBE NEWSWIRE ) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cerevel Therapeutics Holdings, Inc. ( \"Cerevel\" or \"the Company\" ) CERE, Bain Capital ...",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "IPO",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.905476"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.108179"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.02684,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "META",
          "relevance_score": "0.061949",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.123526",
          "ticker_sentiment_score": "-0.039951",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.184363",
          "ticker_sentiment_score": "-0.006273",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "CERE INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Cerevel Therapeutics Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit",
      "url": "https://www.benzinga.com/pressreleases/25/04/g44658859/cere-investor-alert-bronstein-gewirtz-grossman-llc-announces-that-cerevel-therapeutics-holdings-in",
      "time_published": "20250406T200000",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "NEW YORK, April 06, 2025 ( GLOBE NEWSWIRE ) -- Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cerevel Therapeutics Holdings, Inc. ( \"Cerevel\" or \"the Company\" ) CERE, Bain Capital ...",
      "banner_image": "https://ml.globenewswire.com/media/1a031130-a9cc-48ff-b281-d1e47c9a91a5/small/bronstein-gewirtz-grossman-llc-logo-png.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "IPO",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.905476"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.108179"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.026844,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "META",
          "relevance_score": "0.061949",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.123526",
          "ticker_sentiment_score": "-0.039951",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.184363",
          "ticker_sentiment_score": "-0.006273",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "PCE Inflation Increased In Line With Expectation",
      "url": "https://www.zacks.com/stock/news/2407670/pce-inflation-increased-in-line-with-expectation",
      "time_published": "20250131T154500",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Today's pre-market activity is positive, with futures in the green across major indexes: the Dow is +110 points at this hour, with the S&P 500 +26 and the Nasdaq leading the way, +158 points. The small-cap Russell 2000 is +5.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/4e/1601.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Economy - Fiscal",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.769861"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.099048,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CL",
          "relevance_score": "0.183895",
          "ticker_sentiment_score": "0.171419",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.183895",
          "ticker_sentiment_score": "0.171419",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "CVX",
          "relevance_score": "0.183895",
          "ticker_sentiment_score": "0.00921",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "XOM",
          "relevance_score": "0.183895",
          "ticker_sentiment_score": "0.00921",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "U.S. Pharmaceutical Imports Might Soon Face Tariffs: 3 Stocks That Could Tumble as a Result",
      "url": "https://www.fool.com/investing/2025/05/24/us-pharmaceutical-imports-tariffs-stocks/",
      "time_published": "20250524T081100",
      "authors": [
        "James Brumley"
      ],
      "summary": "There's little doubt these pharmaceutical companies' costs will soon be rising at least a little.",
      "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F819100%2Faccountant-with-calculator.jpg&op=resize&w=700",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.495866"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.019328,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.18343",
          "ticker_sentiment_score": "-0.069927",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AMGN",
          "relevance_score": "0.153275",
          "ticker_sentiment_score": "0.028035",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.122894",
          "ticker_sentiment_score": "0.043322",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BMY",
          "relevance_score": "0.030838",
          "ticker_sentiment_score": "0.036632",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 4% Dividend Yields - AbbVie  ( NYSE:ABBV ) , Bristol-Myers Squibb  ( NYSE:BMY ) ",
      "url": "https://www.benzinga.com/24/12/42287319/wall-streets-most-accurate-analysts-give-their-take-on-3-health-care-stocks-with-over-4-dividend-yields",
      "time_published": "20241203T123949",
      "authors": [
        "Avi Kapoor"
      ],
      "summary": "During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.",
      "banner_image": "https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03043144/image-15.png",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.13736,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.17715",
          "ticker_sentiment_score": "0.155275",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "C",
          "relevance_score": "0.17715",
          "ticker_sentiment_score": "-0.052159",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PDCO",
          "relevance_score": "0.17715",
          "ticker_sentiment_score": "0.104572",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MS",
          "relevance_score": "0.089129",
          "ticker_sentiment_score": "-0.054715",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BMY",
          "relevance_score": "0.17715",
          "ticker_sentiment_score": "-0.189582",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "Analysts Estimate Pfizer  ( PFE )  to Report a Decline in Earnings: What to Look Out for",
      "url": "https://www.zacks.com/stock/news/2452783/analysts-estimate-pfizer-pfe-to-report-a-decline-in-earnings-what-to-look-out-for",
      "time_published": "20250422T140058",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Pfizer (PFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default190.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.316726"
        }
      ],
      "overall_sentiment_score": 0.114618,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "PFE",
          "relevance_score": "0.262522",
          "ticker_sentiment_score": "-0.028133",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.176825",
          "ticker_sentiment_score": "-0.001435",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Merck  ( MRK )  Earnings Expected to Grow: Should You Buy?",
      "url": "https://www.zacks.com/stock/news/2404710/merck-mrk-earnings-expected-to-grow-should-you-buy",
      "time_published": "20250128T150048",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Merck (MRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default30.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.316726"
        }
      ],
      "overall_sentiment_score": 0.140287,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.175539",
          "ticker_sentiment_score": "0.021243",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More - Eli Lilly  ( NYSE:LLY ) ",
      "url": "https://www.benzinga.com/24/12/42638844/large-biopharma-lags-market-jp-morgans-2025-outlook-on-eli-lilly-merck-and-more",
      "time_published": "20241222T195134",
      "authors": [
        "Vandana Singh"
      ],
      "summary": "According to JP Morgan, U.S. large-cap biopharma stocks have underperformed the broader market for two consecutive years, with mixed sentiment shaping investor outlook for 2025.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2024/12/22/Healthcare--Opioid-Epidemic-And-Drug-Abu.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.744043"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.363138,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ELAN",
          "relevance_score": "0.175221",
          "ticker_sentiment_score": "0.195574",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "VTRS",
          "relevance_score": "0.175221",
          "ticker_sentiment_score": "0.345107",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "LLY",
          "relevance_score": "0.175221",
          "ticker_sentiment_score": "0.262117",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ZTS",
          "relevance_score": "0.175221",
          "ticker_sentiment_score": "0.195574",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "IDXX",
          "relevance_score": "0.175221",
          "ticker_sentiment_score": "0.195574",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.175221",
          "ticker_sentiment_score": "0.396574",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "GILD",
          "relevance_score": "0.175221",
          "ticker_sentiment_score": "0.344367",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "REGN",
          "relevance_score": "0.175221",
          "ticker_sentiment_score": "0.217986",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "BMY",
          "relevance_score": "0.175221",
          "ticker_sentiment_score": "0.249624",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "PRGO",
          "relevance_score": "0.175221",
          "ticker_sentiment_score": "0.345107",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Genmab to Present New and Updated Results from its Robust Epcoritamab  ( EPKINLY\u00ae )  Development Program at the 2025 European Hematology Association  ( EHA )  Congress",
      "url": "https://www.globenewswire.com/news-release/2025/05/14/3081307/0/en/Genmab-to-Present-New-and-Updated-Results-from-its-Robust-Epcoritamab-EPKINLY-Development-Program-at-the-2025-European-Hematology-Association-EHA-Congress.html",
      "time_published": "20250514T141500",
      "authors": [
        "Genmab A/S"
      ],
      "summary": "Media ReleaseCOPENHAGEN, Denmark. May ...",
      "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/368a5dab-dfc5-4e1d-bfa6-2af5e5216fce",
      "source": "GlobeNewswire",
      "category_within_source": "n/a",
      "source_domain": "www.globenewswire.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.076436,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.172342",
          "ticker_sentiment_score": "0.11994",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "CERE DEADLINE TUESDAY: ROSEN, NATIONAL TRIAL COUNSEL, Encourages Cerevel Therapeutics Holdings, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 3 Deadline in Securities Class Action - CERE",
      "url": "https://www.benzinga.com/pressreleases/25/06/g45712873/cere-deadline-tuesday-rosen-national-trial-counsel-encourages-cerevel-therapeutics-holdings-inc-in",
      "time_published": "20250601T222500",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "NEW YORK, June 01, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds persons or entities that ( 1 ) sold or otherwise disposed of the publicly-traded common stock of Cerevel Therapeutics Holdings, Inc.",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "IPO",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.98396"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.210142,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "META",
          "relevance_score": "0.05749",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.05749",
          "ticker_sentiment_score": "0.032031",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.171282",
          "ticker_sentiment_score": "0.096132",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "CERE DEADLINE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Cerevel Therapeutics Holdings, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 3 Deadline in Securities Class Action - CERE",
      "url": "https://www.benzinga.com/pressreleases/25/05/g45655537/cere-deadline-rosen-national-trial-lawyers-encourages-cerevel-therapeutics-holdings-inc-investors-",
      "time_published": "20250528T192700",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "NEW YORK, May 28, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds persons or entities that ( 1 ) sold or otherwise disposed of the publicly-traded common stock of Cerevel Therapeutics Holdings, Inc.",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "IPO",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.98396"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.210142,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "META",
          "relevance_score": "0.05749",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.05749",
          "ticker_sentiment_score": "0.032031",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.171282",
          "ticker_sentiment_score": "0.096132",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Merck's ADC Drug Gets FDA Breakthrough Therapy Tag in NSCLC",
      "url": "https://www.zacks.com/stock/news/2379130/mercks-adc-drug-gets-fda-breakthrough-therapy-tag-in-nsclc",
      "time_published": "20241204T174000",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "This is the first breakthrough therapy designation granted to MRK's sacituzumab tirumotecan in the United States.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ef/472.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.161647"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.108037,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "SKXJF",
          "relevance_score": "0.113866",
          "ticker_sentiment_score": "0.018258",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.170075",
          "ticker_sentiment_score": "0.093815",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DSKYF",
          "relevance_score": "0.113866",
          "ticker_sentiment_score": "0.018258",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AZN",
          "relevance_score": "0.225425",
          "ticker_sentiment_score": "0.102255",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.279653",
          "ticker_sentiment_score": "0.116234",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "ROSEN, A LEADING NATIONAL FIRM, Encourages Cerevel Therapeutics Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CERE",
      "url": "https://www.benzinga.com/pressreleases/25/04/g44929639/rosen-a-leading-national-firm-encourages-cerevel-therapeutics-holdings-inc-investors-to-secure-cou",
      "time_published": "20250422T161700",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "NEW YORK, April 22, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of all persons or entities that: ( 1 ) sold or otherwise disposed of the publicly-traded common stock of Cerevel Therapeutics ...",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "IPO",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.98396"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.17946,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "META",
          "relevance_score": "0.056407",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.056407",
          "ticker_sentiment_score": "-0.005014",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.168099",
          "ticker_sentiment_score": "0.031456",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Cerevel Therapeutics Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CERE",
      "url": "https://www.benzinga.com/pressreleases/25/04/g44887472/rosen-global-investor-counsel-encourages-cerevel-therapeutics-holdings-inc-investors-to-secure-cou",
      "time_published": "20250418T211239",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "NEW YORK, April 18, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of all persons or entities that: ( 1 ) sold or otherwise disposed of the publicly-traded common stock of Cerevel Therapeutics ...",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "IPO",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.98396"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.17946,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "META",
          "relevance_score": "0.056407",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.056407",
          "ticker_sentiment_score": "-0.005014",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.168099",
          "ticker_sentiment_score": "0.031456",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Cerevel Therapeutics Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CERE",
      "url": "https://www.benzinga.com/pressreleases/25/04/g44803038/rosen-a-leading-investor-rights-law-firm-encourages-cerevel-therapeutics-holdings-inc-investors-to",
      "time_published": "20250414T213300",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "NEW YORK, April 14, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of all persons or entities that: ( 1 ) sold or otherwise disposed of the publicly-traded common stock of Cerevel Therapeutics ...",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "IPO",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.98396"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.17946,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "META",
          "relevance_score": "0.056407",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.056407",
          "ticker_sentiment_score": "-0.005014",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.168099",
          "ticker_sentiment_score": "0.031456",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "VKTX Finishes Enrolment in Mid-Stage Study on Oral Weight-Loss Drug",
      "url": "https://www.zacks.com/stock/news/2436123/vktx-finishes-enrolment-in-mid-stage-study-on-oral-weight-loss-drug",
      "time_published": "20250327T123100",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Viking enrolls around 280 participants in the phase II study evaluating the oral version of its obesity drug. Data from this study is expected in 2H25.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/82/41137.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.177913,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.168099",
          "ticker_sentiment_score": "0.265331",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "VKTX",
          "relevance_score": "0.276491",
          "ticker_sentiment_score": "0.138013",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.168099",
          "ticker_sentiment_score": "0.177753",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "GS",
          "relevance_score": "0.056407",
          "ticker_sentiment_score": "0.143043",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "CERE DEADLINE NOTICE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Cerevel Therapeutics Holdings, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 3 Deadline in Securities Class Action - CERE",
      "url": "https://www.benzinga.com/pressreleases/25/05/g45602925/cere-deadline-notice-rosen-trusted-investor-counsel-encourages-cerevel-therapeutics-holdings-inc-i",
      "time_published": "20250525T223200",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "NEW YORK, May 26, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds persons or entities that ( 1 ) sold or otherwise disposed of the publicly-traded common stock of Cerevel Therapeutics Holdings, Inc.",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "IPO",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.98396"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.192779,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "META",
          "relevance_score": "0.056275",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.056275",
          "ticker_sentiment_score": "-0.005013",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.167709",
          "ticker_sentiment_score": "0.060938",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "ROSEN, LEADING INVESTOR COUNSEL, Encourages Cerevel Therapeutics Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CERE",
      "url": "https://www.benzinga.com/pressreleases/25/05/g45576057/rosen-leading-investor-counsel-encourages-cerevel-therapeutics-holdings-inc-investors-to-secure-co",
      "time_published": "20250522T205400",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "NEW YORK, May 22, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds persons or entities that ( 1 ) sold or otherwise disposed of the publicly-traded common stock of Cerevel Therapeutics Holdings, Inc.",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "IPO",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.98396"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.192779,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "META",
          "relevance_score": "0.056275",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.056275",
          "ticker_sentiment_score": "-0.005013",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.167709",
          "ticker_sentiment_score": "0.060938",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Cerevel Therapeutics Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CERE",
      "url": "https://www.benzinga.com/pressreleases/25/05/g45508923/rosen-global-investor-counsel-encourages-cerevel-therapeutics-holdings-inc-investors-to-secure-cou",
      "time_published": "20250520T000000",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "NEW YORK, May 19, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds persons or entities that ( 1 ) sold or otherwise disposed of the publicly-traded common stock of Cerevel Therapeutics Holdings, Inc.",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "IPO",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.98396"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.192779,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "META",
          "relevance_score": "0.056275",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.056275",
          "ticker_sentiment_score": "-0.005013",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.167709",
          "ticker_sentiment_score": "0.060938",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Cerevel Therapeutics Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CERE",
      "url": "https://www.benzinga.com/pressreleases/25/05/g45205474/rosen-a-highly-recognized-law-firm-encourages-cerevel-therapeutics-holdings-inc-investors-to-secur",
      "time_published": "20250505T193900",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "NEW YORK, May 05, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds persons or entities that ( 1 ) sold or otherwise disposed of the publicly-traded common stock of Cerevel Therapeutics Holdings, Inc.",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "IPO",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.98396"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.192779,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "META",
          "relevance_score": "0.056275",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.056275",
          "ticker_sentiment_score": "-0.005013",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.167709",
          "ticker_sentiment_score": "0.060938",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "ROSEN, A LEADING LAW FIRM, Encourages Cerevel Therapeutics Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CERE",
      "url": "https://www.benzinga.com/pressreleases/25/04/g45053909/rosen-a-leading-law-firm-encourages-cerevel-therapeutics-holdings-inc-investors-to-secure-counsel-",
      "time_published": "20250428T205000",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "NEW YORK, April 28, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds persons or entities that ( 1 ) sold or otherwise disposed of the publicly-traded common stock of Cerevel Therapeutics Holdings, Inc.",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "IPO",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.98396"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.192779,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "META",
          "relevance_score": "0.056275",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.056275",
          "ticker_sentiment_score": "-0.005013",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.167709",
          "ticker_sentiment_score": "0.060938",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "ROSEN, A TOP RANKED LAW FIRM, Encourages Cerevel Therapeutics Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CERE",
      "url": "https://www.benzinga.com/pressreleases/25/04/g45022328/rosen-a-top-ranked-law-firm-encourages-cerevel-therapeutics-holdings-inc-investors-to-secure-couns",
      "time_published": "20250425T201928",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "NEW YORK, April 25, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds persons or entities that ( 1 ) sold or otherwise disposed of the publicly-traded common stock of Cerevel Therapeutics Holdings, Inc.",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "IPO",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.98396"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.192779,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "META",
          "relevance_score": "0.056275",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.056275",
          "ticker_sentiment_score": "-0.005013",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.167709",
          "ticker_sentiment_score": "0.060938",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "3 Fantastic Stocks That Could Enjoy a Santa Claus Rally",
      "url": "https://www.fool.com/investing/2024/12/21/3-fantastic-stocks-that-could-enjoy-a-santa-claus/",
      "time_published": "20241221T114800",
      "authors": [
        "Keith Speights",
        "and Prosper Junior Bakiny",
        "David Jagielski"
      ],
      "summary": "Santa Claus will soon be on his way delivering presents to kids around the world. But could the jolly gift-giver bring something for investors, too? So-called \"Santa Claus rallies\" can occur near the end of the year.Three Motley Fool contributors think they've identified fantastic stocks that ...",
      "banner_image": "https://g.foolcdn.com/editorial/images/801623/santa-claus-buggy-chart.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.614606"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.999186"
        }
      ],
      "overall_sentiment_score": 0.211687,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "VRTX",
          "relevance_score": "0.167612",
          "ticker_sentiment_score": "-0.010377",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.327909",
          "ticker_sentiment_score": "0.311137",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.167612",
          "ticker_sentiment_score": "0.140496",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Royalty Pharma Declares Second Quarter 2025 Dividend",
      "url": "https://www.globenewswire.com/news-release/2025/04/21/3064990/0/en/Royalty-Pharma-Declares-Second-Quarter-2025-Dividend.html",
      "time_published": "20250421T201500",
      "authors": [
        "Royalty Pharma plc"
      ],
      "summary": "NEW YORK, April 21, 2025 ( GLOBE NEWSWIRE ) -- The board of directors of Royalty Pharma plc ( Nasdaq: RPRX ) has approved the payment of a dividend for the second quarter of 2025 of $0.22 per Class A ordinary share.",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/d605b3b0-7ba0-46e1-a2d4-439ca98694f8",
      "source": "GlobeNewswire",
      "category_within_source": "n/a",
      "source_domain": "www.globenewswire.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.183506,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "RPRX",
          "relevance_score": "0.709186",
          "ticker_sentiment_score": "0.320221",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.167322",
          "ticker_sentiment_score": "0.107354",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "December PCE Steady with Expectations; Plenty of Mixed Q4 Earnings",
      "url": "https://www.zacks.com/stock/news/2407657/december-pce-steady-with-expectations-plenty-of-mixed-q4-earnings",
      "time_published": "20250131T152500",
      "authors": [
        "Mark Vickery"
      ],
      "summary": "PCE results were as in-line with expectations as one could expect: +0.3% on headline month over month, +2.6% year over year.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f4/619.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Economy - Fiscal",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.838487"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.089448,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CL",
          "relevance_score": "0.166743",
          "ticker_sentiment_score": "0.149318",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.166743",
          "ticker_sentiment_score": "0.149318",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CVX",
          "relevance_score": "0.166743",
          "ticker_sentiment_score": "0.008588",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "XOM",
          "relevance_score": "0.166743",
          "ticker_sentiment_score": "0.008588",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Profit From the Silver Tsunami: Must-Watch Senior Care & Aging Stocks",
      "url": "https://www.zacks.com/stock/news/2484525/profit-from-the-silver-tsunami-must-watch-senior-care-aging-stocks",
      "time_published": "20250604T143100",
      "authors": [
        "Urmimala Biswas"
      ],
      "summary": "BSX, ABBV, AMGN and DXCM are tapping into the aging boom with cutting-edge tech, chronic care drugs and senior-focused innovations.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/b8/94743.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.459462"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.294488,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "BSX",
          "relevance_score": "0.099614",
          "ticker_sentiment_score": "0.069316",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CHCT",
          "relevance_score": "0.099614",
          "ticker_sentiment_score": "0.205907",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "XLO",
          "relevance_score": "0.033282",
          "ticker_sentiment_score": "0.112953",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.165258",
          "ticker_sentiment_score": "0.14302",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CTRE",
          "relevance_score": "0.099614",
          "ticker_sentiment_score": "0.205907",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "AMGN",
          "relevance_score": "0.13255",
          "ticker_sentiment_score": "0.063904",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DXCM",
          "relevance_score": "0.229769",
          "ticker_sentiment_score": "0.196015",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "CRYPTO:NXT",
          "relevance_score": "0.033282",
          "ticker_sentiment_score": "0.247837",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Pharma Stock Roundup: EU Nod to Expanded Use of ABBV, AZN Drugs & More",
      "url": "https://www.zacks.com/stock/news/2447878/pharma-stock-roundup-eu-nod-to-expanded-use-of-abbv-azn-drugs-more",
      "time_published": "20250411T154700",
      "authors": [
        "Kinjel Shah"
      ],
      "summary": "EU approves expanded use of ABBV's Rinvoq and AZN's Imfinzi and Enhertu. NVS set to invest $23B to boost U.S. manufacturing.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/39/612.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.316726"
        }
      ],
      "overall_sentiment_score": 0.125119,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "SKXJF",
          "relevance_score": "0.054983",
          "ticker_sentiment_score": "0.052073",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.163909",
          "ticker_sentiment_score": "-0.02139",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DSKYF",
          "relevance_score": "0.054983",
          "ticker_sentiment_score": "0.052073",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AZN",
          "relevance_score": "0.269776",
          "ticker_sentiment_score": "-0.061855",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.054983",
          "ticker_sentiment_score": "-0.272984",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "Novartis' Cosentyx Fails Late-Stage Giant Cell Arteritis Trial - Novartis  ( NYSE:NVS ) ",
      "url": "https://www.benzinga.com/news/health-care/25/07/46243947/novartis-cosentyx-fails-late-stage-giant-cell-arteritis-trial",
      "time_published": "20250703T130012",
      "authors": [
        "Vandana Singh"
      ],
      "summary": "Cosentyx missed primary endpoint in GCA trial but reduced steroid use and toxicity compared to placebo. Cosentyx sales rose 16% year over year to $1.5 billion in Q1 2025, driven by demand across approved indications. Geopolitical tensions, Fed uncertainty, and fast-moving headlines are driving ...",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2025/07/03/Novartis-building.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        }
      ],
      "overall_sentiment_score": 0.161836,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "NVS",
          "relevance_score": "0.24289",
          "ticker_sentiment_score": "-0.081047",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.163354",
          "ticker_sentiment_score": "0.106998",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Avalo Therapeutics 'Represents An Attractive Pure-Play,' Analyst Initiates Coverage With Over 300% Stock Upside - Avalo Therapeutics  ( NASDAQ:AVTX ) ",
      "url": "https://www.benzinga.com/general/biotech/25/03/44480227/avalo-therapeutics-represents-an-attractive-pure-play-analyst-initiates-coverage-with-over-300-st",
      "time_published": "20250325T192044",
      "authors": [
        "Vandana Singh"
      ],
      "summary": "Stifel initiated coverage on Avalo Therapeutics ( AVTX ) with a Buy rating and a $36 price target, citing AVTX-009's strong potential in HS. Avalo's Phase 2 LOTUS trial for AVTX-009 in HS will enroll 180 adults, with topline data expected in 2026. Feel unsure about the market's next move?",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2025/03/25/bz-pharma-briefs.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        }
      ],
      "overall_sentiment_score": 0.246399,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.162255",
          "ticker_sentiment_score": "0.202796",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "AVTX",
          "relevance_score": "0.780804",
          "ticker_sentiment_score": "0.487017",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "OSE Immunotherapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update",
      "url": "https://www.globenewswire.com/news-release/2025/03/26/3049997/0/en/OSE-Immunotherapeutics-Reports-Full-Year-2024-Financial-Results-and-Provides-Corporate-Update.html",
      "time_published": "20250326T172000",
      "authors": [
        "OSE Immunotherapeutics"
      ],
      "summary": "OSE Immunotherapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update Total income of \u20ac83.4 million. Cash level of \u20ac64.2 million1 as of December 31, 2024, ensuring financial visibility until Q1 2027",
      "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/e79ae2c6-fc13-4a02-9759-4ecc9c4fdb22",
      "source": "GlobeNewswire",
      "category_within_source": "n/a",
      "source_domain": "www.globenewswire.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        }
      ],
      "overall_sentiment_score": 0.264183,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.160312",
          "ticker_sentiment_score": "0.180668",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Top Research Reports for AbbVie, TJX & Charles Schwab",
      "url": "https://www.zacks.com/research-daily/2449200/top-research-reports-for-abbvie-tjx-charles-schwab",
      "time_published": "20250415T203000",
      "authors": [
        "Mark Vickery"
      ],
      "summary": "Today's Research Daily features new research reports on 16 major stocks, including AbbVie Inc. (ABBV), The TJX Companies, Inc. (TJX) and The Charles Schwab Corporation (SCHW), as well as two micro-cap stocks, Enzo Biochem, Inc. (ENZ) and CVD Equipment Corporation (CVV).",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/10/83654.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.25"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.25"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.796627"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.650727"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.25"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.25"
        }
      ],
      "overall_sentiment_score": 0.165176,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ENZ",
          "relevance_score": "0.107255",
          "ticker_sentiment_score": "0.099836",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SCHW",
          "relevance_score": "0.107255",
          "ticker_sentiment_score": "0.099836",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CVV",
          "relevance_score": "0.160277",
          "ticker_sentiment_score": "0.165536",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.160277",
          "ticker_sentiment_score": "0.209163",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "TJX",
          "relevance_score": "0.160277",
          "ticker_sentiment_score": "0.17031",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Royalty Pharma to Present at TD Cowen's 45th Annual Health Care Conference",
      "url": "https://www.globenewswire.com/news-release/2025/02/27/3034344/0/en/Royalty-Pharma-to-Present-at-TD-Cowen-s-45th-Annual-Health-Care-Conference.html",
      "time_published": "20250227T211500",
      "authors": [
        "Royalty Pharma plc"
      ],
      "summary": "NEW YORK, Feb. 27, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) today announced that it will participate in a fireside chat at TD Cowen's 45th Annual Health Care Conference on March 4, 2025 at 2:30 p.m. ET.",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/d605b3b0-7ba0-46e1-a2d4-439ca98694f8",
      "source": "GlobeNewswire",
      "category_within_source": "n/a",
      "source_domain": "www.globenewswire.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.183506,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "RPRX",
          "relevance_score": "0.682689",
          "ticker_sentiment_score": "0.287942",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.158519",
          "ticker_sentiment_score": "0.102301",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "J&J Seeks FDA Nod for Subcutaneous Tremfya as Induction Regimen in UC",
      "url": "https://www.zacks.com/stock/news/2374611/jj-seeks-fda-nod-for-subcutaneous-tremfya-as-induction-regimen-in-uc",
      "time_published": "20241125T140800",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "If approved, JNJ's Tremfya will be the first IL-23 inhibitor to offer a choice of subcutaneous or intravenous use as induction treatment in ulcerative colitis.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ff/1612.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.260148,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.210274",
          "ticker_sentiment_score": "0.243306",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.158519",
          "ticker_sentiment_score": "0.274495",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.210274",
          "ticker_sentiment_score": "0.200519",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Royalty Pharma to Present at the Goldman Sachs 46th Annual Global Healthcare Conference",
      "url": "https://www.globenewswire.com/news-release/2025/06/04/3093991/0/en/Royalty-Pharma-to-Present-at-the-Goldman-Sachs-46th-Annual-Global-Healthcare-Conference.html",
      "time_published": "20250604T201500",
      "authors": [
        "Royalty Pharma plc"
      ],
      "summary": "NEW YORK, June 04, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) today announced that it will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10, 2025 at 2:00 p.m. ET.",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/d605b3b0-7ba0-46e1-a2d4-439ca98694f8",
      "source": "GlobeNewswire",
      "category_within_source": "n/a",
      "source_domain": "www.globenewswire.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.15171,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "GS",
          "relevance_score": "0.157483",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RPRX",
          "relevance_score": "0.679474",
          "ticker_sentiment_score": "0.235475",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.157483",
          "ticker_sentiment_score": "0.101876",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Royalty Pharma Announces Dividend Increase",
      "url": "https://www.globenewswire.com/news-release/2025/01/09/3007363/0/en/Royalty-Pharma-Announces-Dividend-Increase.html",
      "time_published": "20250109T211500",
      "authors": [
        "Royalty Pharma plc"
      ],
      "summary": "NEW YORK, Jan. 09, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) today announced that its board of directors has declared a dividend for the first quarter of 2025 of $0.22 per Class A ordinary share, reflecting a 5% increase in the company's quarterly dividend over the previous ...",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/d605b3b0-7ba0-46e1-a2d4-439ca98694f8",
      "source": "GlobeNewswire",
      "category_within_source": "n/a",
      "source_domain": "www.globenewswire.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.167638,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "RPRX",
          "relevance_score": "0.67628",
          "ticker_sentiment_score": "0.290134",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.156461",
          "ticker_sentiment_score": "0.101458",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Popular Ozempic, Wegovy Selected For Next Round Of Medicare Drug Price Negotiations - Novo Nordisk  ( NYSE:NVO ) , Pfizer  ( NYSE:PFE ) ",
      "url": "https://www.benzinga.com/25/01/43062779/popular-ozempic-wegovy-selected-for-next-round-of-medicare-drug-price-negotiations",
      "time_published": "20250117T171520",
      "authors": [
        "Vandana Singh"
      ],
      "summary": "15 new drugs selected for negotiation accounted for $41 billion in Medicare Part D costs between 2023 and 2024. Medicare beneficiaries are projected to save $7.2 billion annually from the $2,000 out-of-pocket cap starting in 2025. Get Real-Time News and Alerts for Your Portfolio On Friday, the ...",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2025/01/17/Miracle-Weight-Loss-Drug-Ozempic-And-Sim.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": -0.016956,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.154455",
          "ticker_sentiment_score": "-0.61328",
          "ticker_sentiment_label": "Bearish"
        },
        {
          "ticker": "TEVA",
          "relevance_score": "0.154455",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AZN",
          "relevance_score": "0.154455",
          "ticker_sentiment_score": "-0.584736",
          "ticker_sentiment_label": "Bearish"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.154455",
          "ticker_sentiment_score": "-0.584736",
          "ticker_sentiment_label": "Bearish"
        },
        {
          "ticker": "BMY",
          "relevance_score": "0.154455",
          "ticker_sentiment_score": "-0.420266",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "The Zacks Analyst Blog AbbVie, The TJX, The Charles Schwab, Enzo Biochem and CVD Equipment",
      "url": "https://www.zacks.com/stock/news/2449552/the-zacks-analyst-blog-abbvie-the-tjx-the-charles-schwab-enzo-biochem-and-cvd-equipment",
      "time_published": "20250416T083300",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "AbbVie, The TJX, The Charles Schwab, Enzo Biochem and CVD Equipment are included in this Analyst Blog.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/10/83654.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.25"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.25"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.929393"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.650727"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.25"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.25"
        }
      ],
      "overall_sentiment_score": 0.157705,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ENZ",
          "relevance_score": "0.102888",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SCHW",
          "relevance_score": "0.102888",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CVV",
          "relevance_score": "0.153797",
          "ticker_sentiment_score": "0.102495",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.153797",
          "ticker_sentiment_score": "0.140499",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TJX",
          "relevance_score": "0.153797",
          "ticker_sentiment_score": "0.107376",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Ironwood's Q3 Earnings Lag Estimates, Revenues Top, Stock Down",
      "url": "https://www.zacks.com/stock/news/2367601/ironwoods-q3-earnings-lag-estimates-revenues-top-stock-down",
      "time_published": "20241108T160300",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "IRWD's third-quarter earnings miss estimates while revenues beat the same. The company maintains revenue guidance for 2024. Stock falls.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/67/1932.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.993781"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.01914,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ALPMF",
          "relevance_score": "0.051551",
          "ticker_sentiment_score": "0.142461",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.153797",
          "ticker_sentiment_score": "0.102714",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IRWD",
          "relevance_score": "0.253514",
          "ticker_sentiment_score": "0.049307",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AZN",
          "relevance_score": "0.204072",
          "ticker_sentiment_score": "0.101616",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LSTA",
          "relevance_score": "0.204072",
          "ticker_sentiment_score": "0.087692",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Pharma Stocks Rebound as Trump Announces a 90-Day Pause on Tariffs",
      "url": "https://www.zacks.com/stock/news/2443438/pharma-stocks-rebound-as-trump-announces-a-90-day-pause-on-tariffs",
      "time_published": "20250410T125400",
      "authors": [
        "Ekta Bagri"
      ],
      "summary": "The news of a likely import tariff hurt the share price of pharma giants like Novo Nordisk (NVO), Eli Lilly (LLY) and AstraZeneca (AZN), but Trump's announcement of a pause on reciprocal tariffs offsets the losses.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/6e/37920.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.858979"
        }
      ],
      "overall_sentiment_score": 0.119701,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.301315",
          "ticker_sentiment_score": "0.162922",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.15347",
          "ticker_sentiment_score": "0.149657",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AZN",
          "relevance_score": "0.228431",
          "ticker_sentiment_score": "0.056012",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.301315",
          "ticker_sentiment_score": "0.162922",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Mustang Bio Announces Sale of Fixed Assets and Exit of Facility - Fortress Biotech  ( NASDAQ:FBIO ) , Mustang Bio  ( NASDAQ:MBIO ) ",
      "url": "https://www.benzinga.com/pressreleases/25/02/g44024709/mustang-bio-announces-sale-of-fixed-assets-and-exit-of-facility",
      "time_published": "20250227T210527",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "WALTHAM, Mass., Feb. 27, 2025 ( GLOBE NEWSWIRE ) -- Mustang Bio, Inc. ( \"Mustang\" or the \"Company\" ) MBIO, a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell therapies into potential cures for difficult-to-treat cancers, today announced the ...",
      "banner_image": "https://ml.globenewswire.com/media/75bd19b8-c298-4600-953e-f9b6215c043c/small/mustangbiologo-jpg.jpg",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.744043"
        }
      ],
      "overall_sentiment_score": 0.133893,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "FBIO",
          "relevance_score": "0.152983",
          "ticker_sentiment_score": "0.1736",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.152983",
          "ticker_sentiment_score": "0.168439",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "MBIO",
          "relevance_score": "0.370418",
          "ticker_sentiment_score": "0.310824",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Vanguard High Dividend Yield ETF vs Vanguard Dividend Appreciation ETF: Which Is Best for You?",
      "url": "https://www.fool.com/investing/2025/03/11/vanguard-high-dividend-yield-etf-vs-vanguard-divid/",
      "time_published": "20250311T132100",
      "authors": [
        "Matt Frankel"
      ],
      "summary": "Vanguard has some excellent dividend ETFs, but they are right for different investors.",
      "banner_image": "https://g.foolcdn.com/editorial/images/810273/holding-money-2022b.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.2"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.2"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.967645"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.2"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.2"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.2"
        }
      ],
      "overall_sentiment_score": -0.148826,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "AAPL",
          "relevance_score": "0.152499",
          "ticker_sentiment_score": "-0.226701",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "AVGO",
          "relevance_score": "0.152499",
          "ticker_sentiment_score": "-0.226701",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "BAC",
          "relevance_score": "0.436009",
          "ticker_sentiment_score": "-0.463209",
          "ticker_sentiment_label": "Bearish"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.152499",
          "ticker_sentiment_score": "-0.226701",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.152499",
          "ticker_sentiment_score": "-0.226701",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "UNH",
          "relevance_score": "0.152499",
          "ticker_sentiment_score": "-0.226701",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "MSFT",
          "relevance_score": "0.436009",
          "ticker_sentiment_score": "-0.463209",
          "ticker_sentiment_label": "Bearish"
        },
        {
          "ticker": "COST",
          "relevance_score": "0.152499",
          "ticker_sentiment_score": "-0.226701",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "MA",
          "relevance_score": "0.152499",
          "ticker_sentiment_score": "-0.226701",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "WFC",
          "relevance_score": "0.152499",
          "ticker_sentiment_score": "-0.226701",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "V",
          "relevance_score": "0.152499",
          "ticker_sentiment_score": "-0.226701",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "HD",
          "relevance_score": "0.152499",
          "ticker_sentiment_score": "-0.226701",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "WMT",
          "relevance_score": "0.152499",
          "ticker_sentiment_score": "-0.226701",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "2 High-Yield Dividend ETFs to Buy to Generate Passive Income",
      "url": "https://www.fool.com/investing/2025/02/23/2-high-yield-dividend-etfs-to-buy-to-generate-pass/",
      "time_published": "20250223T120000",
      "authors": [
        "Neha Chamaria"
      ],
      "summary": "With yields ranging between 3.6% and 7.3%, these dividend ETFs are great bets for generating passive income.",
      "banner_image": "https://media.ycharts.com/charts/47f5b420ec09df618169e8653a7e76f4.png",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.25"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "1.0"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.25"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.360215"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.25"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.25"
        }
      ],
      "overall_sentiment_score": 0.315329,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "META",
          "relevance_score": "0.051111",
          "ticker_sentiment_score": "0.232927",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.152499",
          "ticker_sentiment_score": "0.222142",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.051111",
          "ticker_sentiment_score": "0.253579",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "CVX",
          "relevance_score": "0.25142",
          "ticker_sentiment_score": "0.109944",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "KO",
          "relevance_score": "0.152499",
          "ticker_sentiment_score": "0.137198",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MA",
          "relevance_score": "0.102013",
          "ticker_sentiment_score": "0.253458",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Genmab to Highlight New Data Evaluating Late-Stage Oncology Portfolio at the 2025 American Society of Clinical Oncology  ( ASCO )  Annual Meeting",
      "url": "https://www.globenewswire.com/news-release/2025/05/22/3087164/0/en/Genmab-to-Highlight-New-Data-Evaluating-Late-Stage-Oncology-Portfolio-at-the-2025-American-Society-of-Clinical-Oncology-ASCO-Annual-Meeting.html",
      "time_published": "20250522T210500",
      "authors": [
        "Genmab A/S"
      ],
      "summary": "Media ReleaseCOPENHAGEN, Denmark. May ...",
      "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/368a5dab-dfc5-4e1d-bfa6-2af5e5216fce",
      "source": "GlobeNewswire",
      "category_within_source": "n/a",
      "source_domain": "www.globenewswire.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.0144,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.15173",
          "ticker_sentiment_score": "0.065778",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "The Zacks Analyst Blog AbbVie's, Rinvoq and AstraZeneca's and Novartis",
      "url": "https://www.zacks.com/stock/news/2448101/the-zacks-analyst-blog-abbvies-rinvoq-and-astrazenecas-and-novartis",
      "time_published": "20250414T061700",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "AbbVie's, Rinvoq and AstraZeneca's and Novartis are included in this Analyst Blog.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e5/1416.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.413559"
        }
      ],
      "overall_sentiment_score": 0.134161,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "SKXJF",
          "relevance_score": "0.050044",
          "ticker_sentiment_score": "0.066051",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.149346",
          "ticker_sentiment_score": "-0.071954",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DSKYF",
          "relevance_score": "0.050044",
          "ticker_sentiment_score": "0.066051",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AZN",
          "relevance_score": "0.246333",
          "ticker_sentiment_score": "-0.091366",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.050044",
          "ticker_sentiment_score": "-0.272448",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "Buy Pfizer  ( PFE )  Stock for a Rebound After Crushing Q1 EPS Expectations?",
      "url": "https://www.zacks.com/stock/news/2458534/buy-pfizer-pfe-stock-for-a-rebound-after-crushing-q1-eps-expectations",
      "time_published": "20250430T003200",
      "authors": [
        "Shaun Pruitt"
      ],
      "summary": "Pfizer (PFE) shares spiked 3% in Tuesday's trading session as the pharmaceutical giant was able to crush its Q1 earnings expectations.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/89/447.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.998947"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.503496"
        }
      ],
      "overall_sentiment_score": 0.105489,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.222157",
          "ticker_sentiment_score": "-0.017845",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.149192",
          "ticker_sentiment_score": "-0.126505",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.149192",
          "ticker_sentiment_score": "0.052757",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.926036",
          "ticker_sentiment_score": "0.189722",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.149192",
          "ticker_sentiment_score": "-0.126505",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Why Vertex Pharmaceuticals Was Such a Healthy Stock on Tuesday",
      "url": "https://www.fool.com/investing/2025/04/22/why-vertex-pharmaceuticals-was-such-a-healthy-stoc/",
      "time_published": "20250422T213705",
      "authors": [
        "Eric Volkman"
      ],
      "summary": "Vertex Pharmaceuticals ( NASDAQ: VRTX ) had a fine Tuesday on the stock exchange. The biotech's shares closed the day nearly 3% higher in price, on the back of two positive mentions by analysts tracking the company's fortunes. That rise was slightly more pronounced than the S&P 500 index's 2.5% ...",
      "banner_image": "https://g.foolcdn.com/editorial/images/815690/two-people-seated-at-a-lab-desk-featuring-a-pc-screen-and-microscope.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.796627"
        }
      ],
      "overall_sentiment_score": 0.174935,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "VRTX",
          "relevance_score": "0.29234",
          "ticker_sentiment_score": "0.379958",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.148731",
          "ticker_sentiment_score": "-0.100903",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.148731",
          "ticker_sentiment_score": "-0.100903",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks - Novo Nordisk  ( NYSE:NVO ) , Merck & Co  ( NYSE:MRK ) , Alnylam Pharmaceuticals  ( NASDAQ:ALNY ) , Eli Lilly  ( NYSE:LLY ) ",
      "url": "https://www.benzinga.com/general/biotech/24/11/41855578/bristol-myers-squibb-leads-biopharma-recovery-with-almost-25-growth-in-market-cap-but-novo-nordis",
      "time_published": "20241108T193505",
      "authors": [
        "Vandana Singh"
      ],
      "summary": "The biopharmaceutical sector showed signs of recovery in the third quarter of 2024, fueled by increased investor optimism following the U.S. Federal Reserve's interest rate cuts in September.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2024/11/08/Wegovy.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.263867,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "NVO",
          "relevance_score": "0.148731",
          "ticker_sentiment_score": "-0.288291",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "ALNY",
          "relevance_score": "0.148731",
          "ticker_sentiment_score": "0.292055",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "GLDAF",
          "relevance_score": "0.148731",
          "ticker_sentiment_score": "0.112666",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LLY",
          "relevance_score": "0.148731",
          "ticker_sentiment_score": "-0.186951",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.148731",
          "ticker_sentiment_score": "0.211306",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "GILD",
          "relevance_score": "0.221481",
          "ticker_sentiment_score": "0.318081",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "BMY",
          "relevance_score": "0.221481",
          "ticker_sentiment_score": "0.230164",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "SNY",
          "relevance_score": "0.148731",
          "ticker_sentiment_score": "0.116145",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Why Is Israel-Based Generic Drug Focused Teva Pharmaceutical Stock Trading Higher On Monday? - Alvotech  ( NASDAQ:ALVO ) , Teva Pharmaceutical Indus  ( NYSE:TEVA ) ",
      "url": "https://www.benzinga.com/general/biotech/25/05/45199025/why-is-israel-based-generic-drug-focused-teva-pharmaceutical-stock-trading-higher-on-monday",
      "time_published": "20250505T154305",
      "authors": [
        "Vandana Singh"
      ],
      "summary": "Selarsdi is FDA-approved in all Stelara-equivalent forms for psoriasis, arthritis, Crohn's, and colitis. Three biosimilar BLAs from Teva-Alvotech are under FDA review, with approvals expected in Q4 2025. Today's manic market swings are creating the perfect setup for Matt's next volatility trade.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2025/05/05/Teva-Pharmaceuticals.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        }
      ],
      "overall_sentiment_score": 0.230775,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ALVO",
          "relevance_score": "0.596796",
          "ticker_sentiment_score": "0.240771",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.147366",
          "ticker_sentiment_score": "0.198834",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "TEVA",
          "relevance_score": "0.219477",
          "ticker_sentiment_score": "0.079677",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "REGN",
          "relevance_score": "0.147366",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Royalty Pharma to Present at Upcoming Investor Conferences",
      "url": "https://www.globenewswire.com/news-release/2024/11/27/2988444/0/en/Royalty-Pharma-to-Present-at-Upcoming-Investor-Conferences.html",
      "time_published": "20241127T211500",
      "authors": [
        "Royalty Pharma plc"
      ],
      "summary": "NEW YORK, Nov. 27, 2024 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) today announced that it will participate in the following upcoming investor conferences during the month of December: ...",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/d605b3b0-7ba0-46e1-a2d4-439ca98694f8",
      "source": "GlobeNewswire",
      "category_within_source": "n/a",
      "source_domain": "www.globenewswire.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.142583,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "EVR",
          "relevance_score": "0.146916",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RPRX",
          "relevance_score": "0.645516",
          "ticker_sentiment_score": "0.209242",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.146916",
          "ticker_sentiment_score": "0.097661",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "The Zacks Analyst Blog Highlights Berkshire Hathaway, AbbVie, Intuitive Surgical, Hamilton Beach Brands and AXIL Brands",
      "url": "https://www.zacks.com/stock/news/2479289/the-zacks-analyst-blog-highlights-berkshire-hathaway-abbvie-intuitive-surgical-hamilton-beach-brands-and-axil-brands",
      "time_published": "20250530T100300",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "Zacks highlights strong showings from ABBV, ISRG, HBB and AXIL, while BRK.B gains on insurance growth and capital strength despite headwinds.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/31/1512.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.795202"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.283313,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "HBB",
          "relevance_score": "0.109956",
          "ticker_sentiment_score": "0.083903",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.146247",
          "ticker_sentiment_score": "0.155051",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "HBCNF",
          "relevance_score": "0.036756",
          "ticker_sentiment_score": "0.251121",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ISRG",
          "relevance_score": "0.18223",
          "ticker_sentiment_score": "0.051299",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BRK-A",
          "relevance_score": "0.073434",
          "ticker_sentiment_score": "0.064959",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "5 Large Drug Stocks That Are Poised to Ride on Sector Recovery",
      "url": "https://www.zacks.com/commentary/2502995/5-large-drug-stocks-that-are-poised-to-ride-on-sector-recovery",
      "time_published": "20250616T130600",
      "authors": [
        "Kinjel Shah"
      ],
      "summary": "In the Large-Cap Pharmaceuticals industry, AbbVie, Novartis, Pfizer, Sanofi and Bayer are worth retaining amid macro pressure and rising innovation.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/52/873.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.995077"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.999491"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.980509"
        }
      ],
      "overall_sentiment_score": 0.18571,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.144646",
          "ticker_sentiment_score": "0.19455",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "BPMC",
          "relevance_score": "0.020776",
          "ticker_sentiment_score": "0.05655",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.124164",
          "ticker_sentiment_score": "0.054973",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SNY",
          "relevance_score": "0.144646",
          "ticker_sentiment_score": "0.119288",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Pharma Stock Roundup: EU Nod to MRK's Welireg, IONS' Q4 Results & More",
      "url": "https://www.zacks.com/stock/news/2419373/pharma-stock-roundup-eu-nod-to-mrks-welireg-ions-q4-results-more",
      "time_published": "20250221T134100",
      "authors": [
        "Kinjel Shah"
      ],
      "summary": "EC approves MRK's Welireg for two indications. FDA grants priority review to SNY and REGN's Dupixent sBLA for bullous pemphigoid.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/39/612.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        }
      ],
      "overall_sentiment_score": 0.139122,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "IONS",
          "relevance_score": "0.28387",
          "ticker_sentiment_score": "0.113292",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.144275",
          "ticker_sentiment_score": "-0.102874",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.072435",
          "ticker_sentiment_score": "-0.125911",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SNY",
          "relevance_score": "0.28387",
          "ticker_sentiment_score": "0.246277",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "The Zacks Analyst Blog Eli Lilly, J&J, AbbVie, AstraZeneca and Pfizer",
      "url": "https://www.zacks.com/stock/news/2391344/the-zacks-analyst-blog-eli-lilly-jj-abbvie-astrazeneca-and-pfizer",
      "time_published": "20250103T074500",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "Eli Lilly, J&J, AbbVie, AstraZeneca and Pfizer are included in this Analyst Blog.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.999365"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.995015"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.995921"
        }
      ],
      "overall_sentiment_score": 0.19158,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.126403",
          "ticker_sentiment_score": "0.05353",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.144275",
          "ticker_sentiment_score": "0.091787",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AZN",
          "relevance_score": "0.197413",
          "ticker_sentiment_score": "0.15246",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.144275",
          "ticker_sentiment_score": "0.074514",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "5 Large Drug Stocks to Watch as Industry Recovers",
      "url": "https://www.zacks.com/commentary/2434569/5-large-drug-stocks-to-watch-as-industry-recovers",
      "time_published": "20250325T104700",
      "authors": [
        "Kinjel Shah"
      ],
      "summary": "R&D innovation is likely to remain a major focus area in 2025. In the Large-Cap Pharmaceuticals industry, AbbVie (ABBV), Novo Nordisk (NVO), Novartis (NVS), Pfizer (PFE) and Bayer (BAYRY) are worth retaining in one's portfolio ...",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/52/873.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.980922"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.99737"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.967321"
        }
      ],
      "overall_sentiment_score": 0.18987,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.141965",
          "ticker_sentiment_score": "0.12518",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ITCI",
          "relevance_score": "0.020387",
          "ticker_sentiment_score": "0.07309",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.121856",
          "ticker_sentiment_score": "0.16968",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.141965",
          "ticker_sentiment_score": "0.065547",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Top Stock Reports for Alphabet, AbbVie & Walt Disney",
      "url": "https://www.zacks.com/research-daily/2559723/top-stock-reports-for-alphabet-abbvie-walt-disney",
      "time_published": "20250701T203100",
      "authors": [
        "Mark Vickery"
      ],
      "summary": "GOOGL, ABBV, and DIS face distinct headwinds, but cloud strength, immunology growth, and parks momentum support long-term investor interest.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/a5/689.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.650727"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.249565,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MSFT",
          "relevance_score": "0.071145",
          "ticker_sentiment_score": "-0.087812",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GOOG",
          "relevance_score": "0.211191",
          "ticker_sentiment_score": "0.262805",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.141726",
          "ticker_sentiment_score": "0.177222",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Royalty Pharma to Announce First Quarter 2025 Financial Results on May 8, 2025",
      "url": "https://www.globenewswire.com/news-release/2025/04/17/3063839/0/en/Royalty-Pharma-to-Announce-First-Quarter-2025-Financial-Results-on-May-8-2025.html",
      "time_published": "20250417T201500",
      "authors": [
        "Royalty Pharma plc"
      ],
      "summary": "NEW YORK, April 17, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) today announced that it will report its first quarter 2025 financial results on Thursday, May 8, 2025 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:30 ...",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/d605b3b0-7ba0-46e1-a2d4-439ca98694f8",
      "source": "GlobeNewswire",
      "category_within_source": "n/a",
      "source_domain": "www.globenewswire.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.135727,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "RPRX",
          "relevance_score": "0.628066",
          "ticker_sentiment_score": "0.213261",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.141726",
          "ticker_sentiment_score": "0.095681",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Trump threatens to impose up to 200% tariff on pharmaceuticals 'very soon'",
      "url": "https://www.cnbc.com/2025/07/08/trump-threatens-pharmaceutical-tariffs-200.html",
      "time_published": "20250708T175822",
      "authors": [],
      "summary": "Trump suggested that those levies would not go into effect immediately, saying he will \"give people about a year, year and a half\" ...",
      "banner_image": null,
      "source": "CNBC",
      "category_within_source": "Business",
      "source_domain": "www.cnbc.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": -0.078815,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.140076",
          "ticker_sentiment_score": "0.058371",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.140076",
          "ticker_sentiment_score": "0.058371",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Should You Invest in the VanEck Pharmaceutical ETF  ( PPH ) ?",
      "url": "https://www.zacks.com/stock/news/2475069/should-you-invest-in-the-vaneck-pharmaceutical-etf-pph",
      "time_published": "20250521T102006",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Sector ETF report for PPH ...",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default130.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.181917,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.140076",
          "ticker_sentiment_score": "0.065699",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.140076",
          "ticker_sentiment_score": "0.065699",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IVZ",
          "relevance_score": "0.140076",
          "ticker_sentiment_score": "0.043427",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.140076",
          "ticker_sentiment_score": "0.065699",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Merck  ( MRK )  Q1 Earnings and Revenues Top Estimates",
      "url": "https://www.zacks.com/stock/news/2454445/merck-mrk-q1-earnings-and-revenues-top-estimates",
      "time_published": "20250424T114007",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Merck (MRK) delivered earnings and revenue surprises of 3.26% and 0.93%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default229.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999997"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        }
      ],
      "overall_sentiment_score": 0.12801,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.140076",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Royalty Pharma to Announce Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025",
      "url": "https://www.globenewswire.com/news-release/2025/01/28/3016783/0/en/Royalty-Pharma-to-Announce-Fourth-Quarter-and-Full-Year-2024-Financial-Results-on-February-11-2025.html",
      "time_published": "20250128T211500",
      "authors": [
        "Royalty Pharma plc"
      ],
      "summary": "NEW YORK, Jan. 28, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) today announced that it will report its fourth quarter and full year 2024 financial results on Tuesday, February 11, 2025 before the U.S. financial markets open.",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/d605b3b0-7ba0-46e1-a2d4-439ca98694f8",
      "source": "GlobeNewswire",
      "category_within_source": "n/a",
      "source_domain": "www.globenewswire.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.135727,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "RPRX",
          "relevance_score": "0.622414",
          "ticker_sentiment_score": "0.208908",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.140076",
          "ticker_sentiment_score": "0.095066",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Should You Invest in the VanEck Pharmaceutical ETF  ( PPH ) ?",
      "url": "https://www.zacks.com/stock/news/2432523/should-you-invest-in-the-vaneck-pharmaceutical-etf-pph",
      "time_published": "20250320T102007",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Sector ETF report for PPH ...",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default164.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.195617,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.137671",
          "ticker_sentiment_score": "0.065088",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.137671",
          "ticker_sentiment_score": "0.065088",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IVZ",
          "relevance_score": "0.137671",
          "ticker_sentiment_score": "0.043012",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.137671",
          "ticker_sentiment_score": "0.065088",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Should You Invest in the Vanguard Health Care ETF  ( VHT ) ?",
      "url": "https://www.zacks.com/stock/news/2375772/should-you-invest-in-the-vanguard-health-care-etf-vht",
      "time_published": "20241127T112007",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Sector ETF report for ...",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default269.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.261648,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.137671",
          "ticker_sentiment_score": "0.065088",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SPGI",
          "relevance_score": "0.069094",
          "ticker_sentiment_score": "0.125983",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.137671",
          "ticker_sentiment_score": "0.065088",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "UNH",
          "relevance_score": "0.137671",
          "ticker_sentiment_score": "0.065088",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Should You Invest in the VanEck Pharmaceutical ETF  ( PPH ) ?",
      "url": "https://www.zacks.com/stock/news/2397907/should-you-invest-in-the-vaneck-pharmaceutical-etf-pph",
      "time_published": "20250116T112008",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Sector ETF report for PPH ...",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default25.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.999998"
        }
      ],
      "overall_sentiment_score": 0.147577,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.137278",
          "ticker_sentiment_score": "0.064989",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.137278",
          "ticker_sentiment_score": "0.064989",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IVZ",
          "relevance_score": "0.137278",
          "ticker_sentiment_score": "0.042944",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.137278",
          "ticker_sentiment_score": "0.064989",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Should You Invest in the Vanguard Health Care ETF  ( VHT ) ?",
      "url": "https://www.zacks.com/stock/news/2437219/should-you-invest-in-the-vanguard-health-care-etf-vht",
      "time_published": "20250331T102006",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Sector ETF report for ...",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default273.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.272295,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.136113",
          "ticker_sentiment_score": "0.064698",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SPGI",
          "relevance_score": "0.068306",
          "ticker_sentiment_score": "0.125875",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.136113",
          "ticker_sentiment_score": "0.064698",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "UNH",
          "relevance_score": "0.136113",
          "ticker_sentiment_score": "0.064698",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Should You Invest in the Vanguard Health Care ETF  ( VHT ) ?",
      "url": "https://www.zacks.com/stock/news/2481813/should-you-invest-in-the-vanguard-health-care-etf-vht",
      "time_published": "20250603T102005",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Sector ETF report for ...",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default218.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.223817,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.135347",
          "ticker_sentiment_score": "0.064508",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SPGI",
          "relevance_score": "0.067919",
          "ticker_sentiment_score": "0.125823",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.135347",
          "ticker_sentiment_score": "0.064508",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "UNH",
          "relevance_score": "0.135347",
          "ticker_sentiment_score": "0.064508",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Obesity Drugs Help With Weight Loss But Are Adding Fat Elsewhere - Eli Lilly  ( NYSE:LLY ) ",
      "url": "https://www.benzinga.com/markets/large-cap/25/06/46036868/obesity-drugs-help-with-weight-loss-but-are-adding-fat-elsewhere",
      "time_published": "20250620T193955",
      "authors": [
        "Vandana Singh"
      ],
      "summary": "The U.S. imported $36 billion in hormone ingredients from Ireland this year-double last year's amount. Nearly all hormone shipments were sent to Indiana, home to Eli Lilly's headquarters. Ready to turn the market's comeback into steady cash flow? Grab the top 3 stocks to buy right here.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2025/06/20/Weight-Loss-Injection-Pen---Mounjaro-Inj.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        }
      ],
      "overall_sentiment_score": 0.128117,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.266101",
          "ticker_sentiment_score": "0.04164",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.134968",
          "ticker_sentiment_score": "0.119662",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "AnaptysBio Upgraded After RA Drug Matches Top Therapies In Phase 2 Trial - AnaptysBio  ( NASDAQ:ANAB ) ",
      "url": "https://www.benzinga.com/analyst-stock-ratings/upgrades/25/06/45778542/anaptysbios-arthritis-drug-matches-top-therapies-in-phase-2-trial-analyst-sees-tur",
      "time_published": "20250604T182316",
      "authors": [
        "Vandana Singh"
      ],
      "summary": "69% of rosnilimab patients achieved low disease activity by Week 14; 83% remained in LDA at Week 34. All doses showed statistically significant ACR20 and DAS-28 CRP reductions at Week 12 vs placebo. Get access to the leaderboards pointing to tomorrow's biggest stock movers. AnaptysBio, Inc.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2025/06/04/biotech-lab.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        }
      ],
      "overall_sentiment_score": 0.140191,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ANAB",
          "relevance_score": "0.266101",
          "ticker_sentiment_score": "0.108647",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LLY",
          "relevance_score": "0.134968",
          "ticker_sentiment_score": "-0.063759",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.134968",
          "ticker_sentiment_score": "-0.035714",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BMY",
          "relevance_score": "0.134968",
          "ticker_sentiment_score": "-0.035714",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.134968",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Should You Invest in the Vanguard Health Care ETF  ( VHT ) ?",
      "url": "https://www.zacks.com/stock/news/2405180/should-you-invest-in-the-vanguard-health-care-etf-vht",
      "time_published": "20250129T112008",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Sector ETF report for ...",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default123.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.999998"
        }
      ],
      "overall_sentiment_score": 0.237004,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.13459",
          "ticker_sentiment_score": "0.064321",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SPGI",
          "relevance_score": "0.067536",
          "ticker_sentiment_score": "0.125774",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.13459",
          "ticker_sentiment_score": "0.064321",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "UNH",
          "relevance_score": "0.13459",
          "ticker_sentiment_score": "0.064321",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Jim Cramer Says Even 'Safety' Stocks Look Risky, Warns Of 'Wild Card' In Washington And Rising Treasury Yields As Reasons To Stay Away From Sure Bets - Colgate-Palmolive  ( NYSE:CL ) , AbbVie  ( NYSE:ABBV ) ",
      "url": "https://www.benzinga.com/markets/equities/25/05/45427965/jim-cramer-says-even-safety-stocks-look-risky-warns-of-wild-card-in-washington-and-rising-treasu",
      "time_published": "20250515T050821",
      "authors": [
        "Shomik Sen Bhattacharjee"
      ],
      "summary": "Jim Cramer thinks that the bond market now offers a clearer risk-reward trade-off than so-called \"safety\" stocks, warning that rising 10-year Treasury yields and a political \"wild card\" in Washington make even dividend stalwarts feel shaky.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2025/05/15/Jim-Cramer.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Markets",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.980922"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.019838,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "GIS",
          "relevance_score": "0.199584",
          "ticker_sentiment_score": "-0.116353",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.263942",
          "ticker_sentiment_score": "0.045269",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PG",
          "relevance_score": "0.199584",
          "ticker_sentiment_score": "-0.09496",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PLSQF",
          "relevance_score": "0.067158",
          "ticker_sentiment_score": "0.144484",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CL",
          "relevance_score": "0.133841",
          "ticker_sentiment_score": "-0.035954",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PEP",
          "relevance_score": "0.133841",
          "ticker_sentiment_score": "-0.038395",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.133841",
          "ticker_sentiment_score": "-0.035954",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Is Big Pharma About To Win? Goldman Sachs Weighs In On 340B And Medicaid Shifts - AbbVie  ( NYSE:ABBV ) , Bristol-Myers Squibb  ( NYSE:BMY ) ",
      "url": "https://www.benzinga.com/trading-ideas/movers/25/01/43403416/is-big-pharma-about-to-win-goldman-sachs-weighs-in-on-340b-and-medicaid-shifts",
      "time_published": "20250131T203140",
      "authors": [
        "Nabaparna Bhattacharya"
      ],
      "summary": "Goldman Sachs analyst warns 340B reforms could shift profits to biopharma, benefiting companies like Merck and Gilead. Proposed Medicaid cuts may create risks for biopharma, impacting drugs like AbbVie's Humira and Gilead's Biktarvy. Get Pro-Level Earnings Insights Before the Market Moves",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2025/01/31/Medicaid-Loses-Access-to-Life-Saving-Tre.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.360215"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.149913,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.13347",
          "ticker_sentiment_score": "-0.003738",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.13347",
          "ticker_sentiment_score": "-0.003738",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GILD",
          "relevance_score": "0.199037",
          "ticker_sentiment_score": "0.075024",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GS",
          "relevance_score": "0.13347",
          "ticker_sentiment_score": "-0.009178",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BMY",
          "relevance_score": "0.13347",
          "ticker_sentiment_score": "0.142933",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2024 Financial Results",
      "url": "https://www.globenewswire.com/news-release/2025/03/11/3040456/0/en/Xilio-Therapeutics-Announces-Pipeline-and-Business-Updates-and-Fourth-Quarter-and-Full-Year-2024-Financial-Results.html",
      "time_published": "20250311T113000",
      "authors": [
        "Inc.",
        "Xilio Therapeutics"
      ],
      "summary": "Additional Phase 2 data for vilastobart, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with MSS CRC anticipated in the middle of ...",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/7e55cc25-f46f-423c-bf2a-e77ebaf69665",
      "source": "GlobeNewswire",
      "category_within_source": "n/a",
      "source_domain": "www.globenewswire.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Economy - Fiscal",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.992549"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.905476"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.111521,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "XLO",
          "relevance_score": "0.044579",
          "ticker_sentiment_score": "-0.015931",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.133182",
          "ticker_sentiment_score": "0.077291",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GILD",
          "relevance_score": "0.029728",
          "ticker_sentiment_score": "0.022071",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BNXYF",
          "relevance_score": "0.014867",
          "ticker_sentiment_score": "0.22011",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Royalty Pharma to Present at the Goldman Sachs 46th Annual Global Healthcare Conference - Royalty Pharma  ( NASDAQ:RPRX ) ",
      "url": "https://www.benzinga.com/pressreleases/25/06/g45780635/royalty-pharma-to-present-at-the-goldman-sachs-46th-annual-global-healthcare-conference",
      "time_published": "20250604T201500",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "NEW YORK, June 04, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc RPRX today announced that it will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10, 2025 at 2:00 p.m. ET.",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.197836,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "GS",
          "relevance_score": "0.1331",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RPRX",
          "relevance_score": "0.597963",
          "ticker_sentiment_score": "0.217945",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.1331",
          "ticker_sentiment_score": "0.092545",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Royalty Pharma Declares Second Quarter 2025 Dividend - Royalty Pharma  ( NASDAQ:RPRX ) ",
      "url": "https://www.benzinga.com/pressreleases/25/04/g44910782/royalty-pharma-declares-second-quarter-2025-dividend",
      "time_published": "20250421T201500",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "NEW YORK, April 21, 2025 ( GLOBE NEWSWIRE ) -- The board of directors of Royalty Pharma plc RPRX has approved the payment of a dividend for the second quarter of 2025 of $0.22 per Class A ordinary share. The dividend will be paid on June 10, 2025, to shareholders of record at the close of ...",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        }
      ],
      "overall_sentiment_score": 0.240439,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "RPRX",
          "relevance_score": "0.595343",
          "ticker_sentiment_score": "0.292134",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.132368",
          "ticker_sentiment_score": "0.092288",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Should You Invest in the Invesco Pharmaceuticals ETF  ( PJP ) ?",
      "url": "https://www.zacks.com/stock/news/2381261/should-you-invest-in-the-invesco-pharmaceuticals-etf-pjp",
      "time_published": "20241210T112008",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Sector ETF report for ...",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default292.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.220947,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.132004",
          "ticker_sentiment_score": "0.070801",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.132004",
          "ticker_sentiment_score": "0.070801",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IVZ",
          "relevance_score": "0.196877",
          "ticker_sentiment_score": "0.141519",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.132004",
          "ticker_sentiment_score": "0.070801",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "5 Large Drug Stocks to Keep An Eye On in the New Year",
      "url": "https://www.zacks.com/commentary/2390562/5-large-drug-stocks-to-keep-an-eye-on-in-the-new-year",
      "time_published": "20250102T134100",
      "authors": [
        "Kinjel Shah"
      ],
      "summary": "R&D innovation is likely to remain a major focus area in 2025. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), J&J (JNJ), AbbVie (ABBV), AstraZeneca (AZN) and Pfizer (PFE) are worth retaining in one's portfolio.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f5/284.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.996023"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.99737"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.995921"
        }
      ],
      "overall_sentiment_score": 0.191778,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.11324",
          "ticker_sentiment_score": "0.0615",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.131953",
          "ticker_sentiment_score": "0.107484",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AZN",
          "relevance_score": "0.187608",
          "ticker_sentiment_score": "0.173711",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.131953",
          "ticker_sentiment_score": "0.081189",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Should You Invest in the Fidelity MSCI Health Care Index ETF  ( FHLC ) ?",
      "url": "https://www.zacks.com/stock/news/2559078/should-you-invest-in-the-fidelity-msci-health-care-index-etf-fhlc",
      "time_published": "20250701T102006",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Sector ETF report for ...",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default336.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.264207,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.130571",
          "ticker_sentiment_score": "0.0504",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.130571",
          "ticker_sentiment_score": "0.0504",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.130571",
          "ticker_sentiment_score": "0.0504",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "The Zacks Analyst Blog Highlights Merck, Sanofi, Regeneron and Ionis",
      "url": "https://www.zacks.com/stock/news/2419906/the-zacks-analyst-blog-highlights-merck-sanofi-regeneron-and-ionis",
      "time_published": "20250224T094600",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "Merck, Sanofi, Regeneron and Ionis are included in this Analyst Blog.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ef/472.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        }
      ],
      "overall_sentiment_score": 0.162195,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "IONS",
          "relevance_score": "0.318897",
          "ticker_sentiment_score": "0.118317",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.130571",
          "ticker_sentiment_score": "-0.097574",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.065506",
          "ticker_sentiment_score": "-0.125209",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SNY",
          "relevance_score": "0.318897",
          "ticker_sentiment_score": "0.23283",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Should You Invest in the Invesco Pharmaceuticals ETF  ( PJP ) ?",
      "url": "https://www.zacks.com/stock/news/2509884/should-you-invest-in-the-invesco-pharmaceuticals-etf-pjp",
      "time_published": "20250618T102007",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Sector ETF report for ...",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default250.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.182348,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.130217",
          "ticker_sentiment_score": "0.070327",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.130217",
          "ticker_sentiment_score": "0.070327",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IVZ",
          "relevance_score": "0.194242",
          "ticker_sentiment_score": "0.11726",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.130217",
          "ticker_sentiment_score": "0.070327",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Royalty Pharma Announces Dividend Increase - Royalty Pharma  ( NASDAQ:RPRX ) ",
      "url": "https://www.benzinga.com/pressreleases/25/01/g42902266/royalty-pharma-announces-dividend-increase",
      "time_published": "20250109T211500",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "NEW YORK, Jan. 09, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc RPRX today announced that its board of directors has declared a dividend for the first quarter of 2025 of $0.22 per Class A ordinary share, reflecting a 5% increase in the company's quarterly dividend over the previous quarter's ...",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.220317,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "RPRX",
          "relevance_score": "0.587597",
          "ticker_sentiment_score": "0.267888",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.130217",
          "ticker_sentiment_score": "0.091543",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Royalty Pharma to Present at Upcoming Investor Conferences - Royalty Pharma  ( NASDAQ:RPRX ) ",
      "url": "https://www.benzinga.com/pressreleases/24/11/g42224599/royalty-pharma-to-present-at-upcoming-investor-conferences",
      "time_published": "20241127T211500",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "NEW YORK, Nov. 27, 2024 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc RPRX today announced that it will participate in the following upcoming investor conferences during the month of December: 7th Annual Evercore ISI HealthCONx Conference on Tuesday, December 3 at 12:55 p.m. ET",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.177417,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "EVR",
          "relevance_score": "0.130217",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RPRX",
          "relevance_score": "0.587597",
          "ticker_sentiment_score": "0.225785",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.130217",
          "ticker_sentiment_score": "0.091543",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Royalty Pharma Announces Upcoming Investor Day",
      "url": "https://www.globenewswire.com/news-release/2025/03/27/3050522/0/en/Royalty-Pharma-Announces-Upcoming-Investor-Day.html",
      "time_published": "20250327T121500",
      "authors": [
        "Royalty Pharma plc"
      ],
      "summary": "NEW YORK, March 27, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) today announced that it will host an Investor Day in New York City on Thursday, September 11, 2025, starting at 8:30 a.m. ET. Royalty Pharma senior executives will provide an update on the company's plans to drive ...",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/d605b3b0-7ba0-46e1-a2d4-439ca98694f8",
      "source": "GlobeNewswire",
      "category_within_source": "n/a",
      "source_domain": "www.globenewswire.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.176713,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "RPRX",
          "relevance_score": "0.672055",
          "ticker_sentiment_score": "0.312864",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.129516",
          "ticker_sentiment_score": "0.091303",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Should You Invest in the Invesco Pharmaceuticals ETF  ( PJP ) ?",
      "url": "https://www.zacks.com/stock/news/2415096/should-you-invest-in-the-invesco-pharmaceuticals-etf-pjp",
      "time_published": "20250213T112003",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Sector ETF report for ...",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default32.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.175499,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.128822",
          "ticker_sentiment_score": "0.062937",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.128822",
          "ticker_sentiment_score": "0.062937",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IVZ",
          "relevance_score": "0.192183",
          "ticker_sentiment_score": "0.138703",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.128822",
          "ticker_sentiment_score": "0.062937",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Genmab to Submit Supplemental Biologics License Application  ( sBLA )  to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide  ( R2 )  in Patients with Relapsed/Refractory Follicular Lymphoma  ( FL ) ",
      "url": "https://www.globenewswire.com/news-release/2025/05/02/3072977/0/en/Genmab-to-Submit-Supplemental-Biologics-License-Application-sBLA-to-U-S-Food-and-Drug-Administration-for-Epcoritamab-Plus-Rituximab-and-Lenalidomide-R2-in-Patients-with-Relapsed-Re.html",
      "time_published": "20250502T001400",
      "authors": [
        "Genmab A/S"
      ],
      "summary": "Company Announcement ...",
      "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/368a5dab-dfc5-4e1d-bfa6-2af5e5216fce",
      "source": "GlobeNewswire",
      "category_within_source": "n/a",
      "source_domain": "www.globenewswire.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.054898,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "GMAB",
          "relevance_score": "0.299478",
          "ticker_sentiment_score": "0.105408",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.127321",
          "ticker_sentiment_score": "0.105747",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Trump signs order to boost domestic drug manufacturing as pharma tariff threat looms",
      "url": "https://www.cnbc.com/2025/05/05/trump-order-us-drug-manufacturing.html",
      "time_published": "20250505T205649",
      "authors": [],
      "summary": "The order comes ahead of Trump's planned tariffs on pharmaceuticals imported into the U.S.",
      "banner_image": null,
      "source": "CNBC",
      "category_within_source": "Business",
      "source_domain": "www.cnbc.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.064147,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "GLDAF",
          "relevance_score": "0.250386",
          "ticker_sentiment_score": "0.036186",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.126784",
          "ticker_sentiment_score": "0.103206",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.126784",
          "ticker_sentiment_score": "-0.095045",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.126784",
          "ticker_sentiment_score": "0.103206",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Pfizer Stock Falls to New 52-Week Low: Should You Buy the Dip?",
      "url": "https://www.zacks.com/stock/news/2443399/pfizer-stock-falls-to-new-52-week-low-should-you-buy-the-dip",
      "time_published": "20250410T134400",
      "authors": [
        "Kinjel Shah"
      ],
      "summary": "PFE stock is likely to be a great pick for value investors, considering its cheap valuation, as well as for income investors due to its sky-high dividend yield.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/89/447.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.999365"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.614606"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.118165,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "NVO",
          "relevance_score": "0.042421",
          "ticker_sentiment_score": "0.073888",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LLY",
          "relevance_score": "0.126784",
          "ticker_sentiment_score": "0.042578",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.126784",
          "ticker_sentiment_score": "0.042578",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVAX",
          "relevance_score": "0.042421",
          "ticker_sentiment_score": "-0.04435",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MRNA",
          "relevance_score": "0.042421",
          "ticker_sentiment_score": "-0.04435",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.510742",
          "ticker_sentiment_score": "0.161316",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "BNTX",
          "relevance_score": "0.126784",
          "ticker_sentiment_score": "-0.053156",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Should You Invest in the SPDR S&P Biotech ETF  ( XBI ) ?",
      "url": "https://www.zacks.com/stock/news/2408001/should-you-invest-in-the-spdr-sp-biotech-etf-xbi",
      "time_published": "20250203T112023",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Sector ETF report for ...",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default93.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.184385,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "STT",
          "relevance_score": "0.063594",
          "ticker_sentiment_score": "0.031007",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.126784",
          "ticker_sentiment_score": "0.069436",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GILD",
          "relevance_score": "0.126784",
          "ticker_sentiment_score": "0.069436",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NBIX",
          "relevance_score": "0.126784",
          "ticker_sentiment_score": "0.069436",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Pharma Stock Roundup: PFE, LLY, NVO, LLY and AZN's Q4 Earnings Update",
      "url": "https://www.zacks.com/stock/news/2411835/pharma-stock-roundup-pfe-lly-nvo-lly-and-azns-q4-earnings-update",
      "time_published": "20250207T134100",
      "authors": [
        "Kinjel Shah"
      ],
      "summary": "PFE, LLY, NVO, LLY and AZN announce fourth-quarter earnings.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/52/873.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.999999"
        },
        {
          "topic": "Economy - Macro",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.097883,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.250065",
          "ticker_sentiment_score": "0.054398",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.126617",
          "ticker_sentiment_score": "0.048862",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AZN",
          "relevance_score": "0.188928",
          "ticker_sentiment_score": "-0.060672",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.188928",
          "ticker_sentiment_score": "0.125573",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.157896",
          "ticker_sentiment_score": "0.108645",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Should You Invest in the SPDR S&P Biotech ETF  ( XBI ) ?",
      "url": "https://www.zacks.com/stock/news/2442329/should-you-invest-in-the-spdr-sp-biotech-etf-xbi",
      "time_published": "20250409T102006",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Sector ETF report for ...",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default77.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.150278,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "STT",
          "relevance_score": "0.063258",
          "ticker_sentiment_score": "0.031005",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.126119",
          "ticker_sentiment_score": "0.069267",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GILD",
          "relevance_score": "0.126119",
          "ticker_sentiment_score": "0.069267",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AMGN",
          "relevance_score": "0.126119",
          "ticker_sentiment_score": "0.069267",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Royalty Pharma to Announce Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025 - Royalty Pharma  ( NASDAQ:RPRX ) ",
      "url": "https://www.benzinga.com/pressreleases/25/01/g43287507/royalty-pharma-to-announce-fourth-quarter-and-full-year-2024-financial-results-on-february-11-2025",
      "time_published": "20250128T211521",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "NEW YORK, Jan. 28, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc RPRX today announced that it will report its fourth quarter and full year 2024 financial results on Tuesday, February 11, 2025 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast ...",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.170525,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "RPRX",
          "relevance_score": "0.567746",
          "ticker_sentiment_score": "0.195809",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.124809",
          "ticker_sentiment_score": "0.089734",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "FDA Okays LLY's Omvoh for Second Inflammatory Bowel Disease Condition",
      "url": "https://www.zacks.com/stock/news/2398001/fda-okays-llys-omvoh-for-second-inflammatory-bowel-disease-condition",
      "time_published": "20250116T124900",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "FDA approves Lilly's Omvoh for Crohn's disease, expanding its use to the second major type of IBD condition.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f5/284.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.161647"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.294914,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.465901",
          "ticker_sentiment_score": "0.311788",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.123526",
          "ticker_sentiment_score": "0.248863",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "RXDX",
          "relevance_score": "0.061949",
          "ticker_sentiment_score": "0.026028",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SNY",
          "relevance_score": "0.184363",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Should WisdomTree U.S. High Dividend ETF  ( DHS )  Be on Your Investing Radar?",
      "url": "https://www.zacks.com/stock/news/2414228/should-wisdomtree-us-high-dividend-etf-dhs-be-on-your-investing-radar",
      "time_published": "20250212T112005",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Style Box ETF report for ...",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default88.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "1.0"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.451494"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.21273,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.123209",
          "ticker_sentiment_score": "0.068541",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "WT",
          "relevance_score": "0.358152",
          "ticker_sentiment_score": "0.17223",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.123209",
          "ticker_sentiment_score": "0.068541",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "XOM",
          "relevance_score": "0.123209",
          "ticker_sentiment_score": "0.068541",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Should First Trust Morningstar Dividend Leaders ETF  ( FDL )  Be on Your Investing Radar?",
      "url": "https://www.zacks.com/stock/news/2397021/should-first-trust-morningstar-dividend-leaders-etf-fdl-be-on-your-investing-radar",
      "time_published": "20250115T112006",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Style Box ETF report for ...",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default331.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.25"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "1.0"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.451494"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.25"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.25"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.25"
        }
      ],
      "overall_sentiment_score": 0.240055,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MORN",
          "relevance_score": "0.24289",
          "ticker_sentiment_score": "0.207937",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.122894",
          "ticker_sentiment_score": "0.068464",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CVX",
          "relevance_score": "0.122894",
          "ticker_sentiment_score": "0.068464",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "VZ",
          "relevance_score": "0.122894",
          "ticker_sentiment_score": "0.068464",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Should SPDR Portfolio S&P 500 High Dividend ETF  ( SPYD )  Be on Your Investing Radar?",
      "url": "https://www.zacks.com/stock/news/2435971/should-spdr-portfolio-sp-500-high-dividend-etf-spyd-be-on-your-investing-radar",
      "time_published": "20250327T102006",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Style Box ETF report for ...",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default259.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.25"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.25"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "1.0"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.25"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.451494"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.25"
        }
      ],
      "overall_sentiment_score": 0.222191,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CVS",
          "relevance_score": "0.122269",
          "ticker_sentiment_score": "0.068311",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "STT",
          "relevance_score": "0.061315",
          "ticker_sentiment_score": "0.111015",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.122269",
          "ticker_sentiment_score": "0.068311",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PM",
          "relevance_score": "0.122269",
          "ticker_sentiment_score": "0.068311",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Should Invesco Large Cap Value ETF  ( PWV )  Be on Your Investing Radar?",
      "url": "https://www.zacks.com/stock/news/2389223/should-invesco-large-cap-value-etf-pwv-be-on-your-investing-radar",
      "time_published": "20241230T112008",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Style Box ETF report for ...",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default359.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "1.0"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.451494"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.265939,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.122269",
          "ticker_sentiment_score": "0.068311",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CSCO",
          "relevance_score": "0.122269",
          "ticker_sentiment_score": "0.068311",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IVZ",
          "relevance_score": "0.182506",
          "ticker_sentiment_score": "0.179113",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "IBM",
          "relevance_score": "0.122269",
          "ticker_sentiment_score": "0.068311",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Should Invesco Large Cap Value ETF  ( PWV )  Be on Your Investing Radar?",
      "url": "https://www.zacks.com/stock/news/2424117/should-invesco-large-cap-value-etf-pwv-be-on-your-investing-radar",
      "time_published": "20250303T112006",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Style Box ETF report for ...",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default138.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "1.0"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.451494"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.267401,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "IVZ",
          "relevance_score": "0.182047",
          "ticker_sentiment_score": "0.177308",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "IBM",
          "relevance_score": "0.121959",
          "ticker_sentiment_score": "0.061385",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.121959",
          "ticker_sentiment_score": "0.061385",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Monoclonal Antibody Therapeutics Market Size to Reach USD 619.60 Billion by 2031, Driven by Production of mAB-Based Drugs to Treat Several Diseases and Innovative Product Launches Propels | The Insight Partners",
      "url": "https://www.benzinga.com/pressreleases/25/05/g45692104/monoclonal-antibody-therapeutics-market-size-to-reach-usd-619-60-billion-by-2031-driven-by-product",
      "time_published": "20250530T120915",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "US & Canada, May 30, 2025 ( GLOBE NEWSWIRE ) -- The report carries an in-depth analysis of market trends, key players, and future opportunities. The monoclonal antibody therapeutics market study focuses on an array of products and technologies that are expected to fuel the demand in the coming ...",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.538269"
        }
      ],
      "overall_sentiment_score": 0.213934,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "AZN",
          "relevance_score": "0.061003",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.12165",
          "ticker_sentiment_score": "-0.065306",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BMY",
          "relevance_score": "0.061003",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Royalty Pharma to Announce First Quarter 2025 Financial Results on May 8, 2025 - Royalty Pharma  ( NASDAQ:RPRX ) ",
      "url": "https://www.benzinga.com/pressreleases/25/04/g44877582/royalty-pharma-to-announce-first-quarter-2025-financial-results-on-may-8-2025",
      "time_published": "20250417T201500",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "NEW YORK, April 17, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc RPRX today announced that it will report its first quarter 2025 financial results on Thursday, May 8, 2025 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:30 a.m.",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.181886,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "RPRX",
          "relevance_score": "0.555911",
          "ticker_sentiment_score": "0.196746",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.12165",
          "ticker_sentiment_score": "0.088722",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Should WisdomTree U.S. High Dividend ETF  ( DHS )  Be on Your Investing Radar?",
      "url": "https://www.zacks.com/stock/news/2383144/should-wisdomtree-us-high-dividend-etf-dhs-be-on-your-investing-radar",
      "time_published": "20241213T112005",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Style Box ETF report for ...",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default279.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "1.0"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.451494"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.203849,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MO",
          "relevance_score": "0.12165",
          "ticker_sentiment_score": "0.068161",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.12165",
          "ticker_sentiment_score": "0.068161",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "WT",
          "relevance_score": "0.353898",
          "ticker_sentiment_score": "0.170702",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "XOM",
          "relevance_score": "0.12165",
          "ticker_sentiment_score": "0.068161",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Should First Trust Morningstar Dividend Leaders ETF  ( FDL )  Be on Your Investing Radar?",
      "url": "https://www.zacks.com/stock/news/2370779/should-first-trust-morningstar-dividend-leaders-etf-fdl-be-on-your-investing-radar",
      "time_published": "20241115T112006",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Style Box ETF report for ...",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default33.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.25"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "1.0"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.451494"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.25"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.25"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.25"
        }
      ],
      "overall_sentiment_score": 0.238152,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MORN",
          "relevance_score": "0.238718",
          "ticker_sentiment_score": "0.205048",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.120733",
          "ticker_sentiment_score": "0.067941",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CVX",
          "relevance_score": "0.120733",
          "ticker_sentiment_score": "0.067941",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "VZ",
          "relevance_score": "0.120733",
          "ticker_sentiment_score": "0.067941",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Should Schwab U.S. Dividend Equity ETF  ( SCHD )  Be on Your Investing Radar?",
      "url": "https://www.zacks.com/stock/news/2441626/should-schwab-us-dividend-equity-etf-schd-be-on-your-investing-radar",
      "time_published": "20250408T102008",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Style Box ETF report for ...",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default289.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "1.0"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.451494"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.244782,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "SCHW",
          "relevance_score": "0.060388",
          "ticker_sentiment_score": "0.124007",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.120431",
          "ticker_sentiment_score": "0.067868",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "KO",
          "relevance_score": "0.120431",
          "ticker_sentiment_score": "0.067868",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AMGN",
          "relevance_score": "0.120431",
          "ticker_sentiment_score": "0.067868",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Novo Nordisk cuts 2025 guidance on weaker-than-expected Wegovy sales, posts first-quarter profit beat",
      "url": "https://www.cnbc.com/2025/05/07/novo-nordisk-nvo-earnings-q1-2025.html",
      "time_published": "20250507T055023",
      "authors": [],
      "summary": "Novo Nordisk on Wednesday reported a better-than-expected rise in net profit but lowered its full-year sales growth forecast.",
      "banner_image": null,
      "source": "CNBC",
      "category_within_source": "Top News",
      "source_domain": "www.cnbc.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.451494"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": -0.056604,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "AZN",
          "relevance_score": "0.11983",
          "ticker_sentiment_score": "-0.088154",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.11983",
          "ticker_sentiment_score": "0.167302",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.11983",
          "ticker_sentiment_score": "-0.088154",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "MARA Holdings, RadNet, Bit Digital, Coinbase And Other Big Stocks Moving Higher On Monday - MARA Holdings  ( NASDAQ:MARA ) ",
      "url": "https://www.benzinga.com/24/11/41880495/mara-holdings-radnet-bit-digital-coinbase-and-other-big-stocks-moving-higher-on-monday",
      "time_published": "20241111T151425",
      "authors": [
        "Avi Kapoor"
      ],
      "summary": "U.S. stocks were higher, with the Dow Jones index gaining more than 400 points on Monday. Shares of MARA Holdings, Inc. MARA rose sharply during Monday's session amid strength in Bitcoin. Prices for Bitcoin surged above the $82,000 level on Monday. MARA Holdings shares jumped 17.3% to $22.59 on ...",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2024/11/11/Bitcoin-WULF-MARA-MSTR-COIN-HUT.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.25"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.25"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.25"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.25"
        }
      ],
      "overall_sentiment_score": 0.392611,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "HUM",
          "relevance_score": "0.11983",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CI",
          "relevance_score": "0.236972",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HIMS",
          "relevance_score": "0.236972",
          "ticker_sentiment_score": "0.562626",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "HUT",
          "relevance_score": "0.236972",
          "ticker_sentiment_score": "0.356942",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "MS",
          "relevance_score": "0.11983",
          "ticker_sentiment_score": "0.115455",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CANG",
          "relevance_score": "0.236972",
          "ticker_sentiment_score": "0.562626",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "RXRX",
          "relevance_score": "0.236972",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.11983",
          "ticker_sentiment_score": "0.175934",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "NNOX",
          "relevance_score": "0.236972",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "COIN",
          "relevance_score": "0.236972",
          "ticker_sentiment_score": "0.446058",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "BMY",
          "relevance_score": "0.236972",
          "ticker_sentiment_score": "0.271575",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "IREN",
          "relevance_score": "0.236972",
          "ticker_sentiment_score": "0.149077",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CAN",
          "relevance_score": "0.11983",
          "ticker_sentiment_score": "0.18965",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "RIOT",
          "relevance_score": "0.236972",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BTBT",
          "relevance_score": "0.236972",
          "ticker_sentiment_score": "0.574847",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "HOOD",
          "relevance_score": "0.236972",
          "ticker_sentiment_score": "0.179869",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "AFRM",
          "relevance_score": "0.236972",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RDNT",
          "relevance_score": "0.236972",
          "ticker_sentiment_score": "0.403776",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "BTDR",
          "relevance_score": "0.236972",
          "ticker_sentiment_score": "0.410124",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "CRYPTO:BTC",
          "relevance_score": "0.708701",
          "ticker_sentiment_score": "0.594638",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "CRYPTO:NANO",
          "relevance_score": "0.11983",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Should First Trust Morningstar Dividend Leaders ETF  ( FDL )  Be on Your Investing Radar?",
      "url": "https://www.zacks.com/stock/news/2474363/should-first-trust-morningstar-dividend-leaders-etf-fdl-be-on-your-investing-radar",
      "time_published": "20250520T102005",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Style Box ETF report for ...",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default110.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.25"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "1.0"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.451494"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.25"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.25"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.25"
        }
      ],
      "overall_sentiment_score": 0.224172,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MORN",
          "relevance_score": "0.236396",
          "ticker_sentiment_score": "0.205312",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.119532",
          "ticker_sentiment_score": "0.067655",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CVX",
          "relevance_score": "0.119532",
          "ticker_sentiment_score": "0.067655",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "VZ",
          "relevance_score": "0.119532",
          "ticker_sentiment_score": "0.067655",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Should First Trust Morningstar Dividend Leaders ETF  ( FDL )  Be on Your Investing Radar?",
      "url": "https://www.zacks.com/stock/news/2430530/should-first-trust-morningstar-dividend-leaders-etf-fdl-be-on-your-investing-radar",
      "time_published": "20250317T102005",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Style Box ETF report for ...",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default223.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.25"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "1.0"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.451494"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.25"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.25"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.25"
        }
      ],
      "overall_sentiment_score": 0.235747,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MORN",
          "relevance_score": "0.236396",
          "ticker_sentiment_score": "0.212292",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.119532",
          "ticker_sentiment_score": "0.067655",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CVX",
          "relevance_score": "0.119532",
          "ticker_sentiment_score": "0.067655",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "VZ",
          "relevance_score": "0.119532",
          "ticker_sentiment_score": "0.067655",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Should Schwab U.S. Dividend Equity ETF  ( SCHD )  Be on Your Investing Radar?",
      "url": "https://www.zacks.com/stock/news/2409777/should-schwab-us-dividend-equity-etf-schd-be-on-your-investing-radar",
      "time_published": "20250205T112007",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Style Box ETF report for ...",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default294.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "1.0"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.451494"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.22631,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "SCHW",
          "relevance_score": "0.059636",
          "ticker_sentiment_score": "0.124001",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.11894",
          "ticker_sentiment_score": "0.064126",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.11894",
          "ticker_sentiment_score": "0.064126",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Genmab Announces Financial Results for the First Quarter of 2024",
      "url": "https://www.globenewswire.com/news-release/2025/05/08/3077457/0/en/Genmab-Announces-Financial-Results-for-the-First-Quarter-of-2024.html",
      "time_published": "20250508T150100",
      "authors": [
        "Genmab A/S"
      ],
      "summary": "May 8, 2025 Copenhagen, Denmark. Interim Report for the First Quarter Ended March ...",
      "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/368a5dab-dfc5-4e1d-bfa6-2af5e5216fce",
      "source": "GlobeNewswire",
      "category_within_source": "n/a",
      "source_domain": "www.globenewswire.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.161647"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.310843"
        }
      ],
      "overall_sentiment_score": 0.085115,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "NVS",
          "relevance_score": "0.039679",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.118647",
          "ticker_sentiment_score": "0.053911",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GMAB",
          "relevance_score": "0.415802",
          "ticker_sentiment_score": "0.098205",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.079261",
          "ticker_sentiment_score": "0.04867",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Should SPDR S&P Dividend ETF  ( SDY )  Be on Your Investing Radar?",
      "url": "https://www.zacks.com/stock/news/2437829/should-spdr-sp-dividend-etf-sdy-be-on-your-investing-radar",
      "time_published": "20250401T102006",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Style Box ETF report for ...",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default22.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.25"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "1.0"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.451494"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.25"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.25"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.25"
        }
      ],
      "overall_sentiment_score": 0.201196,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "STT",
          "relevance_score": "0.059488",
          "ticker_sentiment_score": "0.111",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.118647",
          "ticker_sentiment_score": "0.067448",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "VZ",
          "relevance_score": "0.118647",
          "ticker_sentiment_score": "0.067448",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "O",
          "relevance_score": "0.059488",
          "ticker_sentiment_score": "0.059994",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Pharma ETFs in Focus on Trump's Drug Price Overhaul",
      "url": "https://www.zacks.com/stock/news/2466882/pharma-etfs-in-focus-on-trumps-drug-price-overhaul",
      "time_published": "20250512T143000",
      "authors": [
        "Sweta Killa"
      ],
      "summary": "Trump's plan to slash the price of prescription drugs by 30% put pharma ETFs in focus.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ab/2180.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.999953"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.360215"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.125235,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.118354",
          "ticker_sentiment_score": "0.025653",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CVS",
          "relevance_score": "0.118354",
          "ticker_sentiment_score": "0.025653",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.118354",
          "ticker_sentiment_score": "0.025653",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IVZ",
          "relevance_score": "0.176717",
          "ticker_sentiment_score": "0.046318",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "UNH",
          "relevance_score": "0.118354",
          "ticker_sentiment_score": "0.025653",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.118354",
          "ticker_sentiment_score": "0.025653",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Earnings Data Deluge",
      "url": "https://www.zacks.com/stock/news/2455992/earnings-data-deluge",
      "time_published": "20250425T150800",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Pre-market futures are in the red slightly this morning - not enough to deplete this week's worth of gains ( although it's still early ) - and bond yields are drifting downward. There are no economic reports out ahead of the final opening bell of the week, but we do have another bushel of Q1 ...",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/d5/8276.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.25"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.25"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.365926"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.838487"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.25"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.25"
        }
      ],
      "overall_sentiment_score": 0.047797,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "MSFT",
          "relevance_score": "0.117774",
          "ticker_sentiment_score": "-0.03167",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AAPL",
          "relevance_score": "0.117774",
          "ticker_sentiment_score": "-0.03167",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LAZ",
          "relevance_score": "0.117774",
          "ticker_sentiment_score": "0.136135",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CL",
          "relevance_score": "0.117774",
          "ticker_sentiment_score": "0.014101",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.117774",
          "ticker_sentiment_score": "0.183764",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "AN",
          "relevance_score": "0.059049",
          "ticker_sentiment_score": "0.107153",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AMZN",
          "relevance_score": "0.117774",
          "ticker_sentiment_score": "-0.03167",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Omeros' New Leukemia Drug Team Ignites Hope For Cancer Fight - Omeros  ( NASDAQ:OMER ) ",
      "url": "https://www.benzinga.com/general/biotech/25/04/44772476/omeros-advances-high-potential-leukemia-drug-development-stock-moves-higher",
      "time_published": "20250411T190633",
      "authors": [
        "Vandana Singh"
      ],
      "summary": "OncotoX-AML showed superior survival benefit in preclinical studies vs. venetoclax and azacitidine. Therapy kills AML blasts and stem cells at low doses without neutropenia or blood toxicity. Feel unsure about the market's next move?",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2025/04/11/Medical-Research-And-Development-Center-.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        }
      ],
      "overall_sentiment_score": 0.23732,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "OMER",
          "relevance_score": "0.584822",
          "ticker_sentiment_score": "0.035095",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.117774",
          "ticker_sentiment_score": "0.206286",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "BMY",
          "relevance_score": "0.117774",
          "ticker_sentiment_score": "0.206286",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Is Invesco Large Cap Value ETF  ( PWV )  a Strong ETF Right Now?",
      "url": "https://www.zacks.com/stock/news/2502859/is-invesco-large-cap-value-etf-pwv-a-strong-etf-right-now",
      "time_published": "20250616T102006",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Smart Beta ETF report for ...",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default102.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.999998"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.333341,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "IVZ",
          "relevance_score": "0.175433",
          "ticker_sentiment_score": "0.291359",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "PM",
          "relevance_score": "0.117486",
          "ticker_sentiment_score": "0.060435",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.117486",
          "ticker_sentiment_score": "0.060435",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Galapagos Announces Executive Leadership Updates",
      "url": "https://www.globenewswire.com/news-release/2025/04/21/3064984/0/en/Galapagos-Announces-Executive-Leadership-Updates.html",
      "time_published": "20250421T201000",
      "authors": [
        "Galapagos NV"
      ],
      "summary": "Mr. Henry Gosebruch appointed by the Galapagos Board of Directors as founding CEO of newly created ...",
      "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/13b034e2-76d4-408b-bffb-c80d85420b03",
      "source": "GlobeNewswire",
      "category_within_source": "n/a",
      "source_domain": "www.globenewswire.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "IPO",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.682689"
        }
      ],
      "overall_sentiment_score": 0.303845,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "GLPG",
          "relevance_score": "0.555553",
          "ticker_sentiment_score": "0.424982",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.116914",
          "ticker_sentiment_score": "0.091068",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GILD",
          "relevance_score": "0.023464",
          "ticker_sentiment_score": "0.206078",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Is Invesco Large Cap Value ETF  ( PWV )  a Strong ETF Right Now?",
      "url": "https://www.zacks.com/stock/news/2448856/is-invesco-large-cap-value-etf-pwv-a-strong-etf-right-now",
      "time_published": "20250415T102006",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Smart Beta ETF report for ...",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default278.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.999996"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.320967,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.116914",
          "ticker_sentiment_score": "0.060317",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CSCO",
          "relevance_score": "0.116914",
          "ticker_sentiment_score": "0.060317",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IVZ",
          "relevance_score": "0.174587",
          "ticker_sentiment_score": "0.316432",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "IBM",
          "relevance_score": "0.116914",
          "ticker_sentiment_score": "0.060317",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Royalty Pharma Announces Upcoming Investor Day - Royalty Pharma  ( NASDAQ:RPRX ) ",
      "url": "https://www.benzinga.com/pressreleases/25/03/g44512372/royalty-pharma-announces-upcoming-investor-day",
      "time_published": "20250327T121500",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "NEW YORK, March 27, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc RPRX today announced that it will host an Investor Day in New York City on Thursday, September 11, 2025, starting at 8:30 a.m.",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.202248,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "RPRX",
          "relevance_score": "0.620083",
          "ticker_sentiment_score": "0.29811",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.116348",
          "ticker_sentiment_score": "0.087101",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Is Invesco Pharmaceuticals ETF  ( PJP )  a Strong ETF Right Now?",
      "url": "https://www.zacks.com/stock/news/2425687/is-invesco-pharmaceuticals-etf-pjp-a-strong-etf-right-now",
      "time_published": "20250305T112007",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Smart Beta ETF report for ...",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default160.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.999997"
        }
      ],
      "overall_sentiment_score": 0.293553,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.116067",
          "ticker_sentiment_score": "0.060144",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.116067",
          "ticker_sentiment_score": "0.060144",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.116067",
          "ticker_sentiment_score": "0.060144",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IVZ",
          "relevance_score": "0.173333",
          "ticker_sentiment_score": "0.298625",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Is SPDR S&P Biotech ETF  ( XBI )  a Strong ETF Right Now?",
      "url": "https://www.zacks.com/stock/news/2425683/is-spdr-sp-biotech-etf-xbi-a-strong-etf-right-now",
      "time_published": "20250305T112008",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Smart Beta ETF report for ...",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default51.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.999965"
        }
      ],
      "overall_sentiment_score": 0.231952,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ALNY",
          "relevance_score": "0.115787",
          "ticker_sentiment_score": "0.066792",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "STT",
          "relevance_score": "0.058047",
          "ticker_sentiment_score": "0.061968",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.115787",
          "ticker_sentiment_score": "0.066792",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NBIX",
          "relevance_score": "0.115787",
          "ticker_sentiment_score": "0.066792",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Is First Trust Capital Strength ETF  ( FTCS )  a Strong ETF Right Now?",
      "url": "https://www.zacks.com/stock/news/2377716/is-first-trust-capital-strength-etf-ftcs-a-strong-etf-right-now",
      "time_published": "20241202T181834",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Smart Beta ETF report for ...",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default150.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.999892"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.295914,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "EA",
          "relevance_score": "0.115787",
          "ticker_sentiment_score": "0.066792",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PKG",
          "relevance_score": "0.115787",
          "ticker_sentiment_score": "0.066792",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.115787",
          "ticker_sentiment_score": "0.066792",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Is ProShares S&P 500 Dividend Aristocrats ETF  ( NOBL )  a Strong ETF Right Now?",
      "url": "https://www.zacks.com/stock/news/2465804/is-proshares-sp-500-dividend-aristocrats-etf-nobl-a-strong-etf-right-now",
      "time_published": "20250509T102005",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Smart Beta ETF report for ...",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default215.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.999994"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.236194,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MORN",
          "relevance_score": "0.057628",
          "ticker_sentiment_score": "0.18609",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.114956",
          "ticker_sentiment_score": "0.061034",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BRO",
          "relevance_score": "0.114956",
          "ticker_sentiment_score": "0.061034",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ED",
          "relevance_score": "0.114956",
          "ticker_sentiment_score": "0.061034",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Is SPDR Portfolio S&P 500 High Dividend ETF  ( SPYD )  a Strong ETF Right Now?",
      "url": "https://www.zacks.com/stock/news/2446486/is-spdr-portfolio-sp-500-high-dividend-etf-spyd-a-strong-etf-right-now",
      "time_published": "20250411T102003",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Smart Beta ETF report for ...",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default11.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.25"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.25"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "1.0"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.25"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.25"
        }
      ],
      "overall_sentiment_score": 0.275894,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CVS",
          "relevance_score": "0.114682",
          "ticker_sentiment_score": "0.059865",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "STT",
          "relevance_score": "0.05749",
          "ticker_sentiment_score": "0.088957",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.114682",
          "ticker_sentiment_score": "0.059865",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PM",
          "relevance_score": "0.114682",
          "ticker_sentiment_score": "0.059865",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Is WisdomTree U.S. High Dividend ETF  ( DHS )  a Strong ETF Right Now?",
      "url": "https://www.zacks.com/stock/news/2385015/is-wisdomtree-us-high-dividend-etf-dhs-a-strong-etf-right-now",
      "time_published": "20241218T112005",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Smart Beta ETF report for ...",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default287.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.999999"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.271095,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MO",
          "relevance_score": "0.114682",
          "ticker_sentiment_score": "0.060978",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.114682",
          "ticker_sentiment_score": "0.060978",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "WT",
          "relevance_score": "0.334762",
          "ticker_sentiment_score": "0.240229",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "XOM",
          "relevance_score": "0.114682",
          "ticker_sentiment_score": "0.060978",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Is Invesco Large Cap Value ETF  ( PWV )  a Strong ETF Right Now?",
      "url": "https://www.zacks.com/stock/news/2412439/is-invesco-large-cap-value-etf-pwv-a-strong-etf-right-now",
      "time_published": "20250210T112007",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Smart Beta ETF report for ...",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default2.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.999999"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.319945,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.114409",
          "ticker_sentiment_score": "0.060923",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CSCO",
          "relevance_score": "0.114409",
          "ticker_sentiment_score": "0.060923",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IVZ",
          "relevance_score": "0.226477",
          "ticker_sentiment_score": "0.268953",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "IBM",
          "relevance_score": "0.114409",
          "ticker_sentiment_score": "0.060923",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Is Invesco Pharmaceuticals ETF  ( PJP )  a Strong ETF Right Now?",
      "url": "https://www.zacks.com/stock/news/2390304/is-invesco-pharmaceuticals-etf-pjp-a-strong-etf-right-now",
      "time_published": "20250101T112007",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Smart Beta ETF report for ...",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default127.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.999996"
        }
      ],
      "overall_sentiment_score": 0.304212,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "IVZ",
          "relevance_score": "0.22595",
          "ticker_sentiment_score": "0.294725",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "LLY",
          "relevance_score": "0.114137",
          "ticker_sentiment_score": "0.048656",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.114137",
          "ticker_sentiment_score": "0.048656",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Is ProShares S&P 500 Dividend Aristocrats ETF  ( NOBL )  a Strong ETF Right Now?",
      "url": "https://www.zacks.com/stock/news/2425692/is-proshares-sp-500-dividend-aristocrats-etf-nobl-a-strong-etf-right-now",
      "time_published": "20250305T112006",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Smart Beta ETF report for ...",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default329.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.999981"
        }
      ],
      "overall_sentiment_score": 0.240852,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MORN",
          "relevance_score": "0.057079",
          "ticker_sentiment_score": "0.186063",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ROP",
          "relevance_score": "0.113866",
          "ticker_sentiment_score": "0.059703",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.113866",
          "ticker_sentiment_score": "0.059703",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Is First Trust Capital Strength ETF  ( FTCS )  a Strong ETF Right Now?",
      "url": "https://www.zacks.com/stock/news/2490327/is-first-trust-capital-strength-etf-ftcs-a-strong-etf-right-now",
      "time_published": "20250609T102004",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Smart Beta ETF report for ...",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default307.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.999892"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.338816,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MSFT",
          "relevance_score": "0.113597",
          "ticker_sentiment_score": "0.05965",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TEL",
          "relevance_score": "0.113597",
          "ticker_sentiment_score": "0.05965",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.113597",
          "ticker_sentiment_score": "0.05965",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Cerevel Therapeutics Holdings, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. June 3, 2025 Deadline to file Lead Plaintiff Motion",
      "url": "https://www.benzinga.com/pressreleases/25/05/g45507939/cerevel-therapeutics-holdings-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-lo",
      "time_published": "20250519T215916",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "LOS ANGELES, May 19, 2025 ( GLOBE NEWSWIRE ) -- The Portnoy Law Firm advises Cerevel Therapeutics Holdings, Inc. ( \"Cerevel\" or the \"Company\" ) CERE investors of a class action representing investors that bought securities between October 11, 2023 through August 1, 2024, inclusive ( the \"Class ...",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "IPO",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.110485,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "PFE",
          "relevance_score": "0.113062",
          "ticker_sentiment_score": "-0.023206",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.113062",
          "ticker_sentiment_score": "-0.023206",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Drug Stocks Recover as Trump's Order Proves Not as Bad as Feared",
      "url": "https://www.zacks.com/stock/news/2467638/drug-stocks-recover-as-trumps-order-proves-not-as-bad-as-feared",
      "time_published": "20250513T113600",
      "authors": [
        "Kinjel Shah"
      ],
      "summary": "President Trump issues an executive order that will push drugmakers to offer prescription drugs to U.S. cash-pay consumers at lower prices.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f5/284.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": -0.021532,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.112532",
          "ticker_sentiment_score": "0.0401",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.112532",
          "ticker_sentiment_score": "0.0401",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AMGN",
          "relevance_score": "0.112532",
          "ticker_sentiment_score": "0.0401",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.112532",
          "ticker_sentiment_score": "0.0401",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Trump's Tax Cut Could Add $4.6 Trillion To Deficit, With $48 Billion Tax Relief For Top 100 Firms: Robert Reich - Albertsons Companies  ( NYSE:ACI ) , AbbVie  ( NYSE:ABBV ) ",
      "url": "https://www.benzinga.com/25/02/43774882/donald-trumps-tax-cut-could-add-46-trillion-to-deficit-says-robert-reich-emphasizing-48-billion-relief-for-top-10",
      "time_published": "20250218T100208",
      "authors": [
        "Rishabh Mishra"
      ],
      "summary": "Tax cuts for rich individual will shoot up the deficits by $4.6 trillion. Top 100 U.S. firms can expect a total annual tax cut of $48 billion. Get access to your new suite of high-powered trading tools, including real-time stock ratings, insider trades, and government trading signals. Former ...",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2025/02/18/TRUMP-Coin-Can-Buy-You-Donald-Trump-Them.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Markets",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.2"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.2"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.2"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.2"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.2"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.955357"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.046384,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "TGT",
          "relevance_score": "0.111747",
          "ticker_sentiment_score": "0.02597",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "META",
          "relevance_score": "0.111747",
          "ticker_sentiment_score": "0.066382",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MPC",
          "relevance_score": "0.111747",
          "ticker_sentiment_score": "0.023668",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "C",
          "relevance_score": "0.111747",
          "ticker_sentiment_score": "0.025946",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BAC",
          "relevance_score": "0.111747",
          "ticker_sentiment_score": "0.025946",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CVX",
          "relevance_score": "0.111747",
          "ticker_sentiment_score": "0.023668",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACI",
          "relevance_score": "0.111747",
          "ticker_sentiment_score": "0.02597",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.111747",
          "ticker_sentiment_score": "0.022504",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "KR",
          "relevance_score": "0.111747",
          "ticker_sentiment_score": "0.02597",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.111747",
          "ticker_sentiment_score": "0.022504",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GS",
          "relevance_score": "0.111747",
          "ticker_sentiment_score": "0.025946",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IVZ",
          "relevance_score": "0.056011",
          "ticker_sentiment_score": "0.161092",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.111747",
          "ticker_sentiment_score": "0.022504",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BMY",
          "relevance_score": "0.111747",
          "ticker_sentiment_score": "0.022504",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "COST",
          "relevance_score": "0.111747",
          "ticker_sentiment_score": "0.02597",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PSX",
          "relevance_score": "0.111747",
          "ticker_sentiment_score": "0.023668",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "WFC",
          "relevance_score": "0.111747",
          "ticker_sentiment_score": "0.025946",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "XOM",
          "relevance_score": "0.111747",
          "ticker_sentiment_score": "0.023668",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "VLO",
          "relevance_score": "0.111747",
          "ticker_sentiment_score": "0.023668",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CCZ",
          "relevance_score": "0.056011",
          "ticker_sentiment_score": "0.059007",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "WMT",
          "relevance_score": "0.111747",
          "ticker_sentiment_score": "0.02597",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Why Is Bristol Myers Squibbs Stock Trading Lower On Thursday? - Bristol-Myers Squibb  ( NYSE:BMY ) ",
      "url": "https://www.benzinga.com/25/04/44950727/bristol-myers-cobenfy-falls-short-on-primary-endpoint-in-phase-3-schizophrenia-trial",
      "time_published": "20250423T135533",
      "authors": [
        "Vandana Singh"
      ],
      "summary": "ARISE trial showed a 2-point PANSS reduction with Cobenfy adjunctive therapy, but it missed statistical significance ( P = 0.11 ) . FDA approved Cobenfy in Sept. 2024; global schizophrenia sales could reach $3.7 billion, says analyst Matt Phipps. Feel unsure about the market's next move?",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2025/04/23/Rueil-malmaison--France---August-13--202.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.360215"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        }
      ],
      "overall_sentiment_score": 0.160645,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.111488",
          "ticker_sentiment_score": "0.025819",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.111488",
          "ticker_sentiment_score": "-0.2367",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "BMY",
          "relevance_score": "0.220809",
          "ticker_sentiment_score": "-0.02384",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Is SPDR S&P Dividend ETF  ( SDY )  a Strong ETF Right Now?",
      "url": "https://www.zacks.com/stock/news/2434541/is-spdr-sp-dividend-etf-sdy-a-strong-etf-right-now",
      "time_published": "20250325T102006",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Smart Beta ETF report for ...",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default52.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.25"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "1.0"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.25"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.25"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.25"
        }
      ],
      "overall_sentiment_score": 0.269247,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "STT",
          "relevance_score": "0.055881",
          "ticker_sentiment_score": "0.083883",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.111488",
          "ticker_sentiment_score": "0.059242",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "VZ",
          "relevance_score": "0.111488",
          "ticker_sentiment_score": "0.059242",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "O",
          "relevance_score": "0.055881",
          "ticker_sentiment_score": "0.053895",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Conflicting Claims on U.S./China Trade Sends Pre-Markets in the Red",
      "url": "https://www.zacks.com/stock/news/2455951/conflicting-claims-on-uschina-trade-sends-pre-markets-in-the-red",
      "time_published": "20250425T143500",
      "authors": [
        "Mark Vickery"
      ],
      "summary": "The closer we get to July 10th without a new trade deal, the more precarious these tariff charges become.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c8/1661.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.25"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.25"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.980922"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.972193"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.25"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.25"
        }
      ],
      "overall_sentiment_score": 0.045296,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "MSFT",
          "relevance_score": "0.109956",
          "ticker_sentiment_score": "-0.03194",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AAPL",
          "relevance_score": "0.109956",
          "ticker_sentiment_score": "-0.03194",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LAZ",
          "relevance_score": "0.109956",
          "ticker_sentiment_score": "0.12051",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CL",
          "relevance_score": "0.109956",
          "ticker_sentiment_score": "0.011297",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.109956",
          "ticker_sentiment_score": "0.179058",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "AN",
          "relevance_score": "0.055109",
          "ticker_sentiment_score": "0.098005",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AMZN",
          "relevance_score": "0.109956",
          "ticker_sentiment_score": "-0.03194",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory  ( R/R )  Diffuse Large B-Cell Lymphoma  ( DLBCL )  Eligible for Autologous Stem Cell Transplantation  ( ASCT ) ",
      "url": "https://www.globenewswire.com/news-release/2025/06/15/3099409/0/en/Genmab-Announces-Epcoritamab-Investigational-Combination-Therapy-Demonstrates-High-Response-Rates-in-Patients-with-Relapsed-or-Refractory-R-R-Diffuse-Large-B-Cell-Lymphoma-DLBCL-El.html",
      "time_published": "20250615T090000",
      "authors": [
        "Genmab A/S"
      ],
      "summary": "Media ReleaseCOPENHAGEN, Denmark. June ...",
      "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/368a5dab-dfc5-4e1d-bfa6-2af5e5216fce",
      "source": "GlobeNewswire",
      "category_within_source": "n/a",
      "source_domain": "www.globenewswire.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.047781,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.108076",
          "ticker_sentiment_score": "0.083368",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Cerevel Therapeutics Holdings, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. June 3, 2025; Deadline to file Lead Plaintiff Motion",
      "url": "https://www.benzinga.com/pressreleases/25/05/g45633567/cerevel-therapeutics-holdings-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-lo",
      "time_published": "20250527T215110",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "Investors can contact the law firm at no cost to learn more about recovering their losses",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "IPO",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.074907,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "PFE",
          "relevance_score": "0.107495",
          "ticker_sentiment_score": "-0.022725",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.107495",
          "ticker_sentiment_score": "-0.022725",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Pharma Stock Roundup: BAYRY Q1 Earnings, NVO & GSK's New Deals",
      "url": "https://www.zacks.com/stock/news/2472737/pharma-stock-roundup-bayry-q1-earnings-nvo-gsks-new-deals",
      "time_published": "20250516T120600",
      "authors": [
        "Kinjel Shah"
      ],
      "summary": "Bayer reports first-quarter results. NVO and GSK announce licensing deals with smaller biotechs.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/cc/389.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.105054,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.107335",
          "ticker_sentiment_score": "0.052915",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GSK",
          "relevance_score": "0.177933",
          "ticker_sentiment_score": "0.116627",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.314374",
          "ticker_sentiment_score": "0.036238",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SEPN",
          "relevance_score": "0.071677",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Investigational Epcoritamab  ( DuoBody\u00ae CD3xCD20 )  Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory  ( R/R )  Follicular Lymphoma  ( FL ) ",
      "url": "https://www.globenewswire.com/news-release/2024/12/08/2993359/0/en/Investigational-Epcoritamab-DuoBody-CD3xCD20-Combination-Therapy-Demonstrates-High-Response-Rates-in-Clinical-Trial-of-Patients-With-Relapsed-or-Refractory-R-R-Follicular-Lymphoma-.html",
      "time_published": "20241208T001200",
      "authors": [
        "Genmab A/S"
      ],
      "summary": "Media ReleaseCOPENHAGEN, Denmark. December ...",
      "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/368a5dab-dfc5-4e1d-bfa6-2af5e5216fce",
      "source": "GlobeNewswire",
      "category_within_source": "n/a",
      "source_domain": "www.globenewswire.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.052508,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.106636",
          "ticker_sentiment_score": "0.069201",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "CytomX Therapeutics to Present at the Barclays 27th Annual Global Healthcare Conference",
      "url": "https://www.globenewswire.com/news-release/2025/03/05/3037337/37704/en/CytomX-Therapeutics-to-Present-at-the-Barclays-27th-Annual-Global-Healthcare-Conference.html",
      "time_published": "20250305T130000",
      "authors": [
        "CytomX Therapeutics Inc."
      ],
      "summary": "SOUTH SAN FRANCISCO, Calif., March 05, 2025 ( GLOBE NEWSWIRE ) -- CytomX Therapeutics, Inc. ( Nasdaq: CTMX ) , a leader in the field of masked, conditionally activated biologics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will present at the Barclays 27th ...",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/c252869d-a4c1-4e56-88e8-d80b85d20c35",
      "source": "GlobeNewswire",
      "category_within_source": "n/a",
      "source_domain": "www.globenewswire.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.100224,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.10607",
          "ticker_sentiment_score": "0.045934",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BCS",
          "relevance_score": "0.10607",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CTMX",
          "relevance_score": "0.210274",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MRNA",
          "relevance_score": "0.10607",
          "ticker_sentiment_score": "0.045934",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BMY",
          "relevance_score": "0.10607",
          "ticker_sentiment_score": "0.045934",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference",
      "url": "https://www.globenewswire.com/news-release/2024/11/27/2988176/37704/en/CytomX-Therapeutics-to-Present-at-the-36th-Annual-Piper-Sandler-Healthcare-Conference.html",
      "time_published": "20241127T130000",
      "authors": [
        "CytomX Therapeutics Inc."
      ],
      "summary": "SOUTH SAN FRANCISCO, Calif., Nov. 27, 2024 ( GLOBE NEWSWIRE ) -- CytomX Therapeutics, Inc. ( Nasdaq: CTMX ) , a leader in the field of masked, conditionally activated biologics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a fireside chat ...",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/c252869d-a4c1-4e56-88e8-d80b85d20c35",
      "source": "GlobeNewswire",
      "category_within_source": "n/a",
      "source_domain": "www.globenewswire.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.09784,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.10607",
          "ticker_sentiment_score": "0.047068",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CTMX",
          "relevance_score": "0.210274",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MRNA",
          "relevance_score": "0.10607",
          "ticker_sentiment_score": "0.047068",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BMY",
          "relevance_score": "0.10607",
          "ticker_sentiment_score": "0.047068",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Where Will Viking Therapeutics Be in 3 Years?",
      "url": "https://www.fool.com/investing/2025/05/02/where-will-viking-therapeutics-be-in-3-years/",
      "time_published": "20250502T082000",
      "authors": [
        "Justin Pope"
      ],
      "summary": "Viking's leading drug candidate could be a blockbuster in the weight loss market, which experts believe could grow to $150 billion over the coming years.",
      "banner_image": "https://g.foolcdn.com/editorial/images/816260/weight-loss-drug.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "IPO",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.929393"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.161647"
        }
      ],
      "overall_sentiment_score": 0.062972,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "VKTX",
          "relevance_score": "0.354138",
          "ticker_sentiment_score": "0.162663",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.104455",
          "ticker_sentiment_score": "-0.106585",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.05234",
          "ticker_sentiment_score": "0.066019",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.104455",
          "ticker_sentiment_score": "-0.106585",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Pfizer Stock Up Almost 6% in 3 Months: Time to Buy, Sell or Hold?",
      "url": "https://www.zacks.com/stock/news/2427687/pfizer-stock-up-almost-6-in-3-months-time-to-buy-sell-or-hold",
      "time_published": "20250310T125200",
      "authors": [
        "Kinjel Shah"
      ],
      "summary": "Investors may stay invested in PFE stock to see how its new growth drivers perform.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/89/447.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.503496"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.614606"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.266143"
        }
      ],
      "overall_sentiment_score": 0.178443,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.103331",
          "ticker_sentiment_score": "0.064986",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.103331",
          "ticker_sentiment_score": "0.064986",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.103331",
          "ticker_sentiment_score": "0.064986",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.483888",
          "ticker_sentiment_score": "0.220218",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Protein Therapeutics Market Size to be Worth USD 549.4 billion by 2031, at a CAGR of 6.3% | Transparency Market Research, Inc.",
      "url": "https://www.benzinga.com/pressreleases/24/11/g42003353/protein-therapeutics-market-size-to-be-worth-usd-549-4-billion-by-2031-at-a-cagr-of-6-3-transparen",
      "time_published": "20241115T110000",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "Wilmington, Delaware, United States, Transparency Market Research Inc. -, Nov. 15, 2024 ( GLOBE NEWSWIRE ) -- The protein therapeutics market ( \ub2e8\ubc31\uc9c8 \uce58\ub8cc\uc81c \uc2dc\uc7a5 ) was valued at US$ 318.4 billion in 2022. A CAGR of 6.3% is predicted from 2023 to 2031, reaching more than US$ 549.4 billion by 2031.",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/ba7b98d3-0c98-4dd7-95c7-ac0441eebbed/protein-therapeutics-market.jpg",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        }
      ],
      "overall_sentiment_score": 0.172406,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "GOOG",
          "relevance_score": "0.034381",
          "ticker_sentiment_score": "0.052816",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TMO",
          "relevance_score": "0.034381",
          "ticker_sentiment_score": "-0.153487",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "SKXJF",
          "relevance_score": "0.034381",
          "ticker_sentiment_score": "-0.153487",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.102888",
          "ticker_sentiment_score": "0.01095",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DSKYF",
          "relevance_score": "0.034381",
          "ticker_sentiment_score": "-0.153487",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "WMGTF",
          "relevance_score": "0.102888",
          "ticker_sentiment_score": "0.101121",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BMY",
          "relevance_score": "0.068698",
          "ticker_sentiment_score": "-0.075839",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SNY",
          "relevance_score": "0.034381",
          "ticker_sentiment_score": "-0.153487",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "TAK",
          "relevance_score": "0.034381",
          "ticker_sentiment_score": "-0.153487",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "The Zacks Analyst Blog Highlights Bayer, Novo Nordisk, GSK, Merck and AbbVie",
      "url": "https://www.zacks.com/stock/news/2474030/the-zacks-analyst-blog-highlights-bayer-novo-nordisk-gsk-merck-and-abbvie",
      "time_published": "20250519T135100",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Bayer, Novo Nordisk, GSK, Merck and AbbVie are part of the Zacks top Analyst Blog.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ef/472.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.114349,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.101725",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GSK",
          "relevance_score": "0.201803",
          "ticker_sentiment_score": "0.102371",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.329992",
          "ticker_sentiment_score": "0.028134",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SEPN",
          "relevance_score": "0.067919",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "US Stock Futures Fall As Markets Brace For Earnings From Microsoft, Meta, Apple And Apple This Week: 'Earnings Estimates Don't Signal A Recession' Says Leading Analyst - Apple  ( NASDAQ:AAPL ) , AbbVie  ( NYSE:ABBV ) ",
      "url": "https://www.benzinga.com/analyst-ratings/analyst-color/25/04/45034627/us-stock-futures-fall-as-markets-brace-for-earnings-from-microsoft-meta-apple-and-a",
      "time_published": "20250428T103637",
      "authors": [
        "Vishaal Sanjay"
      ],
      "summary": "U.S. stock futures are down in early-morning trade on Monday, after ending the previous week on a high note, with back-to-back sessions of strong rallies.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2025/04/28/The-Magnificent-Seven--7-Of-The-Largest-.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Markets",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.142857"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.142857"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.142857"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.142857"
        },
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.142857"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.980922"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.142857"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.999994"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.142857"
        },
        {
          "topic": "Economy - Macro",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.087605,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "AON",
          "relevance_score": "0.101582",
          "ticker_sentiment_score": "-0.038066",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "META",
          "relevance_score": "0.101582",
          "ticker_sentiment_score": "-0.053225",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AAPL",
          "relevance_score": "0.101582",
          "ticker_sentiment_score": "-0.053225",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "WELL",
          "relevance_score": "0.201523",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HCA",
          "relevance_score": "0.101582",
          "ticker_sentiment_score": "-0.038066",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NXPI",
          "relevance_score": "0.201523",
          "ticker_sentiment_score": "0.060513",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.101582",
          "ticker_sentiment_score": "-0.038066",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IVZ",
          "relevance_score": "0.050894",
          "ticker_sentiment_score": "0.222467",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "DPZ",
          "relevance_score": "0.101582",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MSFT",
          "relevance_score": "0.101582",
          "ticker_sentiment_score": "-0.053225",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DMPZF",
          "relevance_score": "0.050894",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ROP",
          "relevance_score": "0.101582",
          "ticker_sentiment_score": "0.070325",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "WM",
          "relevance_score": "0.101582",
          "ticker_sentiment_score": "0.134701",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CDNS",
          "relevance_score": "0.101582",
          "ticker_sentiment_score": "0.064978",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SZIHF",
          "relevance_score": "0.050894",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AMZN",
          "relevance_score": "0.101582",
          "ticker_sentiment_score": "-0.053225",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "AI Meets Oncology: Caris Life Sciences' $5.35B IPO Tests Investor Appetite for Precision Medicine - Moderna  ( NASDAQ:MRNA ) ",
      "url": "https://www.benzinga.com/news/topics/25/06/45987754/ai-meets-oncology-caris-life-sciences-5-35b-ipo-tests-investor-appetite-for-precision-medicine",
      "time_published": "20250618T010107",
      "authors": [
        "Hina Nainani"
      ],
      "summary": "Caris Life Sciences, an AI-driven precision oncology company, is targeting a $5.35 billion valuation in its U.S. initial public offering, aiming to raise up to $423.5 million.",
      "banner_image": "https://cdnwp-s3.benzinga.com/wp-content/uploads/2024/10/22181427/Paolo-and-Gali.jpg?optimize=medium&dpr=2&auto=webp&width=230",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "IPO",
          "relevance_score": "0.451494"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.905476"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.839681"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.178342,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "GH",
          "relevance_score": "0.101367",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "C",
          "relevance_score": "0.050786",
          "ticker_sentiment_score": "0.171016",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.101367",
          "ticker_sentiment_score": "0.128169",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABNB",
          "relevance_score": "0.050786",
          "ticker_sentiment_score": "0.285613",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "GS",
          "relevance_score": "0.050786",
          "ticker_sentiment_score": "0.171016",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "MRNA",
          "relevance_score": "0.101367",
          "ticker_sentiment_score": "0.128169",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TEM",
          "relevance_score": "0.101367",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "UBER",
          "relevance_score": "0.050786",
          "ticker_sentiment_score": "0.285613",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Top Analyst Reports for AbbVie, Lockheed Martin & Dell",
      "url": "https://www.zacks.com/research-daily/2429552/top-analyst-reports-for-abbvie-lockheed-martin-dell",
      "time_published": "20250314T204700",
      "authors": [
        "Mark Vickery"
      ],
      "summary": "Today's Research Daily features new research reports on 12 major stocks, including AbbVie Inc. (ABBV), Lockheed Martin Corporation (LMT) and Dell Technologies Inc. (DELL), as well as a micro-cap stock Hamilton Beach Brands Holding Company (HBB).",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/df/1357.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.928769"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.268923,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "LNVGF",
          "relevance_score": "0.050044",
          "ticker_sentiment_score": "-0.029028",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MSFT",
          "relevance_score": "0.050044",
          "ticker_sentiment_score": "0.255397",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "META",
          "relevance_score": "0.050044",
          "ticker_sentiment_score": "0.255397",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "NVDA",
          "relevance_score": "0.050044",
          "ticker_sentiment_score": "0.255397",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "LMT",
          "relevance_score": "0.050044",
          "ticker_sentiment_score": "0.166218",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "HBCNF",
          "relevance_score": "0.050044",
          "ticker_sentiment_score": "0.213027",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.09989",
          "ticker_sentiment_score": "0.178028",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "OSE Immunotherapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update",
      "url": "https://www.benzinga.com/pressreleases/25/03/g44499205/ose-immunotherapeutics-reports-full-year-2024-financial-results-and-provides-corporate-update",
      "time_published": "20250326T172000",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "Total income of \u20ac83.4 million. Cash level of \u20ac64.2 million1 as of December 31, 2024, ensuring financial visibility until Q1 2027 Three strategic agreements signed: licensing and collaboration with AbbVie ( worth up to $713 million ) , and anti-SIRP\u03b1 program expansions ( worth up to \u20ac1.1 billion ) ...",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        }
      ],
      "overall_sentiment_score": 0.27535,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.099683",
          "ticker_sentiment_score": "0.140777",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Pfizer Stock Falls 8% in a Month: Should You Buy the Dip?",
      "url": "https://www.zacks.com/stock/news/2379380/pfizer-stock-falls-8-in-a-month-should-you-buy-the-dip",
      "time_published": "20241205T133000",
      "authors": [
        "Kinjel Shah"
      ],
      "summary": "Investors with a long-term horizon may consider buying PFE stock at its present attractive valuation.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ce/3721.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.5855"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.818451"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.266143"
        }
      ],
      "overall_sentiment_score": 0.065336,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.146916",
          "ticker_sentiment_score": "-0.074164",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.098255",
          "ticker_sentiment_score": "0.074854",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.098255",
          "ticker_sentiment_score": "-0.061694",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.462953",
          "ticker_sentiment_score": "0.149125",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Pharma Stock Roundup: RHHBY to Buy PSTX, MRK, AZN See Pipeline Success",
      "url": "https://www.zacks.com/stock/news/2377348/pharma-stock-roundup-rhhby-to-buy-pstx-mrk-azn-see-pipeline-success",
      "time_published": "20241129T200000",
      "authors": [
        "Kinjel Shah"
      ],
      "summary": "RHHBY is set to acquire Poseida. MRK and AZN's late-stage studies for expanded use of new drugs meet their respective goals.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/66/1019.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.316726"
        }
      ],
      "overall_sentiment_score": 0.131987,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "PSTX",
          "relevance_score": "0.191549",
          "ticker_sentiment_score": "0.118333",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.096477",
          "ticker_sentiment_score": "-0.073587",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AZN",
          "relevance_score": "0.144275",
          "ticker_sentiment_score": "0.067967",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.048327",
          "ticker_sentiment_score": "-0.128896",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Sanofi Down 10% in 3 Months: How Should You Play the Stock?",
      "url": "https://www.zacks.com/stock/news/2392838/sanofi-down-10-in-3-months-how-should-you-play-the-stock",
      "time_published": "20250107T140000",
      "authors": [
        "Kinjel Shah"
      ],
      "summary": "SNY's reasonable valuation, improving top-line performance, contributions from new product launches and positive pipeline progress are good enough reasons to stay invested in the stock ...",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/d6/2257.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.714479"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.990999"
        }
      ],
      "overall_sentiment_score": 0.12378,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.095707",
          "ticker_sentiment_score": "0.039663",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.095707",
          "ticker_sentiment_score": "0.039663",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AZN",
          "relevance_score": "0.095707",
          "ticker_sentiment_score": "-0.002152",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.04794",
          "ticker_sentiment_score": "0.036906",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SNY",
          "relevance_score": "0.565529",
          "ticker_sentiment_score": "0.236698",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Democrats press Pfizer, J&J and others over low tax bills and lobbying as Senate debates Trump's plan",
      "url": "https://www.cnbc.com/2025/06/17/pfizer-merck-jj-others-face-scrutiny-over-tax-loophole-extension.html",
      "time_published": "20250617T140001",
      "authors": [],
      "summary": "The lawmakers accuse Pfizer, Merck, J&J, AbbVie and Amgen of paying little to nothing in federal taxes despite generating billions of dollars annually.",
      "banner_image": null,
      "source": "CNBC",
      "category_within_source": "Business",
      "source_domain": "www.cnbc.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        },
        {
          "topic": "Blockchain",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.041304,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.094576",
          "ticker_sentiment_score": "-0.012728",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GS",
          "relevance_score": "0.047371",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.187827",
          "ticker_sentiment_score": "-0.003075",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.047371",
          "ticker_sentiment_score": "-0.017947",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "The Zacks Analyst Blog Highlights Roche, Poseida Therapeutics, Merck, AstraZeneca and Novartis",
      "url": "https://www.zacks.com/stock/news/2377440/the-zacks-analyst-blog-highlights-roche-poseida-therapeutics-merck-astrazeneca-and-novartis",
      "time_published": "20241202T100000",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "Roche, Poseida Therapeutics, Merck, AstraZeneca and Novartis are included in this Analyst Blog.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e5/1416.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.365926"
        }
      ],
      "overall_sentiment_score": 0.119975,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "PSTX",
          "relevance_score": "0.187827",
          "ticker_sentiment_score": "0.097997",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.094576",
          "ticker_sentiment_score": "-0.073236",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AZN",
          "relevance_score": "0.141448",
          "ticker_sentiment_score": "0.032951",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.047371",
          "ticker_sentiment_score": "-0.12869",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Whale buys back ETH holdings after losing $2.67M by selling early",
      "url": "https://cointelegraph.com/news/crypto-trader-mistimed-eth-sale-loses-2-6m",
      "time_published": "20250522T114844",
      "authors": [
        "Ezra Reguerra"
      ],
      "summary": "A crypto trader spent $3.8 million to buy Ether at a significantly higher price after selling the asset for almost the same amount about a month ago. On May 22, blockchain analytics firm Lookonchain reported that a crypto wallet spent $3.8 million to purchase 1,425 Ether ( ETH ) at $2,670 per ...",
      "banner_image": "https://s3.cointelegraph.com/uploads/2025-05/0196f7b2-d104-76b5-a3d8-1c331f973208",
      "source": "Cointelegraph",
      "category_within_source": "n/a",
      "source_domain": "cointelegraph.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.684621"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Blockchain",
          "relevance_score": "0.310843"
        }
      ],
      "overall_sentiment_score": 0.189269,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "BABA",
          "relevance_score": "0.093653",
          "ticker_sentiment_score": "0.095093",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.093653",
          "ticker_sentiment_score": "0.042735",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BAC",
          "relevance_score": "0.093653",
          "ticker_sentiment_score": "0.042735",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "KO",
          "relevance_score": "0.093653",
          "ticker_sentiment_score": "0.095093",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CRYPTO:BTC",
          "relevance_score": "0.18602",
          "ticker_sentiment_score": "0.0178",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CRYPTO:ETH",
          "relevance_score": "0.922387",
          "ticker_sentiment_score": "0.370005",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Pfizer Rises 5.6% in a Month: How Should You Play the Stock?",
      "url": "https://www.zacks.com/stock/news/2391519/pfizer-rises-56-in-a-month-how-should-you-play-the-stock",
      "time_published": "20250103T135300",
      "authors": [
        "Kinjel Shah"
      ],
      "summary": "Investors may stay invested in PFE stock to see how its new growth drivers perform ...",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f2/4113.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.54554"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.96136"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.214378"
        }
      ],
      "overall_sentiment_score": 0.170783,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.093108",
          "ticker_sentiment_score": "0.063118",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.093108",
          "ticker_sentiment_score": "0.063118",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.093108",
          "ticker_sentiment_score": "0.063118",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.58705",
          "ticker_sentiment_score": "0.237218",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Pharma Stock Roundup: NVO's Obesity Study Failure, FDA Nod to PFE, LLY",
      "url": "https://www.zacks.com/stock/news/2388207/pharma-stock-roundup-nvos-obesity-study-failure-fda-nod-to-pfe-lly",
      "time_published": "20241226T141100",
      "authors": [
        "Kinjel Shah"
      ],
      "summary": "NVO's novel obesity candidate shows lower-than-expected weight loss in the study. FDA approves LLY's Zepbound for sleep apnea.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/39/612.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        }
      ],
      "overall_sentiment_score": 0.038399,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "AZN",
          "relevance_score": "0.230017",
          "ticker_sentiment_score": "0.05037",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.27432",
          "ticker_sentiment_score": "-0.1171",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LLY",
          "relevance_score": "0.093108",
          "ticker_sentiment_score": "-0.004254",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SKXJF",
          "relevance_score": "0.139265",
          "ticker_sentiment_score": "0.027877",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.093108",
          "ticker_sentiment_score": "-0.13066",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DSKYF",
          "relevance_score": "0.139265",
          "ticker_sentiment_score": "0.027877",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.093108",
          "ticker_sentiment_score": "-0.004254",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SNY",
          "relevance_score": "0.27432",
          "ticker_sentiment_score": "0.032887",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Should Pfizer Stock Be in Your Portfolio Post a Robust Q4 Performance?",
      "url": "https://www.zacks.com/stock/news/2412619/should-pfizer-stock-be-in-your-portfolio-post-a-robust-q4-performance",
      "time_published": "20250210T141100",
      "authors": [
        "Kinjel Shah"
      ],
      "summary": "Investors may stay invested in PFE stock to see how its new growth drivers perform.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/cc/389.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.413559"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.993781"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.266143"
        }
      ],
      "overall_sentiment_score": 0.189317,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.092748",
          "ticker_sentiment_score": "0.063059",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.092748",
          "ticker_sentiment_score": "0.063059",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.092748",
          "ticker_sentiment_score": "0.063059",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.551119",
          "ticker_sentiment_score": "0.277353",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Myricx Bio Announces Expansion of its Leadership Team to Advance NMTi-ADCs into Clinical Development",
      "url": "https://www.benzinga.com/pressreleases/25/04/g44679834/myricx-bio-announces-expansion-of-its-leadership-team-to-advance-nmti-adcs-into-clinical-developme",
      "time_published": "20250408T091636",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "Steen Lisby, M.D., D.MSc. joins as Chief Medical Officer Jesper Valbj\u00f8rn, M.Sc. joins as Senior Vice President CMC Ongoing team expansion at Myricx Bio's new facilities in London's Canary Wharf biotech hub following 2024 \u00a390 million ( $114 million ) series A financing",
      "banner_image": "https://ml-eu.globenewswire.com/media/d36680ff-a70b-4eef-a5e2-d230e807f299/small/myricxbio-logo-rgb-png.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.190547,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "NVS",
          "relevance_score": "0.046006",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.09186",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GMAB",
          "relevance_score": "0.227007",
          "ticker_sentiment_score": "0.17242",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.046006",
          "ticker_sentiment_score": "0.128366",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.046006",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.046006",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Pharma Stock Roundup: RHHBY Obesity Drug Rights Buyout, NVO Pipeline Update",
      "url": "https://www.zacks.com/stock/news/2429867/pharma-stock-roundup-rhhby-obesity-drug-rights-buyout-nvo-pipeline-update",
      "time_published": "20250313T170500",
      "authors": [
        "Kinjel Shah"
      ],
      "summary": "NVO reports disappointing data from a phase III study on a novel obesity candidate, CagriSema. RHHBY buys rights to obesity candidate from Zealand Pharma.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/07/905.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        }
      ],
      "overall_sentiment_score": 0.016818,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "PTGX",
          "relevance_score": "0.090474",
          "ticker_sentiment_score": "0.071601",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.090474",
          "ticker_sentiment_score": "-0.141346",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.266828",
          "ticker_sentiment_score": "-0.072346",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.179788",
          "ticker_sentiment_score": "0.033131",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ARVN",
          "relevance_score": "0.179788",
          "ticker_sentiment_score": "0.033131",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "3 Top Cancer Biotechs to Keep An Eye On in 2025",
      "url": "https://www.zacks.com/stock/news/2427139/3-top-cancer-biotechs-to-keep-an-eye-on-in-2025",
      "time_published": "20250307T132200",
      "authors": [
        "Kinjel Shah"
      ],
      "summary": "If the cancer space appeals to you, it's time to consider stocks like Novartis, Exact Sciences and Monte Rosa.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/3e/2848.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.495866"
        }
      ],
      "overall_sentiment_score": -0.084253,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.089965",
          "ticker_sentiment_score": "0.099934",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.089965",
          "ticker_sentiment_score": "0.099934",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GLUE",
          "relevance_score": "0.13459",
          "ticker_sentiment_score": "-0.013985",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AZN",
          "relevance_score": "0.089965",
          "ticker_sentiment_score": "0.099934",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "EXAS",
          "relevance_score": "0.222429",
          "ticker_sentiment_score": "-0.083779",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.089965",
          "ticker_sentiment_score": "0.099934",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference - CytomX Therapeutics  ( NASDAQ:CTMX ) ",
      "url": "https://www.benzinga.com/pressreleases/24/11/g42212288/cytomx-therapeutics-to-present-at-the-36th-annual-piper-sandler-healthcare-conference",
      "time_published": "20241127T130000",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "SOUTH SAN FRANCISCO, Calif., Nov. 27, 2024 ( GLOBE NEWSWIRE ) -- CytomX Therapeutics, Inc.",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.109565,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.087824",
          "ticker_sentiment_score": "0.041182",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CTMX",
          "relevance_score": "0.259267",
          "ticker_sentiment_score": "0.063415",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MRNA",
          "relevance_score": "0.087824",
          "ticker_sentiment_score": "0.041182",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BMY",
          "relevance_score": "0.087824",
          "ticker_sentiment_score": "0.041182",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Corvus Pharmaceuticals Appoints Richard A. van den Broek to Board of Directors - Corvus Pharma  ( NASDAQ:CRVS ) ",
      "url": "https://www.benzinga.com/pressreleases/25/04/g44722655/corvus-pharmaceuticals-appoints-richard-a-van-den-broek-to-board-of-directors",
      "time_published": "20250409T200154",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "SOUTH SAN FRANCISCO, Calif., April 09, 2025 ( GLOBE NEWSWIRE ) -- Corvus Pharmaceuticals, Inc. CRVS, a clinical-stage biopharmaceutical company, announced today that Richard van den Broek, managing partner at HSMR Advisors, has been appointed to the Company's board of directors.",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        }
      ],
      "overall_sentiment_score": 0.153512,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.087503",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CRVS",
          "relevance_score": "0.417304",
          "ticker_sentiment_score": "-0.123329",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PLSE",
          "relevance_score": "0.087503",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Don't Fall for These 3 Dividend Stocks: They May Have to Make a Cut.",
      "url": "https://www.fool.com/investing/2025/05/18/dont-fall-for-these-3-dividend-stocks-they-may-hav/",
      "time_published": "20250518T160500",
      "authors": [
        "Collin Brantmeyer"
      ],
      "summary": "Here are three dividend-paying stocks that warrant closer examination.",
      "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F816363%2Fdrug-development-pharmaceutical-pharma-research-researchers-doctors.jpg&op=resize&w=700",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.980509"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.413559"
        }
      ],
      "overall_sentiment_score": 0.079599,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "MDT",
          "relevance_score": "0.17179",
          "ticker_sentiment_score": "0.080382",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.2138",
          "ticker_sentiment_score": "0.024125",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.0864",
          "ticker_sentiment_score": "0.117334",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "CytomX Therapeutics Announces 2024 Financial Results and Provides Business Update",
      "url": "https://www.globenewswire.com/news-release/2025/03/06/3038628/37704/en/CytomX-Therapeutics-Announces-2024-Financial-Results-and-Provides-Business-Update.html",
      "time_published": "20250306T211000",
      "authors": [
        "CytomX Therapeutics Inc."
      ],
      "summary": "- Continued progress with lead program, CX-2051 ( EpCAM PROBODY\u00ae Topo-1 ADC ) , in Phase 1a study in advanced colorectal cancer with initial Phase 1a clinical data to be presented in ...",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/c252869d-a4c1-4e56-88e8-d80b85d20c35",
      "source": "GlobeNewswire",
      "category_within_source": "n/a",
      "source_domain": "www.globenewswire.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.538269"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.153426,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.085553",
          "ticker_sentiment_score": "0.087279",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CTMX",
          "relevance_score": "0.085553",
          "ticker_sentiment_score": "0.052269",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MRNA",
          "relevance_score": "0.064218",
          "ticker_sentiment_score": "0.075273",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BMY",
          "relevance_score": "0.064218",
          "ticker_sentiment_score": "0.075273",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Grab These 3 Healthcare Mutual Funds for Steady Returns",
      "url": "https://www.zacks.com/stock/news/2407212/grab-these-3-healthcare-mutual-funds-for-steady-returns",
      "time_published": "20250131T100000",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Below, we share with you three top-ranked healthcare mutual funds. Each has a Zacks Mutual Fund Rank #1 (Strong Buy).",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c0/2297.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.341119,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "JHG",
          "relevance_score": "0.252114",
          "ticker_sentiment_score": "0.216357",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "HCSG",
          "relevance_score": "0.085324",
          "ticker_sentiment_score": "0.089972",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.085324",
          "ticker_sentiment_score": "0.06178",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Buy These 3 Healthcare Mutual Funds to Boost Your Portfolio",
      "url": "https://www.zacks.com/stock/news/2379964/buy-these-3-healthcare-mutual-funds-to-boost-your-portfolio",
      "time_published": "20241206T111200",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Below, we share with you three top-ranked healthcare mutual funds. Each has earned a Zacks Mutual Fund Rank #1.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e7/288.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.349553,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "JHG",
          "relevance_score": "0.251247",
          "ticker_sentiment_score": "0.213953",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.085022",
          "ticker_sentiment_score": "0.056355",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GS",
          "relevance_score": "0.085022",
          "ticker_sentiment_score": "0.161412",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "HCSG",
          "relevance_score": "0.085022",
          "ticker_sentiment_score": "0.089904",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "The Zacks Analyst Blog Highlights Novo Nordisk, Roche, Pfizer, Arvinas and J&J",
      "url": "https://www.zacks.com/stock/news/2430349/the-zacks-analyst-blog-highlights-novo-nordisk-roche-pfizer-arvinas-and-jj",
      "time_published": "20250314T143800",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Novo Nordisk, Roche, Pfizer, Arvinas and J&J are part of the Zacks top Analyst Blog.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/7d/1177.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.316726"
        }
      ],
      "overall_sentiment_score": 0.035948,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "PTGX",
          "relevance_score": "0.084722",
          "ticker_sentiment_score": "0.008362",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.084722",
          "ticker_sentiment_score": "-0.13963",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.290361",
          "ticker_sentiment_score": "-0.064192",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.209728",
          "ticker_sentiment_score": "0.030143",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ARVN",
          "relevance_score": "0.209728",
          "ticker_sentiment_score": "0.030143",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Dow Dips Over 300 Points; US Inflation Increases More Than Expected - Kindly MD  ( NASDAQ:KDLY ) , Atomera  ( NASDAQ:ATOM ) ",
      "url": "https://www.benzinga.com/25/02/43661293/dow-dips-over-300-points-us-inflation-increases-more-than-expected",
      "time_published": "20250212T151046",
      "authors": [
        "Avi Kapoor"
      ],
      "summary": "U.S. stocks traded lower this morning, with the Dow Jones index falling over 300 points on Wednesday. Following the market opening Wednesday, the Dow traded down 0.79% to 44,240.00 while the NASDAQ fell 0.47% to 19,551.48. The S&P 500 also fell, dropping, 0.61% to 6,031.34.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2025/02/12/Obsolescence-Due-To-Inflation.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.25"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.25"
        },
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.684621"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.25"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.495866"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.25"
        }
      ],
      "overall_sentiment_score": 0.05128,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "SPIR",
          "relevance_score": "0.166169",
          "ticker_sentiment_score": "-0.21886",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "SMWB",
          "relevance_score": "0.166169",
          "ticker_sentiment_score": "-0.305289",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "STAB",
          "relevance_score": "0.083541",
          "ticker_sentiment_score": "0.050851",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "KDLY",
          "relevance_score": "0.166169",
          "ticker_sentiment_score": "0.50812",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "TIVC",
          "relevance_score": "0.166169",
          "ticker_sentiment_score": "0.068826",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "XLO",
          "relevance_score": "0.083541",
          "ticker_sentiment_score": "0.33072",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.083541",
          "ticker_sentiment_score": "0.33072",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ATOM",
          "relevance_score": "0.166169",
          "ticker_sentiment_score": "-0.138103",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Kailera Therapeutics Appoints Scott M. Akamine as Chief Legal Officer",
      "url": "https://www.benzinga.com/pressreleases/24/11/g41898642/kailera-therapeutics-appoints-scott-m-akamine-as-chief-legal-officer",
      "time_published": "20241112T130014",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "BOSTON and SAN DIEGO, Nov. 12, 2024 ( GLOBE NEWSWIRE ) -- Kailera Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of next-generation therapies for the treatment of obesity and related conditions, today announced the appointment of Scott M.",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.272582,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.083251",
          "ticker_sentiment_score": "0.060233",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "CytomX Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025 - CytomX Therapeutics  ( NASDAQ:CTMX ) ",
      "url": "https://www.benzinga.com/pressreleases/25/02/g44004122/cytomx-therapeutics-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025",
      "time_published": "20250227T130000",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 ( GLOBE NEWSWIRE ) -- CytomX Therapeutics, Inc. CTMX, a leader in the field of masked, conditionally activated biologic therapeutics, today announced that it will report full year 2024 financial results on Thursday, March 6, 2025, after the close of U.S. ...",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.092742,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.082677",
          "ticker_sentiment_score": "0.040629",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CTMX",
          "relevance_score": "0.244518",
          "ticker_sentiment_score": "0.058531",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MRNA",
          "relevance_score": "0.082677",
          "ticker_sentiment_score": "0.040629",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BMY",
          "relevance_score": "0.082677",
          "ticker_sentiment_score": "0.040629",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Top Research Reports for Berkshire Hathaway, AbbVie & Intuitive Surgical",
      "url": "https://www.zacks.com/research-daily/2478986/top-research-reports-for-berkshire-hathaway-abbvie-intuitive-surgical",
      "time_published": "20250529T201500",
      "authors": [
        "Mark Vickery"
      ],
      "summary": "Berkshire Hathaway, AbbVie and Intuitive Surgical beat estimates as analysts highlight growth drivers, headwinds and strategic moves in new reports.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/13/11325.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.795202"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.297701,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "HBB",
          "relevance_score": "0.041323",
          "ticker_sentiment_score": "0.159499",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.082535",
          "ticker_sentiment_score": "0.208041",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "HBCNF",
          "relevance_score": "0.041323",
          "ticker_sentiment_score": "0.253557",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ISRG",
          "relevance_score": "0.123526",
          "ticker_sentiment_score": "0.056817",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BRK-A",
          "relevance_score": "0.041323",
          "ticker_sentiment_score": "0.13874",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "3 Stocks That Will Profit From Trump's Drug Price Cut - AbbVie  ( NYSE:ABBV ) , Amgen  ( NASDAQ:AMGN ) ",
      "url": "https://www.benzinga.com/25/05/45473520/3-stocks-that-will-profit-from-trumps-drug-price-cut",
      "time_published": "20250516T170848",
      "authors": [
        "Nic Chahine"
      ],
      "summary": "President Trump's new Executive Order takes aim at high drug prices. Discover the top trade setups and strategies beating the S&P this year -live this Wednesday at 6 PM ET. Reserve your free spot now.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2025/05/16/Lawsuit-against-drug-companies.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.503496"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.744043"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.089371,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "NVO",
          "relevance_score": "0.082204",
          "ticker_sentiment_score": "0.023048",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SEPN",
          "relevance_score": "0.054857",
          "ticker_sentiment_score": "0.022039",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LLY",
          "relevance_score": "0.082204",
          "ticker_sentiment_score": "0.134869",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.082204",
          "ticker_sentiment_score": "0.071748",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GS",
          "relevance_score": "0.027445",
          "ticker_sentiment_score": "0.0211",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AMGN",
          "relevance_score": "0.054857",
          "ticker_sentiment_score": "-0.055843",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BMY",
          "relevance_score": "0.054857",
          "ticker_sentiment_score": "0.042007",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Top Cancer Stocks to Supercharge Your 2025 Portfolio",
      "url": "https://www.zacks.com/stock/news/2492631/top-cancer-stocks-to-supercharge-your-2025-portfolio",
      "time_published": "20250610T142300",
      "authors": [
        "Kinjel Shah"
      ],
      "summary": "Pfizer, Novartis and Fate Therapeutics are making bold oncology moves as demand surges for next-gen cancer therapies.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/86/1981.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.495866"
        }
      ],
      "overall_sentiment_score": 0.115502,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.08197",
          "ticker_sentiment_score": "0.14",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.08197",
          "ticker_sentiment_score": "0.14",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FATE",
          "relevance_score": "0.203045",
          "ticker_sentiment_score": "0.101714",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AZN",
          "relevance_score": "0.08197",
          "ticker_sentiment_score": "0.14",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.356723",
          "ticker_sentiment_score": "0.24761",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "OPHLF",
          "relevance_score": "0.041039",
          "ticker_sentiment_score": "0.163551",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "3 Stocks That Will Profit From Trump's Drug Price Cut - AbbVie  ( NYSE:ABBV ) , Amgen  ( NASDAQ:AMGN ) ",
      "url": "https://www.benzinga.com/markets/25/05/45473520/3-stocks-that-will-profit-from-trumps-drug-price-cut",
      "time_published": "20250516T170838",
      "authors": [
        "Nic Chahine"
      ],
      "summary": "President Trump's new Executive Order takes aim at high drug prices. Here are three that are poised to profit regardless of DC politics. Discover the top trade setups and strategies beating the S&P this year -live this Wednesday at 6 PM ET. Reserve your free spot now.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2025/05/16/Lawsuit-against-drug-companies.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.503496"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.744043"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.096554,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "NVO",
          "relevance_score": "0.081645",
          "ticker_sentiment_score": "0.023015",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SEPN",
          "relevance_score": "0.054483",
          "ticker_sentiment_score": "0.022035",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LLY",
          "relevance_score": "0.081645",
          "ticker_sentiment_score": "0.134736",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.081645",
          "ticker_sentiment_score": "0.071639",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GS",
          "relevance_score": "0.027257",
          "ticker_sentiment_score": "0.021084",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AMGN",
          "relevance_score": "0.054483",
          "ticker_sentiment_score": "-0.055823",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BMY",
          "relevance_score": "0.054483",
          "ticker_sentiment_score": "0.042005",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "CEREVEL ALERT: Bragar Eagel & Squire, P.C. is Investigating Cerevel Therapeutics Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm",
      "url": "https://www.benzinga.com/pressreleases/25/06/g45784442/cerevel-alert-bragar-eagel-squire-p-c-is-investigating-cerevel-therapeutics-holdings-inc-on-behalf",
      "time_published": "20250605T010000",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "NEW YORK, June 04, 2025 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Cerevel Therapeutics Holdings, Inc. ( CERE ) on behalf of long-term stockholders following a class action complaint that was ...",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "IPO",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.538269"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.108179"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.072124,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "META",
          "relevance_score": "0.081001",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.081001",
          "ticker_sentiment_score": "0.066361",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "3 ETFs to Buy Now for Passive Dividend Income",
      "url": "https://www.fool.com/investing/2025/03/09/3-etfs-to-buy-now-for-passive-dividend-income/",
      "time_published": "20250309T101500",
      "authors": [
        "and Lee Samaha",
        "Scott Levine",
        "Daniel Foelber"
      ],
      "summary": "With volatility spiking and stock market indexes like the S&P 500 ( SNPINDEX: ^GSPC ) and Nasdaq Composite ( NASDAQINDEX: ^IXIC ) down on the year, investors may be looking for ways to diversify their portfolios and collect some passive income.Exchange-traded funds ( ETFs ) are one way to invest ...",
      "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F810162%2Fgettyimages-1440152120-1201x742-1536a11.jpg&op=resize&w=700",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "1.0"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.288318,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "AAPL",
          "relevance_score": "0.080323",
          "ticker_sentiment_score": "0.12012",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AVGO",
          "relevance_score": "0.080323",
          "ticker_sentiment_score": "0.12012",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CSCO",
          "relevance_score": "0.080323",
          "ticker_sentiment_score": "0.047731",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "KO",
          "relevance_score": "0.12023",
          "ticker_sentiment_score": "0.096245",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.080323",
          "ticker_sentiment_score": "0.163099",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.080323",
          "ticker_sentiment_score": "0.047731",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AMGN",
          "relevance_score": "0.080323",
          "ticker_sentiment_score": "0.047731",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.080323",
          "ticker_sentiment_score": "0.047731",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "UNH",
          "relevance_score": "0.080323",
          "ticker_sentiment_score": "0.163099",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "MSFT",
          "relevance_score": "0.080323",
          "ticker_sentiment_score": "0.12012",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "COST",
          "relevance_score": "0.080323",
          "ticker_sentiment_score": "0.12012",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MA",
          "relevance_score": "0.040212",
          "ticker_sentiment_score": "0.114756",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "V",
          "relevance_score": "0.080323",
          "ticker_sentiment_score": "0.12012",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PG",
          "relevance_score": "0.080323",
          "ticker_sentiment_score": "0.163099",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "XOM",
          "relevance_score": "0.080323",
          "ticker_sentiment_score": "0.163099",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "HD",
          "relevance_score": "0.080323",
          "ticker_sentiment_score": "0.163099",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "WMT",
          "relevance_score": "0.080323",
          "ticker_sentiment_score": "0.12012",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Two Data Analyses from Clinical Trials Show Epcoritamab  ( DuoBody\u00ae CD3xCD20 )  Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma  ( DLBCL ) ",
      "url": "https://www.globenewswire.com/news-release/2024/12/09/2993970/0/en/Two-Data-Analyses-from-Clinical-Trials-Show-Epcoritamab-DuoBody-CD3xCD20-Induces-Durable-Complete-Responses-as-Monotherapy-and-Combination-Treatment-in-Patients-With-Diffuse-Large-.html",
      "time_published": "20241209T170000",
      "authors": [
        "Genmab A/S"
      ],
      "summary": "Media ReleaseCOPENHAGEN, Denmark. December ...",
      "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/368a5dab-dfc5-4e1d-bfa6-2af5e5216fce",
      "source": "GlobeNewswire",
      "category_within_source": "n/a",
      "source_domain": "www.globenewswire.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.002379,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.080296",
          "ticker_sentiment_score": "0.066048",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Top Cancer Stocks to Buy to Boost Your Portfolio's Health",
      "url": "https://www.zacks.com/stock/news/2449875/top-cancer-stocks-to-buy-to-boost-your-portfolios-health",
      "time_published": "20250416T134500",
      "authors": [
        "Kinjel Shah"
      ],
      "summary": "If the cancer space appeals to you, it's time to consider stocks like Pyxis Oncology, Verastem Oncology and Relay Therapeutics.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/86/1981.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.360215"
        }
      ],
      "overall_sentiment_score": 0.014883,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "PYXS",
          "relevance_score": "0.116914",
          "ticker_sentiment_score": "0.0105",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.078099",
          "ticker_sentiment_score": "0.103192",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RLAY",
          "relevance_score": "0.268505",
          "ticker_sentiment_score": "0.018605",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AZN",
          "relevance_score": "0.078099",
          "ticker_sentiment_score": "0.103192",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.078099",
          "ticker_sentiment_score": "0.103192",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "VSTM",
          "relevance_score": "0.155451",
          "ticker_sentiment_score": "-0.005479",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Crude Oil Down Over 2%; Upstart Shares Jump Following Earnings - CVS Health  ( NYSE:CVS ) , Atomera  ( NASDAQ:ATOM ) ",
      "url": "https://www.benzinga.com/news/earnings/25/02/43666595/crude-oil-down-over-2-upstart-shares-jump-following-earnings",
      "time_published": "20250212T170800",
      "authors": [
        "Avi Kapoor"
      ],
      "summary": "U.S. stocks traded lower midway through trading, with the Dow Jones index dipping more than 200 points on Wednesday. The Dow traded down 0.47% to 44,383.04 while the NASDAQ fell 0.01% to 19,642.01. The S&P 500 also fell, dropping, 0.27% to 6,052.27. Health care shares rose by 0.2% on Wednesday.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2025/02/12/Aerial-Front-View-Of-A-Heavy-Crude-Oil-T.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.2"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.2"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.2"
        },
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.87644"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.2"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.744043"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.2"
        }
      ],
      "overall_sentiment_score": 0.125227,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "SPIR",
          "relevance_score": "0.154455",
          "ticker_sentiment_score": "-0.208882",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "SMWB",
          "relevance_score": "0.154455",
          "ticker_sentiment_score": "-0.292048",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "STAB",
          "relevance_score": "0.077593",
          "ticker_sentiment_score": "0.050213",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TIVC",
          "relevance_score": "0.154455",
          "ticker_sentiment_score": "0.065579",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "XLO",
          "relevance_score": "0.077593",
          "ticker_sentiment_score": "0.327204",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.077593",
          "ticker_sentiment_score": "0.327204",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "UPST",
          "relevance_score": "0.154455",
          "ticker_sentiment_score": "0.426404",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ATOM",
          "relevance_score": "0.154455",
          "ticker_sentiment_score": "-0.131596",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "3 Franklin Templeton Mutual Funds Worth Considering in Current Times",
      "url": "https://www.zacks.com/stock/news/2399570/3-franklin-templeton-mutual-funds-worth-considering-in-current-times",
      "time_published": "20250120T115300",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Invest in Franklin Templeton mutual funds like FNRAX, FQTEX and FVHIX for growth and stability in your portfolio.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/d9/554.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.25"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.25"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.459462"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.25"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.25"
        }
      ],
      "overall_sentiment_score": 0.263292,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MMLP",
          "relevance_score": "0.077593",
          "ticker_sentiment_score": "0.103347",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "APD",
          "relevance_score": "0.077593",
          "ticker_sentiment_score": "0.051596",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "COP",
          "relevance_score": "0.077593",
          "ticker_sentiment_score": "0.054636",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "XOM",
          "relevance_score": "0.077593",
          "ticker_sentiment_score": "0.054636",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "WYNN",
          "relevance_score": "0.077593",
          "ticker_sentiment_score": "0.103347",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.077593",
          "ticker_sentiment_score": "0.051596",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NEE",
          "relevance_score": "0.077593",
          "ticker_sentiment_score": "0.051596",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "MingMed seeks Hong Kong listing to fund research and launch Botox alternative",
      "url": "https://www.scmp.com/business/article/3314750/mingmed-seeks-hong-kong-listing-fund-research-and-launch-botox-alternative",
      "time_published": "20250618T013015",
      "authors": [
        "Eric Ng"
      ],
      "summary": "MingMed Biotechnology is seeking a Hong Kong listing this year to raise funds to research and market a genetically engineered alternative to Botox in China. The drug developer, based in the Nansha district of Guangzhou, said it would set up an incubation centre in the Hong Kong Science and ...",
      "banner_image": "https://cdn.i-scmp.com/sites/default/files/styles/1020x680/public/d8/images/canvas/2025/06/17/7521e4b5-7204-47ab-9333-bd8f92a79acc_dd4fb9bd.jpg?itok=a844kfrD&v=1750146598",
      "source": "South China Morning Post",
      "category_within_source": "Business",
      "source_domain": "www.scmp.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.026471,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.076847",
          "ticker_sentiment_score": "-0.067746",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SZIHF",
          "relevance_score": "0.076847",
          "ticker_sentiment_score": "0.042438",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "3 Healthcare Mutual Funds to Buy for Consistent Returns",
      "url": "https://www.zacks.com/stock/news/2435393/3-healthcare-mutual-funds-to-buy-for-consistent-returns",
      "time_published": "20250326T122800",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Below, we will discuss three healthcare mutual funds, namely FBIOX, FSPHX and FSMEX. Each has earned a Zacks Mutual Fund Rank #1.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/4c/2710.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.366172,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "HCSG",
          "relevance_score": "0.076602",
          "ticker_sentiment_score": "0.095601",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SEM",
          "relevance_score": "0.227007",
          "ticker_sentiment_score": "0.252848",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.076602",
          "ticker_sentiment_score": "0.055322",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Analysts Remain Bullish on Caribou Biosciences  ( CRBU )  Despite Ongoing Slump in its Shares",
      "url": "https://markets.businessinsider.com/news/stocks/analysts-remain-bullish-on-caribou-biosciences-crbu-despite-ongoing-slump-in-its-shares-1034480579",
      "time_published": "20250315T025058",
      "authors": [
        "Tipranks"
      ],
      "summary": "Analysts Remain Bullish on Caribou Biosciences (CRBU) Despite Ongoing Slump in its Shares ...",
      "banner_image": "https://blog.tipranks.com/wp-content/uploads/2025/03/CRBU-Stock-Chart-3-14-25.png?utm_source=markets.businessinsider.com&utm_medium=referral",
      "source": "Business Insider",
      "category_within_source": "RSS",
      "source_domain": "markets.businessinsider.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.990893"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        }
      ],
      "overall_sentiment_score": 0.153218,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CRBU",
          "relevance_score": "0.369319",
          "ticker_sentiment_score": "0.238313",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.076602",
          "ticker_sentiment_score": "-0.00917",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "3 Top-Ranked Healthcare Mutual Funds to Buy for Steady Gains",
      "url": "https://www.zacks.com/stock/news/2506257/3-top-ranked-healthcare-mutual-funds-to-buy-for-steady-gains",
      "time_published": "20250617T120600",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Fidelity's top-ranked healthcare funds FBIOX, FSPHX, and FSMEX offer steady returns and sector stability for long-term investors.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/79/7332.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.353598,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "HCSG",
          "relevance_score": "0.076358",
          "ticker_sentiment_score": "0.095554",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SEM",
          "relevance_score": "0.152018",
          "ticker_sentiment_score": "0.121508",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.076358",
          "ticker_sentiment_score": "0.055296",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "CEREVEL ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Cerevel Therapeutics Holdings, Inc. and Encourages Investors to Contact the Firm",
      "url": "https://www.benzinga.com/pressreleases/25/04/g44753693/cerevel-alert-bragar-eagel-squire-p-c-announces-that-a-class-action-lawsuit-has-been-filed-against",
      "time_published": "20250411T010000",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "NEW YORK, April 10, 2025 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Cerevel Therapeutics Holdings, Inc. ( \"Cerevel\" or the \"Company\" ) ( CERE ) in the United States District ...",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "IPO",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.538269"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.214378"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.084266,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "META",
          "relevance_score": "0.076358",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.076358",
          "ticker_sentiment_score": "0.065702",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Paresthesia Treatment Market Outlook: USD 8.0 Billion by 2034, Growing with an Aging Population and Rising Healthcare Expenditures | Analysis by TMR",
      "url": "https://www.benzinga.com/pressreleases/25/02/g43566423/paresthesia-treatment-market-outlook-usd-8-0-billion-by-2034-growing-with-an-aging-population-and-",
      "time_published": "20250207T163940",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "Wilmington, Delaware, United States, Transparency Market Research Inc. , Feb. 07, 2025 ( GLOBE NEWSWIRE ) -- The Global Paresthesia Treatment Market is experiencing substantial growth, driven by the increasing prevalence of neurological disorders, advancements in medical technology, and rising ...",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/6b7544e5-cd6b-429e-8d3c-7235d8808319/paresthesia-treatment-market-2025.png",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.279262,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MFCSF",
          "relevance_score": "0.037622",
          "ticker_sentiment_score": "0.252635",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "GOOG",
          "relevance_score": "0.037622",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BAYZF",
          "relevance_score": "0.075161",
          "ticker_sentiment_score": "0.099974",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.075161",
          "ticker_sentiment_score": "0.099974",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVS",
          "relevance_score": "0.075161",
          "ticker_sentiment_score": "0.099974",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.075161",
          "ticker_sentiment_score": "0.099974",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AMGN",
          "relevance_score": "0.075161",
          "ticker_sentiment_score": "0.099974",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "WMGTF",
          "relevance_score": "0.112532",
          "ticker_sentiment_score": "0.10442",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.075161",
          "ticker_sentiment_score": "0.099974",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AZN",
          "relevance_score": "0.075161",
          "ticker_sentiment_score": "0.099974",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TEVA",
          "relevance_score": "0.075161",
          "ticker_sentiment_score": "0.099974",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MDT",
          "relevance_score": "0.037622",
          "ticker_sentiment_score": "0.087457",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GSK",
          "relevance_score": "0.075161",
          "ticker_sentiment_score": "0.099974",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SNY",
          "relevance_score": "0.075161",
          "ticker_sentiment_score": "0.099974",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "SpyGlass Pharma Appoints Chetan Pujara, Ph.D., as Chief Research & Development Officer",
      "url": "https://markets.businessinsider.com/news/stocks/spyglass-pharma-appoints-chetan-pujara-ph-d-as-chief-research-development-officer-1034520611",
      "time_published": "20250327T120029",
      "authors": [
        "markets.businessinsider.com"
      ],
      "summary": "\u2022 Dr. Pujara brings extensive industry experience to guide late-stage development of the SpyGlass Drug Delivery Platform ALISO VIEJO, Calif., March 27, 2025 ( GLOBE NEWSWIRE ) -- SpyGlass Pharma\u2122, a privately-held ophthalmic biotechnology company, today announced the appointment of Chetan Pujara, ...",
      "banner_image": "https://ml.globenewswire.com/media/ZmRkMzRiNjMtNDU4NC00M2JmLWFlYjEtM2ZiMGVhNjZjYWVkLTEyNjQwMTktMjAyNS0wMy0yNy1lbg==/tiny/Spyglass-Pharma-Inc-.png",
      "source": "Business Insider",
      "category_within_source": "RSS",
      "source_domain": "markets.businessinsider.com",
      "topics": [
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.278842,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.074926",
          "ticker_sentiment_score": "0.078702",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "US Stock Futures Climb After Apple Beats Q4 Expectations: Expert Says Tech Stocks Hold Above Key Level Despite DeepSeek Impact - Apple  ( NASDAQ:AAPL ) , AbbVie  ( NYSE:ABBV ) ",
      "url": "https://www.benzinga.com/25/01/43380449/us-stock-futures-climb-aiming-for-third-weekly-advance-expert-says-tech-stocks-hold-above-key-level-despite-deeps",
      "time_published": "20250131T113651",
      "authors": [
        "Rishabh Mishra"
      ],
      "summary": "U.S. stock futures climbed on Friday, pointing to a third straight week of gains fueled by strong corporate earnings. Futures were higher for all four major indices. The dollar index strengthened after Donald Trump announced Thursday that the U.S. will implement a 25% tariff on imports from ...",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2025/01/31/Wall-Street.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.2"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.2"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.2"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.2"
        },
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Economy - Fiscal",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.995077"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.999998"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.2"
        },
        {
          "topic": "Economy - Macro",
          "relevance_score": "0.310843"
        }
      ],
      "overall_sentiment_score": 0.157012,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "META",
          "relevance_score": "0.07446",
          "ticker_sentiment_score": "0.031552",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AAPL",
          "relevance_score": "0.148273",
          "ticker_sentiment_score": "0.096057",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CVX",
          "relevance_score": "0.07446",
          "ticker_sentiment_score": "0.081691",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CL",
          "relevance_score": "0.07446",
          "ticker_sentiment_score": "0.078659",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVS",
          "relevance_score": "0.07446",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.07446",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IVZ",
          "relevance_score": "0.037271",
          "ticker_sentiment_score": "0.199542",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "CIFR",
          "relevance_score": "0.07446",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MSFT",
          "relevance_score": "0.07446",
          "ticker_sentiment_score": "0.031552",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PSX",
          "relevance_score": "0.07446",
          "ticker_sentiment_score": "-0.023439",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SFTBF",
          "relevance_score": "0.037271",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "XOM",
          "relevance_score": "0.07446",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LPLA",
          "relevance_score": "0.037271",
          "ticker_sentiment_score": "0.041032",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CHTR",
          "relevance_score": "0.148273",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "KITT",
          "relevance_score": "0.07446",
          "ticker_sentiment_score": "0.117092",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FOREX:USD",
          "relevance_score": "0.07446",
          "ticker_sentiment_score": "0.038098",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Nasdaq, S&P 500 Futures Rise Solidly, Fueled By Corporate Earnings - Apple  ( NASDAQ:AAPL ) , AbbVie  ( NYSE:ABBV ) ",
      "url": "https://www.benzinga.com/government/regulations/25/01/43380449/us-stock-futures-climb-after-apple-beats-q4-expectations-expert-says-tech-stocks-hold-abov",
      "time_published": "20250131T113640",
      "authors": [
        "Rishabh Mishra"
      ],
      "summary": "U.S. stock futures climbed on Friday, pointing to a third straight week of gains fueled by strong corporate earnings. Futures were higher for all four major indices. The dollar index strengthened after Donald Trump announced Thursday that the U.S. will implement a 25% tariff on imports from ...",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2025/01/31/Wall-Street.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.2"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.2"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.2"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.2"
        },
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Economy - Fiscal",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.995077"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.999998"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.2"
        },
        {
          "topic": "Economy - Macro",
          "relevance_score": "0.310843"
        }
      ],
      "overall_sentiment_score": 0.157012,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "META",
          "relevance_score": "0.074345",
          "ticker_sentiment_score": "0.03154",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AAPL",
          "relevance_score": "0.148045",
          "ticker_sentiment_score": "0.095967",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CVX",
          "relevance_score": "0.074345",
          "ticker_sentiment_score": "0.08168",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CL",
          "relevance_score": "0.074345",
          "ticker_sentiment_score": "0.078649",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVS",
          "relevance_score": "0.074345",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.074345",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IVZ",
          "relevance_score": "0.037213",
          "ticker_sentiment_score": "0.19951",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "CIFR",
          "relevance_score": "0.074345",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MSFT",
          "relevance_score": "0.074345",
          "ticker_sentiment_score": "0.03154",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PSX",
          "relevance_score": "0.074345",
          "ticker_sentiment_score": "-0.023435",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SFTBF",
          "relevance_score": "0.037213",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "XOM",
          "relevance_score": "0.074345",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LPLA",
          "relevance_score": "0.037213",
          "ticker_sentiment_score": "0.041025",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CHTR",
          "relevance_score": "0.148045",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "KITT",
          "relevance_score": "0.074345",
          "ticker_sentiment_score": "0.117076",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FOREX:USD",
          "relevance_score": "0.074345",
          "ticker_sentiment_score": "0.038089",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Elon Musk's Net Worth Surpasses Market Cap Of US Giants Like BofA, Johnson & Johnson, Salesforce, Chevron, Coca-Cola And More: Only 25 Companies Have Higher Market Cap - Tesla  ( NASDAQ:TSLA ) ",
      "url": "https://www.benzinga.com/markets/equities/24/12/42435201/elon-musks-net-worth-surpasses-market-cap-of-us-giants-like-bofa-johnson-johnson-salesforce-chev",
      "time_published": "20241211T130825",
      "authors": [
        "Rishabh Mishra"
      ],
      "summary": "Only 25 listed companies have a higher market capitalization than Elon Musk's net worth. Musk has added $155 billion to his wealth this year so far. Elon Musk's net worth is now more than the market capitalization of most of the listed companies in the U.S. and the world.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2024/12/11/Why-It-Matters_0.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.166667"
        }
      ],
      "overall_sentiment_score": 0.273488,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "META",
          "relevance_score": "0.07423",
          "ticker_sentiment_score": "0.123133",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVDA",
          "relevance_score": "0.147818",
          "ticker_sentiment_score": "0.247127",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "BAC",
          "relevance_score": "0.07423",
          "ticker_sentiment_score": "-0.007105",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CVX",
          "relevance_score": "0.07423",
          "ticker_sentiment_score": "-0.007105",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "KO",
          "relevance_score": "0.07423",
          "ticker_sentiment_score": "-0.007105",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.07423",
          "ticker_sentiment_score": "-0.007105",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.07423",
          "ticker_sentiment_score": "-0.077354",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HESAF",
          "relevance_score": "0.07423",
          "ticker_sentiment_score": "-0.077354",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ASML",
          "relevance_score": "0.07423",
          "ticker_sentiment_score": "-0.077354",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SSNLF",
          "relevance_score": "0.07423",
          "ticker_sentiment_score": "-0.077354",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "COST",
          "relevance_score": "0.07423",
          "ticker_sentiment_score": "0.107953",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TSLA",
          "relevance_score": "0.290607",
          "ticker_sentiment_score": "0.286785",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "MA",
          "relevance_score": "0.07423",
          "ticker_sentiment_score": "0.107953",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "XOM",
          "relevance_score": "0.07423",
          "ticker_sentiment_score": "0.107953",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Investigational Epcoritamab  ( DuoBody\u00ae CD3xCD20 )  Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory  ( R/R )  Chronic Lymphocytic Leukemia  ( CLL )  in Preliminary Analysis",
      "url": "https://www.globenewswire.com/news-release/2024/12/08/2993388/0/en/Investigational-Epcoritamab-DuoBody-CD3xCD20-Monotherapy-Achieves-High-Overall-and-Complete-Response-Rates-in-Clinical-Trial-of-Patients-With-Relapsed-or-Refractory-R-R-Chronic-Lym.html",
      "time_published": "20241208T160000",
      "authors": [
        "Genmab A/S"
      ],
      "summary": "Media ReleaseCOPENHAGEN, Denmark. December ...",
      "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/368a5dab-dfc5-4e1d-bfa6-2af5e5216fce",
      "source": "GlobeNewswire",
      "category_within_source": "n/a",
      "source_domain": "www.globenewswire.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": -0.014333,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.073154",
          "ticker_sentiment_score": "0.060395",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Deal Dispatch: Biden Punts TikTok Ban To Trump, Fate Hangs - Another Private Equity Owned Retailer Goes Bankrupt - AbbVie  ( NYSE:ABBV ) , Biogen  ( NASDAQ:BIIB ) ",
      "url": "https://www.benzinga.com/ma/25/01/43066009/biden-tiktok-ban-trump-private-equity-bankrupt-retailer",
      "time_published": "20250117T195853",
      "authors": [
        "Anthony Noto"
      ],
      "summary": "Fabric retailer Joann joins the growing quilt ofretail casualties: Party City, Big Lots, The Body Shop and Container Store to name a few. Cleveland-Cliffs CEO Lourenco Goncalves' rhetoric at a press conference escalated tensions with US Steel and Nippon. Get Wall Street's Hottest Chart Every ...",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2025/01/17/benzinga-deal-dispatch2.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Mergers",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.2"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.2"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.2"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.2"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.2"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.360215"
        }
      ],
      "overall_sentiment_score": 0.088894,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "DD",
          "relevance_score": "0.109123",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TCSG",
          "relevance_score": "0.072876",
          "ticker_sentiment_score": "0.068391",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.072876",
          "ticker_sentiment_score": "0.095673",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CCK",
          "relevance_score": "0.072876",
          "ticker_sentiment_score": "0.380009",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "SAGE",
          "relevance_score": "0.072876",
          "ticker_sentiment_score": "0.0397",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.072876",
          "ticker_sentiment_score": "0.095673",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GS",
          "relevance_score": "0.109123",
          "ticker_sentiment_score": "0.031121",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "WMGTF",
          "relevance_score": "0.036476",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BMY",
          "relevance_score": "0.072876",
          "ticker_sentiment_score": "0.095673",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SANW",
          "relevance_score": "0.109123",
          "ticker_sentiment_score": "0.272509",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "SSTK",
          "relevance_score": "0.036476",
          "ticker_sentiment_score": "0.24395",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "NGVT",
          "relevance_score": "0.072876",
          "ticker_sentiment_score": "0.117888",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LNTH",
          "relevance_score": "0.072876",
          "ticker_sentiment_score": "0.189739",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "LLY",
          "relevance_score": "0.072876",
          "ticker_sentiment_score": "-0.270977",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "SLRX",
          "relevance_score": "0.072876",
          "ticker_sentiment_score": "0.145183",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CLF",
          "relevance_score": "0.145145",
          "ticker_sentiment_score": "-0.191826",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "GSK",
          "relevance_score": "0.109123",
          "ticker_sentiment_score": "0.237137",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "BIIB",
          "relevance_score": "0.072876",
          "ticker_sentiment_score": "0.0397",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RVNC",
          "relevance_score": "0.072876",
          "ticker_sentiment_score": "0.380009",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "GSK Stock Rises Almost 22% in 6 Months: Time to Buy, Sell or Hold?",
      "url": "https://www.zacks.com/stock/news/2510863/gsk-stock-rises-almost-22-in-6-months-time-to-buy-sell-or-hold",
      "time_published": "20250618T142200",
      "authors": [
        "Kinjel Shah"
      ],
      "summary": "GSK stock is up 21.5% in six months, fueled by strong Specialty Medicines growth and a promising pipeline despite vaccine headwinds.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ab/2180.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.658903"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.614606"
        }
      ],
      "overall_sentiment_score": 0.220184,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.072655",
          "ticker_sentiment_score": "0.058582",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.072655",
          "ticker_sentiment_score": "0.058582",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AZN",
          "relevance_score": "0.036365",
          "ticker_sentiment_score": "0.055891",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.072655",
          "ticker_sentiment_score": "0.058582",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Royalty Pharma Appoints Vlad Coric, M.D. to the Company's Board of Directors",
      "url": "https://www.globenewswire.com/news-release/2025/04/08/3058015/0/en/Royalty-Pharma-Appoints-Vlad-Coric-M-D-to-the-Company-s-Board-of-Directors.html",
      "time_published": "20250408T201500",
      "authors": [
        "Royalty Pharma plc"
      ],
      "summary": "NEW YORK, April 08, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) today announced the appointment of Vlad Coric, M.D. to the company's Board of Directors, effective immediately. Vlad Coric is the Chairman and Chief Executive Officer of Biohaven, a biopharmaceutical company ...",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/d605b3b0-7ba0-46e1-a2d4-439ca98694f8",
      "source": "GlobeNewswire",
      "category_within_source": "n/a",
      "source_domain": "www.globenewswire.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.25362,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "BHVN",
          "relevance_score": "0.28387",
          "ticker_sentiment_score": "0.256512",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "RPRX",
          "relevance_score": "0.475461",
          "ticker_sentiment_score": "0.321713",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.072435",
          "ticker_sentiment_score": "0.078487",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.072435",
          "ticker_sentiment_score": "0.169379",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "BMY",
          "relevance_score": "0.072435",
          "ticker_sentiment_score": "0.067403",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "If You Invested $1000 in Halozyme Therapeutics a Decade Ago, This is How Much It'd Be Worth Now",
      "url": "https://www.zacks.com/stock/news/2383784/if-you-invested-1000-in-halozyme-therapeutics-a-decade-ago-this-is-how-much-itd-be-worth-now",
      "time_published": "20241216T133005",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default77.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.929393"
        }
      ],
      "overall_sentiment_score": 0.187489,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "HALO",
          "relevance_score": "0.474207",
          "ticker_sentiment_score": "0.324065",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.072217",
          "ticker_sentiment_score": "0.043228",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Here's How Much a $1000 Investment in Halozyme Therapeutics Made 10 Years Ago Would Be Worth Today",
      "url": "https://www.zacks.com/stock/news/2394245/heres-how-much-a-1000-investment-in-halozyme-therapeutics-made-10-years-ago-would-be-worth-today",
      "time_published": "20250109T133006",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default128.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.87644"
        }
      ],
      "overall_sentiment_score": 0.203505,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "HALO",
          "relevance_score": "0.471718",
          "ticker_sentiment_score": "0.325831",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.071784",
          "ticker_sentiment_score": "0.043211",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "If You Invested $1000 in Halozyme Therapeutics a Decade Ago, This is How Much It'd Be Worth Now",
      "url": "https://www.zacks.com/stock/news/2403616/if-you-invested-1000-in-halozyme-therapeutics-a-decade-ago-this-is-how-much-itd-be-worth-now",
      "time_published": "20250127T133012",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Holding on to popular or trending stocks for the long-term can make your portfolio a winner.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default361.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.929393"
        }
      ],
      "overall_sentiment_score": 0.205899,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "HALO",
          "relevance_score": "0.470482",
          "ticker_sentiment_score": "0.358395",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.07157",
          "ticker_sentiment_score": "0.043203",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "3Daughters Announces Appointment of John Poulos to the Board of Directors",
      "url": "https://www.benzinga.com/pressreleases/25/02/g43620808/3daughters-announces-appointment-of-john-poulos-to-the-board-of-directors",
      "time_published": "20250211T130023",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "FORT LAUDERDALE, Fla., Feb. 11, 2025 ( GLOBE NEWSWIRE ) -- 3Daughters, Inc., a clinical development company fueling revolutionary healthcare for women, is excited to announce that John Poulos will be joining its Board of Directors.",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.357944,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.071357",
          "ticker_sentiment_score": "0.185365",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Here's How Much You'd Have If You Invested $1000 in Halozyme Therapeutics a Decade Ago",
      "url": "https://www.zacks.com/stock/news/2414346/heres-how-much-youd-have-if-you-invested-1000-in-halozyme-therapeutics-a-decade-ago",
      "time_published": "20250212T133007",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.",
      "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default8.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.87644"
        }
      ],
      "overall_sentiment_score": 0.208062,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "HALO",
          "relevance_score": "0.464393",
          "ticker_sentiment_score": "0.317243",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.070517",
          "ticker_sentiment_score": "0.043165",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Nasdaq Edges Higher; CVS Health Shares Jump Following Upbeat Earnings - CVS Health  ( NYSE:CVS ) , Atomera  ( NASDAQ:ATOM ) ",
      "url": "https://www.benzinga.com/news/earnings/25/02/43671791/nasdaq-edges-higher-cvs-health-shares-jump-following-upbeat-earnings",
      "time_published": "20250212T194226",
      "authors": [
        "Avi Kapoor"
      ],
      "summary": "U.S. stocks traded mostly lower toward the end of trading, while the Nasdaq Composite edged higher on Wednesday. The Dow traded down 0.47% to 44,381.89 while the NASDAQ rose 0.08% to 19,660.45. The S&P 500 also fell, dropping, 0.25% to 6,053.09. Consumer discretionary shares rose by 0.3% on ...",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2025/02/12/Nasdaq-index.jpeg?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.87644"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.891286"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.166667"
        }
      ],
      "overall_sentiment_score": 0.134758,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "SPIR",
          "relevance_score": "0.139669",
          "ticker_sentiment_score": "-0.196916",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "CVS",
          "relevance_score": "0.139669",
          "ticker_sentiment_score": "0.325978",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "SMWB",
          "relevance_score": "0.139669",
          "ticker_sentiment_score": "-0.276194",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "STAB",
          "relevance_score": "0.070105",
          "ticker_sentiment_score": "0.04959",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TIVC",
          "relevance_score": "0.139669",
          "ticker_sentiment_score": "0.061707",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "XLO",
          "relevance_score": "0.070105",
          "ticker_sentiment_score": "0.323836",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.070105",
          "ticker_sentiment_score": "0.323836",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "UPST",
          "relevance_score": "0.139669",
          "ticker_sentiment_score": "0.405031",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ATOM",
          "relevance_score": "0.139669",
          "ticker_sentiment_score": "-0.123766",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Merck Q4 Earnings Coming Up: Buy, Hold or Sell MRK Stock Now?",
      "url": "https://www.zacks.com/stock/news/2404548/merck-q4-earnings-coming-up-buy-hold-or-sell-mrk-stock-now",
      "time_published": "20250128T142400",
      "authors": [
        "Kinjel Shah"
      ],
      "summary": "When Merck reports fourth-quarter earnings, investors are likely to focus on the sales of its blockbuster oncology medicine, Keytruda.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/cd/2084.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.980922"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.998626"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.134141,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.070002",
          "ticker_sentiment_score": "0.097823",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SKXJF",
          "relevance_score": "0.035035",
          "ticker_sentiment_score": "-0.127385",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.070002",
          "ticker_sentiment_score": "0.097823",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DSKYF",
          "relevance_score": "0.035035",
          "ticker_sentiment_score": "-0.127385",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AZN",
          "relevance_score": "0.173832",
          "ticker_sentiment_score": "0.060254",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.035035",
          "ticker_sentiment_score": "0.093678",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "3 Healthcare Funds to Buy Amid Tariff Turmoil",
      "url": "https://www.zacks.com/stock/news/2441718/3-healthcare-funds-to-buy-amid-tariff-turmoil",
      "time_published": "20250408T124700",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "The increasing U.S.-China tariffs and volatile markets underscore the resilience of healthcare mutual funds, such as FPHAX, JNGLX and PHSTX, during economic uncertainty.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/4c/2710.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        }
      ],
      "overall_sentiment_score": 0.164364,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "JHG",
          "relevance_score": "0.138863",
          "ticker_sentiment_score": "0.134122",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.069697",
          "ticker_sentiment_score": "0.049162",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AZN",
          "relevance_score": "0.069697",
          "ticker_sentiment_score": "0.042134",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.138863",
          "ticker_sentiment_score": "0.052023",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "UNH",
          "relevance_score": "0.138863",
          "ticker_sentiment_score": "0.055667",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Shades for Migraine Drives Awareness and Action to Break Migraine Stigma",
      "url": "https://www.benzinga.com/pressreleases/25/06/g45859953/shades-for-migraine-drives-awareness-and-action-to-break-migraine-stigma",
      "time_published": "20250610T133000",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "Providence, RI, June 10, 2025 ( GLOBE NEWSWIRE ) -- The nonprofit Association of Migraine Disorders is changing the conversation around migraine disease through its global Shades for Migraine awareness campaign.",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.116336,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "PFE",
          "relevance_score": "0.069294",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.069294",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "SpyGlass Pharma Appoints Chetan Pujara, Ph.D., as Chief Research & Development Officer",
      "url": "https://www.benzinga.com/pressreleases/25/03/g44512019/spyglass-pharma-appoints-chetan-pujara-ph-d-as-chief-research-development-officer",
      "time_published": "20250327T120029",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "Dr. Pujara brings extensive industry experience to guide late-stage development of the SpyGlass Drug Delivery Platform ALISO VIEJO, Calif., March 27, 2025 ( GLOBE NEWSWIRE ) -- SpyGlass Pharma\u2122, a privately-held ophthalmic biotechnology company, today announced the appointment of Chetan Pujara, ...",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.283607,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.069294",
          "ticker_sentiment_score": "0.078271",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Questex's Fierce Pharma Unveils Powerhouse Conference Program for the Inaugural Fierce Pharma Week, Where Pharma's Future Takes Shape",
      "url": "https://www.benzinga.com/pressreleases/25/06/g46052159/questexs-fierce-pharma-unveils-powerhouse-conference-program-for-the-inaugural-fierce-pharma-week-",
      "time_published": "20250623T140000",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "Unites Pharma Marketing, PR & Communications, New Product Planning & Commercialization, and Medical Affairs Communities; Thought Leaders from AbbVie, AstraZeneca, BMS, GSK, Johnson & Johnson, NBCUniversal, Pfizer, Takeda and More Deliver Unparalleled Education",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.175525,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "AZN",
          "relevance_score": "0.069194",
          "ticker_sentiment_score": "0.081279",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GMAB",
          "relevance_score": "0.03463",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.069194",
          "ticker_sentiment_score": "0.006067",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ALNY",
          "relevance_score": "0.03463",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.069194",
          "ticker_sentiment_score": "0.081279",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.069194",
          "ticker_sentiment_score": "0.069224",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BMY",
          "relevance_score": "0.069194",
          "ticker_sentiment_score": "-0.120492",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SGIOF",
          "relevance_score": "0.03463",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SNY",
          "relevance_score": "0.03463",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Is the Vanguard Value ETF the Best Ultra-Low-Cost Fund for Generating Passive Income?",
      "url": "https://www.fool.com/investing/2025/04/08/buy-value-etf-dividend-passive-income-stock/",
      "time_published": "20250408T094000",
      "authors": [
        "Daniel Foelber"
      ],
      "summary": "Collecting passive income from stocks is a simple and effective way to participate in the market without having the return based solely on stock prices going up.Exchange-traded funds ( ETFs ) that invest in dividend stocks provide the added benefit of diversification, making them solid options ...",
      "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F813697%2Fa-person-sitting-on-a-couch-and-looking-down-while-holding-a-pen.jpg&op=resize&w=700",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "1.0"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.451494"
        }
      ],
      "overall_sentiment_score": 0.281377,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "META",
          "relevance_score": "0.067727",
          "ticker_sentiment_score": "0.118348",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVDA",
          "relevance_score": "0.067727",
          "ticker_sentiment_score": "0.118348",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AVGO",
          "relevance_score": "0.067727",
          "ticker_sentiment_score": "0.084207",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BRK-A",
          "relevance_score": "0.067727",
          "ticker_sentiment_score": "0.084207",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.067727",
          "ticker_sentiment_score": "0.084207",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.067727",
          "ticker_sentiment_score": "0.084207",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "UNH",
          "relevance_score": "0.067727",
          "ticker_sentiment_score": "0.084207",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MSFT",
          "relevance_score": "0.067727",
          "ticker_sentiment_score": "0.118348",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TSLA",
          "relevance_score": "0.067727",
          "ticker_sentiment_score": "0.118348",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PG",
          "relevance_score": "0.067727",
          "ticker_sentiment_score": "0.084207",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "XOM",
          "relevance_score": "0.067727",
          "ticker_sentiment_score": "0.084207",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HD",
          "relevance_score": "0.067727",
          "ticker_sentiment_score": "0.084207",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "WMT",
          "relevance_score": "0.067727",
          "ticker_sentiment_score": "0.084207",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Jim Cramer's top 10 things to watch in the stock market Monday",
      "url": "https://www.cnbc.com/2025/05/12/jim-cramers-top-10-things-to-watch-in-the-stock-market-monday.html",
      "time_published": "20250512T125134",
      "authors": [],
      "summary": "Stocks are soaring after the U.S. and China agreed to temporarily slash their tariff rates.",
      "banner_image": null,
      "source": "CNBC",
      "category_within_source": "Top News",
      "source_domain": "www.cnbc.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.905476"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.122684,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CRWV",
          "relevance_score": "0.1331",
          "ticker_sentiment_score": "0.019635",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JCI",
          "relevance_score": "0.066784",
          "ticker_sentiment_score": "0.176767",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "BCS",
          "relevance_score": "0.1331",
          "ticker_sentiment_score": "0.122567",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.066784",
          "ticker_sentiment_score": "0.033371",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.066784",
          "ticker_sentiment_score": "0.033371",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BA",
          "relevance_score": "0.066784",
          "ticker_sentiment_score": "0.080609",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BNXYF",
          "relevance_score": "0.066784",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Amneal Receives U.S. FDA Approval for Prednisolone Acetate Ophthalmic Suspension",
      "url": "https://www.globenewswire.com/news-release/2025/06/12/3098246/0/en/Amneal-Receives-U-S-FDA-Approval-for-Prednisolone-Acetate-Ophthalmic-Suspension.html",
      "time_published": "20250612T120000",
      "authors": [
        "Amneal Pharmaceuticals LLC"
      ],
      "summary": "BRIDGEWATER, N.J., June 12, 2025 ( GLOBE NEWSWIRE ) -- Amneal Pharmaceuticals, Inc. ( \"Amneal\" or the \"Company\" ) today announced the U.S. Food and Drug Administration ( FDA ) approval of prednisolone acetate ophthalmic suspension, 1% sterile which references Pred Forte\u00ae.",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/99df1bf7-98fa-4a24-af54-91097505be20",
      "source": "GlobeNewswire",
      "category_within_source": "n/a",
      "source_domain": "www.globenewswire.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.310843"
        }
      ],
      "overall_sentiment_score": 0.076639,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "AMRX",
          "relevance_score": "0.195814",
          "ticker_sentiment_score": "0.112731",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.065866",
          "ticker_sentiment_score": "0.051055",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Peripheral Spondyloarthritis Market to Expand at 6.8% CAGR, Reaching US$ 5,220.7 Million by 2034 | Fact.MR Report",
      "url": "https://www.benzinga.com/pressreleases/24/12/g42410098/peripheral-spondyloarthritis-market-to-expand-at-6-8-cagr-reaching-us-5-220-7-million-by-2034-fact",
      "time_published": "20241210T123000",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "Rockville, MD, Dec. 10, 2024 ( GLOBE NEWSWIRE ) -- According to Fact.MR, a market research and competitive intelligence provider, the global peripheral spondyloarthritis market is estimated to reach a valuation of US$ 2,704.0 million in 2024 and is expected to grow at a CAGR of 6.8% during the ...",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/ad8cd409-69e0-4aa6-b179-3fe6bcdf2b4d/peripheral-spondyloarthritis-market.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.275261,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "PFE",
          "relevance_score": "0.065595",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.065595",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BMY",
          "relevance_score": "0.065595",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Pharmaceutical stocks fall as Trump doubles down on tariffs threat",
      "url": "https://www.cnbc.com/2025/04/09/trump-pharmaceutical-tariffs-announcement.html",
      "time_published": "20250409T155136",
      "authors": [],
      "summary": "Trump on Tuesday said his administration will be announcing a \"major\" tariff on pharmaceuticals \"very shortly.\" ...",
      "banner_image": null,
      "source": "CNBC",
      "category_within_source": "Business",
      "source_domain": "www.cnbc.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Economy - Fiscal",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": -0.074324,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.065506",
          "ticker_sentiment_score": "-0.082473",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AZN",
          "relevance_score": "0.065506",
          "ticker_sentiment_score": "-0.082473",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.065506",
          "ticker_sentiment_score": "-0.082473",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BMY",
          "relevance_score": "0.065506",
          "ticker_sentiment_score": "-0.082473",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.130571",
          "ticker_sentiment_score": "-0.019139",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "VKTX Initiates Phase 3 Study on Obesity Candidate VK2735",
      "url": "https://www.zacks.com/stock/news/2554915/vktx-initiates-phase-3-study-on-obesity-candidate-vk2735",
      "time_published": "20250626T151200",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Viking begins phase III VANQUISH program for VK2735, targeting weight loss in obese adults with or without type II diabetes.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/58/608.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.093768,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.255641",
          "ticker_sentiment_score": "0.115672",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "VKTX",
          "relevance_score": "0.255641",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.064973",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GS",
          "relevance_score": "0.064973",
          "ticker_sentiment_score": "0.017042",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AMGN",
          "relevance_score": "0.255641",
          "ticker_sentiment_score": "0.120169",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.255641",
          "ticker_sentiment_score": "0.115672",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Go Beyond MAGS ETF: Tap Broadening of the Rally With TOPT ETF",
      "url": "https://www.zacks.com/stock/news/2376875/go-beyond-mags-etf-tap-broadening-of-the-rally-with-topt-etf",
      "time_published": "20241129T130000",
      "authors": [
        "Sanghamitra Saha"
      ],
      "summary": "iShares launched TOPT ETF last month. The new ETF offers exposure to Mag-7 stocks while some more U.S. biggies with value focus get a place in TOPT.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/93/1042.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.2"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.2"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.2"
        },
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.2"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.999326"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.2"
        }
      ],
      "overall_sentiment_score": 0.251766,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MSFT",
          "relevance_score": "0.129168",
          "ticker_sentiment_score": "0.143395",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVDA",
          "relevance_score": "0.129168",
          "ticker_sentiment_score": "0.143395",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "COST",
          "relevance_score": "0.064797",
          "ticker_sentiment_score": "0.034091",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AVGO",
          "relevance_score": "0.064797",
          "ticker_sentiment_score": "0.034091",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TSLA",
          "relevance_score": "0.064797",
          "ticker_sentiment_score": "0.242652",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "MA",
          "relevance_score": "0.064797",
          "ticker_sentiment_score": "0.034091",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BRK-A",
          "relevance_score": "0.064797",
          "ticker_sentiment_score": "0.034091",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.064797",
          "ticker_sentiment_score": "0.034091",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HD",
          "relevance_score": "0.064797",
          "ticker_sentiment_score": "0.034091",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Avalo Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors - Avalo Therapeutics  ( NASDAQ:AVTX ) ",
      "url": "https://www.benzinga.com/pressreleases/25/06/g45991737/avalo-therapeutics-announces-appointment-of-rita-jain-m-d-to-board-of-directors",
      "time_published": "20250618T110000",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "WAYNE, Pa., June 18, 2025 ( GLOBE NEWSWIRE ) -- Avalo Therapeutics, Inc. AVTX, a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced the appointment of Rita Jain, M.D. to its Board of Directors.",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.20496,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ANAB",
          "relevance_score": "0.064276",
          "ticker_sentiment_score": "0.008026",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IMVT",
          "relevance_score": "0.064276",
          "ticker_sentiment_score": "0.008026",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CLDX",
          "relevance_score": "0.064276",
          "ticker_sentiment_score": "0.008026",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AKBA",
          "relevance_score": "0.064276",
          "ticker_sentiment_score": "0.008026",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AVTX",
          "relevance_score": "0.481177",
          "ticker_sentiment_score": "0.336968",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.064276",
          "ticker_sentiment_score": "0.008026",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.064276",
          "ticker_sentiment_score": "0.008026",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Worried About a Stock Market Crash? Park Your Money in These 2 High-Yielding ETFs for Safety.",
      "url": "https://www.fool.com/investing/2025/02/07/worried-about-a-stock-market-crash-park-your-money/",
      "time_published": "20250207T094400",
      "authors": [
        "David Jagielski"
      ],
      "summary": "Investing in the stock market may not seem like a great idea these days given how expensive many stocks are and the uncertainty around the economy. But even if individual stocks don't look terribly tempting to you, one option to consider may be some exchange-traded funds ( ETFs ) .",
      "banner_image": "https://media.ycharts.com/charts/e674d1e4c5b194aa68cbc78e18d34dba.png",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.999992"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.225292,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "PLD",
          "relevance_score": "0.063763",
          "ticker_sentiment_score": "0.10808",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.063763",
          "ticker_sentiment_score": "0.313917",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "KO",
          "relevance_score": "0.063763",
          "ticker_sentiment_score": "0.313917",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "BMY",
          "relevance_score": "0.063763",
          "ticker_sentiment_score": "0.313917",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "O",
          "relevance_score": "0.063763",
          "ticker_sentiment_score": "0.10808",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PSA",
          "relevance_score": "0.063763",
          "ticker_sentiment_score": "0.10808",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Is Bristol Myers Squibb Stock a Buy?",
      "url": "https://www.fool.com/investing/2024/11/21/is-bristol-myers-squibb-stock-a-buy/",
      "time_published": "20241121T130000",
      "authors": [
        "Prosper Junior Bakiny"
      ],
      "summary": "It's been a challenging past few years for Bristol Myers Squibb ( NYSE: BMY ) . The company's financial results dipped following the loss of patent exclusivity of two important medicines in its arsenal: cancer drugs Revlimid ( its former top-selling product ) and Abraxane.",
      "banner_image": "https://g.foolcdn.com/editorial/images/797903/doctor-with-patient-talking.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.929393"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.360215"
        }
      ],
      "overall_sentiment_score": 0.147036,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.063258",
          "ticker_sentiment_score": "-0.064333",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BMY",
          "relevance_score": "0.126119",
          "ticker_sentiment_score": "-0.022871",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "The looming 'patent cliff' facing Big Pharma",
      "url": "https://www.ft.com/content/360cb65b-a9ab-4fed-b8b3-7c34f2560938",
      "time_published": "20250709T043002",
      "authors": [
        "Hannah Kuchler",
        "Patrick Temple-West"
      ],
      "summary": "When blockbuster drugs lose IP protections it can wipe out billions of dollars in revenue for companies ...",
      "banner_image": "https://www.ft.com/__origami/service/image/v2/images/raw/https%3A%2F%2Fpublic.flourish.studio%2Fvisualisation%2F24073732%2Fthumbnail%3FcacheBuster%3D973353?source=cp-content-pipeline&fit=scale-down&quality=highest&width=2626&dpr=1",
      "source": "Financial Times",
      "category_within_source": "Companies",
      "source_domain": "www.ft.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.955357"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.360215"
        }
      ],
      "overall_sentiment_score": 0.057359,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "PFE",
          "relevance_score": "0.03155",
          "ticker_sentiment_score": "0.037088",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.06305",
          "ticker_sentiment_score": "-0.095095",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BMY",
          "relevance_score": "0.03155",
          "ticker_sentiment_score": "0.017234",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "HDV Is a Popular Dividend ETF for Passive Income. But Is It the Best?",
      "url": "https://www.fool.com/investing/2025/07/01/hdv-is-a-popular-dividend-etf-for-passive-income-b/",
      "time_published": "20250701T090000",
      "authors": [
        "Patrick Sanders"
      ],
      "summary": "Artificial intelligence ( AI ) , big tech, and cryptocurrencies all have their fans among investors, and with good reason. All can add to a well-balanced portfolio that will help make you richer over time. But you shouldn't forget about income investing -- buying stocks that reward you for ...",
      "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F822062%2Fgetty-dividend-income.jpg&op=resize&w=700",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.142857"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.142857"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.142857"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.142857"
        },
        {
          "topic": "Blockchain",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.142857"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "1.0"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.142857"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.142857"
        }
      ],
      "overall_sentiment_score": 0.370329,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CVS",
          "relevance_score": "0.062926",
          "ticker_sentiment_score": "0.090033",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AVGO",
          "relevance_score": "0.062926",
          "ticker_sentiment_score": "0.110465",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CSCO",
          "relevance_score": "0.062926",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CVX",
          "relevance_score": "0.12546",
          "ticker_sentiment_score": "0.088573",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "KO",
          "relevance_score": "0.062926",
          "ticker_sentiment_score": "0.175169",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "COP",
          "relevance_score": "0.062926",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.062926",
          "ticker_sentiment_score": "0.175169",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "CCI",
          "relevance_score": "0.062926",
          "ticker_sentiment_score": "0.090033",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.062926",
          "ticker_sentiment_score": "0.175169",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "TXN",
          "relevance_score": "0.062926",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "T",
          "relevance_score": "0.12546",
          "ticker_sentiment_score": "0.145718",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PG",
          "relevance_score": "0.062926",
          "ticker_sentiment_score": "0.110465",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "XOM",
          "relevance_score": "0.12546",
          "ticker_sentiment_score": "0.158961",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "MORN",
          "relevance_score": "0.062926",
          "ticker_sentiment_score": "0.175169",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "HAS",
          "relevance_score": "0.062926",
          "ticker_sentiment_score": "0.090033",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PM",
          "relevance_score": "0.062926",
          "ticker_sentiment_score": "0.090033",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "WMT",
          "relevance_score": "0.062926",
          "ticker_sentiment_score": "0.110465",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Dr. Oz Officially Confirmed as Head of the Centers for Medicare and Medicaid Services. Here's What Retirees Need to Know So Far.",
      "url": "https://www.fool.com/retirement/2025/04/09/dr-oz-officially-confirmed-as-head-of-the-centers/",
      "time_published": "20250409T094400",
      "authors": [
        "Keith Speights"
      ],
      "summary": "From TV star to powerful government official. That's the path taken by President Donald Trump and his new administrator of the Centers for Medicare and Medicaid Services ( CMS ) -- Dr. Mehmet Oz.Oz was a heart surgeon and medical school professor for years.",
      "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F814046%2Fdoctor-talking-to-senior-man-patient-medical-medicine-healthcare.jpg&op=resize&w=700",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.177198,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.062926",
          "ticker_sentiment_score": "0.047333",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "UNH",
          "relevance_score": "0.062926",
          "ticker_sentiment_score": "0.047333",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.062926",
          "ticker_sentiment_score": "0.047333",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Investors Are Flocking to These 3 Vanguard Sector ETFs. Should You Buy Them Too?",
      "url": "https://www.fool.com/investing/2025/03/28/investors-flocking-to-these-3-vanguard-etfs-should/",
      "time_published": "20250328T094200",
      "authors": [
        "Keith Speights"
      ],
      "summary": "Following the crowd has been disparaged quite a bit in the past. But sometimes the crowd knows what it's doing. Going in the same direction in those cases is wise.I bring this up because investors are flocking to a handful of sectors right now, as evidenced by the performances of three Vanguard ...",
      "banner_image": "https://g.foolcdn.com/editorial/images/812491/oil-rig-with-workers-talking.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "1.0"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.28072,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CEG",
          "relevance_score": "0.062761",
          "ticker_sentiment_score": "0.131075",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CVX",
          "relevance_score": "0.062761",
          "ticker_sentiment_score": "0.273504",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "COP",
          "relevance_score": "0.062761",
          "ticker_sentiment_score": "0.273504",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.062761",
          "ticker_sentiment_score": "0.087027",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.062761",
          "ticker_sentiment_score": "0.087027",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AEP",
          "relevance_score": "0.062761",
          "ticker_sentiment_score": "0.131075",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "UNH",
          "relevance_score": "0.062761",
          "ticker_sentiment_score": "0.087027",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NEE",
          "relevance_score": "0.062761",
          "ticker_sentiment_score": "0.131075",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "XOM",
          "relevance_score": "0.062761",
          "ticker_sentiment_score": "0.273504",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "LLY",
          "relevance_score": "0.062761",
          "ticker_sentiment_score": "0.087027",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DUK",
          "relevance_score": "0.062761",
          "ticker_sentiment_score": "0.131075",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "EOG",
          "relevance_score": "0.062761",
          "ticker_sentiment_score": "0.273504",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "SO",
          "relevance_score": "0.062761",
          "ticker_sentiment_score": "0.131075",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Can Mounjaro, Zepbound Help Lilly Maintain Dominance in Obesity Space?",
      "url": "https://www.zacks.com/stock/news/2494230/can-mounjaro-zepbound-help-lilly-maintain-dominance-in-obesity-space",
      "time_published": "20250611T133800",
      "authors": [
        "Kinjel Shah"
      ],
      "summary": "LLY banks on soaring Mounjaro and Zepbound sales to defend its obesity edge amid intensifying competition.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.451494"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.143631,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.362505",
          "ticker_sentiment_score": "0.187192",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "VKTX",
          "relevance_score": "0.246582",
          "ticker_sentiment_score": "0.040567",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.062597",
          "ticker_sentiment_score": "-0.024067",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GS",
          "relevance_score": "0.062597",
          "ticker_sentiment_score": "0.023046",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AMGN",
          "relevance_score": "0.246582",
          "ticker_sentiment_score": "0.040567",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.246582",
          "ticker_sentiment_score": "-0.048904",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Investing $60,000 in These 3 Funds Could Generate Annual Income of Over $6,500",
      "url": "https://www.fool.com/investing/2025/04/13/investing-60000-in-these-3-funds-could-generate-an/",
      "time_published": "20250413T084900",
      "authors": [
        "Keith Speights"
      ],
      "summary": "Income investors could pay attention to the price fluctuations of the assets they own. But they don't have to. What really matters for them is that the dividends and distributions keep flowing steadily -- and the higher the yield, the better.Where can you find great candidates to achieve these ...",
      "banner_image": "https://g.foolcdn.com/editorial/images/814488/hands-behind-head.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.25"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.25"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.25"
        },
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.25"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.989041"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.576289"
        }
      ],
      "overall_sentiment_score": 0.17892,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MSFT",
          "relevance_score": "0.062434",
          "ticker_sentiment_score": "0.137504",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "META",
          "relevance_score": "0.062434",
          "ticker_sentiment_score": "0.137504",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.062434",
          "ticker_sentiment_score": "0.031112",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SLFPF",
          "relevance_score": "0.124486",
          "ticker_sentiment_score": "0.235125",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "MORN",
          "relevance_score": "0.124486",
          "ticker_sentiment_score": "0.043346",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.062434",
          "ticker_sentiment_score": "0.031112",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CAH",
          "relevance_score": "0.062434",
          "ticker_sentiment_score": "0.137504",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "UNH",
          "relevance_score": "0.062434",
          "ticker_sentiment_score": "0.031112",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "The Last Time the Stock Market Started a Year This Badly Was 2022. Is Another Crash Coming?",
      "url": "https://www.fool.com/investing/2025/04/10/the-last-time-the-stock-market-started-a-year-this/",
      "time_published": "20250410T100000",
      "authors": [
        "David Jagielski"
      ],
      "summary": "As of Monday's close, the S&P 500 has fallen by about 15% this year ( although the index regained about half of that after President Donald Trump put most of his tariff plan on pause ) . The index is coming off two straight years of gains in excess of 20%, so a bit of a slowdown was arguably ...",
      "banner_image": "https://media.ycharts.com/charts/03eca53976d293147c97d62370c516bd.png",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.976913"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.066369,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.061631",
          "ticker_sentiment_score": "0.191473",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "PG",
          "relevance_score": "0.061631",
          "ticker_sentiment_score": "0.191473",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "XOM",
          "relevance_score": "0.061631",
          "ticker_sentiment_score": "0.191473",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "10 things to watch in the stock market Monday including bitcoin and Tesla",
      "url": "https://www.cnbc.com/2025/03/03/10-things-to-watch-in-the-stock-market-monday-including-bitcoin-and-tesla-.html",
      "time_published": "20250303T140432",
      "authors": [],
      "summary": "Wall Street is set for a higher open Monday, building off Friday's rally.",
      "banner_image": null,
      "source": "CNBC",
      "category_within_source": "Top News",
      "source_domain": "www.cnbc.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.2"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.2"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.2"
        },
        {
          "topic": "Blockchain",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.2"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.839681"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.2"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.310843"
        }
      ],
      "overall_sentiment_score": 0.194912,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "BUD",
          "relevance_score": "0.061631",
          "ticker_sentiment_score": "0.175344",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "EVR",
          "relevance_score": "0.122894",
          "ticker_sentiment_score": "0.153398",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "NVDA",
          "relevance_score": "0.061631",
          "ticker_sentiment_score": "-0.074239",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AVGO",
          "relevance_score": "0.061631",
          "ticker_sentiment_score": "-0.074239",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TSLA",
          "relevance_score": "0.122894",
          "ticker_sentiment_score": "0.100724",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MS",
          "relevance_score": "0.061631",
          "ticker_sentiment_score": "0.045074",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.061631",
          "ticker_sentiment_score": "0.059002",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BBY",
          "relevance_score": "0.061631",
          "ticker_sentiment_score": "0.12967",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.061631",
          "ticker_sentiment_score": "0.059002",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LUV",
          "relevance_score": "0.061631",
          "ticker_sentiment_score": "-0.04017",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CRYPTO:BTC",
          "relevance_score": "0.122894",
          "ticker_sentiment_score": "0.114414",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CRYPTO:ETH",
          "relevance_score": "0.061631",
          "ticker_sentiment_score": "0.100015",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "NVO Stock Slips 4% as Roche Inks Obesity Drug Deal With Zealand",
      "url": "https://www.zacks.com/stock/news/2429869/nvo-stock-slips-4-as-roche-inks-obesity-drug-deal-with-zealand",
      "time_published": "20250313T172300",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "With Roche's latest deal, a new contender enters the obesity space, which could threaten NVO and LLY's dominance in the market.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/82/41137.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        }
      ],
      "overall_sentiment_score": 0.033592,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.122581",
          "ticker_sentiment_score": "0.155209",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "VKTX",
          "relevance_score": "0.242285",
          "ticker_sentiment_score": "0.248675",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.061473",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.242285",
          "ticker_sentiment_score": "0.074238",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "These Vanguard ETFs Show Where the Smart Money Is Moving Now",
      "url": "https://www.fool.com/investing/2025/03/03/these-vanguard-etfs-show-where-the-smart-money-is/",
      "time_published": "20250303T094900",
      "authors": [
        "Keith Speights"
      ],
      "summary": "Don't discount the power of momentum. Some studies have found that momentum trading -- buying stocks or exchange-traded funds ( ETFs ) that are going up -- often works over the short to medium term. So what is going up these days?",
      "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F809425%2Fetf-board-and-person.jpg&op=resize&w=700",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.25"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.25"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "1.0"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.25"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.25"
        }
      ],
      "overall_sentiment_score": 0.324643,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "COST",
          "relevance_score": "0.061003",
          "ticker_sentiment_score": "0.179066",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "KO",
          "relevance_score": "0.061003",
          "ticker_sentiment_score": "0.179066",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.061003",
          "ticker_sentiment_score": "0.169392",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "PG",
          "relevance_score": "0.061003",
          "ticker_sentiment_score": "0.179066",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "LLY",
          "relevance_score": "0.061003",
          "ticker_sentiment_score": "0.169392",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.061003",
          "ticker_sentiment_score": "0.169392",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "PM",
          "relevance_score": "0.061003",
          "ticker_sentiment_score": "0.179066",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "UNH",
          "relevance_score": "0.061003",
          "ticker_sentiment_score": "0.169392",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "WMT",
          "relevance_score": "0.061003",
          "ticker_sentiment_score": "0.179066",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Ozempic is in the next round of Medicare drug price negotiations. See the full list of 15 medications",
      "url": "https://www.cnbc.com/2025/01/17/medicare-drug-price-negotiations-list-includes-ozempic.html",
      "time_published": "20250117T132316",
      "authors": [],
      "summary": "The talks around drugs including Novo Nordisk's Wegovy, GSK's Trelegy Ellipta, and Pfizer's Xtandi will set Medicare prices that go into effect in 2027.",
      "banner_image": null,
      "source": "CNBC",
      "category_within_source": "Business",
      "source_domain": "www.cnbc.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.360215"
        },
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.052829,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.059711",
          "ticker_sentiment_score": "-0.231198",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "IRWD",
          "relevance_score": "0.029876",
          "ticker_sentiment_score": "-0.200013",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "AZN",
          "relevance_score": "0.029876",
          "ticker_sentiment_score": "0.020987",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.029876",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.059711",
          "ticker_sentiment_score": "0.102506",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BMY",
          "relevance_score": "0.029876",
          "ticker_sentiment_score": "-0.189176",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "This Vanguard ETF Has 23% of Its Portfolio Invested in Tech Stocks, but It Can Still Help You Generate Decades of Passive Income",
      "url": "https://www.fool.com/investing/2025/01/17/buy-vanguard-dividend-passive-income-growth-stock/",
      "time_published": "20250117T134500",
      "authors": [
        "Daniel Foelber"
      ],
      "summary": "The technology sector has crushed the S&P 500 over the past three, five, and 10 years as leading tech stocks like Apple, Nvidia, Microsoft, and Broadcom have grown in value.Investors gravitate mainly toward these stocks because of their growth potential, not their dividend yields.",
      "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F803899%2Fgettyimages-2153758481-1200x800-5b2df79-3.jpg&op=resize&w=700",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "1.0"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.682689"
        }
      ],
      "overall_sentiment_score": 0.302314,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "NVDA",
          "relevance_score": "0.059341",
          "ticker_sentiment_score": "0.047171",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AVGO",
          "relevance_score": "0.176717",
          "ticker_sentiment_score": "0.165023",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "BAC",
          "relevance_score": "0.059341",
          "ticker_sentiment_score": "0.20603",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "KO",
          "relevance_score": "0.059341",
          "ticker_sentiment_score": "0.08301",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HON",
          "relevance_score": "0.059341",
          "ticker_sentiment_score": "0.05001",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.059341",
          "ticker_sentiment_score": "0.08301",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.059341",
          "ticker_sentiment_score": "0.08301",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "UNH",
          "relevance_score": "0.118354",
          "ticker_sentiment_score": "0.138449",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MSFT",
          "relevance_score": "0.176717",
          "ticker_sentiment_score": "0.165023",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "COST",
          "relevance_score": "0.059341",
          "ticker_sentiment_score": "0.08301",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LMT",
          "relevance_score": "0.059341",
          "ticker_sentiment_score": "0.05001",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MA",
          "relevance_score": "0.059341",
          "ticker_sentiment_score": "0.20603",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "UNP",
          "relevance_score": "0.059341",
          "ticker_sentiment_score": "0.05001",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PG",
          "relevance_score": "0.059341",
          "ticker_sentiment_score": "0.08301",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "WMT",
          "relevance_score": "0.059341",
          "ticker_sentiment_score": "0.08301",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Pharma Stock Roundup: PFE Ends Hemophilia Deal With SGMO & More",
      "url": "https://www.zacks.com/stock/news/2391501/pharma-stock-roundup-pfe-ends-hemophilia-deal-with-sgmo-more",
      "time_published": "20250103T134600",
      "authors": [
        "Kinjel Shah"
      ],
      "summary": "PFE ends deal with SGMO for hemophilia A gene therapy candidate. NVS' gene therapy for SMA meets goal in study.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/cc/389.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        }
      ],
      "overall_sentiment_score": 0.076009,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.118064",
          "ticker_sentiment_score": "-0.163501",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "SGMO",
          "relevance_score": "0.176287",
          "ticker_sentiment_score": "0.013287",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.059194",
          "ticker_sentiment_score": "-0.125",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.176287",
          "ticker_sentiment_score": "-0.194574",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.447528",
          "ticker_sentiment_score": "0.091832",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Is the SPDR S&P 500 ETF Trust the Smartest Investment You Can Make Today?",
      "url": "https://www.fool.com/investing/2025/03/09/is-the-spdr-sp-500-etf-trust-the-smartest-investme/",
      "time_published": "20250309T161000",
      "authors": [
        "Adria Cimino"
      ],
      "summary": "With the three major indexes slipping over the past few weeks, now may not seem like the best time to invest in stocks. It's always more tempting to buy when we see a particular stock or asset rising, as we can easily imagine our returns if the momentum keeps going.",
      "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F810315%2Fgettyimages-1279395367.jpg&op=resize&w=700",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "1.0"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.5"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.179342,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "KO",
          "relevance_score": "0.058759",
          "ticker_sentiment_score": "0.03308",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HPNN",
          "relevance_score": "0.058759",
          "ticker_sentiment_score": "0.148",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.058759",
          "ticker_sentiment_score": "0.03308",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Want to Avoid the \"Magnificent Seven\" and Generate Passive Income? This Vanguard ETF May Be for You",
      "url": "https://www.fool.com/investing/2025/04/28/magnificent-seven-passive-income-vanguard-etf/",
      "time_published": "20250428T124500",
      "authors": [
        "Daniel Foelber"
      ],
      "summary": "The \"Magnificent Seven\" -- Apple, Microsoft, Nvidia ( NASDAQ: NVDA ) , Amazon, Alphabet, Meta Platforms, and Tesla -- took the market by storm in 2023 and 2024 by contributing a sizable portion of gains in major indexes like the S&P 500 and Nasdaq Composite.But that momentum has ground to a halt ...",
      "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F815944%2Fremote-work-from-home-laptop-businesswoman-1200x800-5b2df79.jpg&op=resize&w=700",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "1.0"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.310843"
        }
      ],
      "overall_sentiment_score": 0.346425,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "META",
          "relevance_score": "0.115232",
          "ticker_sentiment_score": "0.360931",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "NVDA",
          "relevance_score": "0.115232",
          "ticker_sentiment_score": "0.235117",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "AVGO",
          "relevance_score": "0.057767",
          "ticker_sentiment_score": "0.067",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CSCO",
          "relevance_score": "0.057767",
          "ticker_sentiment_score": "0.067",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BAC",
          "relevance_score": "0.057767",
          "ticker_sentiment_score": "0.067",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "KO",
          "relevance_score": "0.057767",
          "ticker_sentiment_score": "0.067",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.057767",
          "ticker_sentiment_score": "0.067",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.057767",
          "ticker_sentiment_score": "0.067",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IVZ",
          "relevance_score": "0.057767",
          "ticker_sentiment_score": "0.198",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "UNH",
          "relevance_score": "0.057767",
          "ticker_sentiment_score": "0.067",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MSFT",
          "relevance_score": "0.115232",
          "ticker_sentiment_score": "0.11422",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TSLA",
          "relevance_score": "0.115232",
          "ticker_sentiment_score": "0.11422",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IBM",
          "relevance_score": "0.057767",
          "ticker_sentiment_score": "0.067",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PG",
          "relevance_score": "0.057767",
          "ticker_sentiment_score": "0.067",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "XOM",
          "relevance_score": "0.057767",
          "ticker_sentiment_score": "0.067",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "WMT",
          "relevance_score": "0.057767",
          "ticker_sentiment_score": "0.067",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Amgen Looks to Take Share of Booming Obesity Space: Will It Succeed?",
      "url": "https://www.zacks.com/stock/news/2556095/amgen-looks-to-take-share-of-booming-obesity-space-will-it-succeed",
      "time_published": "20250627T141000",
      "authors": [
        "Kinjel Shah"
      ],
      "summary": "Amgen aims to challenge obesity drug leaders with MariTide, a potential monthly treatment now in late-stage trials.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/13/816.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.796627"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.682689"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.038051,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.171282",
          "ticker_sentiment_score": "0.156478",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "VKTX",
          "relevance_score": "0.227007",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.05749",
          "ticker_sentiment_score": "0.079021",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GS",
          "relevance_score": "0.05749",
          "ticker_sentiment_score": "0.098263",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AMGN",
          "relevance_score": "0.572379",
          "ticker_sentiment_score": "0.218382",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.227007",
          "ticker_sentiment_score": "0.192818",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "2 High-Yielding ETFs That Can Generate Dividend Income for Your Portfolio for Decades",
      "url": "https://www.fool.com/investing/2025/06/13/2-high-yielding-etfs-that-can-generate-dividend-in/",
      "time_published": "20250613T092900",
      "authors": [
        "David Jagielski"
      ],
      "summary": "Investing in dividend stocks is a great way to generate a steady stream of recurring income for your portfolio. But ideally, you don't invest in just one or two dividend stocks, because then you run the risk of a dividend cut or suspension suddenly affecting the income that you've been relying on.",
      "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F820830%2Fa-person-withdrawing-money-from-an-atm.jpg&op=resize&w=700",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.25"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.25"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "1.0"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.25"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.25"
        }
      ],
      "overall_sentiment_score": 0.280203,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CVS",
          "relevance_score": "0.057352",
          "ticker_sentiment_score": "0.079069",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.057352",
          "ticker_sentiment_score": "0.079069",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HD",
          "relevance_score": "0.057352",
          "ticker_sentiment_score": "0.180995",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "KO",
          "relevance_score": "0.057352",
          "ticker_sentiment_score": "0.180995",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "VZ",
          "relevance_score": "0.057352",
          "ticker_sentiment_score": "0.180995",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "AbCellera Biologics  ( ABCL )  Q4 2024 Earnings Call Transcript",
      "url": "https://www.fool.com/earnings/call-transcripts/2025/02/27/abcellera-biologics-abcl-q4-2024-earnings-call-tra/",
      "time_published": "20250228T031512",
      "authors": [
        "Motley Fool Transcribing"
      ],
      "summary": "ABCL earnings call for the period ending December 31, 2024.",
      "banner_image": "https://g.foolcdn.com/misc-assets/fool-transcripts-logo.png",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "1.0"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.993856"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.265685,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.056502",
          "ticker_sentiment_score": "0.150969",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "GS",
          "relevance_score": "0.008078",
          "ticker_sentiment_score": "0.133336",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BIIB",
          "relevance_score": "0.008078",
          "ticker_sentiment_score": "0.032764",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SNY",
          "relevance_score": "0.008078",
          "ticker_sentiment_score": "0.044517",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Apellis Announces Keli Walbert to Join the Board of Directors - Apellis Pharmaceuticals  ( NASDAQ:APLS ) ",
      "url": "https://www.benzinga.com/pressreleases/25/01/g42908822/apellis-announces-keli-walbert-to-join-the-board-of-directors",
      "time_published": "20250110T120000",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "WALTHAM, Mass., Jan. 10, 2025 ( GLOBE NEWSWIRE ) -- Apellis Pharmaceuticals, Inc. APLS today announced that Keli Walbert will join the Apellis Board of Directors, effective immediately. Ms. Walbert brings more than two decades of biopharmaceutical commercial leadership experience to the Board.",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.614606"
        }
      ],
      "overall_sentiment_score": 0.336945,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "APLS",
          "relevance_score": "0.167322",
          "ticker_sentiment_score": "0.180956",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.056143",
          "ticker_sentiment_score": "0.085",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Pharma Stock Roundup: LLY Ups U.S. Manufacturing Investments & More",
      "url": "https://www.zacks.com/stock/news/2423651/pharma-stock-roundup-lly-ups-us-manufacturing-investments-more",
      "time_published": "20250228T144600",
      "authors": [
        "Kinjel Shah"
      ],
      "summary": "LLY is increasing its manufacturing capacity in the United States by building four new plants. AZN's phase III study on camizestrant meets primary endpoint.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/52/873.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        }
      ],
      "overall_sentiment_score": 0.169638,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.325924",
          "ticker_sentiment_score": "0.223239",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.055881",
          "ticker_sentiment_score": "-0.230985",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "AZN",
          "relevance_score": "0.166551",
          "ticker_sentiment_score": "0.072223",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.111488",
          "ticker_sentiment_score": "-0.077792",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.055881",
          "ticker_sentiment_score": "0.10989",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Achievements and Progress Heading into 2025 for Oncology Treatments and Therapies Fuel an Optimistic Outlook - AstraZeneca  ( NASDAQ:AZN ) , AbbVie  ( NYSE:ABBV ) ",
      "url": "https://www.benzinga.com/pressreleases/24/12/g42684574/achievements-and-progress-heading-into-2025-for-oncology-treatments-and-therapies-fuel-an-optimist",
      "time_published": "20241226T140000",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "PALM BEACH, Fla., Dec. 26, 2024 ( GLOBE NEWSWIRE ) -- FN Media Group News Commentary - The breast cancer drugs market is experiencing rapid expansion due to the diverse applications of drugs in various breast cancer treatment scenarios.",
      "banner_image": "https://ml.globenewswire.com/media/f326183f-8829-42af-8851-525b1d7503ed/small/finacialnews-logo-final-01-2-png.png",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.993856"
        }
      ],
      "overall_sentiment_score": 0.131515,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.055881",
          "ticker_sentiment_score": "-0.022032",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AZN",
          "relevance_score": "0.069819",
          "ticker_sentiment_score": "-0.010213",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CRDF",
          "relevance_score": "0.097626",
          "ticker_sentiment_score": "0.017536",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GSK",
          "relevance_score": "0.055881",
          "ticker_sentiment_score": "-0.002003",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Septerna Stock Surges on Oral Obesity Drug Deal With Novo Nordisk",
      "url": "https://www.zacks.com/stock/news/2471589/septerna-stock-surges-on-oral-obesity-drug-deal-with-novo-nordisk",
      "time_published": "20250515T124600",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "SEPN is entitled to receive around $2.2 billion from NVO under the new collaboration deal, which aims to develop oral pills for obesity and other diseases.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/12/31139.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.25"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.25"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.25"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.25"
        }
      ],
      "overall_sentiment_score": 0.177534,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CVS",
          "relevance_score": "0.054607",
          "ticker_sentiment_score": "0.107111",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "VKTX",
          "relevance_score": "0.108958",
          "ticker_sentiment_score": "0.104756",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.548805",
          "ticker_sentiment_score": "0.220146",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "SEPN",
          "relevance_score": "0.506613",
          "ticker_sentiment_score": "0.290227",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "LLY",
          "relevance_score": "0.215894",
          "ticker_sentiment_score": "0.08654",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.054607",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GS",
          "relevance_score": "0.054607",
          "ticker_sentiment_score": "0.020995",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AMGN",
          "relevance_score": "0.215894",
          "ticker_sentiment_score": "0.211093",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Nicox's Denali Phase 3 Trial of NCX 470 Fully Enrolled in China Earlier than Expected",
      "url": "https://www.globenewswire.com/news-release/2024/12/02/2989439/0/en/Nicox-s-Denali-Phase-3-Trial-of-NCX-470-Fully-Enrolled-in-China-Earlier-than-Expected.html",
      "time_published": "20241202T063000",
      "authors": [
        "NICOX SA"
      ],
      "summary": "Attachment ...",
      "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/c4c68e53-e467-4048-b580-d1596c4d6d8e",
      "source": "GlobeNewswire",
      "category_within_source": "n/a",
      "source_domain": "www.globenewswire.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.161652,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.054483",
          "ticker_sentiment_score": "-0.039026",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NICXF",
          "relevance_score": "0.215415",
          "ticker_sentiment_score": "0.164846",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Polycystic Ovarian Syndrome Treatment Market Set for USD 4.3 Billion by 2034 as Demand for Personalized Medicine Rises | Exclusive Report by TMR",
      "url": "https://www.benzinga.com/pressreleases/25/03/g44194242/polycystic-ovarian-syndrome-treatment-market-set-for-usd-4-3-billion-by-2034-as-demand-for-persona",
      "time_published": "20250307T154925",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "Wilmington, Delaware, Transparency Market Research Inc. -, March 07, 2025 ( GLOBE NEWSWIRE ) -- Rising awareness about women's reproductive health and increasing prevalence of hormonal disorders are driving the growth of the Polycystic Ovarian Syndrome Treatment Market.",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/3510cf19-c124-4e24-8a2f-864116e23fe5/dielectric-fluid-market.jpg",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.796627"
        }
      ],
      "overall_sentiment_score": 0.263612,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "GOOG",
          "relevance_score": "0.027226",
          "ticker_sentiment_score": "0.050894",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.027226",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AZN",
          "relevance_score": "0.027226",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BAYZF",
          "relevance_score": "0.054421",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVS",
          "relevance_score": "0.054421",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.054421",
          "ticker_sentiment_score": "0.108784",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TEVA",
          "relevance_score": "0.054421",
          "ticker_sentiment_score": "-0.034866",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AMRX",
          "relevance_score": "0.027226",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "WMGTF",
          "relevance_score": "0.081552",
          "ticker_sentiment_score": "0.057328",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.054421",
          "ticker_sentiment_score": "0.030877",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BMY",
          "relevance_score": "0.027226",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SNY",
          "relevance_score": "0.027226",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Tremfya's Promising Debut Boosts Momentum for IL-23 Class in Ulcerative Colitis Treatment, According to Spherix Global Insights",
      "url": "https://www.benzinga.com/pressreleases/24/11/g42009841/tremfyas-promising-debut-boosts-momentum-for-il-23-class-in-ulcerative-colitis-treatment-according",
      "time_published": "20241115T143834",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "EXTON, PA, Nov. 15, 2024 ( GLOBE NEWSWIRE ) -- In what has been a transformative year for ulcerative colitis ( UC ) treatment, the IL-23 class has solidified its role as a key therapeutic treatment option.",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.285679,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.054236",
          "ticker_sentiment_score": "0.073905",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.054236",
          "ticker_sentiment_score": "0.073905",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Pharmaceutical Market Size is projected to reach US$ 2.84 billion by 2031 at 7.1% CAGR - The Insight Partners",
      "url": "https://www.benzinga.com/pressreleases/25/04/g44981580/pharmaceutical-market-size-is-projected-to-reach-us-2-84-billion-by-2031-at-7-1-cagr-the-insight-p",
      "time_published": "20250424T140858",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "US & Canada, April 24, 2025 ( GLOBE NEWSWIRE ) -- According to a new comprehensive report from The Insight Partners, the pharmaceutical market is observing significant growth owing to the increasing disease burden worldwide and surging demand for innovative treatments.",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/0a19810d-16f4-40cf-8650-32a76b87e988/image1.png",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.858979"
        }
      ],
      "overall_sentiment_score": 0.272958,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "AZN",
          "relevance_score": "0.027042",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.081001",
          "ticker_sentiment_score": "0.079382",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "VTRS",
          "relevance_score": "0.027042",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HKMPF",
          "relevance_score": "0.054052",
          "ticker_sentiment_score": "0.054799",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVS",
          "relevance_score": "0.027042",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.054052",
          "ticker_sentiment_score": "0.056795",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TEVA",
          "relevance_score": "0.027042",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "UCBJF",
          "relevance_score": "0.027042",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GSK",
          "relevance_score": "0.027042",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.027042",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BMY",
          "relevance_score": "0.027042",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SNY",
          "relevance_score": "0.027042",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "EPKINLY\u00ae  ( epcoritamab )  Approved by Japan Ministry of Health, Labour and Welfare for Additional Indication as a Treatment for Relapsed or Refractory Follicular Lymphoma",
      "url": "https://www.globenewswire.com/news-release/2025/02/20/3029562/0/en/EPKINLY-epcoritamab-Approved-by-Japan-Ministry-of-Health-Labour-and-Welfare-for-Additional-Indication-as-a-Treatment-for-Relapsed-or-Refractory-Follicular-Lymphoma.html",
      "time_published": "20250220T130000",
      "authors": [
        "Genmab A/S"
      ],
      "summary": "Media ReleaseCOPENHAGEN, Denmark. February ...",
      "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/368a5dab-dfc5-4e1d-bfa6-2af5e5216fce",
      "source": "GlobeNewswire",
      "category_within_source": "n/a",
      "source_domain": "www.globenewswire.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.064469,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "NINTF",
          "relevance_score": "0.018009",
          "ticker_sentiment_score": "0.002615",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.053992",
          "ticker_sentiment_score": "0.072766",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "CytomX Gears Up to Report Q1 Earnings: Here's What to Expect",
      "url": "https://www.zacks.com/stock/news/2455999/cytomx-gears-up-to-report-q1-earnings-heres-what-to-expect",
      "time_published": "20250425T141400",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "On the Q1 2025 earnings call, investors can expect updates regarding the progress in the development of CTMX's lead candidate, CX-2051, for colorectal cancer.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/10/83654.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999992"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.122591,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.052801",
          "ticker_sentiment_score": "0.070674",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CTMX",
          "relevance_score": "0.308891",
          "ticker_sentiment_score": "0.073122",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVAX",
          "relevance_score": "0.157483",
          "ticker_sentiment_score": "-0.090448",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ARGX",
          "relevance_score": "0.208914",
          "ticker_sentiment_score": "-0.058718",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MRNA",
          "relevance_score": "0.052801",
          "ticker_sentiment_score": "0.070674",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AMGN",
          "relevance_score": "0.208914",
          "ticker_sentiment_score": "0.061578",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "5 Vanguard ETFs to Buy With $1,000 and Hold Forever",
      "url": "https://www.fool.com/investing/2025/06/27/5-vanguard-etfs-to-buy-with-1000-and-hold-forever/",
      "time_published": "20250627T120000",
      "authors": [
        "Geoffrey Seiler"
      ],
      "summary": "Investing in exchange-traded funds ( ETFs ) is a great way for both new and experienced investors to gain market exposure, and Vanguard is one of the best places to begin, given that the investment firm is known as the low-cost leader.",
      "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F822753%2Fgettyimages-1964849486.jpg&op=resize&w=700",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.166667"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "1.0"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.166667"
        }
      ],
      "overall_sentiment_score": 0.338722,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MSFT",
          "relevance_score": "0.052685",
          "ticker_sentiment_score": "0.072002",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVDA",
          "relevance_score": "0.052685",
          "ticker_sentiment_score": "0.072002",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BAC",
          "relevance_score": "0.052685",
          "ticker_sentiment_score": "0.167641",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "BRK-A",
          "relevance_score": "0.052685",
          "ticker_sentiment_score": "0.167641",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.052685",
          "ticker_sentiment_score": "0.167641",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "XOM",
          "relevance_score": "0.052685",
          "ticker_sentiment_score": "0.167641",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.052685",
          "ticker_sentiment_score": "0.167641",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "HD",
          "relevance_score": "0.052685",
          "ticker_sentiment_score": "0.167641",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "UNH",
          "relevance_score": "0.052685",
          "ticker_sentiment_score": "0.167641",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "WMT",
          "relevance_score": "0.052685",
          "ticker_sentiment_score": "0.167641",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors",
      "url": "https://www.globenewswire.com/news-release/2025/05/01/3072208/0/en/Foghorn-Therapeutics-Appoints-Neil-Gallagher-and-Stuart-Duty-to-its-Board-of-Directors.html",
      "time_published": "20250501T110000",
      "authors": [
        "Foghorn Therapeutics",
        "Inc."
      ],
      "summary": "CAMBRIDGE, Mass., May 01, 2025 ( GLOBE NEWSWIRE ) -- Foghorn\u00ae Therapeutics Inc. ( Nasdaq: FHTX ) , a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced the election of Neil Gallagher, M.D., ...",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/742c7e36-c026-4cb2-b89a-933512e66fea",
      "source": "GlobeNewswire",
      "category_within_source": "n/a",
      "source_domain": "www.globenewswire.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.614606"
        }
      ],
      "overall_sentiment_score": 0.122351,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "EYPT",
          "relevance_score": "0.051551",
          "ticker_sentiment_score": "0.04268",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MIST",
          "relevance_score": "0.051551",
          "ticker_sentiment_score": "0.04268",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SNDX",
          "relevance_score": "0.051551",
          "ticker_sentiment_score": "-0.03881",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.051551",
          "ticker_sentiment_score": "-0.03881",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AZN",
          "relevance_score": "0.051551",
          "ticker_sentiment_score": "-0.03881",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ACHV",
          "relevance_score": "0.051551",
          "ticker_sentiment_score": "0.04268",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Genmab Publishes 2024 Annual Report",
      "url": "https://www.globenewswire.com/news-release/2025/02/12/3025224/0/en/Genmab-Publishes-2024-Annual-Report.html",
      "time_published": "20250212T160100",
      "authors": [
        "Genmab A/S"
      ],
      "summary": "Company Announcement ...",
      "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/368a5dab-dfc5-4e1d-bfa6-2af5e5216fce",
      "source": "GlobeNewswire",
      "category_within_source": "n/a",
      "source_domain": "www.globenewswire.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999982"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.360215"
        }
      ],
      "overall_sentiment_score": 0.131851,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "NVS",
          "relevance_score": "0.025596",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.051166",
          "ticker_sentiment_score": "0.071694",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HALO",
          "relevance_score": "0.025596",
          "ticker_sentiment_score": "0.022738",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GMAB",
          "relevance_score": "0.499559",
          "ticker_sentiment_score": "0.166355",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "BNTX",
          "relevance_score": "0.051166",
          "ticker_sentiment_score": "0.0867",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.025596",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Are These 5 Biotech Stocks Set to Beat Q4 Earnings Estimates?",
      "url": "https://www.zacks.com/stock/news/2408061/are-these-5-biotech-stocks-set-to-beat-q4-earnings-estimates",
      "time_published": "20250203T124300",
      "authors": [
        "Sundeep Ganoria"
      ],
      "summary": "Let us look at some biotech stocks, AMGN, CRSP, MRNA, SRPT and VRTX, which are poised to beat on fourth-quarter earnings.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/80448.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.165696,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CRSP",
          "relevance_score": "0.201944",
          "ticker_sentiment_score": "-0.001575",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SRPT",
          "relevance_score": "0.250902",
          "ticker_sentiment_score": "0.049896",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "VRTX",
          "relevance_score": "0.29887",
          "ticker_sentiment_score": "-0.002157",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.051003",
          "ticker_sentiment_score": "0.101917",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MRNA",
          "relevance_score": "0.345674",
          "ticker_sentiment_score": "0.077262",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AMGN",
          "relevance_score": "0.345674",
          "ticker_sentiment_score": "0.038715",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SNY",
          "relevance_score": "0.051003",
          "ticker_sentiment_score": "0.101917",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Pharma Stock Roundup: FDA Updates for JNJ, GSK, PFE, NVO's Expanded Deal",
      "url": "https://www.zacks.com/stock/news/2394882/pharma-stock-roundup-fda-updates-for-jnj-gsk-pfe-nvos-expanded-deal",
      "time_published": "20250110T131000",
      "authors": [
        "Kinjel Shah"
      ],
      "summary": "FDA grants priority review tag to JNJ's nipocalimab BLA for gMG and asks for new warnings on GSK & PFE's RSV vaccine labels.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/52/873.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        }
      ],
      "overall_sentiment_score": 0.173219,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "NVO",
          "relevance_score": "0.294682",
          "ticker_sentiment_score": "0.139166",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.294682",
          "ticker_sentiment_score": "0.039498",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.050254",
          "ticker_sentiment_score": "-0.129257",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Want Decades of Passive Income? 5 Stocks to Buy Now and Hold Forever",
      "url": "https://www.fool.com/investing/2025/06/26/want-decades-of-passive-income-5-stocks-to-buy-now/",
      "time_published": "20250626T124500",
      "authors": [
        "Justin Pope"
      ],
      "summary": "Forever is a tricky word in the stock market, but these stocks are as safe as they come and will pay you to hold them.",
      "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F822512%2Fgetty-dividend-stocks-growing-money-income-cash.jpg&op=resize&w=700",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.998356"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.9545"
        }
      ],
      "overall_sentiment_score": 0.293386,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "WST",
          "relevance_score": "0.099476",
          "ticker_sentiment_score": "0.063682",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.049835",
          "ticker_sentiment_score": "0.033629",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.099476",
          "ticker_sentiment_score": "0.03595",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CAH",
          "relevance_score": "0.148731",
          "ticker_sentiment_score": "0.159284",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "MDT",
          "relevance_score": "0.148731",
          "ticker_sentiment_score": "0.237888",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.197413",
          "ticker_sentiment_score": "0.142542",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Illumina's AGD Project Completes 250,000 Whole Genomes: Stock to Gain?",
      "url": "https://www.zacks.com/stock/news/2434273/illuminas-agd-project-completes-250000-whole-genomes-stock-to-gain",
      "time_published": "20250324T154700",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "ILMN-NashBio's AGD initiative achieves the milestone of completing 250,000 whole genomes.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.99489"
        }
      ],
      "overall_sentiment_score": 0.219754,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "AZN",
          "relevance_score": "0.049424",
          "ticker_sentiment_score": "0.155093",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "BSX",
          "relevance_score": "0.147516",
          "ticker_sentiment_score": "0.121877",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HIMS",
          "relevance_score": "0.147516",
          "ticker_sentiment_score": "0.048499",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ILMN",
          "relevance_score": "0.504646",
          "ticker_sentiment_score": "0.348522",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.049424",
          "ticker_sentiment_score": "0.155093",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.049424",
          "ticker_sentiment_score": "0.155093",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "CAH",
          "relevance_score": "0.098659",
          "ticker_sentiment_score": "0.052803",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BMY",
          "relevance_score": "0.049424",
          "ticker_sentiment_score": "0.155093",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Canopy Growth, Viatris, Everus, and Cerevel and Encourages Investors to Contact the Firm - Everus Construction Group  ( NYSE:ECG ) , Canopy Gwth  ( NASDAQ:CGC ) ",
      "url": "https://www.benzinga.com/pressreleases/25/05/g45426051/bragar-eagel-squire-p-c-reminds-investors-that-class-action-lawsuits-have-been-filed-against-canop",
      "time_published": "20250515T010000",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "NEW YORK, May 14, 2025 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Canopy Growth Corporation CGC, Viatris Inc. VTRS, Everus Construction Group, Inc.",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "IPO",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.684621"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": -0.108431,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ECG",
          "relevance_score": "0.147216",
          "ticker_sentiment_score": "0.027454",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.049322",
          "ticker_sentiment_score": "0.063978",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CGC",
          "relevance_score": "0.289462",
          "ticker_sentiment_score": "-0.215991",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "VTRS",
          "relevance_score": "0.289462",
          "ticker_sentiment_score": "-0.165101",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "Neutrolis Expands Senior Leadership Team to Drive Development of Growing Pipeline of Non-Immunosuppressive Therapies for NET-mediated Autoimmune Diseases",
      "url": "https://www.benzinga.com/pressreleases/24/12/g42551252/neutrolis-expands-senior-leadership-team-to-drive-development-of-growing-pipeline-of-non-immunosup",
      "time_published": "20241218T130000",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "CAMBRIDGE, Mass., Dec. 18, 2024 ( GLOBE NEWSWIRE ) -- Neutrolis Inc., a clinical stage biotech company focused on targeting Neutrophil Extracellular Traps ( NETs ) for the treatment of autoimmune and inflammatory diseases, today announced the expansion of its senior leadership team to support ...",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.156971,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CHRS",
          "relevance_score": "0.049322",
          "ticker_sentiment_score": "0.105695",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.049322",
          "ticker_sentiment_score": "0.170453",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.049322",
          "ticker_sentiment_score": "0.170453",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Canopy Growth, Viatris, Bakkt, and Cerevel and Encourages Investors to Contact the Firm - Bakkt Hldgs  ( NYSE:BKKT ) , Canopy Gwth  ( NASDAQ:CGC ) ",
      "url": "https://www.benzinga.com/pressreleases/25/05/g45556266/bragar-eagel-squire-p-c-reminds-investors-that-class-action-lawsuits-have-been-filed-against-canop",
      "time_published": "20250522T010000",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "NEW YORK, May 21, 2025 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Canopy Growth Corporation CGC, Viatris Inc. VTRS, Bakkt Holdings, Inc.",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "IPO",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.684621"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.108179"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.108179"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": -0.079774,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.048919",
          "ticker_sentiment_score": "0.063968",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BULL",
          "relevance_score": "0.048919",
          "ticker_sentiment_score": "-0.034029",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BKKT",
          "relevance_score": "0.193852",
          "ticker_sentiment_score": "0.034599",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CGC",
          "relevance_score": "0.2872",
          "ticker_sentiment_score": "-0.216764",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "VTRS",
          "relevance_score": "0.2872",
          "ticker_sentiment_score": "-0.166124",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Solaris, Viatris, Bakkt, and Cerevel and Encourages Investors to Contact the Firm - Solaris Energy  ( NYSE:SEI ) , Bakkt Hldgs  ( NYSE:BKKT ) ",
      "url": "https://www.benzinga.com/pressreleases/25/05/g45273789/bragar-eagel-squire-p-c-reminds-investors-that-class-action-lawsuits-have-been-filed-against-solar",
      "time_published": "20250508T010000",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "NEW YORK, May 07, 2025 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Solaris Energy Infrastructure, Inc. SEI, Viatris Inc. VTRS, Bakkt Holdings, Inc.",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "IPO",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.684621"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.538269"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.108179"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": -0.063292,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.04872",
          "ticker_sentiment_score": "0.063963",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BULL",
          "relevance_score": "0.04872",
          "ticker_sentiment_score": "-0.034027",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BKKT",
          "relevance_score": "0.193078",
          "ticker_sentiment_score": "0.034495",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SEI",
          "relevance_score": "0.145437",
          "ticker_sentiment_score": "0.028503",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "VTRS",
          "relevance_score": "0.286082",
          "ticker_sentiment_score": "-0.165611",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "Breast Cancer Drugs Market Size is Projected to Reach USD 80.34 Billion by 2033, Growing at a CAGR of 8.90%: Straits Research",
      "url": "https://www.benzinga.com/pressreleases/25/03/g44110115/breast-cancer-drugs-market-size-is-projected-to-reach-usd-80-34-billion-by-2033-growing-at-a-cagr-",
      "time_published": "20250304T145000",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "New York, United States, March 04, 2025 ( GLOBE NEWSWIRE ) -- Breast cancer is the prevailing ailment in the population, predominantly affecting women who are witnessing an increase in disease prevalence. Breast cancer primarily originates in the breast tissues.",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": -0.046866,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "META",
          "relevance_score": "0.048523",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.048523",
          "ticker_sentiment_score": "0.14351",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AZN",
          "relevance_score": "0.048523",
          "ticker_sentiment_score": "0.092709",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.096866",
          "ticker_sentiment_score": "0.11344",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "5 Unstoppable Dividend Stocks to Buy If There's a Stock Market Sell-Off",
      "url": "https://www.fool.com/investing/2025/06/11/unstoppable-dividend-stocks-buy-if-sell-off/",
      "time_published": "20250611T090000",
      "authors": [
        "Justin Pope"
      ],
      "summary": "Steady growth and dividend increases over decades can make investors remarkably wealthy.",
      "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F820816%2Fgetty-dividend-stocks-growing-money-income-cash-5.jpg&op=resize&w=700",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.9545"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.316726"
        }
      ],
      "overall_sentiment_score": 0.274974,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.095138",
          "ticker_sentiment_score": "0.089123",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SYK",
          "relevance_score": "0.188928",
          "ticker_sentiment_score": "0.230782",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.095138",
          "ticker_sentiment_score": "0.05508",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ZTS",
          "relevance_score": "0.188928",
          "ticker_sentiment_score": "0.079192",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.047654",
          "ticker_sentiment_score": "0.083969",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MDT",
          "relevance_score": "0.234911",
          "ticker_sentiment_score": "0.243633",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.047654",
          "ticker_sentiment_score": "-0.034459",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Healthy Returns: Here are the drugmakers with new U.S. investments as Trump's pharma tariffs loom",
      "url": "https://www.cnbc.com/2025/04/30/healthy-returns-trumps-pharma-tariffs-fuel-new-us-investments.html",
      "time_published": "20250430T201224",
      "authors": [],
      "summary": "Tariff threats are fueling a new wave of U.S. manufacturing investments from the pharmaceutical industry.",
      "banner_image": null,
      "source": "CNBC",
      "category_within_source": "Top News",
      "source_domain": "www.cnbc.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.918141"
        }
      ],
      "overall_sentiment_score": 0.143533,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABT",
          "relevance_score": "0.046816",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TRMND",
          "relevance_score": "0.046816",
          "ticker_sentiment_score": "0.086979",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.046816",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GLDAF",
          "relevance_score": "0.09347",
          "ticker_sentiment_score": "0.019752",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.046816",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DXCM",
          "relevance_score": "0.09347",
          "ticker_sentiment_score": "0.12762",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.046816",
          "ticker_sentiment_score": "-0.086801",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Novartis appoints Karen Hale, Chief Legal and Compliance Officer, as Klaus Moosmayer, Chief Ethics, Risk & Compliance Officer, steps down from the Executive Committee of Novartis",
      "url": "https://www.globenewswire.com/news-release/2025/03/31/3051935/0/en/Novartis-appoints-Karen-Hale-Chief-Legal-and-Compliance-Officer-as-Klaus-Moosmayer-Chief-Ethics-Risk-Compliance-Officer-steps-down-from-the-Executive-Committee-of-Novartis.html",
      "time_published": "20250331T050000",
      "authors": [
        "Novartis Pharma AG"
      ],
      "summary": "Basel, March 31, 2025 - Novartis announced today the appointment of Karen Hale to the expanded role of Chief Legal and Compliance Officer for Novartis, effective April 14, 2025. She will continue to report to Vas Narasimhan, M.D., CEO of Novartis and remain on the Executive Committee of Novartis ...",
      "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/5d242013-5d1f-440c-8ba6-3b5d3799b035",
      "source": "GlobeNewswire",
      "category_within_source": "n/a",
      "source_domain": "www.globenewswire.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.310843"
        }
      ],
      "overall_sentiment_score": 0.249955,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "META",
          "relevance_score": "0.046724",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.046724",
          "ticker_sentiment_score": "0.040962",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "AbbVie  ( ABBV )  Q4 2024 Earnings Call Transcript",
      "url": "https://www.fool.com/earnings/call-transcripts/2025/01/31/abbvie-abbv-q4-2024-earnings-call-transcript/",
      "time_published": "20250131T184512",
      "authors": [
        "Motley Fool Transcribing"
      ],
      "summary": "ABBV earnings call for the period ending December 31, 2024.",
      "banner_image": "https://g.foolcdn.com/misc-assets/fool-transcripts-logo.png",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        },
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.875462"
        },
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.94762"
        },
        {
          "topic": "Economy - Macro",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.255921,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "C",
          "relevance_score": "0.003593",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BAC",
          "relevance_score": "0.003593",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "WFC",
          "relevance_score": "0.003593",
          "ticker_sentiment_score": "0.138187",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MS",
          "relevance_score": "0.003593",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RGNX",
          "relevance_score": "0.007186",
          "ticker_sentiment_score": "0.143089",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.046682",
          "ticker_sentiment_score": "0.062912",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GS",
          "relevance_score": "0.003593",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FOREX:USD",
          "relevance_score": "0.003593",
          "ticker_sentiment_score": "0.131595",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Pharma Stock Roundup: NVO & JAZZ's Q1 Results, AZN's Pipeline Update",
      "url": "https://www.zacks.com/stock/news/2465915/pharma-stock-roundup-nvo-jazzs-q1-results-azns-pipeline-update",
      "time_published": "20250509T125100",
      "authors": [
        "Kinjel Shah"
      ],
      "summary": "NVO and JAZZ report first-quarter results. AZN's asthma study on Breztri meets key goals.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/cc/389.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.795202"
        },
        {
          "topic": "Economy - Macro",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.116586,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CVS",
          "relevance_score": "0.093108",
          "ticker_sentiment_score": "0.098124",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.046633",
          "ticker_sentiment_score": "-0.134498",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AZN",
          "relevance_score": "0.093108",
          "ticker_sentiment_score": "0.039551",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JAZZ",
          "relevance_score": "0.093108",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.479954",
          "ticker_sentiment_score": "0.221942",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "CMRX",
          "relevance_score": "0.046633",
          "ticker_sentiment_score": "0.049846",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Solaris, Actinium, Bakkt, and Cerevel and Encourages Investors to Contact the Firm - Actinium Pharma  ( AMEX:ATNM ) , Bakkt Hldgs  ( NYSE:BKKT ) ",
      "url": "https://www.benzinga.com/pressreleases/25/04/g45057077/bragar-eagel-squire-p-c-reminds-investors-that-class-action-lawsuits-have-been-filed-against-solar",
      "time_published": "20250429T010000",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "NEW YORK, April 28, 2025 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Solaris Energy Infrastructure, Inc. SEI, Actinium Pharmaceuticals, Inc.",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "IPO",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.684621"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.538269"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.108179"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": -0.014732,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.046452",
          "ticker_sentiment_score": "0.063872",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BULL",
          "relevance_score": "0.046452",
          "ticker_sentiment_score": "-0.034005",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BKKT",
          "relevance_score": "0.184246",
          "ticker_sentiment_score": "0.031862",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SEI",
          "relevance_score": "0.13873",
          "ticker_sentiment_score": "0.026553",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Solaris, Actinium, Bakkt, and Cerevel and Encourages Investors to Contact the Firm - Actinium Pharma  ( AMEX:ATNM ) , Bakkt Hldgs  ( NYSE:BKKT ) ",
      "url": "https://www.benzinga.com/pressreleases/25/04/g44829929/bragar-eagel-squire-p-c-reminds-investors-that-class-action-lawsuits-have-been-filed-against-solar",
      "time_published": "20250416T010000",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "NEW YORK, April 15, 2025 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Solaris Energy Infrastructure, Inc. SEI, Actinium Pharmaceuticals, Inc.",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "IPO",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.684621"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.538269"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.108179"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": -0.014732,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "BKKT",
          "relevance_score": "0.184246",
          "ticker_sentiment_score": "0.031862",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SEI",
          "relevance_score": "0.13873",
          "ticker_sentiment_score": "0.026553",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.046452",
          "ticker_sentiment_score": "0.063872",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "The Zacks Analyst Blog Highlights Amgen, CRISPR, Moderna, Sarepta and Vertex",
      "url": "https://www.zacks.com/stock/news/2410684/the-zacks-analyst-blog-highlights-amgen-crispr-moderna-sarepta-and-vertex",
      "time_published": "20250206T102300",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "Amgen, CRISPR, Moderna, Sarepta and Vertex are included in this Analyst Blog.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/13/816.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        }
      ],
      "overall_sentiment_score": 0.170089,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CRSP",
          "relevance_score": "0.183895",
          "ticker_sentiment_score": "-0.001462",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SRPT",
          "relevance_score": "0.272788",
          "ticker_sentiment_score": "0.031645",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "VRTX",
          "relevance_score": "0.315975",
          "ticker_sentiment_score": "-0.002245",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.046363",
          "ticker_sentiment_score": "0.101507",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MRNA",
          "relevance_score": "0.358152",
          "ticker_sentiment_score": "0.059402",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AMGN",
          "relevance_score": "0.272788",
          "ticker_sentiment_score": "0.023966",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SNY",
          "relevance_score": "0.046363",
          "ticker_sentiment_score": "0.101507",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "The 15 Top Press Releases of January",
      "url": "https://www.benzinga.com/pressreleases/25/02/n43555441/the-15-top-press-releases-of-january",
      "time_published": "20250207T110200",
      "authors": [
        "PRNewswire"
      ],
      "summary": "Including rare Michael Jordan cards, a new OREO from Post Malone and merger news from Frontier Airlines. Plus, a recap of trending topics like CES 2025 and the California wildfires. NEW YORK, Feb. 7, 2025 /PRNewswire/ -- With thousands of press releases published each month, it can be difficult ...",
      "banner_image": "https://mma.prnewswire.com/media/2614954/PRN_Monthly_Roundup_Jan2025.jpg",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.25"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.360215"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.25"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.769861"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.25"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.25"
        }
      ],
      "overall_sentiment_score": 0.240303,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MSFT",
          "relevance_score": "0.046006",
          "ticker_sentiment_score": "0.085658",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "UAL",
          "relevance_score": "0.046006",
          "ticker_sentiment_score": "0.085658",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.046006",
          "ticker_sentiment_score": "0.085658",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BA",
          "relevance_score": "0.046006",
          "ticker_sentiment_score": "0.085658",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Pharma Stock Roundup: EU Nod for PFE's Hympavzi, NVS Ups Sales View",
      "url": "https://www.zacks.com/stock/news/2374304/pharma-stock-roundup-eu-nod-for-pfes-hympavzi-nvs-ups-sales-view",
      "time_published": "20241122T200000",
      "authors": [
        "Kinjel Shah"
      ],
      "summary": "EU approval for PFE's hemophilia drug Hympavzi. Novartis upgrades its mid-term sales guidance.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f5/952.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        }
      ],
      "overall_sentiment_score": 0.169194,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.17879",
          "ticker_sentiment_score": "0.136826",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.045054",
          "ticker_sentiment_score": "-0.128118",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AZN",
          "relevance_score": "0.17879",
          "ticker_sentiment_score": "0.131993",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.045054",
          "ticker_sentiment_score": "-0.128118",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.089965",
          "ticker_sentiment_score": "0.139626",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Lycia Therapeutics Announces the Appointment of Chin Lee, MD, MPH, as Chief Medical Officer and Reveals Immunology Pipeline",
      "url": "https://markets.businessinsider.com/news/stocks/lycia-therapeutics-announces-the-appointment-of-chin-lee-md-mph-as-chief-medical-officer-and-reveals-immunology-pipeline-1034342908",
      "time_published": "20250211T163000",
      "authors": [
        "markets.businessinsider.com"
      ],
      "summary": "SOUTH SAN FRANCISCO, Calif., Feb. 11, 2025 ( GLOBE NEWSWIRE ) -- Lycia Therapeutics, Inc., a biotechnology company developing lysosomal targeting chimera ( LYTAC ) -based protein degradation therapies to eliminate disease at its source, today announced the appointment of Chin Lee, M.D., M.P.H., ...",
      "banner_image": "https://ml.globenewswire.com/media/YWNhNWExN2EtMWU1NS00OTExLWE0MmUtN2Q4ZDJkZThmNTFjLTEyMzM5MTQ=/tiny/Lycia-Therapeutics-Inc-.png",
      "source": "Business Insider",
      "category_within_source": "RSS",
      "source_domain": "markets.businessinsider.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": -0.087978,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "TBPH",
          "relevance_score": "0.04497",
          "ticker_sentiment_score": "0.02278",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.04497",
          "ticker_sentiment_score": "0.02278",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ALLK",
          "relevance_score": "0.134339",
          "ticker_sentiment_score": "0.028085",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CNTB",
          "relevance_score": "0.04497",
          "ticker_sentiment_score": "0.02278",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Crescent Biopharma Appoints Joshua Brumm as Chief Executive Officer and Expands Leadership Team to Advance Pipeline of Potentially Best-in-Class Oncology Therapeutics - GlycoMimetics  ( NASDAQ:GLYC ) ",
      "url": "https://www.benzinga.com/pressreleases/25/04/g44624854/crescent-biopharma-appoints-joshua-brumm-as-chief-executive-officer-and-expands-leadership-team-to",
      "time_published": "20250403T113031",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "Jonathan McNeill, M.D., Appointed President and Chief Operating Officer Ellie Im, M.D., Appointed Chief Medical Officer Additional Leadership Appointments: Rick Scalzo, MBA, as Chief Financial Officer, and Amy Reilly, as Chief Communications Officer",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "IPO",
          "relevance_score": "0.838487"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.214378"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.235173,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "C",
          "relevance_score": "0.022284",
          "ticker_sentiment_score": "0.059968",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MRSN",
          "relevance_score": "0.022284",
          "ticker_sentiment_score": "0.023307",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MS",
          "relevance_score": "0.022284",
          "ticker_sentiment_score": "0.059968",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CNTA",
          "relevance_score": "0.022284",
          "ticker_sentiment_score": "0.023307",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DYN",
          "relevance_score": "0.088964",
          "ticker_sentiment_score": "0.051862",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "XFOR",
          "relevance_score": "0.022284",
          "ticker_sentiment_score": "0.043635",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ALPMF",
          "relevance_score": "0.022284",
          "ticker_sentiment_score": "0.043635",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "EDIT",
          "relevance_score": "0.022284",
          "ticker_sentiment_score": "0.044859",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.044551",
          "ticker_sentiment_score": "0.049287",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GLYC",
          "relevance_score": "0.044551",
          "ticker_sentiment_score": "0.143893",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BIIB",
          "relevance_score": "0.022284",
          "ticker_sentiment_score": "0.028763",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "4 Stocks With Growth Potential That Recently Announced Dividend Hikes",
      "url": "https://www.zacks.com/stock/news/2401111/4-stocks-with-growth-potential-that-recently-announced-dividend-hikes",
      "time_published": "20250122T134700",
      "authors": [
        "Ritujay Ghosh"
      ],
      "summary": "PLBC, BUSE, LKFN and RPRX recently announced dividend hikes.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/d7/352.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.972193"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.996023"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        },
        {
          "topic": "Economy - Macro",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.159351,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "PLBC",
          "relevance_score": "0.343875",
          "ticker_sentiment_score": "0.255175",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "BUSE",
          "relevance_score": "0.343875",
          "ticker_sentiment_score": "0.269124",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "RPRX",
          "relevance_score": "0.303175",
          "ticker_sentiment_score": "0.164333",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.044386",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LKFN",
          "relevance_score": "0.42219",
          "ticker_sentiment_score": "0.297418",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "3 Large-Cap Value Mutual Funds to Buy Amid Market Uncertainty",
      "url": "https://www.zacks.com/stock/news/2447369/3-large-cap-value-mutual-funds-to-buy-amid-market-uncertainty",
      "time_published": "20250411T122200",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Invest in large-cap value funds like PEQSX, DAGVX and ABVIX to preserve your capital and generate future returns.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/6d/19169.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.2"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.2"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.2"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.2"
        },
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.682689"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.2"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.929393"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.310843"
        }
      ],
      "overall_sentiment_score": 0.244292,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CSCO",
          "relevance_score": "0.044141",
          "ticker_sentiment_score": "0.048844",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BAC",
          "relevance_score": "0.044141",
          "ticker_sentiment_score": "0.048844",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "WFC",
          "relevance_score": "0.044141",
          "ticker_sentiment_score": "0.049826",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BRK-A",
          "relevance_score": "0.044141",
          "ticker_sentiment_score": "0.048844",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "XOM",
          "relevance_score": "0.044141",
          "ticker_sentiment_score": "0.049826",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.044141",
          "ticker_sentiment_score": "0.049826",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "UNH",
          "relevance_score": "0.044141",
          "ticker_sentiment_score": "0.049826",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "WMT",
          "relevance_score": "0.088147",
          "ticker_sentiment_score": "0.052538",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Pharma Stock Roundup: LLY's New Deal, GSK & SNY's Pipeline Updates",
      "url": "https://www.zacks.com/stock/news/2479582/pharma-stock-roundup-llys-new-deal-gsk-snys-pipeline-updates",
      "time_published": "20250530T140000",
      "authors": [
        "Kinjel Shah"
      ],
      "summary": "LLY to acquire SiteOne for up to $1 billion. GSK's antibiotic study ends early for efficacy. MRNA loses H5 flu vaccine funding, while SNY sees mixed COPD data.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f5/952.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        }
      ],
      "overall_sentiment_score": 0.031207,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "NVO",
          "relevance_score": "0.087985",
          "ticker_sentiment_score": "-0.129139",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LLY",
          "relevance_score": "0.217639",
          "ticker_sentiment_score": "0.057315",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SKXJF",
          "relevance_score": "0.087985",
          "ticker_sentiment_score": "0.049377",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.04406",
          "ticker_sentiment_score": "-0.122876",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DSKYF",
          "relevance_score": "0.087985",
          "ticker_sentiment_score": "0.049377",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MRNA",
          "relevance_score": "0.217639",
          "ticker_sentiment_score": "0.107946",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SPRO",
          "relevance_score": "0.04406",
          "ticker_sentiment_score": "-0.076377",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GSK",
          "relevance_score": "0.174903",
          "ticker_sentiment_score": "0.011567",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SNY",
          "relevance_score": "0.259727",
          "ticker_sentiment_score": "-0.003979",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Personalized Medicines Market to Surpass Valuation of USD 1352.81 Billion by 2031 | SkyQuest Technology",
      "url": "https://www.benzinga.com/pressreleases/24/11/g42205102/personalized-medicines-market-to-surpass-valuation-of-usd-1352-81-billion-by-2031-skyquest-technol",
      "time_published": "20241127T003000",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "Westford, USA, Nov. 26, 2024 ( GLOBE NEWSWIRE ) -- SkyQuest projects that the global personalized medicines market size will reach a value of USD 1352.81 Billion by 2031, with a CAGR of 11.40% during the forecast period ( 2024-2031 ) .",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        }
      ],
      "overall_sentiment_score": 0.412525,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "MOLN",
          "relevance_score": "0.043979",
          "ticker_sentiment_score": "0.029234",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GH",
          "relevance_score": "0.043979",
          "ticker_sentiment_score": "0.029234",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MDXH",
          "relevance_score": "0.043979",
          "ticker_sentiment_score": "0.029234",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PSNL",
          "relevance_score": "0.043979",
          "ticker_sentiment_score": "0.029234",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "EXAS",
          "relevance_score": "0.043979",
          "ticker_sentiment_score": "0.029234",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BIO",
          "relevance_score": "0.043979",
          "ticker_sentiment_score": "0.029234",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.043979",
          "ticker_sentiment_score": "0.029234",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AMGN",
          "relevance_score": "0.043979",
          "ticker_sentiment_score": "0.029234",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BMY",
          "relevance_score": "0.043979",
          "ticker_sentiment_score": "0.029234",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SOPH",
          "relevance_score": "0.043979",
          "ticker_sentiment_score": "0.029234",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AZN",
          "relevance_score": "0.043979",
          "ticker_sentiment_score": "0.029234",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MYGN",
          "relevance_score": "0.043979",
          "ticker_sentiment_score": "0.029234",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "QGEN",
          "relevance_score": "0.043979",
          "ticker_sentiment_score": "0.029234",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GILD",
          "relevance_score": "0.043979",
          "ticker_sentiment_score": "0.029234",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TAK",
          "relevance_score": "0.043979",
          "ticker_sentiment_score": "0.029234",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Pharma Stock Roundup: LLY's Zepbound Success, FDA Updates for MRK, JNJ",
      "url": "https://www.zacks.com/stock/news/2380033/pharma-stock-roundup-llys-zepbound-success-fda-updates-for-mrk-jnj",
      "time_published": "20241206T131100",
      "authors": [
        "Kinjel Shah"
      ],
      "summary": "LLY's Zepbound shows better weight loss than NVO's Wegovy in a study. FDA updates for MRK, RHHBY, JNJ and AZN drugs grab headlines.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/10/83654.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.316726"
        }
      ],
      "overall_sentiment_score": 0.155629,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.043579",
          "ticker_sentiment_score": "-0.127699",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AZN",
          "relevance_score": "0.130217",
          "ticker_sentiment_score": "0.1242",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.043579",
          "ticker_sentiment_score": "-0.127699",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.043579",
          "ticker_sentiment_score": "-0.122739",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Tonix Pharmaceuticals Targets Rapid Migraine Relief With Non-Oral Treatments - AbbVie  ( NYSE:ABBV ) , Pfizer  ( NYSE:PFE ) ",
      "url": "https://www.benzinga.com/partner/biotech/24/11/41968977/tonix-pharmaceuticals-targets-rapid-migraine-relief-with-non-oral-treatments",
      "time_published": "20241114T123055",
      "authors": [
        "Mangeet Kaur Bouns"
      ],
      "summary": "This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix Pharmaceuticals Holding Corp. with financial support from Tonix.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2024/11/14/Screenshot-2024-11-13-at-11-54-41PM.png?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.495866"
        }
      ],
      "overall_sentiment_score": -0.061313,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.043421",
          "ticker_sentiment_score": "-0.031136",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DSSMY",
          "relevance_score": "0.021718",
          "ticker_sentiment_score": "-0.109327",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TNXP",
          "relevance_score": "0.086713",
          "ticker_sentiment_score": "0.198335",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.043421",
          "ticker_sentiment_score": "-0.031136",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "3 Large-Cap Value Mutual Funds to Build a Solid Portfolio",
      "url": "https://www.zacks.com/stock/news/2427100/3-large-cap-value-mutual-funds-to-build-a-solid-portfolio",
      "time_published": "20250307T123800",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Invest in large-cap value funds like DAGVX, PEYAX and ABVAX to preserve your capital and generate future returns.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e9/88506.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.2"
        },
        {
          "topic": "Energy & Transportation",
          "relevance_score": "0.2"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.2"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.2"
        },
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.576289"
        },
        {
          "topic": "Economy - Fiscal",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.2"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.980922"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.451494"
        }
      ],
      "overall_sentiment_score": 0.176321,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CSCO",
          "relevance_score": "0.043186",
          "ticker_sentiment_score": "0.048708",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BAC",
          "relevance_score": "0.043186",
          "ticker_sentiment_score": "0.048708",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "WFC",
          "relevance_score": "0.043186",
          "ticker_sentiment_score": "0.049687",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BRK-A",
          "relevance_score": "0.043186",
          "ticker_sentiment_score": "0.048708",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "XOM",
          "relevance_score": "0.043186",
          "ticker_sentiment_score": "0.049687",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.043186",
          "ticker_sentiment_score": "0.049687",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "UNH",
          "relevance_score": "0.043186",
          "ticker_sentiment_score": "0.049687",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "WMT",
          "relevance_score": "0.086245",
          "ticker_sentiment_score": "0.052338",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Royalty Pharma Announces R&D Funding Collaboration With Biogen",
      "url": "https://www.globenewswire.com/news-release/2025/02/12/3024862/0/en/Royalty-Pharma-Announces-R-D-Funding-Collaboration-With-Biogen.html",
      "time_published": "20250212T113000",
      "authors": [
        "Royalty Pharma plc"
      ],
      "summary": "Royalty Pharma to provide R&D investment of up to $250 million for Biogen's litifilimab, a potential first-in-class biologic in Phase 3 development for the treatment of lupus Royalty Pharma to provide R&D investment of up to $250 million for Biogen's litifilimab, a potential first-in-class ...",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/d605b3b0-7ba0-46e1-a2d4-439ca98694f8",
      "source": "GlobeNewswire",
      "category_within_source": "n/a",
      "source_domain": "www.globenewswire.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.495866"
        }
      ],
      "overall_sentiment_score": 0.159461,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "RPRX",
          "relevance_score": "0.370908",
          "ticker_sentiment_score": "0.169086",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.0428",
          "ticker_sentiment_score": "0.079064",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BIIB",
          "relevance_score": "0.169975",
          "ticker_sentiment_score": "0.178191",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Online Pharmacy Market Size to Worth USD 543.36 Billion by 2033 | Straits Research",
      "url": "https://www.benzinga.com/pressreleases/25/01/g43308006/online-pharmacy-market-size-to-worth-usd-543-36-billion-by-2033-straits-research",
      "time_published": "20250129T153600",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "New York, United States, Jan. 29, 2025 ( GLOBE NEWSWIRE ) -- An online pharmacy, known as an Internet pharmacy, operates using the Internet as its primary platform. It fulfills customer orders by mail, shipping firms, or an online pharmacy web portal.",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.650727"
        }
      ],
      "overall_sentiment_score": 0.193018,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "META",
          "relevance_score": "0.042647",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.042647",
          "ticker_sentiment_score": "-0.003968",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Targeted cancer drugs may replace chemo for some patients - and drugmakers say they're getting closer",
      "url": "https://www.cnbc.com/2025/06/17/adc-cancer-drugs-pfizer-astrazeneca-merck-bet-on-chemo-replacement.html",
      "time_published": "20250617T110001",
      "authors": [],
      "summary": "Companies like AstraZeneca, Daiichi Sankyo, Pfizer and Merck are learning from previous setbacks in the ADC space to improve their efficacy and safety.",
      "banner_image": null,
      "source": "CNBC",
      "category_within_source": "Business",
      "source_domain": "www.cnbc.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.108179"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.161647"
        }
      ],
      "overall_sentiment_score": -0.002456,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ANDE",
          "relevance_score": "0.028271",
          "ticker_sentiment_score": "0.111386",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AZN",
          "relevance_score": "0.042396",
          "ticker_sentiment_score": "-0.022918",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.014138",
          "ticker_sentiment_score": "-0.020762",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ALPMF",
          "relevance_score": "0.014138",
          "ticker_sentiment_score": "-0.002906",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SKXJF",
          "relevance_score": "0.0706",
          "ticker_sentiment_score": "-0.020341",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.042396",
          "ticker_sentiment_score": "0.012949",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DSKYF",
          "relevance_score": "0.0706",
          "ticker_sentiment_score": "-0.020341",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.0706",
          "ticker_sentiment_score": "0.051291",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BMY",
          "relevance_score": "0.042396",
          "ticker_sentiment_score": "-0.000986",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BNTX",
          "relevance_score": "0.056507",
          "ticker_sentiment_score": "0.072962",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Market Shrugs Off This Drugmaker's Turnaround",
      "url": "https://www.benzinga.com/news/earnings/25/05/45431258/market-shrugs-off-this-drugmakers-turnaround",
      "time_published": "20250515T101040",
      "authors": [
        "Bamboo Works"
      ],
      "summary": "Buoyed by U.S. demand for its blockbuster cancer drug, the Chinese biopharma firm has delivered its first quarterly profit on a GAAP basis Global sales of the company's flagship drug for blood cancers rose 62% to $792 million in the first quarter, while U.S. sales reached $563 million",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2025/05/15/BeiGene-900x600-1.png?width=1200&height=800&fit=crop",
      "source": "Benzinga",
      "category_within_source": "Trading",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.999691"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "IPO",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.166308,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "SHJBF",
          "relevance_score": "0.042196",
          "ticker_sentiment_score": "0.161401",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.042196",
          "ticker_sentiment_score": "0.023704",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ONC",
          "relevance_score": "0.288893",
          "ticker_sentiment_score": "0.171409",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.042196",
          "ticker_sentiment_score": "0.023704",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Lycia Therapeutics Announces the Appointment of Chin Lee, MD, MPH, as Chief Medical Officer and Reveals Immunology Pipeline - Allakos  ( NASDAQ:ALLK ) ",
      "url": "https://www.benzinga.com/pressreleases/25/02/g43630565/lycia-therapeutics-announces-the-appointment-of-chin-lee-md-mph-as-chief-medical-officer-and-revea",
      "time_published": "20250211T163000",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "SOUTH SAN FRANCISCO, Calif., Feb. 11, 2025 ( GLOBE NEWSWIRE ) -- Lycia Therapeutics, Inc., a biotechnology company developing lysosomal targeting chimera ( LYTAC ) -based protein degradation therapies to eliminate disease at its source, today announced the appointment of Chin Lee, M.D., M.P.H., ...",
      "banner_image": "https://ml.globenewswire.com/media/99954460-b64e-4a60-95d2-6ba49af18d1b/small/lycia-logo-color-png.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": -0.066189,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "TBPH",
          "relevance_score": "0.042196",
          "ticker_sentiment_score": "0.022644",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.042196",
          "ticker_sentiment_score": "0.022644",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ALLK",
          "relevance_score": "0.126119",
          "ticker_sentiment_score": "0.027185",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CNTB",
          "relevance_score": "0.042196",
          "ticker_sentiment_score": "0.022644",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Xilio Therapeutics to Present Updated Phase 2 Data for Vilastobart, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Combination with Atezolizumab in Patients with Microsatellite Stable Colorectal Cancer at the 2025 ASCO Annual Meeting",
      "url": "https://www.globenewswire.com/news-release/2025/04/23/3066937/0/en/Xilio-Therapeutics-to-Present-Updated-Phase-2-Data-for-Vilastobart-a-Tumor-Activated-Fc-Enhanced-Anti-CTLA-4-in-Combination-with-Atezolizumab-in-Patients-with-Microsatellite-Stable.html",
      "time_published": "20250423T203000",
      "authors": [
        "Xilio Therapeutics",
        "Inc."
      ],
      "summary": "WALTHAM, Mass., April 23, 2025 ( GLOBE NEWSWIRE ) -- Xilio Therapeutics, Inc. ( Nasdaq: XLO ) , a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced plans to present updated data from its ...",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/7e55cc25-f46f-423c-bf2a-e77ebaf69665",
      "source": "GlobeNewswire",
      "category_within_source": "n/a",
      "source_domain": "www.globenewswire.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Economy - Fiscal",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.078876,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "XLO",
          "relevance_score": "0.164749",
          "ticker_sentiment_score": "-0.054388",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.041466",
          "ticker_sentiment_score": "0.073925",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Royalty Pharma Completes the Acquisition of Its External Manager",
      "url": "https://www.globenewswire.com/news-release/2025/05/16/3083402/0/en/Royalty-Pharma-Completes-the-Acquisition-of-Its-External-Manager.html",
      "time_published": "20250516T203000",
      "authors": [
        "Royalty Pharma plc"
      ],
      "summary": "NEW YORK, May 16, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) today announced that it has successfully closed the acquisition of its external manager, RP Management, LLC ( \"RP Management\" ) . The acquisition received overwhelming support from Royalty Pharma's shareholders, with ...",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/d605b3b0-7ba0-46e1-a2d4-439ca98694f8",
      "source": "GlobeNewswire",
      "category_within_source": "n/a",
      "source_domain": "www.globenewswire.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.955357"
        }
      ],
      "overall_sentiment_score": 0.250485,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "RPRX",
          "relevance_score": "0.392537",
          "ticker_sentiment_score": "0.240885",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.040969",
          "ticker_sentiment_score": "0.075696",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Pharma Stock Roundup: FDA Nod to SNY, AZN & NVS, JNJ Talc Suits Failure",
      "url": "https://www.zacks.com/stock/news/2440538/pharma-stock-roundup-fda-nod-to-sny-azn-nvs-jnj-talc-suits-failure",
      "time_published": "20250404T134600",
      "authors": [
        "Kinjel Shah"
      ],
      "summary": "FDA approves SNY's hemophilia therapy, fitusiran, and NVS' rare kidney disease drug, Vanrafia.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/b2/19786.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.094096,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.040553",
          "ticker_sentiment_score": "-0.121774",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HLN",
          "relevance_score": "0.040553",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AZN",
          "relevance_score": "0.16117",
          "ticker_sentiment_score": "-0.069903",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.040553",
          "ticker_sentiment_score": "-0.121774",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.081001",
          "ticker_sentiment_score": "-0.046562",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SNY",
          "relevance_score": "0.16117",
          "ticker_sentiment_score": "0.040501",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Here's How to Play Pfizer Stock Before Q4 Earnings Release",
      "url": "https://www.zacks.com/stock/news/2404545/heres-how-to-play-pfizer-stock-before-q4-earnings-release",
      "time_published": "20250128T141700",
      "authors": [
        "Kinjel Shah"
      ],
      "summary": "PFE's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in the fourth quarter.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/89/447.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.365926"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.99237"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.266143"
        }
      ],
      "overall_sentiment_score": 0.174677,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.080865",
          "ticker_sentiment_score": "0.060377",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.040484",
          "ticker_sentiment_score": "0.057638",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AZN",
          "relevance_score": "0.040484",
          "ticker_sentiment_score": "0.057638",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.080865",
          "ticker_sentiment_score": "0.060377",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.457566",
          "ticker_sentiment_score": "0.19984",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "BNTX",
          "relevance_score": "0.080865",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Schizophrenia Drugs Market Size is Projected to Reach USD 12.33 Billion by 2033, Growing at a CAGR of 5.10%: Straits Research",
      "url": "https://www.benzinga.com/pressreleases/25/01/g43131526/schizophrenia-drugs-market-size-is-projected-to-reach-usd-12-33-billion-by-2033-growing-at-a-cagr-",
      "time_published": "20250122T151200",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "New York, United States, Jan. 22, 2025 ( GLOBE NEWSWIRE ) -- Pharmaceutical interventions for schizophrenia are designed to effectively treat and mitigate the symptoms associated with schizophrenia, a psychiatric disorder characterized by aberrant cognition, affect, and perception.",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.181584,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ALKS",
          "relevance_score": "0.039548",
          "ticker_sentiment_score": "-0.013896",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "META",
          "relevance_score": "0.039548",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.039548",
          "ticker_sentiment_score": "0.228663",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Enzyme Inhibitor Market to Reach US$ 5.9 Bn by 2034 Amid Rising Demand for Cardiovascular and Oncology Therapies - Transparency Market Research, Inc.",
      "url": "https://www.benzinga.com/pressreleases/24/12/g42504250/enzyme-inhibitor-market-to-reach-us-5-9-bn-by-2034-amid-rising-demand-for-cardiovascular-and-oncol",
      "time_published": "20241216T113000",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "Wilmington, Delaware, Transparency Market Research, Inc., Dec. 16, 2024 ( GLOBE NEWSWIRE ) -- Increasing Use in Disease Management Driving Global Enzyme Inhibitor Industry Growth",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/f7b0f4c1-f2c5-4a4f-a74a-b75ac91fa236/enzyme-inhibitor-market.jpg",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.214378"
        }
      ],
      "overall_sentiment_score": 0.092836,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "GOOG",
          "relevance_score": "0.039483",
          "ticker_sentiment_score": "0.053926",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AZN",
          "relevance_score": "0.07887",
          "ticker_sentiment_score": "0.112666",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BAYZF",
          "relevance_score": "0.039483",
          "ticker_sentiment_score": "-0.128033",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVS",
          "relevance_score": "0.07887",
          "ticker_sentiment_score": "0.08715",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.039483",
          "ticker_sentiment_score": "0.143097",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "WMGTF",
          "relevance_score": "0.118064",
          "ticker_sentiment_score": "0.051133",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GSK",
          "relevance_score": "0.039483",
          "ticker_sentiment_score": "0.143097",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.118064",
          "ticker_sentiment_score": "-0.025789",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BMY",
          "relevance_score": "0.07887",
          "ticker_sentiment_score": "0.112666",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Royalty Pharma Completes the Acquisition of Its External Manager - Royalty Pharma  ( NASDAQ:RPRX ) ",
      "url": "https://www.benzinga.com/pressreleases/25/05/g45477301/royalty-pharma-completes-the-acquisition-of-its-external-manager",
      "time_published": "20250516T203000",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "NEW YORK, May 16, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc RPRX today announced that it has successfully closed the acquisition of its external manager, RP Management, LLC ( \"RP Management\" ) . The acquisition received overwhelming support from Royalty Pharma's shareholders, with 99.9% of ...",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "Mergers",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.989041"
        }
      ],
      "overall_sentiment_score": 0.257193,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "RPRX",
          "relevance_score": "0.376005",
          "ticker_sentiment_score": "0.233716",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.039096",
          "ticker_sentiment_score": "0.075226",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Epidermal Growth Factors  ( EGFs )  Market to Reach US$ 3.7 Billion by 2034 | Expanding Applications in Regenerative Medicine and Cancer Therapy Drive Growth, Latest Report by TMR",
      "url": "https://www.benzinga.com/pressreleases/24/12/g42503394/epidermal-growth-factors-egfs-market-to-reach-us-3-7-billion-by-2034-expanding-applications-in-reg",
      "time_published": "20241216T103000",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "Wilmington, Delaware, Transparency Market Research Inc. , Dec. 16, 2024 ( GLOBE NEWSWIRE ) -- The global Epidermal Growth Factors ( EGFs ) market ( March\u00e9 des Facteurs de croissance \u00e9pidermiques ( EGF ) ) was valued at US$ 1.1 Bn in 2023 and is anticipated to expand at a CAGR of 11.3% from 2024 ...",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/27e1d943-6840-4b94-a03f-719fb05a4273/epidermal-growth-factors-egfs-market.jpg",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        }
      ],
      "overall_sentiment_score": 0.180609,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "GOOG",
          "relevance_score": "0.038717",
          "ticker_sentiment_score": "0.053774",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AZN",
          "relevance_score": "0.115787",
          "ticker_sentiment_score": "0.049244",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BAYZF",
          "relevance_score": "0.038717",
          "ticker_sentiment_score": "0.170484",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.115787",
          "ticker_sentiment_score": "0.175364",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "TMO",
          "relevance_score": "0.077343",
          "ticker_sentiment_score": "0.136257",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVS",
          "relevance_score": "0.038717",
          "ticker_sentiment_score": "-0.254204",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.038717",
          "ticker_sentiment_score": "0.170484",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "AMGN",
          "relevance_score": "0.077343",
          "ticker_sentiment_score": "0.096741",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "WMGTF",
          "relevance_score": "0.115787",
          "ticker_sentiment_score": "0.058068",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GSK",
          "relevance_score": "0.038717",
          "ticker_sentiment_score": "0.170484",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "TSOI",
          "relevance_score": "0.038717",
          "ticker_sentiment_score": "0.09193",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CRYPTO:NANO",
          "relevance_score": "0.038717",
          "ticker_sentiment_score": "0.031583",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Pfizer Trades Above 50-Day Average for a Month: Time to Buy?",
      "url": "https://www.zacks.com/stock/news/2561523/pfizer-trades-above-50-day-average-for-a-month-time-to-buy",
      "time_published": "20250703T124800",
      "authors": [
        "Kinjel Shah"
      ],
      "summary": "PFE trades above its 50-day average for over a month, signaling bullish momentum despite COVID revenue declines and patent risks.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/88/898.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.503496"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.839681"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.266143"
        }
      ],
      "overall_sentiment_score": 0.162758,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.114865",
          "ticker_sentiment_score": "-0.015985",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.038407",
          "ticker_sentiment_score": "0.070139",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AZN",
          "relevance_score": "0.038407",
          "ticker_sentiment_score": "0.070139",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.114865",
          "ticker_sentiment_score": "-0.015985",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.613934",
          "ticker_sentiment_score": "0.182362",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Conceivable Life Sciences Closes $18 Million Series A Financing to Advance Development and Commercialization of the World's First AI-Powered Automated IVF Lab",
      "url": "https://www.benzinga.com/pressreleases/25/01/g42975122/conceivable-life-sciences-closes-18-million-series-a-financing-to-advance-development-and-commerci",
      "time_published": "20250114T143059",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "ARTIS Ventures led the financing with participation from new and existing investors, raising over $39 million to date Funds will support ongoing commercial pilot program in Mexico City and preparations for U.S. launch timed for early 2026",
      "banner_image": "https://ml.globenewswire.com/media/b6e7788e-03c6-4abb-8d9a-9f927b97dd7d/small/cls-logo-stacked-black-grad-r-10-png.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "IPO",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.286223,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "GOOG",
          "relevance_score": "0.076236",
          "ticker_sentiment_score": "0.0924",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ILMN",
          "relevance_score": "0.038162",
          "ticker_sentiment_score": "0.088431",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.038162",
          "ticker_sentiment_score": "0.088431",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Aging Population Fuels Nocturia Market Growth, Projected to Reach US$ 8.5 Billion by 2034 - Latest Research Report by TMR",
      "url": "https://www.benzinga.com/pressreleases/25/02/g43459102/aging-population-fuels-nocturia-market-growth-projected-to-reach-us-8-5-billion-by-2034-latest-res",
      "time_published": "20250204T123000",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "Wilmington, Delaware, Transparency Market Research Inc. -, Feb. 04, 2025 ( GLOBE NEWSWIRE ) -- The global nocturia market ( Pasar Nocturia ) , valued at US$ 3.7 billion in 2023, is projected to grow at a CAGR of 8.0%, reaching US$ 8.5 billion by 2034.",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/a3386d7d-4718-4710-8a27-68cec8f827ce/nocturia-market.jpg",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.538269"
        }
      ],
      "overall_sentiment_score": 0.280974,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "GOOG",
          "relevance_score": "0.03792",
          "ticker_sentiment_score": "0.05361",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AVDL",
          "relevance_score": "0.03792",
          "ticker_sentiment_score": "0.120796",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DNPUF",
          "relevance_score": "0.03792",
          "ticker_sentiment_score": "0.120796",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SSUMF",
          "relevance_score": "0.03792",
          "ticker_sentiment_score": "0.120796",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ALPMF",
          "relevance_score": "0.03792",
          "ticker_sentiment_score": "0.120796",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.03792",
          "ticker_sentiment_score": "0.120796",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TEVA",
          "relevance_score": "0.03792",
          "ticker_sentiment_score": "0.120796",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "WMGTF",
          "relevance_score": "0.113418",
          "ticker_sentiment_score": "0.058032",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "How to Play VKTX Stock Amid Manufacturing Deal With CordenPharma",
      "url": "https://www.zacks.com/stock/news/2429740/how-to-play-vktx-stock-amid-manufacturing-deal-with-cordenpharma",
      "time_published": "20250313T142100",
      "authors": [
        "Sundeep Ganoria"
      ],
      "summary": "Given the optimism around its obesity candidate, we believe investors should stay invested in Viking Therapeutics.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.413559"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.162593,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.258743",
          "ticker_sentiment_score": "0.126293",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "VKTX",
          "relevance_score": "0.60415",
          "ticker_sentiment_score": "0.209651",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.037622",
          "ticker_sentiment_score": "0.070716",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GS",
          "relevance_score": "0.037622",
          "ticker_sentiment_score": "0.110572",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AZN",
          "relevance_score": "0.037622",
          "ticker_sentiment_score": "0.070716",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.18645",
          "ticker_sentiment_score": "0.13132",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Polyneuropathy Treatment Market is Projected to Grow at a 4.9% CAGR, Reaching US$ 3.31 Billion by 2034 | Fact.MR Report",
      "url": "https://www.benzinga.com/pressreleases/25/01/g42839593/polyneuropathy-treatment-market-is-projected-to-grow-at-a-4-9-cagr-reaching-us-3-31-billion-by-203",
      "time_published": "20250107T113000",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "Rockville, MD , Jan. 07, 2025 ( GLOBE NEWSWIRE ) -- According to Fact.MR, a market research and competitive intelligence provider, the global Polyneuropathy Treatment Market is set to reach US$ 2.05 billion in 2024 and further expand at a CAGR of 4.9% from 2024 to 2034.",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/25077c2c-0686-4a6c-bb6a-755c24c235f7/polyneuropathy-treatment-market.png",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.327163,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "NVRO",
          "relevance_score": "0.037622",
          "ticker_sentiment_score": "0.077623",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "OMRNF",
          "relevance_score": "0.037622",
          "ticker_sentiment_score": "0.077623",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABT",
          "relevance_score": "0.037622",
          "ticker_sentiment_score": "0.077623",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.037622",
          "ticker_sentiment_score": "0.077623",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "VTRS",
          "relevance_score": "0.037622",
          "ticker_sentiment_score": "0.077623",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ALPMF",
          "relevance_score": "0.037622",
          "ticker_sentiment_score": "0.077623",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.037622",
          "ticker_sentiment_score": "0.077623",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MDT",
          "relevance_score": "0.037622",
          "ticker_sentiment_score": "0.077623",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.037622",
          "ticker_sentiment_score": "0.077623",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors",
      "url": "https://www.globenewswire.com/news-release/2025/06/10/3097167/0/en/Xilio-Therapeutics-Appoints-Akintunde-Bello-Ph-D-to-its-Board-of-Directors.html",
      "time_published": "20250610T203000",
      "authors": [
        "Xilio Therapeutics",
        "Inc."
      ],
      "summary": "WALTHAM, Mass., June 10, 2025 ( GLOBE NEWSWIRE ) -- Xilio Therapeutics, Inc. ( Nasdaq: XLO ) , a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced the appointment of Akintunde ( Tunde ) Bello, ...",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/7e55cc25-f46f-423c-bf2a-e77ebaf69665",
      "source": "GlobeNewswire",
      "category_within_source": "n/a",
      "source_domain": "www.globenewswire.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Economy - Fiscal",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.172734,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "XLO",
          "relevance_score": "0.184176",
          "ticker_sentiment_score": "0.111144",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.037155",
          "ticker_sentiment_score": "0.08097",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.111144",
          "ticker_sentiment_score": "0.088499",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BMY",
          "relevance_score": "0.037155",
          "ticker_sentiment_score": "-0.017332",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Pfizer Stock Before Q1 Earnings Release: To Buy or Not to Buy?",
      "url": "https://www.zacks.com/stock/news/2453318/pfizer-stock-before-q1-earnings-release-to-buy-or-not-to-buy",
      "time_published": "20250423T105800",
      "authors": [
        "Kinjel Shah"
      ],
      "summary": "PFE's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in the first quarter.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/89/447.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.413559"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.997845"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.12871,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.109123",
          "ticker_sentiment_score": "0.002243",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.036476",
          "ticker_sentiment_score": "0.056903",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AZN",
          "relevance_score": "0.036476",
          "ticker_sentiment_score": "0.056903",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.109123",
          "ticker_sentiment_score": "0.002243",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.44783",
          "ticker_sentiment_score": "0.122472",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BNTX",
          "relevance_score": "0.072876",
          "ticker_sentiment_score": "-0.014248",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Clostridium Difficile Infection Treatment Market Size Worth US$ 2.28 Billion by 2034 at a CAGR Of 6.3% | Fact.MR Report",
      "url": "https://www.benzinga.com/pressreleases/25/01/g43156667/clostridium-difficile-infection-treatment-market-size-worth-us-2-28-billion-by-2034-at-a-cagr-of-6",
      "time_published": "20250123T123000",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "Rockville, MD, Jan. 23, 2025 ( GLOBE NEWSWIRE ) -- The global Clostridium difficile infection treatment market has been estimated at US$ 1.24 billion for 2024 and is projected to expand at a CAGR of 6.3% from 2024 to 2034.",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/6066e4d7-3552-4817-9da3-a7d15f10780d/clostridium-difficile-infection-treatment-market.png",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.240954,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "FSNUF",
          "relevance_score": "0.036091",
          "ticker_sentiment_score": "-0.086207",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AZN",
          "relevance_score": "0.036091",
          "ticker_sentiment_score": "-0.086207",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ALPMF",
          "relevance_score": "0.072108",
          "ticker_sentiment_score": "-0.032407",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ANIP",
          "relevance_score": "0.036091",
          "ticker_sentiment_score": "-0.086207",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVS",
          "relevance_score": "0.036091",
          "ticker_sentiment_score": "-0.086207",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.036091",
          "ticker_sentiment_score": "-0.086207",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TEVA",
          "relevance_score": "0.036091",
          "ticker_sentiment_score": "-0.086207",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.107978",
          "ticker_sentiment_score": "-0.062609",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SNY",
          "relevance_score": "0.036091",
          "ticker_sentiment_score": "-0.086207",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Will These 5 Big Drug Stocks Surpass Q4 Earnings Forecasts?",
      "url": "https://www.zacks.com/stock/news/2408529/will-these-5-big-drug-stocks-surpass-q4-earnings-forecasts",
      "time_published": "20250203T162000",
      "authors": [
        "Zacks Equity Research"
      ],
      "summary": "Let's look at five pharma and drug companies, MRK PFE, LLY, AMGN and BMY, which are scheduled to release their fourth-quarter 2024 results later this week.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ab/2180.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.108179"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.176024,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "JNJ",
          "relevance_score": "0.036037",
          "ticker_sentiment_score": "-0.076298",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LLY",
          "relevance_score": "0.248199",
          "ticker_sentiment_score": "-0.060318",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.036037",
          "ticker_sentiment_score": "-0.076298",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AMGN",
          "relevance_score": "0.178724",
          "ticker_sentiment_score": "-0.036173",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.213674",
          "ticker_sentiment_score": "0.001675",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BMY",
          "relevance_score": "0.178724",
          "ticker_sentiment_score": "-0.034724",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SNY",
          "relevance_score": "0.036037",
          "ticker_sentiment_score": "-0.076298",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "GSK Stock Recovers, Rises Around 17% YTD: Time to Buy, Sell or Hold?",
      "url": "https://www.zacks.com/stock/news/2432823/gsk-stock-recovers-rises-around-17-ytd-time-to-buy-sell-or-hold",
      "time_published": "20250320T143200",
      "authors": [
        "Kinjel Shah"
      ],
      "summary": "We suggest that investors who own GSK's stock remain invested for now, considering its sales and profits are expected to continue improving in the coming years.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e0/1871.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.623304"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.183564,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.071784",
          "ticker_sentiment_score": "0.062578",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.035929",
          "ticker_sentiment_score": "0.059725",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HLN",
          "relevance_score": "0.071784",
          "ticker_sentiment_score": "0.177357",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "AZN",
          "relevance_score": "0.035929",
          "ticker_sentiment_score": "0.059725",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.071784",
          "ticker_sentiment_score": "0.062578",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Inside the deal: Roche and Zealand Pharma's $5.3 billion obesity drug gambit",
      "url": "https://www.cnbc.com/2025/05/02/inside-the-deal-roche-zealand-pharmas-5point3-billion-obesity-drug-bet.html",
      "time_published": "20250502T051905",
      "authors": [],
      "summary": "The ballooning obesity drug market may have a new contender after Roche struck a $5.3 billion deal to develop Danish biotech Zealand Pharma's \"next generation\" weight loss drug.",
      "banner_image": null,
      "source": "CNBC",
      "category_within_source": "Top News",
      "source_domain": "www.cnbc.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.181026,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "NVO",
          "relevance_score": "0.071145",
          "ticker_sentiment_score": "-0.126363",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.035608",
          "ticker_sentiment_score": "0.203195",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "TV STARS WALK THE WALK FROM COAST TO COAST AT PANCAN PURPLESTRIDE, THE ULTIMATE WALK TO END PANCREATIC CANCER",
      "url": "https://www.benzinga.com/pressreleases/25/04/n45053477/tv-stars-walk-the-walk-from-coast-to-coast-at-pancan-purplestride-the-ultimate-walk-to-end-pancrea",
      "time_published": "20250428T203300",
      "authors": [
        "PRNewswire"
      ],
      "summary": "Reality Star Joan Vassos, \"Star Trek\" Team, Days of our Lives' Martha Madison & Cast Members and Lisa Niemi Swayze Take Steps to Raise Funds and Awareness for Pancreatic Cancer",
      "banner_image": "https://mma.prnewswire.com/media/2675067/Pancreatic_Cancer_Action_Network_Dr_Nissen__Kitty_Swink__Lisa_Swayze.jpg",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.049316,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "META",
          "relevance_score": "0.035608",
          "ticker_sentiment_score": "0.12504",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RVMD",
          "relevance_score": "0.035608",
          "ticker_sentiment_score": "0.12504",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.035608",
          "ticker_sentiment_score": "0.12504",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "CAR T-Cell Therapy Market to Surge at 40.2% CAGR Over the Next Five Years",
      "url": "https://www.benzinga.com/pressreleases/25/07/g46351503/car-t-cell-therapy-market-to-surge-at-40-2-cagr-over-the-next-five-years",
      "time_published": "20250710T175929",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "Boston, July 10, 2025 ( GLOBE NEWSWIRE ) -- According to the latest study from BCC Research, the \"Current R&D Status of Chimeric Antigen Receptor ( CAR ) T-Cell Therapy Market\" is expected to grow from $4.6 billion in 2024 to $25.1 billion by the end of 2029, at a compound annual growth rate ( ...",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        }
      ],
      "overall_sentiment_score": 0.126647,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ALLO",
          "relevance_score": "0.035555",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.035555",
          "ticker_sentiment_score": "0.017161",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GILD",
          "relevance_score": "0.035555",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BMY",
          "relevance_score": "0.035555",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.07104",
          "ticker_sentiment_score": "0.015091",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors - Xilio Therapeutics  ( NASDAQ:XLO ) ",
      "url": "https://www.benzinga.com/pressreleases/25/06/g45872505/xilio-therapeutics-appoints-akintunde-bello-ph-d-to-its-board-of-directors",
      "time_published": "20250610T203000",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "WALTHAM, Mass., June 10, 2025 ( GLOBE NEWSWIRE ) -- Xilio Therapeutics, Inc. XLO, a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced the appointment of Akintunde ( Tunde ) Bello, Ph.D., to the ...",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Economy - Fiscal",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.650727"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.17748,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "XLO",
          "relevance_score": "0.174587",
          "ticker_sentiment_score": "0.105354",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.035189",
          "ticker_sentiment_score": "0.0795",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.105295",
          "ticker_sentiment_score": "0.085652",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BMY",
          "relevance_score": "0.035189",
          "ticker_sentiment_score": "-0.017192",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Is Eli Lilly Stock a Portfolio Must-Have Pre-Q2 Earnings?",
      "url": "https://www.zacks.com/stock/news/2456514/is-eli-lilly-stock-a-portfolio-must-have-pre-q2-earnings",
      "time_published": "20250428T114500",
      "authors": [
        "Kinjel Shah"
      ],
      "summary": "Investor focus is likely to be on the sales numbers of LLY's tirzepatide medicines Mounjaro and Zepbound.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.983605"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.955357"
        }
      ],
      "overall_sentiment_score": 0.201269,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.401866",
          "ticker_sentiment_score": "0.138251",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "VKTX",
          "relevance_score": "0.070002",
          "ticker_sentiment_score": "0.044462",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.035035",
          "ticker_sentiment_score": "0.042582",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AMGN",
          "relevance_score": "0.070002",
          "ticker_sentiment_score": "0.044462",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.104835",
          "ticker_sentiment_score": "0.048365",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Pharmaceuticals & Medicine Manufacturing Market Set to Surge at 8.9% CAGR, to Reach US$ 2,516.46 Million by 2034 | Fact.MR Report",
      "url": "https://www.benzinga.com/pressreleases/24/12/g42667458/pharmaceuticals-medicine-manufacturing-market-set-to-surge-at-8-9-cagr-to-reach-us-2-516-46-millio",
      "time_published": "20241224T113000",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "Rockville, MD , Dec. 24, 2024 ( GLOBE NEWSWIRE ) -- According to the newly released report by Fact.MR, a market research and competitive intelligence provider, the global Pharmaceuticals & Medicine Manufacturing Market is evaluated to reach US$ 1,073.08 billion in 2024.",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/6e48fdb3-4d93-4cfc-ae26-9bd07c9c98f0/pharmaceuticals-medicine-manufacturing-market.png",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.334998,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "SSNLF",
          "relevance_score": "0.104835",
          "ticker_sentiment_score": "0.018952",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "WUXAY",
          "relevance_score": "0.035035",
          "ticker_sentiment_score": "0.070483",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AZN",
          "relevance_score": "0.035035",
          "ticker_sentiment_score": "0.070483",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.035035",
          "ticker_sentiment_score": "0.070483",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TMO",
          "relevance_score": "0.035035",
          "ticker_sentiment_score": "0.070483",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FUJIF",
          "relevance_score": "0.035035",
          "ticker_sentiment_score": "0.070483",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVS",
          "relevance_score": "0.035035",
          "ticker_sentiment_score": "0.070483",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.035035",
          "ticker_sentiment_score": "0.070483",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.070002",
          "ticker_sentiment_score": "0.017274",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TSOI",
          "relevance_score": "0.035035",
          "ticker_sentiment_score": "0.165496",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "SNY",
          "relevance_score": "0.035035",
          "ticker_sentiment_score": "0.070483",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Sanofi Trades Below 50 & 200-Day Moving Averages: Time to Buy the Dip?",
      "url": "https://www.zacks.com/stock/news/2545097/sanofi-trades-below-50-200-day-moving-averages-time-to-buy-the-dip",
      "time_published": "20250624T135600",
      "authors": [
        "Kinjel Shah"
      ],
      "summary": "SNY trades below key moving averages but strong Dupixent growth, pipeline wins and rising estimates may keep bulls invested.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c3/648.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.999993"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.769861"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.195434,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "VIGL",
          "relevance_score": "0.069697",
          "ticker_sentiment_score": "0.225455",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.034882",
          "ticker_sentiment_score": "0.039912",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BPMC",
          "relevance_score": "0.069697",
          "ticker_sentiment_score": "0.225455",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "AZN",
          "relevance_score": "0.104379",
          "ticker_sentiment_score": "0.021028",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.034882",
          "ticker_sentiment_score": "0.039912",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SNY",
          "relevance_score": "0.542785",
          "ticker_sentiment_score": "0.283913",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Pharma Stock Roundup: PFE's Final Haleon Stake Sale, AZN, SNY M&A Deals",
      "url": "https://www.zacks.com/stock/news/2433580/pharma-stock-roundup-pfes-final-haleon-stake-sale-azn-sny-ma-deals",
      "time_published": "20250321T162600",
      "authors": [
        "Kinjel Shah"
      ],
      "summary": "Pfizer sells 7.3% remaining stake in Haleon. FDA approves the expanded use of JNJ and NVS drugs.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/cc/389.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.266143"
        }
      ],
      "overall_sentiment_score": 0.20039,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.03453",
          "ticker_sentiment_score": "-0.124221",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HLN",
          "relevance_score": "0.303175",
          "ticker_sentiment_score": "0.149687",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AZN",
          "relevance_score": "0.238133",
          "ticker_sentiment_score": "0.061012",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.068995",
          "ticker_sentiment_score": "-0.07524",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.303175",
          "ticker_sentiment_score": "0.136658",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SNY",
          "relevance_score": "0.137474",
          "ticker_sentiment_score": "0.058256",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Is Eli Lilly Stock a Portfolio Must-Have Pre-Q1 Earnings?  ( Revised ) ",
      "url": "https://www.zacks.com/stock/news/2457067/is-eli-lilly-stock-a-portfolio-must-have-pre-q1-earnings-revised",
      "time_published": "20250428T154100",
      "authors": [
        "Kinjel Shah"
      ],
      "summary": "Investor focus is likely to be on the sales numbers of LLY's tirzepatide medicines Mounjaro and Zepbound.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.983605"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.955357"
        }
      ],
      "overall_sentiment_score": 0.196861,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.395012",
          "ticker_sentiment_score": "0.136606",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "VKTX",
          "relevance_score": "0.068698",
          "ticker_sentiment_score": "0.04439",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.034381",
          "ticker_sentiment_score": "0.042485",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AMGN",
          "relevance_score": "0.068698",
          "ticker_sentiment_score": "0.04439",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.102888",
          "ticker_sentiment_score": "0.048059",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Pfizer Stock Down Almost 11% YTD: Should You Buy the Dip?",
      "url": "https://www.zacks.com/stock/news/2490846/pfizer-stock-down-almost-11-ytd-should-you-buy-the-dip",
      "time_published": "20250609T141800",
      "authors": [
        "Kinjel Shah"
      ],
      "summary": "PFE lags the market as COVID sales drop and patent losses loom, but new drugs and cost cuts may fuel a comeback.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/89/447.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.999976"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.839681"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.266143"
        }
      ],
      "overall_sentiment_score": 0.089578,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "AZN",
          "relevance_score": "0.034039",
          "ticker_sentiment_score": "0.069112",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.101869",
          "ticker_sentiment_score": "0.00219",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SMMT",
          "relevance_score": "0.068016",
          "ticker_sentiment_score": "0.024188",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LLY",
          "relevance_score": "0.101869",
          "ticker_sentiment_score": "0.00219",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AKESF",
          "relevance_score": "0.034039",
          "ticker_sentiment_score": "0.023105",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.034039",
          "ticker_sentiment_score": "0.069112",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.582526",
          "ticker_sentiment_score": "-0.031701",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Non-Infectious Macular Edema Treatment Market is Projected to Expand at 6.9% CAGR to US$ 29.6 Billion by 2034 | Fact.MR Report",
      "url": "https://www.benzinga.com/pressreleases/25/02/g43430834/non-infectious-macular-edema-treatment-market-is-projected-to-expand-at-6-9-cagr-to-us-29-6-billio",
      "time_published": "20250203T123000",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "Rockville, MD, Feb. 03, 2025 ( GLOBE NEWSWIRE ) -- The global non-infectious macular edema treatment market is anticipated to secure a valuation of US$ 15,121.9 million in 2024.",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/2aa09658-c5c4-49c6-824c-aa05d30678dc/non-infectious-macular-edema-treatment-market.png",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.108179"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.365898,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CLSD",
          "relevance_score": "0.033846",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BAYZF",
          "relevance_score": "0.033846",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVS",
          "relevance_score": "0.067632",
          "ticker_sentiment_score": "0.117336",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.033846",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AMGN",
          "relevance_score": "0.067632",
          "ticker_sentiment_score": "0.130398",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.134779",
          "ticker_sentiment_score": "0.11717",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BNXYF",
          "relevance_score": "0.033846",
          "ticker_sentiment_score": "0.172844",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Merck Moves Past 50-Day Average: How to Play MRK Stock Now",
      "url": "https://www.zacks.com/stock/news/2553664/merck-moves-past-50-day-average-how-to-play-mrk-stock-now",
      "time_published": "20250625T135900",
      "authors": [
        "Kinjel Shah"
      ],
      "summary": "MRK breaks above its 50-day average but near-term headwinds and weak China sales challenge the bullish case.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/58/608.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.503496"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.891286"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.116745,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "AKESF",
          "relevance_score": "0.033799",
          "ticker_sentiment_score": "0.157596",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "SKXJF",
          "relevance_score": "0.033799",
          "ticker_sentiment_score": "0.050001",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.033799",
          "ticker_sentiment_score": "-0.018238",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DSKYF",
          "relevance_score": "0.033799",
          "ticker_sentiment_score": "0.050001",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MRNA",
          "relevance_score": "0.101154",
          "ticker_sentiment_score": "0.008897",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SMMT",
          "relevance_score": "0.067536",
          "ticker_sentiment_score": "0.163394",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "The Zacks Analyst Blog Highlights Merck, Pfizer, Eli Lilly, Amgen and Bristol Myers Squibb",
      "url": "https://www.zacks.com/stock/news/2408835/the-zacks-analyst-blog-highlights-merck-pfizer-eli-lilly-amgen-and-bristol-myers-squibb",
      "time_published": "20250204T092300",
      "authors": [
        "Zacks Investment Research"
      ],
      "summary": "Merck, Pfizer, Eli Lilly, Amgen and Bristol Myers Squibb are included in this Analyst Blog.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/89/447.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        },
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.178088,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "JNJ",
          "relevance_score": "0.033562",
          "ticker_sentiment_score": "-0.107272",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LLY",
          "relevance_score": "0.263586",
          "ticker_sentiment_score": "-0.049185",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.033562",
          "ticker_sentiment_score": "-0.107272",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AMGN",
          "relevance_score": "0.133655",
          "ticker_sentiment_score": "-0.022792",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.231647",
          "ticker_sentiment_score": "0.001776",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BMY",
          "relevance_score": "0.19931",
          "ticker_sentiment_score": "-0.029643",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SNY",
          "relevance_score": "0.033562",
          "ticker_sentiment_score": "-0.107272",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Genmab Announces Johnson & Johnson Decision Regarding HexaBody\u00ae-CD38",
      "url": "https://www.globenewswire.com/news-release/2025/03/10/3039878/0/en/Genmab-Announces-Johnson-Johnson-Decision-Regarding-HexaBody-CD38.html",
      "time_published": "20250310T141300",
      "authors": [
        "Genmab A/S"
      ],
      "summary": "Company Announcement ...",
      "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/368a5dab-dfc5-4e1d-bfa6-2af5e5216fce",
      "source": "GlobeNewswire",
      "category_within_source": "n/a",
      "source_domain": "www.globenewswire.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.360215"
        }
      ],
      "overall_sentiment_score": 0.090584,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "GMAB",
          "relevance_score": "0.544869",
          "ticker_sentiment_score": "0.169748",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.033098",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.099066",
          "ticker_sentiment_score": "0.01802",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Pfizer Stock Up 5% Following Q1 Results: Time to Buy, Sell or Hold?",
      "url": "https://www.zacks.com/stock/news/2461730/pfizer-stock-up-5-following-q1-results-time-to-buy-sell-or-hold",
      "time_published": "20250505T121000",
      "authors": [
        "Kinjel Shah"
      ],
      "summary": "Investors may stay invested in PFE stock to see how its new growth drivers perform.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/89/447.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.459462"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.983783"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.214378"
        }
      ],
      "overall_sentiment_score": 0.101133,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.09893",
          "ticker_sentiment_score": "0.00217",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.033052",
          "ticker_sentiment_score": "0.068849",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AZN",
          "relevance_score": "0.033052",
          "ticker_sentiment_score": "0.068849",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.09893",
          "ticker_sentiment_score": "0.00217",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.56889",
          "ticker_sentiment_score": "0.041688",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Oral Solid Dosage Contract Manufacturing Market is Expected to Reach a Valuation of US$ 40,776.0 Million by 2034 | Fact.MR Report",
      "url": "https://www.benzinga.com/pressreleases/25/02/g43459094/oral-solid-dosage-contract-manufacturing-market-is-expected-to-reach-a-valuation-of-us-40-776-0-mi",
      "time_published": "20250204T123000",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "Rockville, MD, Feb. 04, 2025 ( GLOBE NEWSWIRE ) -- The global oral solid dosage contract manufacturing market size is projected to reach US$ 26,457.9 million in 2024. The sales of oral solid dosage contract manufacturing are expected to witness a CAGR of 4.4% from 2024 to 2034.",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/190a7cf9-2377-4728-af53-1084f7cc5f61/coal-mining-market-1-.png",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        }
      ],
      "overall_sentiment_score": 0.338009,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "LZAGF",
          "relevance_score": "0.031738",
          "ticker_sentiment_score": "-0.007637",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.031738",
          "ticker_sentiment_score": "-0.007637",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GILD",
          "relevance_score": "0.031738",
          "ticker_sentiment_score": "0.134466",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.031738",
          "ticker_sentiment_score": "0.134466",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TMO",
          "relevance_score": "0.031738",
          "ticker_sentiment_score": "-0.007637",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Merck Q1 Earnings Coming Up: Should You Buy the Stock Now?",
      "url": "https://www.zacks.com/stock/news/2452421/merck-q1-earnings-coming-up-should-you-buy-the-stock-now",
      "time_published": "20250422T113200",
      "authors": [
        "Kinjel Shah"
      ],
      "summary": "When Merck reports first-quarter earnings, investors are likely to focus on the sales of its blockbuster oncology medicine, Keytruda.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/67/1932.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.998626"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.316726"
        }
      ],
      "overall_sentiment_score": 0.127435,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.063341",
          "ticker_sentiment_score": "0.110329",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AKESF",
          "relevance_score": "0.031696",
          "ticker_sentiment_score": "0.15659",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.031696",
          "ticker_sentiment_score": "0.105365",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AZN",
          "relevance_score": "0.157483",
          "ticker_sentiment_score": "0.059326",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.031696",
          "ticker_sentiment_score": "0.105365",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SMMT",
          "relevance_score": "0.063341",
          "ticker_sentiment_score": "0.162702",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Eli Lilly Stock Down 8.2% in a Month: Should You Buy the Dip?",
      "url": "https://www.zacks.com/stock/news/2449616/eli-lilly-stock-down-82-in-a-month-should-you-buy-the-dip",
      "time_published": "20250416T110500",
      "authors": [
        "Kinjel Shah"
      ],
      "summary": "Despite its expensive valuation, we suggest investors hold LLY stock as the company boasts solid growth prospects.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.995077"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.495866"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.096053,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.54734",
          "ticker_sentiment_score": "0.097973",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "VKTX",
          "relevance_score": "0.09439",
          "ticker_sentiment_score": "0.055376",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.031529",
          "ticker_sentiment_score": "-0.022867",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GS",
          "relevance_score": "0.031529",
          "ticker_sentiment_score": "0.025713",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AMGN",
          "relevance_score": "0.125624",
          "ticker_sentiment_score": "0.086521",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.09439",
          "ticker_sentiment_score": "-0.17289",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer - Artiva Biotherapeutics  ( NASDAQ:ARTV ) ",
      "url": "https://www.benzinga.com/pressreleases/25/04/g44700225/artiva-biotherapeutics-appoints-subhashis-banerjee-m-d-as-chief-medical-officer",
      "time_published": "20250408T200500",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "SAN DIEGO, April 08, 2025 ( GLOBE NEWSWIRE ) -- Artiva Biotherapeutics, Inc. ARTV, a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of ...",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.204747,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "KYTX",
          "relevance_score": "0.062434",
          "ticker_sentiment_score": "0.069012",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "VYNE",
          "relevance_score": "0.062434",
          "ticker_sentiment_score": "0.036062",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IGMS",
          "relevance_score": "0.031241",
          "ticker_sentiment_score": "0.051143",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BMRN",
          "relevance_score": "0.031241",
          "ticker_sentiment_score": "0.060501",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.031241",
          "ticker_sentiment_score": "0.036745",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AMGN",
          "relevance_score": "0.062434",
          "ticker_sentiment_score": "0.063047",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ARTV",
          "relevance_score": "0.093531",
          "ticker_sentiment_score": "0.02865",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.031241",
          "ticker_sentiment_score": "0.036745",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BMY",
          "relevance_score": "0.031241",
          "ticker_sentiment_score": "0.029615",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program",
      "url": "https://www.globenewswire.com/news-release/2025/04/17/3063243/0/en/Atea-Pharmaceuticals-Appoints-Howard-H-Berman-to-Board-of-Directors-and-Announces-Share-Repurchase-Program.html",
      "time_published": "20250417T110000",
      "authors": [
        "Atea Pharmaceuticals",
        "Inc."
      ],
      "summary": "Enters into Agreement with Bradley L. Radoff and Michael Torok Enters into Agreement with Bradley L. Radoff and Michael Torok ...",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/1506ab30-7618-4ed0-98de-e3815adb3aa6",
      "source": "GlobeNewswire",
      "category_within_source": "n/a",
      "source_domain": "www.globenewswire.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.891286"
        }
      ],
      "overall_sentiment_score": 0.212276,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "AVIR",
          "relevance_score": "0.062352",
          "ticker_sentiment_score": "0.046026",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "EVR",
          "relevance_score": "0.062352",
          "ticker_sentiment_score": "0.15218",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.0312",
          "ticker_sentiment_score": "0.045441",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "COYA",
          "relevance_score": "0.09341",
          "ticker_sentiment_score": "0.051065",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Royalty Pharma and Revolution Medicines Enter Into Funding Agreements for Up to $2 Billion",
      "url": "https://www.globenewswire.com/news-release/2025/06/24/3104115/0/en/Royalty-Pharma-and-Revolution-Medicines-Enter-Into-Funding-Agreements-for-Up-to-2-Billion.html",
      "time_published": "20250624T110500",
      "authors": [
        "Royalty Pharma plc"
      ],
      "summary": "NEW YORK, June 24, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) today announced a $2 billion funding arrangement with Revolution Medicines, consisting of a synthetic royalty of up to $1.25 billion on daraxonrasib and a senior secured loan of up to $750 million.",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/d605b3b0-7ba0-46e1-a2d4-439ca98694f8",
      "source": "GlobeNewswire",
      "category_within_source": "n/a",
      "source_domain": "www.globenewswire.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.839681"
        }
      ],
      "overall_sentiment_score": 0.142269,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "RVMD",
          "relevance_score": "0.272451",
          "ticker_sentiment_score": "0.152618",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "RPRX",
          "relevance_score": "0.329751",
          "ticker_sentiment_score": "0.205614",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.030878",
          "ticker_sentiment_score": "0.075514",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Disc Medicine Presents Positive Updated Results from Phase 1b Trial in Patients with Myelofibrosis  ( MF )  and Anemia in an Oral Presentation at the 66th American Society of Hematology  ( ASH )  Annual Meeting - Disc Medicine  ( NASDAQ:IRON ) ",
      "url": "https://www.benzinga.com/pressreleases/24/12/g42381718/disc-medicine-presents-positive-updated-results-from-phase-1b-trial-in-patients-with-myelofibrosis",
      "time_published": "20241209T010000",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "Demonstrated durable hematologic response across all patient subgroups, regardless of baseline transfusion status and concomitant JAK inhibitor therapy Phase 2 study in MF anemia has been initiated, enrolling a broad range of patient types WATERTOWN, Mass., Dec. 08, 2024 ( GLOBE NEWSWIRE ) -- ...",
      "banner_image": "https://ml.globenewswire.com/media/ca38ccab-c7d0-43bf-af35-e67b5bc64683/small/disc-med-stacked-logo-one-color-red-1-png.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.495866"
        }
      ],
      "overall_sentiment_score": 0.02657,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "IRON",
          "relevance_score": "0.1185",
          "ticker_sentiment_score": "0.154601",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.029728",
          "ticker_sentiment_score": "-0.085537",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Royalty Pharma and Revolution Medicines Enter Into Funding Agreements for Up to $2 Billion - Royalty Pharma  ( NASDAQ:RPRX ) ",
      "url": "https://www.benzinga.com/pressreleases/25/06/g46070414/royalty-pharma-and-revolution-medicines-enter-into-funding-agreements-for-up-to-2-billion",
      "time_published": "20250624T110500",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "Up to $1.25 billion ( $250 million upfront ) of synthetic royalty funding and up to $750 million in secured debt Innovative partnership enables Revolution Medicines to retain control over pipeline development and global commercialization of daraxonrasib",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.94762"
        }
      ],
      "overall_sentiment_score": 0.151544,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "RVMD",
          "relevance_score": "0.262366",
          "ticker_sentiment_score": "0.181984",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "RPRX",
          "relevance_score": "0.317775",
          "ticker_sentiment_score": "0.197656",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.029691",
          "ticker_sentiment_score": "0.075068",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "PFE vs. MRK: Which Oncology Drug Giant is a Better Buy Now?",
      "url": "https://www.zacks.com/stock/news/2473659/pfe-vs-mrk-which-oncology-drug-giant-is-a-better-buy-now",
      "time_published": "20250519T122900",
      "authors": [
        "Kinjel Shah"
      ],
      "summary": "Both PFE and MRK have strong product and pipeline portfolios in oncology.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/39/612.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.413559"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.988915"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.360215"
        }
      ],
      "overall_sentiment_score": 0.138083,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.088255",
          "ticker_sentiment_score": "-0.028316",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.029472",
          "ticker_sentiment_score": "0.097717",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AZN",
          "relevance_score": "0.029472",
          "ticker_sentiment_score": "0.097717",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.088255",
          "ticker_sentiment_score": "-0.028316",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.517302",
          "ticker_sentiment_score": "0.121627",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Novo Nordisk Plunges 17% in a Month: Buy, Sell or Hold the Stock?",
      "url": "https://www.zacks.com/stock/news/2455205/novo-nordisk-plunges-17-in-a-month-buy-sell-or-hold-the-stock",
      "time_published": "20250424T151800",
      "authors": [
        "Ahan Chakraborty"
      ],
      "summary": "Despite the current downward trend, long-term investors may stay invested in NVO stock due to strong demand for its GLP-1 drugs.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/de/2471.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.999976"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.795202"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.192371,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.175433",
          "ticker_sentiment_score": "0.110739",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "VKTX",
          "relevance_score": "0.088255",
          "ticker_sentiment_score": "0.069085",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.029472",
          "ticker_sentiment_score": "-0.022658",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GS",
          "relevance_score": "0.029472",
          "ticker_sentiment_score": "0.021595",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AMGN",
          "relevance_score": "0.088255",
          "ticker_sentiment_score": "0.069085",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.470048",
          "ticker_sentiment_score": "0.238875",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program - Atea Pharmaceuticals  ( NASDAQ:AVIR ) , Coya Therapeutics  ( NASDAQ:COYA ) ",
      "url": "https://www.benzinga.com/pressreleases/25/04/g44859786/atea-pharmaceuticals-appoints-howard-h-berman-to-board-of-directors-and-announces-share-repurchase",
      "time_published": "20250417T110000",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "BOSTON, April 17, 2025 ( GLOBE NEWSWIRE ) -- Atea Pharmaceuticals, Inc. AVIR ( \"Atea\" or \"Company\" ) , a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the appointment of Howard H.",
      "banner_image": "https://ml.globenewswire.com/media/1506ab30-7618-4ed0-98de-e3815adb3aa6/small/avir-png.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.967645"
        }
      ],
      "overall_sentiment_score": 0.212163,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "AVIR",
          "relevance_score": "0.058544",
          "ticker_sentiment_score": "0.042999",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "EVR",
          "relevance_score": "0.058544",
          "ticker_sentiment_score": "0.152014",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.029292",
          "ticker_sentiment_score": "0.044978",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "COYA",
          "relevance_score": "0.087717",
          "ticker_sentiment_score": "0.050428",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Lilly Down More Than 15% in a Year: Time to Buy, Sell or Hold?",
      "url": "https://www.zacks.com/stock/news/2571338/lilly-down-more-than-15-in-a-year-time-to-buy-sell-or-hold",
      "time_published": "20250710T140900",
      "authors": [
        "Kinjel Shah"
      ],
      "summary": "LLY has slid 15.7% over the past year, but surging demand for Mounjaro and Zepbound could revive the stock's momentum.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.99977"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.857896"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.136208,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "VKTX",
          "relevance_score": "0.086975",
          "ticker_sentiment_score": "0.076126",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.144448",
          "ticker_sentiment_score": "-0.081687",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LLY",
          "relevance_score": "0.510904",
          "ticker_sentiment_score": "0.104327",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.029043",
          "ticker_sentiment_score": "-0.022612",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "VERV",
          "relevance_score": "0.058047",
          "ticker_sentiment_score": "0.068035",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GS",
          "relevance_score": "0.029043",
          "ticker_sentiment_score": "-0.091278",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AMGN",
          "relevance_score": "0.115787",
          "ticker_sentiment_score": "0.10151",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "LLY vs. NVO: Which Weight-Loss Drug Stock is a Stronger Play Now?",
      "url": "https://www.zacks.com/stock/news/2441956/lly-vs-nvo-which-weight-loss-drug-stock-is-a-stronger-play-now",
      "time_published": "20250408T140900",
      "authors": [
        "Kinjel Shah"
      ],
      "summary": "Both LLY and NVO are leading pharmaceutical companies specializing in diabetes and obesity treatments.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/07/905.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.99977"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.938793"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.184289,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "LLY",
          "relevance_score": "0.605266",
          "ticker_sentiment_score": "0.260955",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "VKTX",
          "relevance_score": "0.084722",
          "ticker_sentiment_score": "0.055264",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.028288",
          "ticker_sentiment_score": "-0.02253",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GS",
          "relevance_score": "0.028288",
          "ticker_sentiment_score": "0.011971",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AMGN",
          "relevance_score": "0.084722",
          "ticker_sentiment_score": "0.055264",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.543535",
          "ticker_sentiment_score": "0.309219",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Disc Medicine Presents Positive Updated Results from Phase 1b Trial in Patients with Myelofibrosis  ( MF )  and Anemia in an Oral Presentation at the 66th American Society of Hematology  ( ASH )  Annual Meeting",
      "url": "https://www.globenewswire.com/news-release/2024/12/09/2993429/0/en/Disc-Medicine-Presents-Positive-Updated-Results-from-Phase-1b-Trial-in-Patients-with-Myelofibrosis-MF-and-Anemia-in-an-Oral-Presentation-at-the-66th-American-Society-of-Hematology-.html",
      "time_published": "20241209T010000",
      "authors": [
        "Disc Medicine Inc"
      ],
      "summary": "WATERTOWN, Mass., Dec. 08, 2024 ( GLOBE NEWSWIRE ) -- Disc Medicine, Inc. ( NASDAQ:IRON ) , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today presented ...",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/ca38ccab-c7d0-43bf-af35-e67b5bc64683",
      "source": "GlobeNewswire",
      "category_within_source": "n/a",
      "source_domain": "www.globenewswire.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.310843"
        }
      ],
      "overall_sentiment_score": 0.026541,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "IRON",
          "relevance_score": "0.084622",
          "ticker_sentiment_score": "0.140951",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.028254",
          "ticker_sentiment_score": "-0.086971",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Rare Neurological Disease Treatment Market to Reach USD 115.8 Billion by 2035, Growing at 9.7% CAGR | Fact.MR Report",
      "url": "https://www.benzinga.com/pressreleases/25/03/g44373578/rare-neurological-disease-treatment-market-to-reach-usd-115-8-billion-by-2035-growing-at-9-7-cagr-",
      "time_published": "20250318T113000",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "Rockville, MD, March 18, 2025 ( GLOBE NEWSWIRE ) -- According to Fact.MR, a market research and competitive intelligence provider, the The global rare neurological disease treatment market was valued at USD 41.8 billion in 2024 and has been forecasted to expand at a noteworthy CAGR of 9.7% to ...",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/4abfce90-d0a7-4e26-a186-638034a787ac/rare-neurological-disease-treatment-market.png",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        }
      ],
      "overall_sentiment_score": 0.302345,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "BAYZF",
          "relevance_score": "0.028122",
          "ticker_sentiment_score": "0.071644",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.028122",
          "ticker_sentiment_score": "0.071644",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.028122",
          "ticker_sentiment_score": "0.071644",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ASOMF",
          "relevance_score": "0.028122",
          "ticker_sentiment_score": "-0.030043",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.028122",
          "ticker_sentiment_score": "0.071644",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BIIB",
          "relevance_score": "0.056209",
          "ticker_sentiment_score": "-0.067138",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SNY",
          "relevance_score": "0.028122",
          "ticker_sentiment_score": "0.071644",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Early data suggest Roche's NXT007 may have the potential to provide haemostatic normalisation in people with haemophilia A",
      "url": "https://www.globenewswire.com/news-release/2025/06/23/3103084/0/en/Early-data-suggest-Roche-s-NXT007-may-have-the-potential-to-provide-haemostatic-normalisation-in-people-with-haemophilia-A.html",
      "time_published": "20250623T050000",
      "authors": [
        "F. Hoffmann-La Roche Ltd"
      ],
      "summary": "Basel, 23 June 2025 - Roche ( SIX: RO, ROG. OTCQX: RHHBY ) announced today positive phase I/II data on NXT007 in people with haemophilia A, supporting its progression into phase III clinical development. NXT007 is a next-generation investigational bispecific antibody, engineered by Chugai, a ...",
      "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/696b7c85-2d23-4f5e-a77b-8c6b2fa45d47",
      "source": "GlobeNewswire",
      "category_within_source": "n/a",
      "source_domain": "www.globenewswire.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.173025,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CHGCF",
          "relevance_score": "0.027763",
          "ticker_sentiment_score": "0.109204",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.027763",
          "ticker_sentiment_score": "0.059468",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "OSE Immunotherapeutics Strengthens Leadership and Executive Committee",
      "url": "https://www.globenewswire.com/news-release/2024/12/02/2989994/0/en/OSE-Immunotherapeutics-Strengthens-Leadership-and-Executive-Committee.html",
      "time_published": "20241202T170000",
      "authors": [
        "OSE Immunotherapeutics"
      ],
      "summary": "NANTES, France, December 2, 2024 - 6:00pm CET - OSE Immunotherapeutics SA ( ISIN: FR0012127173. Mnemo: OSE ) , today announced that it has strengthened the company's leadership and executive team with two new appointments.",
      "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/e79ae2c6-fc13-4a02-9759-4ecc9c4fdb22",
      "source": "GlobeNewswire",
      "category_within_source": "n/a",
      "source_domain": "www.globenewswire.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.312743,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "OMC",
          "relevance_score": "0.027635",
          "ticker_sentiment_score": "0.098708",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.027635",
          "ticker_sentiment_score": "0.098708",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SNY",
          "relevance_score": "0.027635",
          "ticker_sentiment_score": "0.098708",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Novo Nordisk Stock Gains 14% in a Month: What Should Investors Do?",
      "url": "https://www.zacks.com/stock/news/2473030/novo-nordisk-stock-gains-14-in-a-month-what-should-investors-do",
      "time_published": "20250516T130700",
      "authors": [
        "Ahan Chakraborty"
      ],
      "summary": "Despite competitive pressures in the obesity market, long-term investors may stay invested in NVO stock due to strong demand for its GLP-1 drugs.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/de/2471.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.25"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.25"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.999976"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.769861"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.25"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.25"
        }
      ],
      "overall_sentiment_score": 0.260242,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CVS",
          "relevance_score": "0.026591",
          "ticker_sentiment_score": "0.168579",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "VKTX",
          "relevance_score": "0.079656",
          "ticker_sentiment_score": "0.046666",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HIMS",
          "relevance_score": "0.026591",
          "ticker_sentiment_score": "0.168579",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.451494",
          "ticker_sentiment_score": "0.290627",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "SEPN",
          "relevance_score": "0.026591",
          "ticker_sentiment_score": "0.101939",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LLY",
          "relevance_score": "0.184497",
          "ticker_sentiment_score": "0.147166",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.026591",
          "ticker_sentiment_score": "0.041363",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GS",
          "relevance_score": "0.026591",
          "ticker_sentiment_score": "0.021276",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AMGN",
          "relevance_score": "0.10607",
          "ticker_sentiment_score": "0.071251",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "HIV Drugs Market Outlook: Future Trends Indicate a US$ 47.5 Billion Industry by 2034 with a Shift Toward Single-dose Regimens | Report by TMR",
      "url": "https://www.benzinga.com/pressreleases/25/03/g44373526/hiv-drugs-market-outlook-future-trends-indicate-a-us-47-5-billion-industry-by-2034-with-a-shift-to",
      "time_published": "20250318T112818",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "Wilmington, Delaware, Transparency Market Research Inc. -, March 18, 2025 ( GLOBE NEWSWIRE ) -- Advancements in antiretroviral therapy and increasing awareness about HIV prevention are driving market growth.",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/3c767b0d-3510-4a27-a724-768b3d3f0078/hiv-drugs-market.jpg",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.273257,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "GOOG",
          "relevance_score": "0.025845",
          "ticker_sentiment_score": "0.050477",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.077426",
          "ticker_sentiment_score": "0.130355",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.025845",
          "ticker_sentiment_score": "-0.054143",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GILD",
          "relevance_score": "0.051663",
          "ticker_sentiment_score": "0.121826",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TEVA",
          "relevance_score": "0.025845",
          "ticker_sentiment_score": "-0.054143",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "WMGTF",
          "relevance_score": "0.077426",
          "ticker_sentiment_score": "0.094368",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GSK",
          "relevance_score": "0.051663",
          "ticker_sentiment_score": "0.121826",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BMY",
          "relevance_score": "0.025845",
          "ticker_sentiment_score": "-0.054143",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Mixue Group's Splashy Debut, Kroger's Change, Stuffed Crust Pizza, and Med Spas",
      "url": "https://www.fool.com/investing/2025/03/10/mixue-groups-splashy-debut-krogers-change-stuffed/",
      "time_published": "20250310T205300",
      "authors": [
        "Motley Fool Staff"
      ],
      "summary": "There's a lot going on for investors.",
      "banner_image": "https://g.foolcdn.com/editorial/images/810166/now-serving-ipos-exits-extra-cheese.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "IPO",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.999999"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.905476"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.144053,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "EOLS",
          "relevance_score": "0.157375",
          "ticker_sentiment_score": "0.134514",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MDNDF",
          "relevance_score": "0.049991",
          "ticker_sentiment_score": "0.093554",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PZZA",
          "relevance_score": "0.016673",
          "ticker_sentiment_score": "0.04927",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SBUX",
          "relevance_score": "0.041668",
          "ticker_sentiment_score": "0.08126",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "KR",
          "relevance_score": "0.074926",
          "ticker_sentiment_score": "0.011202",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LKNCY",
          "relevance_score": "0.008337",
          "ticker_sentiment_score": "0.084498",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "WBD",
          "relevance_score": "0.008337",
          "ticker_sentiment_score": "0.089951",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CZR",
          "relevance_score": "0.008337",
          "ticker_sentiment_score": "0.102855",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.025008",
          "ticker_sentiment_score": "0.090909",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Lilly Moves Past 50-Day Average: Should You Buy the Stock Now?",
      "url": "https://www.zacks.com/stock/news/2498295/lilly-moves-past-50-day-average-should-you-buy-the-stock-now",
      "time_published": "20250613T144100",
      "authors": [
        "Kinjel Shah"
      ],
      "summary": "LLY breaks above its 50-day average as Mounjaro and Zepbound drive revenues. Is this a new entry point for investors?",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.99999"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.795202"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.164022,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CVS",
          "relevance_score": "0.024322",
          "ticker_sentiment_score": "0.053163",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "VKTX",
          "relevance_score": "0.072876",
          "ticker_sentiment_score": "0.047283",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HIMS",
          "relevance_score": "0.048621",
          "ticker_sentiment_score": "0.056928",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.168996",
          "ticker_sentiment_score": "0.02733",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LLY",
          "relevance_score": "0.457977",
          "ticker_sentiment_score": "0.197403",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.024322",
          "ticker_sentiment_score": "-0.022063",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GS",
          "relevance_score": "0.024322",
          "ticker_sentiment_score": "-0.089521",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AMGN",
          "relevance_score": "0.097062",
          "ticker_sentiment_score": "0.070528",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Lilly Down 17% Since Q1 Results: Should You Buy the Dip in LLY Stock?",
      "url": "https://www.zacks.com/stock/news/2470211/lilly-down-17-since-q1-results-should-you-buy-the-dip-in-lly-stock",
      "time_published": "20250514T125100",
      "authors": [
        "Kinjel Shah"
      ],
      "summary": "Despite its expensive valuation and declining estimates, we suggest investors hold LLY stock as the company boasts solid growth prospects.",
      "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
      "source": "Zacks Commentary",
      "category_within_source": "n/a",
      "source_domain": "www.zacks.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.333333"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.990999"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.983783"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.333333"
        }
      ],
      "overall_sentiment_score": 0.122166,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CVS",
          "relevance_score": "0.071499",
          "ticker_sentiment_score": "-0.008229",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "VKTX",
          "relevance_score": "0.071499",
          "ticker_sentiment_score": "0.046216",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HIMS",
          "relevance_score": "0.023861",
          "ticker_sentiment_score": "0.055295",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVO",
          "relevance_score": "0.142425",
          "ticker_sentiment_score": "0.0168",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LLY",
          "relevance_score": "0.470072",
          "ticker_sentiment_score": "0.11396",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.023861",
          "ticker_sentiment_score": "-0.022005",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GS",
          "relevance_score": "0.023861",
          "ticker_sentiment_score": "0.024743",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AMGN",
          "relevance_score": "0.095233",
          "ticker_sentiment_score": "0.069149",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "CytomX Announces Positive Interim Data From Phase 1 Dose Escalation Study of EpCAM Antibody Drug Conjugate  ( CX-2051 )  Candidate in Patients with Advanced Colorectal Cancer  ( CRC ) ",
      "url": "https://www.globenewswire.com/news-release/2025/05/12/3078935/37704/en/CytomX-Announces-Positive-Interim-Data-From-Phase-1-Dose-Escalation-Study-of-EpCAM-Antibody-Drug-Conjugate-CX-2051-Candidate-in-Patients-with-Advanced-Colorectal-Cancer-CRC.html",
      "time_published": "20250512T101500",
      "authors": [
        "CytomX Therapeutics Inc."
      ],
      "summary": "- 28% confirmed response rate ( 5/18 ) per RECIST v1.1 in unselected patients across doses prioritized for expansion ( 7.2, 8.6 and ...",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/c252869d-a4c1-4e56-88e8-d80b85d20c35",
      "source": "GlobeNewswire",
      "category_within_source": "n/a",
      "source_domain": "www.globenewswire.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.071693,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.023395",
          "ticker_sentiment_score": "-0.008137",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CTMX",
          "relevance_score": "0.162646",
          "ticker_sentiment_score": "0.087809",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MRNA",
          "relevance_score": "0.023395",
          "ticker_sentiment_score": "0.047997",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BMY",
          "relevance_score": "0.023395",
          "ticker_sentiment_score": "0.047997",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Royalty Pharma Announces Shareholder Approval of its External Manager Acquisition",
      "url": "https://www.globenewswire.com/news-release/2025/05/12/3079577/0/en/Royalty-Pharma-Announces-Shareholder-Approval-of-its-External-Manager-Acquisition.html",
      "time_published": "20250512T201500",
      "authors": [
        "Royalty Pharma plc"
      ],
      "summary": "NEW YORK, May 12, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) today announced that shareholders overwhelmingly approved its previously announced external manager acquisition, with 99.9% voting in favor at Royalty Pharma's 2025 Annual General Meeting and Special Meeting of ...",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/d605b3b0-7ba0-46e1-a2d4-439ca98694f8",
      "source": "GlobeNewswire",
      "category_within_source": "n/a",
      "source_domain": "www.globenewswire.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.316726"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.999701"
        }
      ],
      "overall_sentiment_score": 0.285615,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "BEVFF",
          "relevance_score": "0.023214",
          "ticker_sentiment_score": "0.336308",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "RPRX",
          "relevance_score": "0.399557",
          "ticker_sentiment_score": "0.282136",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.023214",
          "ticker_sentiment_score": "0.069617",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Autoinjectors Market is expected to generate a revenue of USD 317.01 Billion by 2031, Globally, at 23.20% CAGR: Verified Market Research\u00ae",
      "url": "https://www.benzinga.com/pressreleases/25/05/g45519080/autoinjectors-market-is-expected-to-generate-a-revenue-of-usd-317-01-billion-by-2031-globally-at-2",
      "time_published": "20250520T140000",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "Lewes, Delaware, May 20, 2025 ( GLOBE NEWSWIRE ) -- The Global Autoinjectors Market Size is projected to grow at a CAGR of 23.20% from 2024 to 2031, according to a new report published by Verified Market Research\u00ae.",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.161647"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.161647"
        }
      ],
      "overall_sentiment_score": 0.220772,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.023102",
          "ticker_sentiment_score": "0.068655",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AZN",
          "relevance_score": "0.023102",
          "ticker_sentiment_score": "0.068655",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BIIB",
          "relevance_score": "0.023102",
          "ticker_sentiment_score": "0.068655",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RSSS",
          "relevance_score": "0.023102",
          "ticker_sentiment_score": "0.164948",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "FDA accepts supplemental Biologics License Application for Roche's Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma",
      "url": "https://www.globenewswire.com/news-release/2024/12/05/2992057/0/en/FDA-accepts-supplemental-Biologics-License-Application-for-Roche-s-Columvi-combination-for-people-with-relapsed-or-refractory-diffuse-large-B-cell-lymphoma.html",
      "time_published": "20241205T060000",
      "authors": [
        "F. Hoffmann-La Roche Ltd"
      ],
      "summary": "Basel, 5 December 2024 - Roche ( SIX: RO, ROG. OTCQX: RHHBY ) announced today that the U.S. Food and Drug Administration ( FDA ) has accepted the company's supplemental Biologics License Application ( sBLA ) for Columvi\u00ae ( glofitamab ) in combination with gemcitabine and oxaliplatin ( GemOx ) for ...",
      "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/696b7c85-2d23-4f5e-a77b-8c6b2fa45d47",
      "source": "GlobeNewswire",
      "category_within_source": "n/a",
      "source_domain": "www.globenewswire.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.218561,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CHGCF",
          "relevance_score": "0.02275",
          "ticker_sentiment_score": "0.106267",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.02275",
          "ticker_sentiment_score": "0.057832",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Royalty Pharma Announces Shareholder Approval of its External Manager Acquisition - Royalty Pharma  ( NASDAQ:RPRX ) ",
      "url": "https://www.benzinga.com/pressreleases/25/05/g45359927/royalty-pharma-announces-shareholder-approval-of-its-external-manager-acquisition",
      "time_published": "20250512T201500",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "Received overwhelming shareholder approval with 99.9% of votes cast in favor Simplified structure benefits shareholders through strengthened shareholder alignment, enhanced governance, significant cash savings and increased economic return on investments",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "Mergers",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.316726"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.999967"
        }
      ],
      "overall_sentiment_score": 0.287833,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "BEVFF",
          "relevance_score": "0.0226",
          "ticker_sentiment_score": "0.284109",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "RPRX",
          "relevance_score": "0.389889",
          "ticker_sentiment_score": "0.274938",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.0226",
          "ticker_sentiment_score": "0.069347",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Five-year results confirm Roche's Polivy combination therapy as new standard of care for previously untreated aggressive lymphoma",
      "url": "https://www.globenewswire.com/news-release/2024/12/08/2993402/0/en/Five-year-results-confirm-Roche-s-Polivy-combination-therapy-as-new-standard-of-care-for-previously-untreated-aggressive-lymphoma.html",
      "time_published": "20241208T173000",
      "authors": [
        "F. Hoffmann-La Roche Ltd"
      ],
      "summary": "Basel, 8 December 2024 - Roche ( SIX: RO, ROG. OTCQX: RHHBY ) announced today data from a five-year follow-up of the pivotal phase III POLARIX study evaluating Polivy\u00ae ( polatuzumab vedotin ) in combination with MabThera\u00ae/Rituxan\u00ae ( rituximab ) , cyclophosphamide, doxorubicin and prednisone ( ...",
      "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/696b7c85-2d23-4f5e-a77b-8c6b2fa45d47",
      "source": "GlobeNewswire",
      "category_within_source": "n/a",
      "source_domain": "www.globenewswire.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.175979,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CHGCF",
          "relevance_score": "0.022347",
          "ticker_sentiment_score": "0.106014",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.022347",
          "ticker_sentiment_score": "0.008287",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.022347",
          "ticker_sentiment_score": "0.060492",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "CHMP recommends EU approval of Roche's Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma",
      "url": "https://www.globenewswire.com/news-release/2025/02/28/3034718/0/en/CHMP-recommends-EU-approval-of-Roche-s-Columvi-combination-for-people-with-relapsed-or-refractory-diffuse-large-B-cell-lymphoma.html",
      "time_published": "20250228T131500",
      "authors": [
        "F. Hoffmann-La Roche Ltd"
      ],
      "summary": "Basel, 28 February 2025 - Roche ( SIX: RO, ROG. OTCQX: RHHBY ) announced today that the European Medicines Agency's Committee for Medicinal Products for Human Use ( CHMP ) has recommended the approval of Columvi\u00ae ( glofitamab ) in combination with gemcitabine and oxaliplatin ( GemOx ) for the ...",
      "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/696b7c85-2d23-4f5e-a77b-8c6b2fa45d47",
      "source": "GlobeNewswire",
      "category_within_source": "n/a",
      "source_domain": "www.globenewswire.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.137449,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CHGCF",
          "relevance_score": "0.022222",
          "ticker_sentiment_score": "0.105936",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.022222",
          "ticker_sentiment_score": "0.057647",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "European Commission approves Roche's Columvi as the first bispecific antibody for diffuse large B-cell lymphoma after initial therapy",
      "url": "https://www.globenewswire.com/news-release/2025/04/14/3060614/0/en/European-Commission-approves-Roche-s-Columvi-as-the-first-bispecific-antibody-for-diffuse-large-B-cell-lymphoma-after-initial-therapy.html",
      "time_published": "20250414T050000",
      "authors": [
        "F. Hoffmann-La Roche Ltd"
      ],
      "summary": "Basel, 14 April 2025 - Roche ( SIX: RO, ROG. OTCQX: RHHBY ) announced today that the European Commission has approved Columvi\u00ae ( glofitamab ) in combination with gemcitabine and oxaliplatin ( GemOx ) for the treatment of adult patients with relapsed or refractory ( R/R ) diffuse large B-cell ...",
      "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/696b7c85-2d23-4f5e-a77b-8c6b2fa45d47",
      "source": "GlobeNewswire",
      "category_within_source": "n/a",
      "source_domain": "www.globenewswire.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.149693,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CHGCF",
          "relevance_score": "0.021504",
          "ticker_sentiment_score": "0.105479",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.021504",
          "ticker_sentiment_score": "0.057391",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Sionna Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results",
      "url": "https://www.globenewswire.com/news-release/2025/03/20/3046084/0/en/Sionna-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results.html",
      "time_published": "20250320T110000",
      "authors": [
        "Sionna Therapeutics",
        "Inc."
      ],
      "summary": "Phase 1 MAD dosing completed for SION-451 and final MAD cohort of SION-719 planned. Interim data in healthy volunteers show potential to provide clinically meaningful benefit to CF patients. Topline data anticipated in first half of ...",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/0cda8c25-e758-4f0d-86f2-875df8411a9a",
      "source": "GlobeNewswire",
      "category_within_source": "n/a",
      "source_domain": "www.globenewswire.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "IPO",
          "relevance_score": "0.928139"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.938793"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.451494"
        }
      ],
      "overall_sentiment_score": 0.104857,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ABBV",
          "relevance_score": "0.021143",
          "ticker_sentiment_score": "0.056995",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SION",
          "relevance_score": "0.618186",
          "ticker_sentiment_score": "0.185406",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Roche's Lunsumio and Polivy combination significantly prolongs remission for people with relapsed or refractory large B-cell lymphoma",
      "url": "https://www.globenewswire.com/news-release/2025/06/20/3102847/0/en/Roche-s-Lunsumio-and-Polivy-combination-significantly-prolongs-remission-for-people-with-relapsed-or-refractory-large-B-cell-lymphoma.html",
      "time_published": "20250620T154500",
      "authors": [
        "F. Hoffmann-La Roche Ltd"
      ],
      "summary": "Basel, 20 June 2025 - Roche ( SIX: RO, ROG. OTCQX: RHHBY ) presented today results from the phase III SUNMO [NCT05171647] study showing Lunsumio\u00ae ( mosunetuzumab ) administered subcutaneously in combination with Polivy\u00ae ( polatuzumab vedotin ) demonstrated a clinically meaningful and ...",
      "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/696b7c85-2d23-4f5e-a77b-8c6b2fa45d47",
      "source": "GlobeNewswire",
      "category_within_source": "n/a",
      "source_domain": "www.globenewswire.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.150694,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CHGCF",
          "relevance_score": "0.020562",
          "ticker_sentiment_score": "0.10487",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.020562",
          "ticker_sentiment_score": "-0.03775",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.020562",
          "ticker_sentiment_score": "0.05705",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "New two-year follow-up of Roche's Columvi extends overall survival in relapsed or refractory diffuse large B-cell lymphoma patients",
      "url": "https://www.globenewswire.com/news-release/2025/05/23/3087237/0/en/New-two-year-follow-up-of-Roche-s-Columvi-extends-overall-survival-in-relapsed-or-refractory-diffuse-large-B-cell-lymphoma-patients.html",
      "time_published": "20250523T050000",
      "authors": [
        "F. Hoffmann-La Roche Ltd"
      ],
      "summary": "Basel, 23 May 2025 - Roche ( SIX: RO, ROG. OTCQX: RHHBY ) announced today two-year follow-up data from the phase III STARGLO study. After a median follow-up of 24.7 months, data showed a 40% improvement in overall survival ( OS ) for patients treated with Columvi\u00ae ( glofitamab ) in combination ...",
      "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/696b7c85-2d23-4f5e-a77b-8c6b2fa45d47",
      "source": "GlobeNewswire",
      "category_within_source": "n/a",
      "source_domain": "www.globenewswire.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.13068,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CHGCF",
          "relevance_score": "0.019846",
          "ticker_sentiment_score": "0.104398",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.019846",
          "ticker_sentiment_score": "0.056785",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Xilio Therapeutics Announces Updated Phase 2 Data for Vilastobart, a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer - Xilio Therapeutics  ( NASDAQ:XLO ) ",
      "url": "https://www.benzinga.com/pressreleases/25/05/g45709802/xilio-therapeutics-announces-updated-phase-2-data-for-vilastobart-a-tumor-activated-anti-ctla-4-in",
      "time_published": "20250531T120000",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "26% preliminary objective response rate observed in heavily pre-treated patients with metastatic microsatellite stable colorectal cancer ( MSS CRC ) without liver metastases",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Economy - Fiscal",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.650727"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.099843,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "XLO",
          "relevance_score": "0.074984",
          "ticker_sentiment_score": "-0.017307",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.018772",
          "ticker_sentiment_score": "0.063558",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Royalty Pharma to Highlight Accomplishments and Provide Business Update at 43rd Annual J.P. Morgan Healthcare Conference",
      "url": "https://www.globenewswire.com/news-release/2025/01/10/3007593/0/en/Royalty-Pharma-to-Highlight-Accomplishments-and-Provide-Business-Update-at-43rd-Annual-J-P-Morgan-Healthcare-Conference.html",
      "time_published": "20250110T123000",
      "authors": [
        "Royalty Pharma plc"
      ],
      "summary": "NEW YORK, Jan. 10, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) today provided an update on its business performance, including recent key accomplishments, and the full year 2024 outlook for Portfolio Receipts. Pablo Legorreta, Royalty Pharma's founder and Chief Executive ...",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/d605b3b0-7ba0-46e1-a2d4-439ca98694f8",
      "source": "GlobeNewswire",
      "category_within_source": "n/a",
      "source_domain": "www.globenewswire.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.623304"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.918141"
        }
      ],
      "overall_sentiment_score": 0.170322,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "BEVFF",
          "relevance_score": "0.018411",
          "ticker_sentiment_score": "0.055024",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RPRX",
          "relevance_score": "0.338948",
          "ticker_sentiment_score": "0.221769",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.018411",
          "ticker_sentiment_score": "0.070078",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Xilio Therapeutics Announces Updated Phase 2 Data for Vilastobart, a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer",
      "url": "https://www.globenewswire.com/news-release/2025/05/31/3091401/0/en/Xilio-Therapeutics-Announces-Updated-Phase-2-Data-for-Vilastobart-a-Tumor-Activated-Anti-CTLA-4-in-Combination-with-Atezolizumab-in-Patients-with-Metastatic-Microsatellite-Stable-C.html",
      "time_published": "20250531T120000",
      "authors": [
        "Xilio Therapeutics",
        "Inc."
      ],
      "summary": "26% preliminary objective response rate observed in heavily pre-treated patients with metastatic microsatellite stable colorectal cancer ( MSS CRC ) without liver metastases ...",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/7e55cc25-f46f-423c-bf2a-e77ebaf69665",
      "source": "GlobeNewswire",
      "category_within_source": "n/a",
      "source_domain": "www.globenewswire.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Economy - Fiscal",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.310843"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.095206,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "XLO",
          "relevance_score": "0.0726",
          "ticker_sentiment_score": "-0.017254",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.018173",
          "ticker_sentiment_score": "0.063331",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Psychedelic Science 2025 Expands Business Track, Announces Select Speakers and Featured Sessions",
      "url": "https://www.benzinga.com/pressreleases/25/05/g45287015/psychedelic-science-2025-expands-business-track-announces-select-speakers-and-featured-sessions",
      "time_published": "20250508T135421",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "Investors, Entrepreneurs, and Industry Experts to Convene at the Premier Psychedelic Science Business Forum in Denver this June Featured Speakers Include Doug Drysdale, Kabir Nath, Dan Grossman, Sherry Rais, Lucia Huang, Nanea Reeves, Josh Hardman, Protik Basu, Neil Buddy Shah, M.D., Cosmo ...",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.365926"
        }
      ],
      "overall_sentiment_score": 0.212295,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "META",
          "relevance_score": "0.018077",
          "ticker_sentiment_score": "0.030541",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CMPS",
          "relevance_score": "0.036146",
          "ticker_sentiment_score": "0.112254",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.018077",
          "ticker_sentiment_score": "0.057998",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Roche provides update on FDA Advisory Committee meeting on Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma",
      "url": "https://www.globenewswire.com/news-release/2025/05/20/3085224/0/en/Roche-provides-update-on-FDA-Advisory-Committee-meeting-on-Columvi-combination-for-people-with-relapsed-or-refractory-diffuse-large-B-cell-lymphoma.html",
      "time_published": "20250520T184000",
      "authors": [
        "F. Hoffmann-La Roche Ltd"
      ],
      "summary": "Basel, 20 May 2025 - Roche ( SIX: RO, ROG. OTCQX: RHHBY ) announced today that a US Food and Drug Administration ( FDA ) Oncologic Drugs Advisory Committee ( ODAC ) discussed the supplemental Biologics License Application ( sBLA ) for Columvi\u00ae ( glofitamab ) in combination with gemcitabine and ...",
      "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/696b7c85-2d23-4f5e-a77b-8c6b2fa45d47",
      "source": "GlobeNewswire",
      "category_within_source": "n/a",
      "source_domain": "www.globenewswire.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.139186,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CHGCF",
          "relevance_score": "0.017955",
          "ticker_sentiment_score": "0.10312",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.017955",
          "ticker_sentiment_score": "0.056067",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi\u00ae and Simponi Aria\u00ae  ( golimumab ) ",
      "url": "https://www.globenewswire.com/news-release/2025/01/27/3015416/0/en/Alvotech-and-Teva-Announce-Filing-Acceptance-of-U-S-Biologics-License-Applications-for-AVT05-a-Proposed-Biosimilar-to-Simponi-and-Simponi-Aria-golimumab.html",
      "time_published": "20250127T110000",
      "authors": [
        "Alvotech"
      ],
      "summary": "Alvotech ( NASDAQ: ALVO ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. ( NYSE and TASE: TEVA ) , today announced that the U.S.",
      "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/17a8091d-68a6-47c1-968e-fcced99f1d44",
      "source": "GlobeNewswire",
      "category_within_source": "n/a",
      "source_domain": "www.globenewswire.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.614606"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.155725,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ALVO",
          "relevance_score": "0.437454",
          "ticker_sentiment_score": "0.212956",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.017769",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TEVA",
          "relevance_score": "0.088668",
          "ticker_sentiment_score": "0.089214",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "KMDA",
          "relevance_score": "0.017769",
          "ticker_sentiment_score": "0.058094",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LTUS",
          "relevance_score": "0.017769",
          "ticker_sentiment_score": "0.058094",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.017769",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi\u00ae and Simponi Aria\u00ae  ( golimumab ) ",
      "url": "https://www.globenewswire.com/news-release/2025/01/27/3015409/0/en/Alvotech-and-Teva-Announce-Filing-Acceptance-of-U-S-Biologics-License-Applications-for-AVT05-a-Proposed-Biosimilar-to-Simponi-and-Simponi-Aria-golimumab.html",
      "time_published": "20250127T110000",
      "authors": [
        "Teva Pharmaceutical Industries Ltd"
      ],
      "summary": "REYKJAVIK, Iceland and PARSIPPANY, N.J., Jan. 27, 2025 ( GLOBE NEWSWIRE ) -- Alvotech ( NASDAQ: ALVO ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical ...",
      "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/c2001734-949b-4cc2-8021-b4b64eda1f13",
      "source": "GlobeNewswire",
      "category_within_source": "n/a",
      "source_domain": "www.globenewswire.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.614606"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.153375,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ALVO",
          "relevance_score": "0.435433",
          "ticker_sentiment_score": "0.209495",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.017677",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TEVA",
          "relevance_score": "0.088211",
          "ticker_sentiment_score": "0.087037",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "KMDA",
          "relevance_score": "0.017677",
          "ticker_sentiment_score": "0.058056",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LTUS",
          "relevance_score": "0.017677",
          "ticker_sentiment_score": "0.058056",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.017677",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi\u00ae and Simponi Aria\u00ae  ( golimumab ) ",
      "url": "https://www.globenewswire.com/news-release/2025/01/27/3015410/0/en/Alvotech-and-Teva-Announce-Filing-Acceptance-of-U-S-Biologics-License-Applications-for-AVT05-a-Proposed-Biosimilar-to-Simponi-and-Simponi-Aria-golimumab.html",
      "time_published": "20250127T110000",
      "authors": [
        "Alvotech"
      ],
      "summary": "REYKJAVIK, Iceland and PARSIPPANY, N.J., Jan. 27, 2025 ( GLOBE NEWSWIRE ) -- Alvotech ( NASDAQ: ALVO ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical ...",
      "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/17a8091d-68a6-47c1-968e-fcced99f1d44",
      "source": "GlobeNewswire",
      "category_within_source": "n/a",
      "source_domain": "www.globenewswire.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.614606"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.153375,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ALVO",
          "relevance_score": "0.435433",
          "ticker_sentiment_score": "0.209495",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.017677",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TEVA",
          "relevance_score": "0.088211",
          "ticker_sentiment_score": "0.087037",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "KMDA",
          "relevance_score": "0.017677",
          "ticker_sentiment_score": "0.058056",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LTUS",
          "relevance_score": "0.017677",
          "ticker_sentiment_score": "0.058056",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.017677",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Nxera Pharma Operational Highlights and Consolidated Results for the Fourth Quarter and Full Year 2024",
      "url": "https://www.globenewswire.com/news-release/2025/02/14/3026423/0/en/Nxera-Pharma-Operational-Highlights-and-Consolidated-Results-for-the-Fourth-Quarter-and-Full-Year-2024.html",
      "time_published": "20250214T063000",
      "authors": [
        "Nxera Pharma"
      ],
      "summary": "Tokyo, Japan and Cambridge, UK, 14 February 2025 - Nxera Pharma Co., Ltd. ( \"Nxera\" or \"the Company\". TSE 4565 ) provides an update on operational activities and reports its consolidated results for the fourth quarter and 12 months ended 31 December 2024. The full report can be viewed here.",
      "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/5cc74d52-c86f-4e21-8684-3496281fee15",
      "source": "GlobeNewswire",
      "category_within_source": "n/a",
      "source_domain": "www.globenewswire.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.684621"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.744043"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.214409,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "GOOG",
          "relevance_score": "0.017612",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.017612",
          "ticker_sentiment_score": "0.060429",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SOLTF",
          "relevance_score": "0.017612",
          "ticker_sentiment_score": "0.060429",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "IDRSF",
          "relevance_score": "0.017612",
          "ticker_sentiment_score": "0.056958",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BMY",
          "relevance_score": "0.017612",
          "ticker_sentiment_score": "0.109414",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SGIOF",
          "relevance_score": "0.035215",
          "ticker_sentiment_score": "0.131041",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FOREX:JPY",
          "relevance_score": "0.418967",
          "ticker_sentiment_score": "0.269561",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "New and updated data for Roche's fixed-duration Columvi and Lunsumio at ASH 2024 reinforce their potential to improve outcomes for people with lymphoma",
      "url": "https://www.globenewswire.com/news-release/2024/12/10/2994191/0/en/New-and-updated-data-for-Roche-s-fixed-duration-Columvi-and-Lunsumio-at-ASH-2024-reinforce-their-potential-to-improve-outcomes-for-people-with-lymphoma.html",
      "time_published": "20241210T060000",
      "authors": [
        "F. Hoffmann-La Roche Ltd"
      ],
      "summary": "Basel, 10 December 2024 - Roche ( SIX: RO, ROG. OTCQX: RHHBY ) announced today that new and updated data from its industry-leading CD20xCD3 T-cell-engaging bispecific antibody programme were presented at the 66th American Society of Hematology ( ASH ) Annual Meeting & Exposition, 7-10 December ...",
      "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/696b7c85-2d23-4f5e-a77b-8c6b2fa45d47",
      "source": "GlobeNewswire",
      "category_within_source": "n/a",
      "source_domain": "www.globenewswire.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.182751,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CHGCF",
          "relevance_score": "0.017483",
          "ticker_sentiment_score": "0.102794",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.017483",
          "ticker_sentiment_score": "-0.037072",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.017483",
          "ticker_sentiment_score": "0.042578",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi\u00ae and Simponi Aria\u00ae  ( golimumab )  - Alvotech  ( NASDAQ:ALVO ) ",
      "url": "https://www.benzinga.com/pressreleases/25/01/g43222798/alvotech-and-teva-announce-filing-acceptance-of-u-s-biologics-license-applications-for-avt05-a-pro",
      "time_published": "20250127T110000",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "REYKJAVIK, Iceland and PARSIPPANY, N.J., Jan. 27, 2025 ( GLOBE NEWSWIRE ) -- Alvotech ALVO, a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. ( ...",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.744043"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.108179"
        }
      ],
      "overall_sentiment_score": 0.150802,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ALVO",
          "relevance_score": "0.467734",
          "ticker_sentiment_score": "0.204454",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.017182",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TEVA",
          "relevance_score": "0.085751",
          "ticker_sentiment_score": "0.078265",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "KMDA",
          "relevance_score": "0.017182",
          "ticker_sentiment_score": "0.048946",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LTUS",
          "relevance_score": "0.017182",
          "ticker_sentiment_score": "0.048946",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.017182",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Atea Pharmaceuticals to Host Virtual HCV KOL Panel on May 14, 2025 - Atea Pharmaceuticals  ( NASDAQ:AVIR ) ",
      "url": "https://www.benzinga.com/pressreleases/25/05/g45129609/atea-pharmaceuticals-to-host-virtual-hcv-kol-panel-on-may-14-2025",
      "time_published": "20250501T110000",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "Panel to Discuss Current Challenges Encountered by Patients with HCV, Results from Atea's Phase 2 Study of the Regimen of Bemnifosbuvir and Ruzasvir, and What a New Optimized HCV Therapy Could Provide for Prescribers and Patients Event to Replace Atea's First Quarter 2025 Earnings Conference Call.",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.77141"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.05908,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "AVIR",
          "relevance_score": "0.042571",
          "ticker_sentiment_score": "0.012748",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.014196",
          "ticker_sentiment_score": "0.051807",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MCLE",
          "relevance_score": "0.014196",
          "ticker_sentiment_score": "0.051807",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HNST",
          "relevance_score": "0.014196",
          "ticker_sentiment_score": "0.027822",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "VIR",
          "relevance_score": "0.014196",
          "ticker_sentiment_score": "0.051807",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Alvotech Reports Results for the First Quarter of 2025 and Provides Business Update",
      "url": "https://www.globenewswire.com/news-release/2025/05/07/3076668/0/en/Alvotech-Reports-Results-for-the-First-Quarter-of-2025-and-Provides-Business-Update.html",
      "time_published": "20250507T204500",
      "authors": [
        "Alvotech"
      ],
      "summary": "REYKJAVIK, Iceland, May 07, 2025 ( GLOBE NEWSWIRE ) -- Alvotech ( NASDAQ: ALVO, or the \"Company\" ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported financial results for the first quarter of 2025 and ...",
      "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/17a8091d-68a6-47c1-968e-fcced99f1d44",
      "source": "GlobeNewswire",
      "category_within_source": "n/a",
      "source_domain": "www.globenewswire.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.875462"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.99676"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.127446,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "GOOG",
          "relevance_score": "0.013137",
          "ticker_sentiment_score": "0.090833",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "META",
          "relevance_score": "0.013137",
          "ticker_sentiment_score": "0.090833",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LTUS",
          "relevance_score": "0.013137",
          "ticker_sentiment_score": "0.056148",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BAYZF",
          "relevance_score": "0.013137",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.013137",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ALVO",
          "relevance_score": "0.390248",
          "ticker_sentiment_score": "0.185847",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "NVS",
          "relevance_score": "0.013137",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.013137",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TEVA",
          "relevance_score": "0.013137",
          "ticker_sentiment_score": "0.056148",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "KMDA",
          "relevance_score": "0.013137",
          "ticker_sentiment_score": "0.056148",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "REGN",
          "relevance_score": "0.013137",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AMGN",
          "relevance_score": "0.013137",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FOREX:ISK",
          "relevance_score": "0.013137",
          "ticker_sentiment_score": "0.083949",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FOREX:SEK",
          "relevance_score": "0.013137",
          "ticker_sentiment_score": "0.083949",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FOREX:USD",
          "relevance_score": "0.02627",
          "ticker_sentiment_score": "0.090148",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Alvotech Reports Results for the First Quarter of 2025 and Provides Business Update",
      "url": "https://www.globenewswire.com/news-release/2025/05/07/3076669/0/en/Alvotech-Reports-Results-for-the-First-Quarter-of-2025-and-Provides-Business-Update.html",
      "time_published": "20250507T204500",
      "authors": [
        "Alvotech"
      ],
      "summary": "REYKJAVIK, Iceland, May 7, 2025 - Alvotech ( NASDAQ: ALVO, or the \"Company\" ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported financial results for the first quarter of 2025 and provided a summary of recent ...",
      "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/17a8091d-68a6-47c1-968e-fcced99f1d44",
      "source": "GlobeNewswire",
      "category_within_source": "n/a",
      "source_domain": "www.globenewswire.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.875462"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.99676"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.127486,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "GOOG",
          "relevance_score": "0.01291",
          "ticker_sentiment_score": "0.090675",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "META",
          "relevance_score": "0.01291",
          "ticker_sentiment_score": "0.090675",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LTUS",
          "relevance_score": "0.01291",
          "ticker_sentiment_score": "0.056046",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BAYZF",
          "relevance_score": "0.01291",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.01291",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ALVO",
          "relevance_score": "0.384064",
          "ticker_sentiment_score": "0.186328",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "NVS",
          "relevance_score": "0.01291",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.01291",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TEVA",
          "relevance_score": "0.01291",
          "ticker_sentiment_score": "0.056046",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "KMDA",
          "relevance_score": "0.01291",
          "ticker_sentiment_score": "0.056046",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "REGN",
          "relevance_score": "0.01291",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AMGN",
          "relevance_score": "0.01291",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FOREX:ISK",
          "relevance_score": "0.01291",
          "ticker_sentiment_score": "0.083823",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FOREX:SEK",
          "relevance_score": "0.01291",
          "ticker_sentiment_score": "0.083823",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FOREX:USD",
          "relevance_score": "0.025817",
          "ticker_sentiment_score": "0.089973",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Royalty Pharma Reports First Quarter 2025 Results",
      "url": "https://www.globenewswire.com/news-release/2025/05/08/3077107/0/en/Royalty-Pharma-Reports-First-Quarter-2025-Results.html",
      "time_published": "20250508T111500",
      "authors": [
        "Royalty Pharma plc"
      ],
      "summary": "NEW YORK, May 08, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) today reported financial results for the first quarter of 2025 and raised full year 2025 guidance for Portfolio Receipts.",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/d605b3b0-7ba0-46e1-a2d4-439ca98694f8",
      "source": "GlobeNewswire",
      "category_within_source": "n/a",
      "source_domain": "www.globenewswire.com",
      "topics": [
        {
          "topic": "Earnings",
          "relevance_score": "0.865346"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "1.0"
        }
      ],
      "overall_sentiment_score": 0.213123,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "RPRX",
          "relevance_score": "0.306821",
          "ticker_sentiment_score": "0.222804",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.011659",
          "ticker_sentiment_score": "0.066529",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BIIB",
          "relevance_score": "0.023315",
          "ticker_sentiment_score": "0.120668",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Royalty Pharma Announces Transformative Step in Company's Evolution With Acquisition of its External Manager and $3 Billion Share Repurchase Program",
      "url": "https://www.globenewswire.com/news-release/2025/01/10/3007576/0/en/Royalty-Pharma-Announces-Transformative-Step-in-Company-s-Evolution-With-Acquisition-of-its-External-Manager-and-3-Billion-Share-Repurchase-Program.html",
      "time_published": "20250110T121500",
      "authors": [
        "Royalty Pharma plc"
      ],
      "summary": "NEW YORK, Jan. 10, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) today announced two major steps to enhance shareholder value.",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/d605b3b0-7ba0-46e1-a2d4-439ca98694f8",
      "source": "GlobeNewswire",
      "category_within_source": "n/a",
      "source_domain": "www.globenewswire.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "1.0"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.413559"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.301356,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "EVR",
          "relevance_score": "0.011602",
          "ticker_sentiment_score": "0.076771",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MSCI",
          "relevance_score": "0.011602",
          "ticker_sentiment_score": "0.176395",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "RPRX",
          "relevance_score": "0.514831",
          "ticker_sentiment_score": "0.419454",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.011602",
          "ticker_sentiment_score": "0.063946",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MS",
          "relevance_score": "0.011602",
          "ticker_sentiment_score": "0.076771",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Royalty Pharma Announces Transformative Step in Company's Evolution With Acquisition of its External Manager and $3 Billion Share Repurchase Program - Royalty Pharma  ( NASDAQ:RPRX ) ",
      "url": "https://www.benzinga.com/pressreleases/25/01/g42909294/royalty-pharma-announces-transformative-step-in-companys-evolution-with-acquisition-of-its-externa",
      "time_published": "20250110T121500",
      "authors": [
        "Globe Newswire"
      ],
      "summary": "Royalty Pharma plc to become an integrated company by acquiring its external manager, RP Management, LLC Significant annual cash savings of greater than $100 million in 2026 growing to over $175 million in 2030, with cumulative savings of more than $1.6 billion over ten years",
      "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
      "source": "Benzinga",
      "category_within_source": "News",
      "source_domain": "www.benzinga.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "1.0"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.413559"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.301404,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "EVR",
          "relevance_score": "0.011569",
          "ticker_sentiment_score": "0.07675",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MSCI",
          "relevance_score": "0.011569",
          "ticker_sentiment_score": "0.176357",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "RPRX",
          "relevance_score": "0.513564",
          "ticker_sentiment_score": "0.347388",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.011569",
          "ticker_sentiment_score": "0.063928",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MS",
          "relevance_score": "0.011569",
          "ticker_sentiment_score": "0.07675",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Teva and Alvotech Announce SELARSDI\u2122  ( ustekinumab-aekn )  Injection Now Available in the U.S.",
      "url": "https://www.globenewswire.com/news-release/2025/02/21/3030306/0/en/Teva-and-Alvotech-Announce-SELARSDI-ustekinumab-aekn-Injection-Now-Available-in-the-U-S.html",
      "time_published": "20250221T110000",
      "authors": [
        "Alvotech"
      ],
      "summary": "Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. ( NYSE and TASE: TEVA ) , and Alvotech ( NASDAQ: ALVO ) today announced the availability of SELARSDI\u2122 ( ustekinumab-aekn ) injection in the U.S., a biosimilar to Stelara\u00ae ( ustekinumab ) , for the treatment of ...",
      "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/17a8091d-68a6-47c1-968e-fcced99f1d44",
      "source": "GlobeNewswire",
      "category_within_source": "n/a",
      "source_domain": "www.globenewswire.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.614606"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.06746,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "GOOG",
          "relevance_score": "0.011015",
          "ticker_sentiment_score": "0.086738",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "META",
          "relevance_score": "0.011015",
          "ticker_sentiment_score": "0.086738",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LTUS",
          "relevance_score": "0.011015",
          "ticker_sentiment_score": "0.055989",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.011015",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ALVO",
          "relevance_score": "0.321253",
          "ticker_sentiment_score": "0.166331",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.011015",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TEVA",
          "relevance_score": "0.055033",
          "ticker_sentiment_score": "0.077897",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "KMDA",
          "relevance_score": "0.011015",
          "ticker_sentiment_score": "0.055989",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Teva and Alvotech Announce SELARSDI\u2122  ( ustekinumab-aekn )  Injection Now Available in the U.S.",
      "url": "https://www.globenewswire.com/news-release/2025/02/21/3030307/0/en/Teva-and-Alvotech-Announce-SELARSDI-ustekinumab-aekn-Injection-Now-Available-in-the-U-S.html",
      "time_published": "20250221T110000",
      "authors": [
        "Alvotech"
      ],
      "summary": "REYKJAVIK, Iceland and PARSIPPANY, N.J., Feb. 21, 2025 ( GLOBE NEWSWIRE ) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. ( NYSE and TASE: TEVA ) , and Alvotech ( NASDAQ: ALVO ) today announced the availability of SELARSDI\u2122 ( ustekinumab-aekn ) injection in the ...",
      "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/17a8091d-68a6-47c1-968e-fcced99f1d44",
      "source": "GlobeNewswire",
      "category_within_source": "n/a",
      "source_domain": "www.globenewswire.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.614606"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.065046,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "GOOG",
          "relevance_score": "0.010995",
          "ticker_sentiment_score": "0.086724",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "META",
          "relevance_score": "0.010995",
          "ticker_sentiment_score": "0.086724",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LTUS",
          "relevance_score": "0.010995",
          "ticker_sentiment_score": "0.055979",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.010995",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ALVO",
          "relevance_score": "0.320696",
          "ticker_sentiment_score": "0.163815",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.010995",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TEVA",
          "relevance_score": "0.054932",
          "ticker_sentiment_score": "0.07689",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "KMDA",
          "relevance_score": "0.010995",
          "ticker_sentiment_score": "0.055979",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Teva and Alvotech Announce SELARSDI\u2122  ( ustekinumab-aekn )  Injection Now Available in the U.S.",
      "url": "https://www.globenewswire.com/news-release/2025/02/21/3030303/0/en/Teva-and-Alvotech-Announce-SELARSDI-ustekinumab-aekn-Injection-Now-Available-in-the-U-S.html",
      "time_published": "20250221T110000",
      "authors": [
        "Teva Pharmaceutical Industries Ltd"
      ],
      "summary": "PARSIPPANY, N.J. and REYKJAV\u00cdK, Iceland, Feb. 21, 2025 ( GLOBE NEWSWIRE ) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. ( NYSE and TASE: TEVA ) , and Alvotech ( NASDAQ: ALVO ) today announced the availability of SELARSDI\u2122 ( ustekinumab-aekn ) injection in the ...",
      "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/c2001734-949b-4cc2-8021-b4b64eda1f13",
      "source": "GlobeNewswire",
      "category_within_source": "n/a",
      "source_domain": "www.globenewswire.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.614606"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.067454,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "GOOG",
          "relevance_score": "0.010975",
          "ticker_sentiment_score": "0.083255",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "META",
          "relevance_score": "0.010975",
          "ticker_sentiment_score": "0.083255",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LTUS",
          "relevance_score": "0.010975",
          "ticker_sentiment_score": "0.05597",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.010975",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ALVO",
          "relevance_score": "0.32014",
          "ticker_sentiment_score": "0.163597",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.010975",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TEVA",
          "relevance_score": "0.054832",
          "ticker_sentiment_score": "0.076885",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "KMDA",
          "relevance_score": "0.010975",
          "ticker_sentiment_score": "0.05597",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Alvotech Reports Record Results for 2024 and Provides Business Update",
      "url": "https://www.globenewswire.com/news-release/2025/03/26/3050210/0/en/Alvotech-Reports-Record-Results-for-2024-and-Provides-Business-Update.html",
      "time_published": "20250326T223600",
      "authors": [
        "Alvotech"
      ],
      "summary": "Alvotech ( NASDAQ: ALVO, or the \"Company\" ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported financial results for full year 2024 and provided a summary of recent pipeline and corporate highlights.",
      "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/17a8091d-68a6-47c1-968e-fcced99f1d44",
      "source": "GlobeNewswire",
      "category_within_source": "n/a",
      "source_domain": "www.globenewswire.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.998682"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.999862"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.106346,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "GOOG",
          "relevance_score": "0.010748",
          "ticker_sentiment_score": "0.089147",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "META",
          "relevance_score": "0.010748",
          "ticker_sentiment_score": "0.089147",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LTUS",
          "relevance_score": "0.010748",
          "ticker_sentiment_score": "0.055062",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BAYZF",
          "relevance_score": "0.010748",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.010748",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ALVO",
          "relevance_score": "0.362707",
          "ticker_sentiment_score": "0.141813",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVS",
          "relevance_score": "0.010748",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.010748",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TEVA",
          "relevance_score": "0.010748",
          "ticker_sentiment_score": "0.055062",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "KMDA",
          "relevance_score": "0.010748",
          "ticker_sentiment_score": "0.055062",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "REGN",
          "relevance_score": "0.010748",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AMGN",
          "relevance_score": "0.010748",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FOREX:ISK",
          "relevance_score": "0.010748",
          "ticker_sentiment_score": "0.125714",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FOREX:SEK",
          "relevance_score": "0.010748",
          "ticker_sentiment_score": "0.125714",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Alvotech Reports Record Results for 2024 and Provides Business Update",
      "url": "https://www.globenewswire.com/news-release/2025/03/26/3050209/0/en/Alvotech-Reports-Record-Results-for-2024-and-Provides-Business-Update.html",
      "time_published": "20250326T223400",
      "authors": [
        "Alvotech"
      ],
      "summary": "REYKJAVIK, Iceland, March 26, 2025 ( GLOBE NEWSWIRE ) -- Alvotech ( NASDAQ: ALVO, or the \"Company\" ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported financial results for full year 2024 and provided a ...",
      "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/17a8091d-68a6-47c1-968e-fcced99f1d44",
      "source": "GlobeNewswire",
      "category_within_source": "n/a",
      "source_domain": "www.globenewswire.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.998682"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.999862"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.106342,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "GOOG",
          "relevance_score": "0.010724",
          "ticker_sentiment_score": "0.08913",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "META",
          "relevance_score": "0.010724",
          "ticker_sentiment_score": "0.08913",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LTUS",
          "relevance_score": "0.010724",
          "ticker_sentiment_score": "0.055051",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BAYZF",
          "relevance_score": "0.010724",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.010724",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ALVO",
          "relevance_score": "0.361952",
          "ticker_sentiment_score": "0.139079",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "NVS",
          "relevance_score": "0.010724",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.010724",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TEVA",
          "relevance_score": "0.010724",
          "ticker_sentiment_score": "0.055051",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "KMDA",
          "relevance_score": "0.010724",
          "ticker_sentiment_score": "0.055051",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "REGN",
          "relevance_score": "0.010724",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AMGN",
          "relevance_score": "0.010724",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FOREX:ISK",
          "relevance_score": "0.010724",
          "ticker_sentiment_score": "0.125693",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FOREX:SEK",
          "relevance_score": "0.010724",
          "ticker_sentiment_score": "0.125693",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Royalty Pharma Reports Q4 and Full Year 2024 Results",
      "url": "https://www.globenewswire.com/news-release/2025/02/11/3024051/0/en/Royalty-Pharma-Reports-Q4-and-Full-Year-2024-Results.html",
      "time_published": "20250211T121500",
      "authors": [
        "Royalty Pharma plc"
      ],
      "summary": "NEW YORK, Feb. 11, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) today reported financial results for the fourth quarter and full year 2024 and introduced full year 2025 guidance for Portfolio Receipts.",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/d605b3b0-7ba0-46e1-a2d4-439ca98694f8",
      "source": "GlobeNewswire",
      "category_within_source": "n/a",
      "source_domain": "www.globenewswire.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "1.0"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "1.0"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.882182"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.266143"
        }
      ],
      "overall_sentiment_score": 0.224419,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "BHVN",
          "relevance_score": "0.010629",
          "ticker_sentiment_score": "0.192372",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "INCY",
          "relevance_score": "0.010629",
          "ticker_sentiment_score": "0.041707",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SNDX",
          "relevance_score": "0.010629",
          "ticker_sentiment_score": "0.041707",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "RPRX",
          "relevance_score": "0.377913",
          "ticker_sentiment_score": "0.296351",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.010629",
          "ticker_sentiment_score": "0.065957",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GERN",
          "relevance_score": "0.010629",
          "ticker_sentiment_score": "0.041707",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI\u2122  ( ustekinumab-aekn )  with Stelara\u00ae  ( ustekinumab ) ",
      "url": "https://www.globenewswire.com/news-release/2025/05/05/3073922/0/en/Teva-and-Alvotech-Announce-FDA-Approval-of-Interchangeability-for-SELARSDI-ustekinumab-aekn-with-Stelara-ustekinumab.html",
      "time_published": "20250505T110000",
      "authors": [
        "Alvotech"
      ],
      "summary": "Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. ( NYSE and TASE: TEVA ) , and Alvotech ( NASDAQ: ALVO ) today announced that the U.S. Food and Drug Administration ( FDA ) has approved SELARSDI\u2122 ( ustekinumab-aekn ) injection as interchangeable with the reference ...",
      "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/17a8091d-68a6-47c1-968e-fcced99f1d44",
      "source": "GlobeNewswire",
      "category_within_source": "n/a",
      "source_domain": "www.globenewswire.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.614606"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.069791,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "GOOG",
          "relevance_score": "0.010366",
          "ticker_sentiment_score": "0.086284",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "META",
          "relevance_score": "0.010366",
          "ticker_sentiment_score": "0.086284",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LTUS",
          "relevance_score": "0.010366",
          "ticker_sentiment_score": "0.055684",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.010366",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ALVO",
          "relevance_score": "0.3033",
          "ticker_sentiment_score": "0.169754",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.010366",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TEVA",
          "relevance_score": "0.051797",
          "ticker_sentiment_score": "0.090652",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "KMDA",
          "relevance_score": "0.010366",
          "ticker_sentiment_score": "0.055684",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "REGN",
          "relevance_score": "0.010366",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI\u2122  ( ustekinumab-aekn )  with Stelara\u00ae  ( ustekinumab ) ",
      "url": "https://www.globenewswire.com/news-release/2025/05/05/3073976/0/en/Teva-and-Alvotech-Announce-FDA-Approval-of-Interchangeability-for-SELARSDI-ustekinumab-aekn-with-Stelara-ustekinumab.html",
      "time_published": "20250505T114900",
      "authors": [
        "Teva Pharmaceutical Industries Ltd"
      ],
      "summary": "PARSIPPANY, N.J. & REYKJAV\u00cdK, Iceland, May 05, 2025 ( GLOBE NEWSWIRE ) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. ( NYSE and TASE: TEVA ) , and Alvotech ( NASDAQ: ALVO ) today announced that the U.S. Food and Drug Administration ( FDA ) has approved SELARSDI\u2122 ...",
      "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/c2001734-949b-4cc2-8021-b4b64eda1f13",
      "source": "GlobeNewswire",
      "category_within_source": "n/a",
      "source_domain": "www.globenewswire.com",
      "topics": [
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "0.614606"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.5"
        }
      ],
      "overall_sentiment_score": 0.06738,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "GOOG",
          "relevance_score": "0.010335",
          "ticker_sentiment_score": "0.086262",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "META",
          "relevance_score": "0.010335",
          "ticker_sentiment_score": "0.086262",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "LTUS",
          "relevance_score": "0.010335",
          "ticker_sentiment_score": "0.05567",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.010335",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ALVO",
          "relevance_score": "0.302429",
          "ticker_sentiment_score": "0.167184",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.010335",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TEVA",
          "relevance_score": "0.05164",
          "ticker_sentiment_score": "0.089634",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "KMDA",
          "relevance_score": "0.010335",
          "ticker_sentiment_score": "0.05567",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "REGN",
          "relevance_score": "0.010335",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Johnson & Johnson  ( JNJ )  Q4 2024 Earnings Call Transcript",
      "url": "https://www.fool.com/earnings/call-transcripts/2025/01/22/johnson-johnson-jnj-q4-2024-earnings-call-transcri/",
      "time_published": "20250122T190014",
      "authors": [
        "Motley Fool Transcribing"
      ],
      "summary": "JNJ earnings call for the period ending December 31, 2024.",
      "banner_image": "https://g.foolcdn.com/misc-assets/fool-transcripts-logo.png",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.5"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.5"
        },
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.650727"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "1.0"
        },
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Mergers & Acquisitions",
          "relevance_score": "0.995973"
        },
        {
          "topic": "Economy - Macro",
          "relevance_score": "0.158519"
        }
      ],
      "overall_sentiment_score": 0.297551,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "BCS",
          "relevance_score": "0.004243",
          "ticker_sentiment_score": "0.079345",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ITCI",
          "relevance_score": "0.029696",
          "ticker_sentiment_score": "0.10978",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BAC",
          "relevance_score": "0.004243",
          "ticker_sentiment_score": "0.106941",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "WFC",
          "relevance_score": "0.004243",
          "ticker_sentiment_score": "0.113765",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MS",
          "relevance_score": "0.004243",
          "ticker_sentiment_score": "0.070348",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.063582",
          "ticker_sentiment_score": "0.127473",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "KVUE",
          "relevance_score": "0.008486",
          "ticker_sentiment_score": "0.088991",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.008486",
          "ticker_sentiment_score": "0.104715",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GS",
          "relevance_score": "0.004243",
          "ticker_sentiment_score": "0.0",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "FOREX:USD",
          "relevance_score": "0.004243",
          "ticker_sentiment_score": "0.0085",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Elon Musk Commits to Tesla. Is That a Good Thing?",
      "url": "https://www.fool.com/investing/2025/05/23/elon-musk-commits-to-tesla-is-that-a-good-thing/",
      "time_published": "20250524T030100",
      "authors": [
        "Motley Fool Staff"
      ],
      "summary": "In this podcast, Motley Fool analyst Jason Moser and host Ricky Mulvey discuss:Then, Motley Fool personal finance expert Robert Brokamp answers listener questions about Roth IRAs and dividend investing.To catch full episodes of all The Motley Fool's free podcasts, check out our podcast center.",
      "banner_image": "https://g.foolcdn.com/editorial/images/819407/elon-hangs-on.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.25"
        },
        {
          "topic": "Technology",
          "relevance_score": "0.25"
        },
        {
          "topic": "Economy - Monetary",
          "relevance_score": "0.158519"
        },
        {
          "topic": "IPO",
          "relevance_score": "0.158519"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.25"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "1.0"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.25"
        },
        {
          "topic": "Earnings",
          "relevance_score": "0.795202"
        }
      ],
      "overall_sentiment_score": 0.188054,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "NFLX",
          "relevance_score": "0.022229",
          "ticker_sentiment_score": "0.066944",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GOOG",
          "relevance_score": "0.007411",
          "ticker_sentiment_score": "0.047284",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "META",
          "relevance_score": "0.007411",
          "ticker_sentiment_score": "0.110397",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AVGO",
          "relevance_score": "0.007411",
          "ticker_sentiment_score": "0.04496",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SPOT",
          "relevance_score": "0.007411",
          "ticker_sentiment_score": "0.047284",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TTD",
          "relevance_score": "0.029636",
          "ticker_sentiment_score": "0.093512",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "SY",
          "relevance_score": "0.007411",
          "ticker_sentiment_score": "0.047711",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.007411",
          "ticker_sentiment_score": "0.04496",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.007411",
          "ticker_sentiment_score": "0.04496",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "DASH",
          "relevance_score": "0.007411",
          "ticker_sentiment_score": "0.07878",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TSLA",
          "relevance_score": "0.103458",
          "ticker_sentiment_score": "0.123102",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PG",
          "relevance_score": "0.007411",
          "ticker_sentiment_score": "0.04496",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "W",
          "relevance_score": "0.014821",
          "ticker_sentiment_score": "0.050038",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CHWY",
          "relevance_score": "0.022229",
          "ticker_sentiment_score": "0.060221",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MCO",
          "relevance_score": "0.007411",
          "ticker_sentiment_score": "0.066703",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HD",
          "relevance_score": "0.110802",
          "ticker_sentiment_score": "0.070235",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "UBER",
          "relevance_score": "0.029636",
          "ticker_sentiment_score": "0.080678",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AMZN",
          "relevance_score": "0.03704",
          "ticker_sentiment_score": "0.071255",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "WMT",
          "relevance_score": "0.044441",
          "ticker_sentiment_score": "0.073257",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Introducing the \"Dividend Seven\" Stocks",
      "url": "https://www.fool.com/investing/2024/12/24/introducing-the-dividend-seven-stocks/",
      "time_published": "20241224T205200",
      "authors": [
        "Motley Fool Staff"
      ],
      "summary": "In this podcast, Motley Fool analysts Matt Argersinger and Anthony Schiavone join host Mary Long to discuss:To catch full episodes of all The Motley Fool's free podcasts, check out our podcast center. To get started investing, check out our beginner's guide to investing in stocks.",
      "banner_image": "https://g.foolcdn.com/editorial/images/800477/introducing-the-dividend-seven.jpg",
      "source": "Motley Fool",
      "category_within_source": "n/a",
      "source_domain": "www.fool.com",
      "topics": [
        {
          "topic": "Life Sciences",
          "relevance_score": "0.2"
        },
        {
          "topic": "Finance",
          "relevance_score": "0.2"
        },
        {
          "topic": "Retail & Wholesale",
          "relevance_score": "0.2"
        },
        {
          "topic": "Financial Markets",
          "relevance_score": "1.0"
        },
        {
          "topic": "Manufacturing",
          "relevance_score": "0.2"
        },
        {
          "topic": "Earnings",
          "relevance_score": "1.0"
        },
        {
          "topic": "Real Estate & Construction",
          "relevance_score": "0.2"
        }
      ],
      "overall_sentiment_score": 0.184764,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "NVDA",
          "relevance_score": "0.00713",
          "ticker_sentiment_score": "0.12441",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "TSLA",
          "relevance_score": "0.00713",
          "ticker_sentiment_score": "0.12441",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BAC",
          "relevance_score": "0.00713",
          "ticker_sentiment_score": "0.047066",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MDNDF",
          "relevance_score": "0.0854",
          "ticker_sentiment_score": "0.080551",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PLD",
          "relevance_score": "0.106636",
          "ticker_sentiment_score": "0.075523",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PEP",
          "relevance_score": "0.01426",
          "ticker_sentiment_score": "0.025356",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.00713",
          "ticker_sentiment_score": "0.047279",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "GS",
          "relevance_score": "0.00713",
          "ticker_sentiment_score": "0.047066",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HD",
          "relevance_score": "0.092486",
          "ticker_sentiment_score": "0.061006",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AMZN",
          "relevance_score": "0.021388",
          "ticker_sentiment_score": "0.104183",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "BNXYF",
          "relevance_score": "0.00713",
          "ticker_sentiment_score": "0.022253",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "HSY",
          "relevance_score": "0.03564",
          "ticker_sentiment_score": "0.148251",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "CRYPTO:BTC",
          "relevance_score": "0.028515",
          "ticker_sentiment_score": "0.050364",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    }
  ]
}